

=> fill wpiX

FILE 'WPIX' ENTERED AT 14:26:27 ON 12 FEB 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE LAST UPDATED: (7 FEB 2001) <20010207/UP>
>>> UPDATE WEEKS:
MOST RECENT DERWENT WEEK 200108 <200108/DW>
DERWENT WEEK FOR CHEMICAL CODING: 200108
DERWENT WEEK FOR POLYMER INDEXING: 200108
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1993 TO DATE

>>> FOR UP-TO-DATE INFORMATION ABOUT THE DERWENT CHEMISTRY
RESOURCE, PLEASE VISIT
<http://www.derwent.com/chemistryresource/index.html> <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE <http://www.derwent.com/cvccodes.html> <<<

=> d fill all abeq tech tot

LINE ANSWER 1 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2001-071346 [08] WPIX

INN N2001-053983 INN C2001-013999

TI Identifying biological macromolecules, e.g. **proteins**, from mass
data, by determining frequency distribution of scores representing
similarity of data for known and unknown compounds.

DD 504 016 T01

IN CHAIT, B T; BRAKSON, J; PENNOE, D

SA (CTRQ) UNIV ROCKEFELLER

CYC 21

PI WO 2000077712 A1 20001221 (200108)* EN 6sp G06F019-00 <--
FW: AT BE CH CY DE DK ES FI FR GB GE IE IT LU MC NL PT SE
W: CA JP US

ADT WO 2000077712 A1 WO 2000-US16633 20000615

PRAI US 1999-333726 19990615

IC ICM **G06F019-00**

AB WO 200077712 A UPAB: 20010207

NOVELTY - Generating a frequency distribution (FD) of scores (S), related
to random identifications of biological molecules (I), for a particular
experimental condition (EC), is new.

DETAILED DESCRIPTION - Generating a frequency distribution (FD) of
scores (S), related to random identifications of biological molecules (I),
for a particular experimental condition (EC), is new. The method
comprises:

(a) generating mass data at EC, for known (I) in a database, and for
a hypothetical (I);

(b) comparing the data to calculate S that is a **function** of
the similarity of the data;

(c) selecting S that represent a high degree of similarity;

(d) repeating the method for other hypothetical (I); and

(e) determining the frequency of selecting each S to generate FD.

INDEPENDENT CLAIMS are also included for the following:

(1) the novel method in which the hypothetical (I) in the first step
is replaced by a (I) randomly selected from the database;

(2) the novel method for identifying, at a particular significance
level, an unknown (I);

(3) determining statistical significance of an identified score for
(I);

(4) FD prepared by the novel method;

(5) identifying a (I) at a particular EC and significance level,
comprising:

(a) selecting a significance level that represents a level of
confidence in a biological molecule identification;

(b) cleaving the unknown biological molecule into constituent parts;
 (c) generating mass data for these constituent parts;
 (d) comparing the mass data with mass data generated for the EC from known biological molecules of a database;
 (e) calculating scores for each comparison, which are a **function** of similarity between mass data of the unknown and known molecules;

(f) selecting a score generated in (e) which corresponds to a comparison which denotes a high degree of similarity, and which corresponds to a particular known molecule;

(g) comparing the score selected in (f) with FD of scores for EC, the distribution relates to random biological molecule identifications, and has a critical score associated with it which corresponds to the significance level; and

(h) determining if the score in (f) is equal to or higher than the critical score;

(6) determining the statistical significance of an identified score for (I), comprising:

(a) selecting a significance level that represents a level of confidence in a biological molecule identification;

(b) calculating a score associated with an unknown biological molecule, the score is a **function** of similarity between mass data of the unknown and known molecules;

(c) comparing the score with a score FD, the distribution is generated by comparing mass data of hypothetical biological molecules with mass data generated for known molecules, and the FD has a significance level associated with it; and

(d) determining if the score associated with the unknown molecule identification is within the significance level; and

(7) a computer program system for performing the novel method.

USE - The method is used to identify unknown (I), particularly **proteins**, nucleic acids and polysaccharides, from mass spectroscopy data and to assess the reliability of the identification.
 Dwg.0/14

FS CFI EPI

FA AB; DCN

MC CFI: B04-C02; B04-E01; B04-N04; B11-C08; B11-C08A;

B12-K04E; D05-H09

EPI: T01-J

TECH

UPTX: 20010207

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Process: FD is particularly a probability density **function** and mass data are generated by computer or, for hypothetical (I), by mass spectrometry. The method is used to generate 1-1010, particularly 100-107 S values. EC defines mass data results from chemical degradation of (I) (particularly enzymatic degradation with trypsin), including the effectiveness of the degradation, or a particular accuracy for mass determination. The comparison of data is limited to known (I) within selected ranges of either mass or isoelectric point, especially to known (I) that are modified, e.g. for **proteins** post-translationally modified. To generate hypothetical (I), at least one known (I) is selected from the database (preferably in the mass range up to 3 MD), mass data generated and those masses selected that correspond to at least one constituent part of the known (I). The procedure is repeated for different (I) until sufficient masses (particularly 1-1000) have been selected to allow generation of hypothetical (I) which consists of a set of constituent parts that is different from all sets of constituents in known (I). Selection of (I) and of the constituent parts is random. Fragment mass data may also be collected for at least one constituent part of known and hypothetical (I), and in this case the comparison is between fragment mass data and EC then defines the energy used to generate these data. In the method of (2), a significance level is chosen that represents a level of confidence in identification of (I), then unknown (I) cleaved into its constituent parts (especially in a predictable manner) and mass data generated for these parts. These data are then compared with data from known (I) to generate an S which is compared with an FD of scores, at EC,

that is related to random identification of (I) and associated with a critical score corresponding to the significance level. The unknown (I) may be a mixture. The fragment mass data are acquired by vibrational or electronic excitation, specifically collisions with electrons, photons, gas molecules or a surface. In the method of (3), S from an unknown (I) is compared with an FP, associated with a predetermined significance level and generated by comparing mass data from known and hypothetical (I). Any S within the significance level-1 (which particularly denotes a probability that identification of (I) is false) is determined.

Preferred Materials: (I) are **proteins**, nucleic acids or polysaccharides.

L123 ANSWER 2 OF 73 WPIK COPYRIGHT 2001 PERWENT INFORMATION LTD

AN 2001-067169 [01] WPIK

DNN NP001-005104 INC 02001-001780

TI Biological marker and phenotype identification system, useful in drug development, using processor to correlate data regarding e.g. cell populations, soluble factor levels and clinical parameters.

DC B04 D10 J04 S03 T01

IN ALLISON, A; BRUNKE, K J; DIETZ, L J; KANTOR, A B; NATAN, M J; RINGOLD, G
FA (SURE-II) SURROMED INC

CYC 89

PI WO 2000065472 A1 20001102 (200101) EN 104p G06F017-00 <--

FW: AT BE CH CY DE DK EA ES FI FR GB GR GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SJ US ZW

W: AE AL AM AT AU BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GR HM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG ME MN MW MX NO NZ PL PT RD RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG UE VH YU ZA ZW

ADT WI 2000065472 A1 WO 2000-0011296 20000426

PEAI US 2000-175475 20000107; US 1999-131105 19990106

IC EPM G06F017-00

AB WO 200065472 A UPAB: 20001130

NOVELTY - A biological marker (BM) identification system comprising an integrated database containing several data categories and data from various organisms corresponding to the data categories, is new.

DETAILED DESCRIPTION - A biological marker (BM) identification system comprises:

(a) an integrated database containing several data categories, i.e. levels of cell populations, cell associated molecules and/or soluble factors in a biological fluid and information associated with clinical parameters of an organism; and

(b) data from various organisms corresponding to the data categories.

A processor correlates data within the categories, to identify the category (or categories) indicating normal biological or pathogenic processes or responses to drug intervention; this category (or these categories) is/are BM.

INDEPENDENT CLAIMS are also included for the following:

(1) a method for identifying a BM for a given disease or medical condition (GD/MC), comprising correlating information associated with several categories (as in (a) above) from several organisms, at least some of which have GD/MC and identifying a data category (i.e. BM) by which the presence of GD/MC can be identified;

(2) a phenotype of an organism comprising several biological parameters, i.e. the results of at least 20 (preferably at least 40) assays relating to cell populations and/or cell associated molecules, the results of at least 20 (preferably at least 40) assays relating to soluble factors and clinical parameters;

(3) a phenotype of a class or subclass of organisms, comprising parameters as in (2) for each member;

(4) a system for creating the phenotype of an organism, involving obtaining parameters as in (2);

(5) a method for evaluating the effect of a perturbation on an organism (or on a class or subclass of organisms), involving comparing the information in the phenotype, as in (2) or (3), of the organism(s) before and after the perturbation;

(6) a system for the identification of BM's of a GD/MC in an animal model, involving an integrated database and processor as above;

(7) a method for identifying a BM for GD/MC in a human, involving determining if a BM in an animal model as in (6) is diagnostic or prognostic of GD/MC in a human;

(8) a method for assaying a candidate drug, involving treating an animal model with the drug and evaluating the effect on a BM as in (6);

(9) a method for monitoring the results of a clinical study in humans with a GD/MC, involving identifying BM's in a human which are homologs of BM's identified in animal models of GD/MC;

(10) a method for designing an improved animal model for a GD/MC in humans, involving identifying human BM's relative to the GD/MC and tailoring the animal model to simulate GD/MC more accurately by elevating or reducing the levels of animal homologs of the human BM;

(11) a method for identifying an animal model of a GD/MC, involving comparing phenotypes (as in (2)) for potential animal models and an organism having the GD/MC, to identify the most closely simulating animal model phenotype; and

(12) a method for evaluating the effects of a the effects of a genetic alteration on a plant or animal, involving comparing information in phenotypes (as in (2)) for the genetically altered and non-altered organism to identify changed parameters.

USE - The systems and phenotypes are useful in drug development. The diseases involved are specifically asthma, allergy, multiple sclerosis or especially rheumatoid arthritis (all claimed). More generally the phenotypes may be of humans, animals, plants or viruses (all claimed); they may also be used for evaluating the effects of a genetic alteration on a plant or animal.

ADVANTAGE - The technology is supplied for providing quantitative, sensitive, reproducible and rapid measurements of multiple and diverse BM's which can accurately **profile** an organism's phenotype or a patient's disease status and response to therapy. More cost-effective drug development is possible. The biological parameters can be identified from small samples of blood.

DESCRIPTION OF DRAWING(S) - The figure is a schematic representation of the types of information assimilated to obtain a biological marker identification system.

Dwr.1/3

FS CPI EPI

FA AB; GI; DCN

MC CPI: B04-F01; B04-F01; B11-C08; E12-K04; D03-H09; J04-B01

EPI: S03-E14H9; T01-J

TECH

UPTX: 20001230

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred System: The data for levels of cell populations and/or cell associated molecules are obtained by microvolume laserscanning cytometry. The data for levels of soluble factors (preferably **proteins** or small molecules) are obtained by microvolume laser scanning cytometry, immunoassays or mass spectrometry. The data categories may also include genotype information. The information associated with clinical parameters is selected from age, sex, weight, height, body type, medical history, environmental factors and categorization of GD/MC.

L125 ANSWER 3 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 2000-686952 [67] WPIX

DNN N2000-507945 DNC C2000-208396

TI Analyzing molecule and **protein** diversity using a computer method comprising defining a set of constraints on possible target surfaces and defining a set of all theoretical target surfaces.

DC B04 D16 S03 S05 T01

IN MOALLEMI, C C; WINTNER, E A

PA (NEOG-N) NEOGENESIS INC

CYC 9L

PI WO 2000060507 A2 20001011 (200067)* EN 103p G06F017-50 <--

FW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SE SE SL SZ T2 US ZW

W: AE AG AL AM AT AU AZ BA BB BG BP BY CA CH CN CR CU DE DK DM DZ
 EE ES FI GE GF GE GH HM HH HU IL IL IN IS JP KE KG KP KR KZ LC LK
 LR LS LT LV MA MD MG MH MN MW MX NC NZ PL PT RD RU SE SG SI
 SK SL TJ TM TR TT UA UB US UC VN YU ZA ZW

ADT AU 2000044511 A 10001023 (200107) G06F017-50 ---
 WO 2000060507 A2 WO 2000-07777 20000331; AU 2000044511 A AU 2000-44511
 20000331

FDT AU 2000044511 A Based on WO 20000507

PRAI US 1999-107486 19990601

IC ICM G06F017-50

AB WO 2000060507 A UPAB: 20001223

NOVELTY - A computer-based method comprising defining a set of constraints on possible target surfaces, and defining a fully enumerated set of theoretical target surfaces under the defined constraints, so that each surface has a defined, continuous volume and a defined, continuous surface area, is new.

DETAILED DESCRIPTION - A computer-based method comprising defining a set of constraints on possible target surfaces, and defining a fully enumerated set of theoretical target surfaces under the defined constraints, so that each surface has a defined, continuous volume and a defined, continuous surface area, is new. The method further comprises mapping sets of objects to the fully enumerated set of theoretical target surfaces to define corresponding subsets of the fully enumerated set of theoretical target surfaces, and analyzing an aspect of diversity of the objects based on degrees of similarities and differences among the corresponding subsets.

An INDEPENDENT CLAIM is also included for a computer programmed to determine the chemical similarity of different molecules, the program comprising:

(a) approximating the surface shape of molecules of interest by linking a series of cubes, each having a dimension R, the locations of the cubes being determined by the calculated electron probability density of the individual molecule of interest, each cube sharing at least one of its six faces with another cube, so that there is a specific number of linked cubes which varies for each molecule of interest;

(b) approximating the chemical reactivity of each individual molecule of interest by assigning each cube of each individual molecule of interest, no more than one **functionality** value from M different chemical **functionality** values;

(c) approximating the surface shape and chemical reactivity of a chemically active surface having a volume equal to V by subtracting a number V/R³ cubes of dimension R from a surface, where each cube space shares at least one face with another cube space and where N cube spaces have one of M different chemical **functionality** values;

(d) calculating an attraction value K for each molecule of interest to the chemically active surface; and

(e) calculating a list of overall attraction values to the chemically active surface.

USE - For analyzing molecule and **protein** diversity.

Dwg. 0/25

PS CFI EE1

FA AB; DCN

MC CFI: B04-N04; B11-C08; B12-K04E; D05-H09

EE1: S03-E14H5; S03-C02; T01-J06A; T01-J07B

TECH UFTX: 10001023

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Materials: The target surfaces comprise negative space target surfaces. The objects comprise positive space object surfaces associated with different molecules. The objects comprise positive space object surfaces associated with different molecules. The objects are mapped by defining corresponding subsets of the set of negative space theoretical target surfaces to which the positive space object surfaces of conformations of molecules are complementary. The aspect of diversity that is analyzed is the difference or similarity between the molecules, which map to those negative space theoretical target surfaces. The objects comprise negative space object surfaces associated with different **proteins**. The objects are mapped by

defining corresponding subsets of the fully enumerated set of negative space theoretical target surfaces to which the negative space object surfaces of the **protein** pockets are similar. The aspect of diversity that is analyzed is the difference or similarity between **protein** pockets, which map to those negative space theoretical target surfaces. Alternatively, the objects comprise positive space object surfaces associated with different molecules and negative space object surfaces associated with different **proteins**. The objects comprise positive space object surfaces associated with different molecules and negative space object surfaces associated with different **proteins**. In the case of molecules, the objects are mapped by defining corresponding subsets of the fully enumerated set of negative space theoretical target surfaces to which the positive space object surfaces of conformations of molecules are complementary. In the case of **proteins**, the objects are mapped by defining corresponding subsets of the fully enumerated set of negative space theoretical target surfaces to which negative space object surfaces of **protein** pockets are similar. The theoretical target surfaces comprise polyhedrons. The objects comprise polyhedrons. The polyhedrons comprise cubes, which are all of the same size and shape. The set of all theoretical target surfaces defines a diversity space within which the diversity of objects can be measured by mapping those objects to the diversity space.

Preferred Methods: The method also includes identifying regions of the diversity space to which no objects map. The method also includes designing molecules that occupy at least one of the unfilled theoretical target surfaces of the diversity space. Complementarity is associated with binding affinities of positive space object surfaces of conformations of molecules to negative space theoretical target surfaces. The constraints comprise volume. The constraints comprise associating each site of the target surface with a pre-selected molecular property. Each of the pre-selected molecular properties is drawn from a larger set of possible molecular properties, e.g. hydrophobic, polarizable, H-bond acceptor, H-bond donor, H-bond donor/acceptor, potentially positively charged or potentially negatively charged. Not all of the sites of the target surface are each associated with a different one of the molecular properties and all of the other sites of the target surface are associated with a common molecular property. The common molecular property is slight hydrophobicity. The degrees of similarities or differences comprise **functional** properties associated with the corresponding subsets of the fully enumerated set of theoretical target surfaces. The degrees of similarities or differences comprise shape properties associated with the corresponding subsets of the fully enumerated set of theoretical target surfaces. The method further comprises defining each of the objects by quantifying molecules into polyhedrons.

L123 ANSWER 4 OF 73 WPIX COPYRIGHT 2001 BERWENT INFORMATION LTD
 AN 2000-665269 [64] WPIX
 DNN H2000-493033 DNE C1000-101590
 TI Identifying novel nucleic acid molecules encoding **proteins** of interest, and natural language processing and extraction of relational information associated with genes and **proteins** found in journal articles.
 DC B04 D16 J03 T01
 IN FRIEDMAN, C; KALACHIKOV, J; KRA, P; KRAUTHAMMER, M G; RCHETSKY, A
 PA (UNCO) UNIV COLUMBIA NEW YORK
 CYC 01
 PI WO 2000063687 A1 20001026 (2000064)* EN 374p 0010001-00
 FW: AT BE CH CY DE DK EA ES FI FR GE GH GM GP IE IT KE LS LU MC MW NL
 OA PT SD SE SI SK TC TG TW
 W: AE AG AL AM AN AO AD BA BB BC BF BY CA CH CN CR CU CZ DE DK EM DZ
 EE ES FI GE GH GI GR HA HB HU IL IN IS JP KE KP KR KZ LC LK
 LF LS LT LU LV MA MD ME MG MN MO MX NO NZ PL PT RO RU SD SE SG SI
 SK SL TJ TM TR TT TS UA UG UD VN YU ZA ZW
 AN 2000041556 A 20001101 (200117) 001N 11-00
 ADT WO 2000063687 A1 WO 2000-0810302 20000414; AN 2000041556 A AU 2000-43556 20000414

FDT AU 2000043556 A Based on WO 200063687
 PRAI US 1999-327383 19990608; US 1999-129469 19990415
 IC ICM G01N031-00

ICS G06F015-00; G06F017-00

AB WO 200063687 A UPAB: 20001209

NOVELTY - Identifying novel nucleic acids molecules encoding a **protein** of interest, using regulatory networks, is new.

DETAILED DESCRIPTION - Identifying novel nucleic acids molecules encoding a **protein** of interest, using regulatory networks, is new. The method comprises:

- (a) selecting a specific **protein** from a species involved in a regulatory network of interest;
- (b) identifying known **proteins** that act upstream and downstream of the **protein**, within the regulatory network;
- (c) constructing the regulatory network of interest from the **proteins** identified in (b);
- (d) for each identified **protein**, selecting a domain or motif and searching by homology for related **proteins** in a second species, a related **protein** has a homologous domain or motif;
- (e) producing a regulatory network for the second species, which incorporates the identified related **proteins**;
- (f) comparing the networks of the two species;
- (g) identifying a **protein** present in only one of the networks; and
- (h) isolating a nucleic acid molecule encoding the **protein** identified in (g) in the species in which it is missing.

INDEPENDENT CLAIMS are also included for the following:

- (1) identifying the effect of a gene knockout on a regulatory pathway, comprising:
 - (a) identifying the shortest non-oriented pathway connecting two gene products;
 - (b) assigning an initial sign value of minus to the knockout since the knockout gene is inactive;
 - (c) moving along the shortest pathway between the two gene products **multiplying** the sign with the sign of the next gene product in the pathway, where minus stands for inhibition and plus stands for induction or activation and zero stands for lack of interaction between two **proteins** in the specified direction; and
 - (d) determining the final sign at the end of the pathway, where minus indicates inhibition and plus indicates induction or activation of the pathway;
 - (2) identifying a novel nucleic acid molecule encoding a **protein** of interest, comprising:
 - (a) selecting a gene of interest and searching a database for homologous sequences;
 - (b) **aligning** the sequences identified in (a);
 - (c) constructing a gene tree using the sequence **alignment**;
 - (d) constructing a species tree;
 - (e) inputting the species tree and gene tree into an algorithm which integrates the species tree and gene tree into a reconciled tree; and
 - (f) identifying orthologous genes present in one species but missing in another;
 - (3) identifying a novel gene, comprising:
 - (a) defining a motif or domain composition of a gene of interest;
 - (b) searching for sequences which correspond to nucleotide sequences in an expression sequence tag database or other cDNA database using a program such as BLAST and retrieving the identified sequences;
 - (c) searching additional databases for expressed sequence tags containing the domains and motifs characteristic for the gene of interest with a hidden Markov model of domains and motifs identified in (A); and
 - (d) identifying nucleotide sequences comprising the gene of interest;
 - (4) extracting information on interactions between biological entities from natural-language text data, comprising:
 - (a) parsing the text data to determine its grammatical structure; and
 - (b) regularizing the parsed text data to form structured word terms;
- and

(5) a computer system for extracting information on biological entities from natural-language text data, comprising:
 (a) means for parsing the natural-language text data; and
 (b) means for regularizing the parsed text data to form structured word terms.

USE - For identifying novel genes and for natural language processing and extraction of relational information associated with genes and proteins that are found in genomics journal articles.

ADVANTAGE - The method allows the rapid retrieval of information from literature and manipulation of derived functional data, removing a researchers need to perform laborious reading and manual integration of research articles.

Dwg. 0/23

FS CFI BPI
 FA AB; DGN
 MC CFI: B04-E01; B11-C09; B12-K04E; D05-H09
 EPI: S03-E09; T01-J

TECH UPTX: 20001209

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The nucleic acid encodes a human **protein**. The related **proteins** are orthologs. The regulatory pathway is involved in apoptosis. The specific **protein** from the first species is involved in tumor suppression.

TECHNOLOGY FOCUS - COMPUTING AND CONTROL - Preferred Method: In the method of (1), the following algorithm is used to integrate the species and gene tree into a reconciled tree:

(a) computing the similarity $\sigma(s_i, s_j)$ for each pair of interior nodes from trees T_g and T_s ;
 (b) finding the maximum $\sigma(s_i, s_j)$;
 (c) saving s_i as a new cluster of orthologs, saving $(s_i)-(s_j)$ as a set of species that are likely to have a gene of this kind (or lost it in evolution);
 (d) eliminating s_i from T_g , $T_g := T_g / s_i$; and
 (e) repeating steps (b)-(d) until T_g is non-empty.

The method of (3) further comprises using each identified expression sequence tag to search sequence databases for overlapping sequences, to assemble longer overlapping stretches of DNA. The method of (4) further comprises preprocessing, the data prior to parsing. Preprocessing comprises identifying biological entities. The method further comprises referring to an additional parameter which indicates the degree to which subphrase parsing is to be carried out. The parsing step may comprise segmenting the text data by sentences and segmenting each sentence at identified words or phrases, or at a prefix. Alternatively, the parsing step comprises skipping undefined words or identifying binary actions and their relationships, and identifying arguments associated with the actions. The method may further comprise performing error recovery when parsing of the data is unsuccessful. The error recovery comprises segmenting the text data and analyzing the segmented data to achieve at least partial parsing of the unsuccessfully parsed data. The tagging step comprises providing the structured data component in a Standard Generalized Markup Language (SGML) compatible format.

Preferred System: The system further comprises means for preprocessing the data prior to parsing, and means for referring to an additional parameter which indicates the degree to which subphrase is to be carried out. The parsing means further comprise means for segmenting the text data into sentences and means for segmenting the sentences at identified words, phrases or prefixes. The parsing means may comprise means for skipping undefined words, means for identifying binary actions and their relationships, and means for identifying arguments associated with the actions. Means for performing error recovery when the parsing is unsuccessful may also be included. These comprise means for segmenting the text data and means for analyzing the segmented text data to achieve at least a partial parsing of the unsuccessfully parsed text data. Tagging means comprise means for providing the structured data component in SGML compatible format.

L123 ANSWER 5 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-6402-9 [62] WPIX

DNN NL000-471469 DMC CL000-193134

TI Estimating property values of sequences by the self-correlation of the property values, for predicting **protein** secondary structure .

DC B04 D16 J04 T01

FA (SEIP-N) SEIBUTSU BUNSHI FOGAKU KENKYUSHO KK

CYC 1

FI JP 1999-07378 A 26000728 (200062)* G06F015-18 <--

ADT JP 1999-07278 A JP 1999-10964 19990112

FRAI JP 1999-10964 19990112

IC ICH G06F015-18

ICG G06F017-18; G06F017-50

ICA G06K014-00; G12N011-00

AB JP2000-07378 A UPAB: 10001130

NOVELTY - A method (M1) for estimating property values, by the self-correlation of the property values which determine the characteristics of the nature of a one-dimensional symbol string when a few of the particulars are placed in sequence, is new.

DETAILED DESCRIPTION - In M1 when the one-dimensional symbol string is expressed as a sequence string depending on the property values, and two symbol strings and property values are given, then the property value is characterized by expressing the similarity of the sequence **profile** as the LPC cepstrum distance, and estimating it from the one-dimensional symbol string which can be constructed from symbols having unknown property values.

An INDEPENDENT CLAIM is also included for estimating the self-correlation of the property values which determine the characteristics of the nature of a one-dimensional symbol string when a few of the particulars are placed in sequence. The most appropriate property value for the determination of the characteristics of its nature, is found from the native sequence, where a few of the particulars in sequence constitute the one-dimensional symbol string. This is done by finding the time sequence pattern between the one-dimensional symbol string, and symbols which artificially shuffled these randomly, and expressing as a sequence string of the shuffle sequence for the property values of each one-dimensional symbol string consisting of sequences having certain property values; then while comparing the similarity, by expressing it as the LPC cepstrum distance between two symbol strings, then estimating by a genetic algorithm so that the LPC cepstrum distance between the native sequence and the shuffle sequence becomes larger, and estimating its property value from the one-dimensional symbol string which can be constructed from symbols having unknown property values.

USE - To determine the properties of amino acid sequences of **proteins** and the base sequences of genes.

ADVANTAGE - The amino-acid index can be estimated from the sequence data only. It is similar to the hydrophobic index, giving the influence of **protein** folding, and the differences in the three-dimensional structure of the **protein** when there is a good deal of secondary **protein** structure.

Dwg.070

FS CFI EPI

FA AB; ICH

MC CFI: B04-N04; B10-B02; B11-C03B; B12-K04; B05-H09; J04-C01

SEI: T01-J03; T01-J15; T01-J16

L123 ANSWER 6 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-594872 [56] WPIX

DNN NL000-440291 DMC CL000-177635

TI Monitoring differential expression of genes in filamentous fungal cells uses fluorescence-labeled nucleic acids isolated from the cells and a substrate of expressed sequence tags.

DC B04 C06 D16 T01

IN BERKA, R M; CLAUSEN, I G; KAUPPINEN, S; OLSEN, P B; KEY, M W; SHUSTER, J R

FA (NOVO) NOVO NORDISK AS; (NOVO) NOVO NORDISK BIOTECH INC

CYC 59

PI WO 2000056762 A2 20000328 (200056)* EN C07K014-37 <--
 PW: AT BE CH CY DE EE EA EG FI FR GB GH GI GR IE IT KE LS LU MC MW NL
 CA PT SD SE SI SK TJ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BP BY CA CH CN CR CU CZ DE DK DM EE ES
 FI GB GD GE GH GM HP HU ID IL IN IS JF KE KG KP KF KZ LC LK LF LS
 LT LU LV MA MD MG MH MF MN MW MX NO NZ PL PT RG RI SD SE SG SI SF SL
 TJ TM TR TT UA UG US VU ZA ZW

AU 2000039154 A 20001019 (200103) C07K014-37 <--
 ABT WO 2000056762 A2 WI 2000-087781 20000322; AU 2000039154 A AU 2000-39154
 20000522

FDT AU 2000039154 A Based on WO 2000056762

PRAI US 1999-073622 19990122

IC ICN C07K014-37

ICS C12Q001-08; G06F017-30; G06F019-00

AB WO 2000056762 A UPAF: 20001106

NOVELTY - New method for monitoring differential expression of genes in a first filamentous fungal (FF) cell relative to expression of the same genes in one or more second filamentous fungal cells uses fluorescence-labeled nucleic acids isolated from the FF cells and a substrate of expressed sequence tags (EST).

DETAILED DESCRIPTION - Method for monitoring differential expression of genes in a first filamentous fungal (FF) cell relative to expression of the same genes in one or more second FF cells comprises:

(1) adding a mixture of fluorescence-labeled nucleic acids isolated from the FF cells to a substrate containing an array of FF expressed sequence tags (EST) in the array, where the nucleic acids from the first and one or more second FF cells are labeled with different first and second fluorescent reporters respectively; and

(2) examining the array by fluorescence under fluorescence excitation conditions where the relative expression of the genes in the FF cells is determined by the observed fluorescence emission color of each spot in the array in which:

(i) the ESTs in the array that hybridize to the nucleic acids obtained from either the first or the one or more second FF cells produce a distinct first fluorescence emission color or one or more second fluorescence emission colors, respectively; and

(ii) the ESTs in the array that hybridize to the nucleic acids obtained from both the first and the one or more second FF cells produce a distinct combined fluorescence emission color.

INDEPENDENT CLAIMS are also included for the following:

(1) a computer readable medium which has recorded on it an array of FF ESTs for monitoring differential expression of genes in a first FF cell relative to expression of the same genes in one or more second FF cells;

(2) a computer-based system for monitoring differential expression of genes in a first FF cell relative to expression of the same genes in one or more second FF cells comprising:

(a) a data storage device comprising FF ESTs selected from sequences 1-7860 (given in the specification), nucleic acid fragments of sequences 1-7860 or nucleic acid sequences with at least 90% homology to sequences 1-7860;

(b) a search device for comparing a target sequence to a FF EST sequence of the data storage device of (a) to identify homologous sequences; and

(c) a retrieval device for obtaining the homologous sequence of (b);

(3) a substrate comprising an array of FF ESTs for monitoring differential expression of genes in a first FF cell relative to expression of the same genes in one or more second FF cells; and

(4) an isolated nucleic acid sequence comprising any of sequences 1-7860.

USE - The ESTs are used in the methods for monitoring differential expression of genes in a first filamentous fungal (FF) cell relative to expression of the same genes in one or more second filamentous fungal cells (claimed). Monitoring the global expression of genes from FF cells allows the production potential of the microorganisms to be improved. New genes may be discovered, possible **functions** of unknown open reading frames can be identified and gene copy number variation and

stability can be monitored. The expression of genes can be used to study how FF cells adapt to changes in culture conditions, environmental stress, spore morphogenesis, recombination, metabolic or catabolic pathway engineering.

ADVANTAGE - Using ESTs provides several advantages over **genomic** or random cDNA clones including elimination of redundancy as one spot on an array equals one gene or open reading frame, and organization of the microarrays based on **function** of the gene products to facilitate analysis of the results.

Seq. O/O

FS CFI EPI

FA AF; DCN

MC CFI: B04-E03; B04-E05; B04-F03A; B11-C07B3; B11-C08E5; **B12-K04E;**

B12-K04F; C04-E01; C04-E05; C04-F03A; C11-C07B3; C11-C08E5;

C12-K04E; C12-K04F; D05-H05; D05-H09;

D05-H10; D05-H12A; D05-H12B

ESI: T01-J; T01-J05E

TECH UPTX: 20001106

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Sequences: The ESTs are *Acremonium*, *Aspergillus*, *Fusarium*, *Hemicella*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolyposcladium* or *Trichoderma* ESTs. The *Fusarium venenatum* ESTs are selected from sequences 1-3770 (given in the specification), nucleic acid fragments of sequences 1-3770 or nucleic acid sequences with at least 90%, preferably 95% and especially 99.9% homology to sequences 1-3770.

The *Aspergillus niger* ESTs are selected from sequences 3771-4376 (given in the specification), nucleic acid fragments of sequences 3771-4376 or nucleic acid sequences with at least 90%, preferably 95% and especially 99.9% homology to sequences 3771-4376.

The *Aspergillus oryzae* ESTs are selected from sequences 4377-7401 (given in the specification), nucleic acid fragments of sequences 4377-7401 or nucleic acid sequences with at least 90%, preferably 95% and especially 99.9% homology to sequences 4377-7401.

The *Trichoderma reesei* ESTs are selected from sequences 7402-7860 (given in the specification), nucleic acid fragments of sequences 7402-7860 or nucleic acid sequences with at least 90%, preferably 95% and especially 99.9% homology to sequences 7402-7860.

Preferred Method: The hybridization conditions are very low, low, low-medium, medium, medium-high, high or very high stringency conditions.

Preferred Substrate: The substrate comprising an array of FF ESTs may be a glass support with hydrophobic or hydrophilic coating on its surface to which the ESTs are electrostatically bound non-covalently, with each EST at a separate, defined position. The substrate may be a multicell substrate with each cell containing a microarray of ESTs.

TECHNOLOGY FOCUS - BIOLOGY - Preferred Cells: The FF cells are *Acremonium*, *Aspergillus*, *Fusarium*, *Hemicella*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolyposcladium* or *Trichoderma* cells. The 2 or more FF cells are the same cell or different cell, preferably *Fusarium venenatum*, *Aspergillus niger* or *Aspergillus oryzae* cells.

TECHNOLOGY FOCUS - COMPUTING AND CONTROL - Preferred Medium: The computer readable medium is a floppy disk, a hard disk, random access memory (RAM), read only memory (ROM) or CDROM.

L123 ANSWER 7 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-573798 [54] WPIX

DNN 2000-424559 ENC 2000-171175

TI Clustering gene expression datapoints in a computer system using a self-organizing map.

DC B04 B16 T01

IN GOLUB, T F; LANDER, E S; MESIROV, J; TAMAYO, P

PA (WHEB); WHITEHEAD INST BIOMEDICAL RES

CYC 17

PI EP 1337158 A2 20000920 (200054)* EN 39p G06F019-00 ---

F: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT

PO SE SI
 CA 2300639 A1 20000315 (200056) EN G06F019-00 <--
 JP 2000341299 A 20001212 (200104) 34p C12Q001-68
 ADT EP 1037158 A2 EP 2000-302025 20000314; CA 2300639 A1 CA 2000-2300639
 20000314; JP 2000341299 A JP 2000-73166 20000315
 PRAI US 1999-114463 19990315
 IC ICM C12Q001-68; G06F019-00
 ICS C12M001-00; C12N001-00; C12N015-09; G01N033-15; G01N033-50
 ICA G06F017-30
 AB EP 1037153 A 01AB: 20001007
 NOVELTY - A method for clustering gene expression datapoints in a computer system using a self-organizing map, is new.
 DETAILED DESCRIPTION - Method for clustering datapoints (each datapoint is a series of gene expression values) in a computer system, comprises:
 (a) receiving the gene expression values of the datapoints;
 (b) using a self-organizing map (SOM), clustering the datapoints so that datapoints that exhibit similar patterns are clustered together into respective clusters; and
 (c) providing an output indicating the clusters of the datapoints.
 INDEPENDENT CLAIMS are also included for the following:
 (1) a method for grouping datapoints in a computer system, where each datapoint is a series of gene expression values, comprising:
 (i) receiving gene expression values of the datapoints;
 (ii) filtering out any datapoints that exhibit an insignificant change in the gene expression value, so that working datapoints remain;
 (iii) normalizing the gene expression value of the working datapoints;
 (iv) using a SOM, grouping the working datapoints so that datapoints that exhibit similar patterns are grouped together into respective clusters; and
 (v) providing an output indicating the groups of the datapoints;
 (2) a computer apparatus for clustering datapoints, where each datapoint is a series of gene expression values, comprising:
 (i) a source of gene expression values of the datapoints;
 (ii) a processor routine coupled to receive datapoints from the source, the processor routine utilizing a SOM for clustering datapoints so that datapoints that exhibit similar patterns are clustered together into respective clusters; and
 (iii) an output device, coupled to the processor routine, for indicating the clusters of datapoints;
 (3) a computer apparatus for grouping datapoints, where each datapoint is a series of gene expression values, comprising:
 (i) a source of gene expression values of the datapoints;
 (ii) a filter coupled to the source, for receiving the gene expression values and filtering out any of the datapoints that exhibit an insignificant change in the gene expression value, so that working datapoints remain;
 (iii) a normalizing process, coupled to the filter, for normalizing the gene expression value of the working datapoints;
 (iv) a processor routine that is responsive to the normalizing process and utilizes a SOM for grouping the working datapoints such that datapoints that exhibit similar patterns are grouped together into respective groups; and
 (v) an output device, coupled to the processor routine, for indicating the clusters of datapoints;
 (4) a method for assessing expression patterns of two or more genes in cells, where the expression patterns are represented by datapoints, and each datapoint is a series of gene expression values, comprising:
 (i) receiving the gene expression values of the datapoints;
 (ii) using a SOM, clustering the datapoints such that datapoints that exhibit similar patterns are clustered together into respective clusters;
 (iii) providing an output indicating the clusters of datapoints; and
 (iv) analyzing the output to determine the similarities or differences between the expression patterns of the genes;
 (5) a method of determining relatedness of expression patterns of two

or more genes, where the expression patterns are represented by datapoints and each datapoint is a series of gene expression values, comprising:

- (i) receiving the gene expression values of the datapoints;
- (ii) using a SOM, clustering the datapoints such that datapoints that exhibit similar patterns are clustered together into respective clusters;
- (iii) providing an output indicating the clusters of datapoints; and
- (iv) analyzing the output to determine the similarities and/or differences between the expression patterns of the genes, thereby determining the relatedness of the genes;

(6) a method for characterizing expression patterns of genes of a sample having unknown characteristics, where the sample is obtained from an individual and subjected to diagnostic tests, and the expression patterns of the genes for the diagnostic tests are represented by datapoints, and each datapoint is a series of gene expression values across multiple genes for the diagnostic test, comprising:

- (i) receiving the gene expression values of the datapoints from the diagnostic tests;
- (ii) using a SOM, clustering the datapoints such that datapoints that exhibit similar patterns are clustered together into respective clusters;
- (iii) providing an output indicating the clusters of datapoints; and
- (iv) comparing the output of the gene expression patterns of the unknown sample against a control, thereby characterizing gene expression patterns of the sample;

(7) a method of identifying a drug target from the expression patterns of two or more genes from cells, where the expression patterns are represented by datapoints and each datapoint is a series of gene expression values, comprising:

- (i) obtaining cells that express genes;
- (ii) subjecting the cells to an agent or condition for testing the drug target;
- (iii) measuring gene expression from the cells subjected to the agent or condition, and from a control, to obtain the gene expression values;
- (iv) receiving the gene expression values of the datapoints;
- (v) using a SOM, clustering the datapoints such that datapoints that exhibit similar patterns are clustered together into respective clusters;
- (vi) comparing the clusters from the genes that have been subjected to the agents or condition with a control; and
- (vii) providing an output indicating clusters, to thereby determine the drug target;

(8) a drug target identified or identifiable by the method of (7);

(9) a computer-readable product on which is recorded a program loadable into the internal memory of a digital computer and comprising software code portions for performing the steps of the above methods.

USE - The method can be used, e.g. to identify drug targets from the expression patterns of two or more genes and to analyze the relatedness of two or more genes, the unknown function of a gene under known conditions, the effect of unknown conditions on a known gene function or the likelihood of successful treatment by a drug (e.g. for a specific tissue sample).

ADVANTAGE - Using SOMs to cluster gene expression patterns into groups exhibiting similar patterns makes it easy to analyze gene expression data from potentially thousands of genes.

DESCRIPTION OF DRAWING(S) - The figure is a schematic diagram illustrating the principle behind the self-organizing map, in which the initial geometry of nodes in a 3x2 rectangular grid is indicated by solid lines connecting the nodes, datapoints are represented by black dots, the nodes are represented by large circles, and trajectories are represented by arrows.

Dwg.1/6

FS CPI EPI

FA AB; GI; DCN

MC CPI: B04-C01; B04-E01; B04-N04; B11-C08E1; B11-C09;

B12-K04A; B12-K04E; D05-H02; D05-H09;

D05-H11; D05-H17; D05-H18; D05-J

EPI: T01-J

L123 ANSWER 8 OF 73 WPIX COPYRIGHT 2001 PERWENT INFORMATION LTD

AN 2000-07-28 [54] WPIX

DNN N2000-424443 DNE C1000-171170

TI Detection of WT1 gene **functional** mutations and EWS-WT1 gene fusion's by monitoring downstream genes regulated by WT1, useful for diagnosis of neoplasia and for anti-cancer drug screening.

DC B04 B10 S00 T01

IN HAREE, D; LEE, S; CLINEP, J; TPUNG, V

PA AFFY-N. AFFYMETRIX INC

CYC 25

PI EP 1036845 A2 20000920 (200054) EN 23p C120001-68

FI: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI

CA 2296782 A1 20000824 (200054) EN C120001-68

JP 2000368500 A 20001107 (200061) JP C120001-68

US 6177248 B1 20010112 (200107) C120001-68

ADT EP 1036845 A2 EP 2000-10-26 20000215; CA 2296782 A1 CA 2000-2296782
20000219; JP 2000368500 A JP 2000-64155 20000203; US 6177243 B1 US
1999-156301 19990224

PRAI US 1999-156301 19990224

IC ICM C120001-68

ICS CG/H001-01; C12N005-10; C12N015-00; C12N015-00; G01N033-15;
G01N033-50; G10N033-53; G01N033-566; G01N033-574; G06F019-00

ICI C12N005-10; C12P001-91

AB EP 1036845 A UFAP: 20001027

NOVELTY - A method for the detection of WT1 gene **functional** mutations or an EWS-WT1 gene fusion by monitoring expression levels of downstream genes, which are regulated by wild type WT1 and/or EWS genes, is new.

DETAILED DESCRIPTION - Methods for detecting a WT1 gene **functional** mutations or EWS-WT1 gene fusions in target cells comprises:

(1) detecting expression of at least 1 downstream genes of WT1 or one or more downstream genes of an EWS-WT1 fusion in a sample of target cells and reference cells having a wild type WT1 and/or EWS gene (the reference cells are otherwise substantially similar to the target cells, the downstream genes are up- or down-regulated by the wild type WT1 and/or EWS gene); and

(2) comparing the expression of the downstream genes in the target cells and the reference cells (a difference in the expression between the target cells and reference cells suggests a WT1 **functional** mutation or EWS-WT1 fusion in the target cells).

INDEPENDENT CLAIMS are also included for the following:

(a) an in-cell **functional** assay for a WT1 sequence alteration comprising a method as above;

(b) methods for detecting a mutation in a target WT1 gene or a translocation fusing EWS and WT1 genes using a computer;

(c) a method of diagnosing neoplasia of a test cell comprising:

(i) hybridizing a transcription indicator of a test cell to a set of nucleic acid probes (the transcription indicator is chosen from mRNA, cDNA and rRNA, the probes comprise a number of nucleic acid molecules each of which is a portion of a gene which is activated by or repressed by WT1 or EWS-WT1 fusion **protein**);

(ii) detecting amounts of transcription indicator which hybridize to each of the set of probes;

(iii) identifying a test cell as neoplastic if hybridization of the transcription indicator of the test cell to a probe which is a WT1- or EWS-WT1-activated gene is lower than hybridization using a transcription indicator from a normal cell, or hybridization of the transcription indicator of the test cell to a probe which a WT1- or EWS-WT1-repressed gene is higher than hybridization using a transcription indicator from a normal cell;

(d) a method of identifying anti-cancer drugs comprising:

(i) contacting a test compound with a human cell;

(ii) determining the expression of the cell of at least one WT1 or EWS-WT1 up- or down-regulated gene; and

(iii) identifying a test compound as a potential anti-cancer drug if it increases expression of at least one WT1 or EWS-WT1 up-regulated gene or decreases expression of a WT1 or EWS-WT1 down-regulated gene in the human cell.

USE - The methods can be used to diagnose cancers, for drug-screening and to **functionally** analyze mutations involving the WT1 gene. The methods use probes based on genes identified as being regulated by WT1 and/or WT1 fusions to EWS. The methods can be used to determine the genetic status of the gene and to identify which have similar effects on downstream genes.

Dwg.079

ES EPI EPI

FA AB; DCN

MC EPI: B04-C01; B04-E01; B04-E02F; B04-F01; B04-F0100E; B04-H01;

B04-N04; B11-C00E1; B11-C00; B12-K04A3;

B12-K04E; D05-H05; D05-H09; D05-H12A; D05-H12C;

D05-H14; D05-H17A; D05-H17C; D05-H17

EPI: S05-C; T01-J

TECH UPTX: 20001027

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Methods: The downstream genes are transcriptionally regulated by the wild type WT1 gene and the expression of the downstream genes is detected by measuring amounts of transcripts of the downstream genes in the reference and target cells. Amounts of transcripts are measure with a high-density nucleic acid array. The downstream genes comprise at least one WT1 up-regulated gene chosen from natural killer cells **protein** 4 precursor (M59505), folate binding **protein** (M25317), HALPHA44 gene for alpha-tubulin (X06956), heat shock **protein** HSP70B (X51753), 90K product (H17969), heat shock 70 KD **protein** 1 (T66317), amphiregulin (K39404), procollagen-alpha 1 (P5155), beta-migrating plasminogen activator inhibitor 1 (M14063), cysteine protease inhibitor from radiated keratinocytes (X05975), brain natriuretic **protein** (M51766), leukemia virus receptor 1 (GLVR1) (M30559), type 1 cytoskeletal 17 keratin (F71879), tubulin alpha-5 chain (H45051), purine nucleoside phosphorylase (T47964), Gem GTPase (U10550), adrenomedullin (D14874), GPI-anchored urokinase plasminogen activator surface receptor (R36636), tissue type plasminogen activator (K13697), gravin (M96122), jun-B (X51343), elongation factor 1 alpha-2 (X79430), homeotic gene regulator (R16977), clone 9112 (X57548), interferon gamma treatment inducible mRNA (M26683), transmembrane receptor **protein** (Z17127), acidic FGF (X65779), cartilage linking **protein** 1 (X17405), interleukin (IL-11) (X58377) and mitochondrial phosphate carrier **protein** (R49231).

The downstream genes comprise at least one WT1 down-regulated gene chosen from caveolin and elongation factor 1 alpha-2. The downstream genes further comprise p11 or EGFR (endothelial growth factor).

The method further comprises indicating the loss of **function** mutation in the WT1 gene in the target cells if the expression of WT1 up-/down-regulated genes is at least two times less/more in the target cells than in the reference cells.

The downstream genes comprise at least one EWS-WT1 up-regulated gene chosen from Pseudorabies virus nuclear antigen (R60906 and T79475), beta chain of IL-2 receptor (M26062), G1/S-specific cyclin D1 (H20529), neuron-specific gamma-2 enolase (M33649), fusion gene NPM-MLF1 resulting from translocation t(3;5)(q35.1;p34) (L49054), collagen alpha3(IV) chain (H63466), T-lymphocyte specific **protein** tyrosine kinase p61ck(1ck) (U23810), insulin-like growth factor binding **protein** 4 (U20981), cathepsin B (L16510), cystatin C (T51534), dual specific mitogen-activated **protein** kinase C (F42241), neuronal-glial cell adhesion molecule (T53118), FIM-1 proto-oncogene serine/threonine **protein** kinase (H14925), carboxylesterase precursor (R54359), **protein**-tyrosine phosphatase PAC-1 (L11129) and interferon-induced **protein** 6-16 (X02432).

Necplasia in kidney cells or Ewing sarcoma cells can be detected using probes of genes, which are activated or repressed by WT1 or EWS-WT1, respectively. The probes comprise portions of the genes and are preferably attached to a solid support and arranged in an array. Preferably, at least

6000 different genes are used as probes. The WT1 genes in a test cell are sequenced to determine the WT1 genotypic status of the cell.

L123 ANSWER 3 OF 73 WPIX COPYRIGHT 1991 PERWENT INFORMATION LTD
 AN 2000-572101 [53] WPIX
 DNN H2000-423219 DNC C12000-170570
 TI Identifying **peptide** with selected **function**, useful particularly for C-amidated hormones, by screening database for combination of nucleic acid and amino acid sequences.
 DC B04 I016 T01
 IN BERGE, G; CAMAFA Y FERPEF, J A; SOLE, C; MARTINEZ, J; THURIEAU, C
 FA CHEN, CNFC CENT NAT RECH JCI; SCRO SCBAS SOC CONTRLS RECH & APPL SCI
 CYC 47
 PI WO 1000050636 A1 10000441 (1000441)* FR -9p; C120001-64
 EW: AT BE CH CY DE DK EA ES FI FR GP GH GM GR IE IT KE LS LU MC MW NL
 OA IT SD SE SI SK TJ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BE BY CA CH CN CU CE DE DK EE ES FI GB
 GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LE LS LT LU
 LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
 TT UA UG US UZ VN YU ZA ZW
 ADT WO 1000050636 A 20000014 (200063) C120001-64
 WO 1000050636 A1 WO 1000-PR100 10000224; AU 2000029209 A AU 2000-29209
 20000224
 FDT AU 2000029209 A Based on WO 1000050636
 PRAI US 1000-10025 19900224
 IC ICM C120001-68
 ICS G06F017-30
 AB WO 1000050636 A UPAB: 20001023
 NOVELTY - Identifying a **peptide** (I) having a particular **function** comprising preparing a database of polynucleotides (PN) and **polypeptides** (PP) of unknown **functions**, screening the database for a combination (A) of nucleotides or amino acids indicative of (I) with a particular **function**, and identifying PN and PP which contain (A), is new.
 DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a similar method for identifying **peptide** precursors (II) having an amidated C-terminus.
 USE - The method is used to identify precursor **peptides** with an amidated C-terminus, especially **polypeptide** hormones, for studying physiologically active substances.
 ADVANTAGE - The method is not limited to (I) expressed by a particular strain, does not depend on physical measurements (isoelectric point or solubility), can be applied to **proteins** which are not apparently related by physical properties, and can identify candidate (I) with very low mutual homology. It can be performed with readily available databases and computers.
 Dwg.0/0
 FS CPI EPI
 FA AB; DCN
 MC CPI: B04-E01; B04-N04; B11-C08; B12-K04E;
 B12-K04F; D05-H09
 EPI: T01-H05B
 TECH UPTX: 20001023
 TECHNOLOGY FOCUS - BIOLOGY - Preferred Process: To identify (II), the database contains both PN and corresponding PP sequences, especially with PP being derived by translation from PN, and each PN is translated into three PP (one for each reading frame). The database also includes annotations related to the sequence, especially origin, source, characteristics and references. The screening step additionally includes location of the AUG start codon and verification that no stop codon is present between this AUG and the end of the coding region for (II). Once PP/PN have been identified, they are compared with sequences of known **function** and those with unknown **function** are retained. These are then examined for similarity with sequences of known **function**, and those for which no similarity can be found are selected for further analysis, or as candidate sequences. Optionally the

selected PF sequences are synthesized and their properties evaluated.
 Preferred Materials: To identify (II), the combination of nucleotides is
 Y1-Y2-Y3-Y4-Y5
 Y1 = 0-12 nucleotides;
 Y2 = codon for Gly;
 Y3 and Y4 = codons for Arg or Lys;
 Y5 = 0-12 nucleotides.

L123 ANSWER 10 OF 13 WFIX COPYRIGHT 2001 DEEWENT INFORMATION LTD
 AN 2000-85-425 [51] WFIX
 DNN BL000-413204 INC 02000-160375
 TI Identifying mutations, useful e.g. for diagnosing cancer or predisposition
 to it, by mathematical analysis of output patterns from DNA microarrays.
 DC P04 015 004 T01
 IN GULATI, S
 PA (VIAL-10) VIALOGY CONF
 CYC 36
 PI WO 2000051056 A2 20000831 (200031) EN 37p G06F019-00 ---
 FW: AT EE CH CY DE DF EA EG FI FF GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SS TC UG UW
 W: AE AL AM AT AU AG BA BB BG BF BY CA CH CN CP CU CZ DE DK DM EE ES
 FI GB GD GE GH GI HF HU ID IL IN IS JP KE KG KP KF KZ LC LK LR LS
 LT LU LV MA MD ME MF MH MI MM MN MO NP NZ PL PT RG RU SE SG SI SK SL
 TM TN TR TT TC UA UG US UZ VN YU ZA ZW
 US 614,061 A 20001107 (200031) G06F019-13 ---
 AU 2000033686 A 20000914 (200063) G06F019-00 ---
 ADT WO 2000051056 A2 WO 2000-024106 20000217; US 61426-1 A US 1999-253792
 19990211; AU 2000033686 A AU 2000-33636 20000217
 FDT AU 2000033686 A Based on WO 2000051056
 PRAI US 1999-253792 19990211
 IC ICM G06F015-18; G06F019-00
 AB WO 2000051056 A UPAB: 20001016
 NOVELTY - A biochip output pattern (OP) is analyzed to identify mutations
 on biological samples applied to it. The OP is tessellated and a stimulus
 pattern (SP) associated with known mutations is generated. A resonance
 pattern (RP), of resonance between SP and tessellated OP, is generated and
 interpreted to yield confirmed mutations.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
 following:
 (1) preconditioning the OP of a biochip, comprising:
 (a) tessellating the output pattern to match a predetermined stimulus
 pattern yielding a tessellated output pattern;
 (b) extracting local parameters from the tessellated output pattern;
 (c) determining if a degree of amplitude wandering representative of
 the local parameters is within an allowable generator **function**
 limit; and
 (d) if not, renormalizing the tessellated output pattern to match
 spectral properties of the stimulus pattern and repeating (b)-(d);
 (2) performing a convergent reverberant dynamics resonance analysis
 on the OP of a biochip to identify mutations, comprising:
 (a) determining resonance dynamics relaxation values based on the
 preconditioned output pattern and resonance stimulus;
 (b) filtering the dynamics relaxation values using ensemble boundary
 and CSR filters to yield a second set of values;
 (c) applying bulk property estimators to the dynamics relaxation
 values to yield a third set of values;
 (d) evaluating the second and third sets of values to determine if
 resonance convergence has been achieved; and
 (e) determining if dynamic paralysis has occurred, and repeating the
 method if it has;
 (3) system for analysing OP of a biochip to identify mutations
 comprising:
 (a) a tessellation unit operative to tessellate the output;
 (b) a stimulus pattern generation unit;
 (c) a resonance pattern generation unit and
 (d) a resonance pattern interpretation unit; and

- (4) system for performing method (2), comprising:
 (a) a determination unit;
 (b) a filter to filter dynamics relaxation values using ensemble boundary and CSP filters;
 (c) an estimator unit;
 (d) an evaluation unit; and
 (e) a paralysis detection unit.

USE - The method is used to identify mutations, particularly for diagnosis of disease (e.g. cancer and acquired immune deficiency syndrome) and to identify susceptibility to disease.

ADVANTAGE - Tessellation of OP improves the repeatability of the analysis.

Swg.0/4

FS CHI EPI

FA AB; DCN

MC CHI: B04-E01; B04-N04; E11-C03; B12-K04A1;

D05-H09; D05-H13; J04-C03

EPI: T01-J

TECH

UPTX: 20001016

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Process: OP is determined from a microarray comprising many cells each with a set of identical immobilized oligonucleotides, different from those in all other cells, particularly a dot spectrogram. Tessellation comprises amplifying highly local morphological variations in OP, and generation of SP is based on Quantum Expressor **Functions** (QEF). OP is tessellated to match the morphological characteristics of QEF. Optionally local parametrics (LP) are isolated from the tessellated OP and a degree of amplitude wandering, representative of LP, is defined. If this degree is not within a predetermined allowable generator **function** limit, the tessellated OP is renormalized to match further spectral properties of the resonance pattern. LP are representative of an integrated density of states within each region of the tessellated OP, and the degree of amplitude wandering is determined by applying a Palm distribution to develop generators for estimation of stochastic wandering. Optionally the tessellated OP and SP are transformed to a metrically transitive random field, optionally followed by renormalization of the tessellated OP. Generation of SP involves selection of a subset of mutations and selection of a subset of nonlinear QEF, then transforming the QEF and tessellated OP into phase space. SP is generated by iterative processing of OP by performing a convergent reverberation to produce a resonance pattern that represents resonance between a selected QEF and the tessellated OP until a predetermined degree of convergence (DC) is achieved between resonance in SP and that expected for the set of mutations. Optionally the resonance dynamics analysis method includes filtering the diagnostic conditions identified by the convergent reverberant dynamics analysis based on clustering properties, and a diagnostic decision is made based on these conditions. If the decision is negative, the availability of an alternative is determined, and if none is available then a new subset of mutations is chosen. The biological sample is DNA, RNA, **proteins**, **peptide**-nucleic acid, or samples from targeted nucleic acid amplification.

L123 ANSWER 11 OF 73 WPIN COPYRIGHT 2001 PERVENT INFORMATION LTD

AN 2000-558335 [51] WPIN

INN NL000-413159 INC 20000-160301

TI Dynamic storage, retrieval and analysis of experimental data e.g cell biological studies and drug discovery using a graphical user interface to represent biological entities and relationships.

EC B04 D16 T01

IN HARRINGTON, C C; CHU, L; TAYLOR, D L; WANG, J

PA (CELL-N) CELLCOMICS INC

CYC 90

FI WO 2000049540 A1 20000824 (200001)* EN 79p GO(F017-50) ---

FW: AT BE CH CY LE DK EA ES FI FF GR GH GM GR IL IT KE LS LU MC MW NL

OA PT SD SE SL SZ TZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CP CU CZ DE DK EM EE ES

FI GR GD GE GH GI HF HU ID IL IN IS JP KE KG KP KR KS LC LK LR LS
 LT LU LV MA MD MG MF MN MW MX ND NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TC UA US UE VN YU ZA ZW

ADT AU 2000030027 A 20000904 (200103) G06F017-50 ---
 WO 2000049540 A1 WO 2000-084371 20000218; AU 2000030027 A AU 2000-30027
 20000218

FDT AU 2000030027 A Based on WO 200049540

PRAI US 1999-129-01 19990219

IC ICM G06F017-50

ICS G06F017-30; G06F019-00

ICI G06F159:00

AB WO 20004954 A UPAB: 20001016

NOVELTY - A method for dynamic storage, retrieval and display of experimental information with determined relationships, is new.

The method uses a graphical user interface (64) from which shapes (80, 84, 86, 88, 100, 102) and arrows (92, 104, 106, 108, 110, 112) representing biological entities and transformations respectively, can be input and edited. Multi-dimensional information based on a predetermined, but expandable, hierarchy is input to relate the information to additional information, e.g. from the Internet.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for displaying experimental information with determined relationships from a remote computer; and

(2) a system for dynamically storing retrieving and displaying of experimental information with determined relationships.

USE - The method and system is useful for storing, retrieving and analyzing experimental information for use in cell biological studies and drug discovery.

ADVANTAGE - The system allows easy storage, retrieval and analysis of biological information associated with biological pathways. It can access hierarchical information associated with biological pathways from **multiple** private and public databases.

DESCRIPTION OF DRAWING(S) - The figure is a block diagram showing a screen display of a graphical user interface used to create, store and analyze biological pathways with determined relationships.

graphical button for selecting a shape 66

graphical button for selecting an arrow 68

graphical button for selecting a cell organelle or compartment 70

outline of a cell 72

an outline of a cell membrane 76

other graphical buttons 74, 80, 82, 84, 86, 88

Dwg.3/11

FS CPI EPI

FA AB; GI

MC CPI: B04-F01; B11-C08; B12-K04; D05-H09

EPI: T01-J05B2B; T01-J05B4F; T01-J05B4P; T01-J06A1; T01-J15X

TECH OPTX: 20001016

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Method: Information associated with the series of shapes interconnected with arrows as a biological pathway with determined relationships, is saved in a database. The pathway defines a hierarchical representation of a biological **function** with determined relationships between the entities and transformations. A computer readable medium stores instructions causing a central processing unit to execute the method. The biological entity represented by a shape may be a cell, a sub-component of a cell or an aggregation of a number of cells. The entities may include active or inactive entities, entity inhibitors, factors exchanged between entities or intermediate entity transformation products. The arrows represent biological transformations between entities. The transformations may include transcription factor activation, cellular hypertrophy, **protein** kinase activation, protease activation, gene expression, receptor activation, apoptosis, internalization of cell surface receptor **proteins**, mitochondrial potential, neurite outgrowth, cell viability or mitotic index for a sub-component of a cell, a cell or cell aggregation. Additional information inputted may be a component view, a

morphology of the entity, an electron microscope photograph, a fluorescent view of the entity, basic information, site information, **function** information, enzyme information, reaction information, transport system information or a pathway view.

L123 ANSWER 12 OF 73 WPIX COPYRIGHT 2001 DEPWENT INFORMATION LTD

AN 2000-548566 [50] WPIX

CR 2000-578283 [50]

DNN H2000-406540 DMC 2000-164107

TI Unencrypting traits using splice gene sequences.

DC R04 C06 P16 P17 T01

IN BERENDES, R R; CAKE, B; LACHNER, M; NESS, J F; PAITEN, P A; YAMAMOTO, T

FA MAXY-NO MAXYGEN INC

CYC 01

PI WO 2000052146 A2 2000052146 (2000052146) * EN 76p C12N009-00

PW: AT BE CH CY DE DK EA EG FI FF GB GH GM GR IE IT PE LS LU MC MW NL

OA FT SD SE SL SS TS UG CW

W: AE AL AM AT AU AZ BA BE BG BR BY CA CH CN CR CU CZ DE DK DM EE ES

FI GB GD GE GH GI HJ HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS

LT LJ LV MA MD MG ME MN MW MX NO NZ PL PT PU RU SD SE SG SI SK SL

TJ TM TR TT TZ UA US UZ VN YU ZA ZW

AT 2000053919 A 2000052146 (2000052146)

C12N009-00

ADT WO 2000052146 A2 WO 2000-055443 2000052146; AU 2000053919 A AU 2000-53919 2000052146

FDT AT 2000053919 A Based on WO 200052146

PRAI US 1999-164618 19991110; US 1999-122943 19990305; US 1999-142299

19990700; US 1999-164617 19991110

IC BOM C12N009-00

ITS A01H001-00; A01H005-00; C12N009-14; C12N015-10; C12N015-02;

C12N015-01; G06F017-50

AB WO 200052146 A CPAB: 2000052146

NOVELTY - Methods of unencrypting trait encrypted gene sequences to provide unencrypted RNA and **proteins**, are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a method (I) of unencrypting trait encrypted gene sequences to provide at least 1 unencrypted RNA or **polypeptide**, comprising:

(a) providing a number of split gene sequences (3rpl) each of which comprises a subsequence of a genetic element;

(b) transcribing the split gene sequences to provide a number of RNA segments; and

(c) trans-splicing at least 2 of the RNA segments together to provide at least 1 unencrypted RNA; or alternately

(d) translating the RNA segments to provide a number of **polypeptide** segments and trans-splicing at least 2 of the **polypeptide** segments together to provide at least 1 unencrypted

polypeptide;

(2) parental organisms (II) and progeny organisms (III) produced via (I);

(3) a vector produced via (I);

(4) a method (III) of unencrypting engineered genetic elements to provide at least 1 unencrypted **functional polypeptide**, comprising:

(a) producing an engineered genetic element corresponding to an encoded **functional polypeptide**;

(b) producing a second engineered genetic element corresponding to a second encoded **polypeptide** which is non-functional in the absence of modification by the first **polypeptide**;

(c) mixing the engineered genetic elements;

(d) expressing the genetic elements to produce their encoded **polypeptides**; and

(e) modifying the second **polypeptide** with the first to produce a **function** second **polypeptide** and therefore at least 1 unencrypted **polypeptide**;

(5) the first and second genetic elements produced via (III);

(6) the first and second **polypeptides** produced via (III);

- (7) host cells and parental and progeny organisms produced via (III);
- (8) vectors produced via (III);
- (9) a composition (IV) comprising 1 or more libraries of 2 populations of split genes, the libraries collectively comprising a number of split gene sequence member types in which combinations or subcombinations of the split gene sequence member types collectively correspond to at least 1 complete genetic element;
- (10) a composition (V) comprising 1 or more libraries of 2 populations of enhancer-linked split gene sequences, the libraries collectively comprising a number of enhancer-linked split gene sequence member types, each regulated by a different trans-acting transcription factor, in which combinations or subcombinations of the enhancer-linked split gene sequence member types collectively correspond to at least 1 complete genetic element;
- (11) a method (VI) for recombining non-overlapping gene sequences, comprising:
- (a) producing a number of non-overlapping gene sequences each corresponding to a different subsequence of a genetic element;
 - (b) producing a number of gap nucleic acid sequences each of which overlaps 1 or more of the non-overlapping gene sequences; and
 - (c) recombining the non-overlapping gene sequences with the gap nucleic acids to provide recombined non-overlapping gene sequences;
- (12) a composition (VII) comprising 1 or more libraries of gap nucleic acids, comprising a number of gap nucleic acid member types, each of which comprises a subsequence identity or is complementary with at least 2 split gene sequence member types; and
- (13) an integrated system (VIII) comprising a computer or computer readable medium, comprising a data set corresponding to a set of character strings corresponding to a set selected from split gene sequences, enhancer-linked split gene sequences, trans-acting transcription factor sequences, engineered genetic elements, non-overlapping gene sequences and gap nucleic acids.

USE - The methods are used for unencrypting trait encrypted gene sequences to provide unencrypted RNA and **proteins**.

Dwg.0/8

FS CFI EPI GMP1

FA AB; DCN

MC CFI: B04-C01; B04-E01; B04-F0100E; **B04-N0400E**; B11-C08E;
 B11-C09; **B12-K04E**; B14-S03; C04-C01; C04-E01; C04-F0100E;
C04-N0400E; C11-C08E; C11-C09; **C12-K04E**; C14-S03;
 D05-C13; D05-H02; D05-H08; **D05-H09**; D05-H12; D05-H14;
 D05-H17; D05-H18
 EPI: T01-J15

TECH UPTX: 20001010

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Methods: In (I) the RNA segments comprise trans-splicing introns and the **polypeptide** segments comprise trans-splicing inteins. (I) further comprises selecting at least 1 unencrypted RNA or **polypeptide** for a desired trait or property. At least 1 of the unencrypted **polypeptides** is a full length **protein**. (I) further comprises translating an unencrypted RNA to provide at least 1 additional unencrypted **polypeptide** (at least 1 of which is a full length **protein**), which is/are then selected for a desired trait or property. At least 1 step occurs in vivo or in vitro. At least 1 of the split gene sequences is cDNA. The first set of split gene sequences is produced by mating a first parent organism (with a second group of split gene sequences (Grp2)) with a second parent organism (with a third group of split gene sequences (Grp3)) to produce a progeny organism comprising at least 1 split gene sequence from the second and third groups (Grp2 and Grp3) to provide the first group of split gene sequences (Grp1). The transcribing step comprises transcribing at least 1 of the Grp2 sequences and at least 1 of the Grp3 sequences to provide the RNA segments. The method further comprises selecting at least 1 progeny organism for a desired trait or property therefore selecting at least 1 unencrypted RNA which is then translated to provide a second unencrypted **polypeptide** (at least 1 of which is a full length **protein**).

) which is selected for a desired trait or property.

(II) are either animals, plants bacteria or fungi (especially a yeast), and are preferably plants selected from the genera *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Euphorbia*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Cleome*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemexia*, *Polygonum*, *Panicum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browallia*, *Lolium*, *Malus*, *Apium*, *Gossypium*, *Viola*, *Lathyrus*, *Lupinus*, *Pachyrhizus*, *Wisteria* and/or *Stizolobium*. In particular, they are crop plants selected from the genera *Aceratis*, *Phleum*, *Lactyllis*, *Sorghum*, *Setaria*, *Uro*, *Cynoe*, *Triticum*, *Sesale*, *Avena*, *Hordeum*, *Saccharum*, *Poa*, *Festuca*, *Stenotaphrum*, *Cynodon*, *Coix*, *Olyrae*, *Pharosa*, *Glycine*, *Cicer*, *Inaseplus*, *Lens* and/or *Arachis*. (II) may be corn, rice, cotton, soybean, sorghum, wheat, oats, barley, millet, sunflower, rapeseed, canola, peas, beans, lentils, peanuts, yam beans, cowpeas, velvet peas, clover, alfalfa, lupine, vetch, lotus, sweet clover, wisteria and/or sweet pea.

At least 1 parental organism comprises a number of enhancer-linked split gene sequences, each comprising a subsequence of the genetic element linked to an enhancer sequence. The first parental organism comprises at least 1 trans-acting transcription factor sequence which is unlinked to the first group of enhancer-linked split gene sequences and the second organism comprises a second group of enhancer-linked split gene sequences each comprising a subsequence of the genetic element linked to a second enhancer sequence. The second parental organism also comprises a second trans-acting transcription factor sequence which is unlinked to the second group of enhancer-linked split gene sequences.

The progeny organism comprises at least 1 of the first group of enhancer-linked split gene sequences, at least 1 trans-acting transcription factor sequence, at least 1 of the second group of enhancer-linked split gene sequences, at least 1 of the second trans-acting transcription factor sequences. At least 1 of the first and second enhancer-linked split gene sequences are transcribed to produce the RNA segments (at least 1 of the first group of enhancer-linked split gene sequences is regulated by the second trans-acting transcription factor and at least 1 of the second group of enhancer-linked split gene sequences is regulated by the first trans-acting transcription factor).

The method further comprises selecting the progeny organism for a desired trait to select an unencrypted RNA which is then translated to produce unencrypted **polypeptides** (at least 1 of which is a full length **protein**) which may then be selected for a desired trait.

At least 1 of the enhancer-linked split gene sequences and the trans-acting transcription factors are cDNA. The split gene sequences are preferably subsequences of toxic genes which are spliced together and expressed in the progeny to produce a toxic **polypeptide** which renders the progeny incapable of reproducing if it is male but capable of reproduction if the progeny is female and vice versa. In the male is incapable of reproduction, the female progeny can reproduce to produce hybrid progeny organisms which do not express the toxic gene and vice versa if the female progeny are incapable of reproduction.

The first group of split gene sequences (Grp1) is produced by infecting a host organism comprising Grp2 with a vector comprising Grp3 to produce a transfected organism comprising at least 1 from each of Grp2 and Grp3. At least 1 of the vectors may be a virus.

In (III), the modification of the second non-functional

polypeptide comprises glycosylation, proteolysis, farnesylation, cholesterol esterification, acetylation, methylation, phosphorylation and/or dephosphorylation. At least 1 step may occur in vivo or in vitro. The engineered genetic elements may be cDNA.

The first engineered genetic element encodes biotin ligase and the second encodes an engineered biotin dependent glyphosate resistance **polypeptide**. The mixing step comprises mating parental organisms comprising the first or second genetic elements to produce progeny comprising both of the engineered genetic elements. The first and second **proteins** are then expressed by the progeny. The parental organisms

are as described above.

Host organisms comprising the first engineered genetic element are infected with a vector encoding the second to produce a organism comprising both (alternatively, a host comprising the second may be infected with a vector comprising the first genetic element), the genetic elements may then be expressed in progeny.

The vector is preferably a virus.

Method (VI) further comprises:

(i) selecting the recombinant non-overlapping gene sequences for at least 1 desired property;

(ii) recombining the recombinant non-overlapping gene sequences; and

(iii) repeating the selection and recombination steps until a desired recombinant genetic element is obtained.

The non-overlapping gene sequences are derived from a cry3Bb gene and the gap nucleic acid sequences are derived from a cryIba, cryI0a and/or a cryIIa gene. At least 1 step may occur in vivo or in vitro.

Preferred Compositions: In (IV) at least 2 populations comprise homologous genetic elements.

In (V), a trans-acting transcription factor from 1 population of enhancer-linked split gene sequences regulates the enhancer-linked split gene sequences of the other.

Preferred System: (VIII) further comprises a sequence search and comparison set for searching for specified nucleic acid sequences. It also comprises an automatic sequencer coupled to an output from the computer or computer medium which accepts instructions from the computer or medium which direct sequencing of sequences selected from split gene sequences, enhancer-linked split gene sequences, trans-acting transcription factor sequences, engineered genetic elements, non-overlapping gene sequences and gap nucleic acids. It may also comprise an automatic synthesizer coupled to an output from the computer or computer medium which accepts instructions from the computer or medium which direct synthesis of the set selected from split gene sequences, enhancer-linked split gene sequences, trans-acting transcription factor sequences, engineered genetic elements, non-overlapping gene sequences and gap nucleic acids. (VIII) further comprises 1 or more robotic control elements for incubating, denaturing, hybridizing and elongating a set of recombinant non-overlapping gene sequences and gap nucleic acids and/or a detector for detecting a nucleic acid produced by elongation of the set of recombinant non-overlapping gene sequences and gap nucleic acids, or an encoded product of them.

L123 ANSWER 13 OF 73 WPIX COPYRIGHT 2001 DEWENT INFORMATION LTD

AN 2000-548599 [50] WPIX

DNN H2000-405865 DDC C1000-163688

TI Streptococcus pneumoniae fabZ **proteins** useful for diagnosing and treating microbial infections.

DC B04 D16 S03 T01

IN KONSTANTINIDIS, A; RUSSELL, R B; WARREN, P V

PA (SMK) SMITHKLINE BEECHAM CORP

CYC 19

PI WO 2000030602 A1 WO 20000602 (200050)* EN 51p A61K035-74

FW: AT BE CH CY DE DK ES FI FR GR GR IE IT LU MC NL PT SE

W: JP

ADT WO 2000030602 A1 WO 1999-020435 19991109

PRAI US 1998-196133 19981119

IC ICM A61K035-74

I23 A61K035-01; A61K035-10; C07K016-00; C12N001-00; C12N015-00;

C12N016-31; C12P021-01; C12Q001-08; G01K033-63; G06F017-30

AB WO 200030602 A UPAB: 20001010

NOVELTY - Nucleic acids (I) encoding a **polypeptide** (II)

designated fabZ, a member of the fatty acid biosynthetic pathway family of **proteins** from Streptococcus pneumoniae.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) an isolated polynucleotide (I), comprising either:

(a) a polynucleotide comprising a sequence encoding a

polypeptide that has 70-95% identity with a fully defined 140

amino acid sequence (IIa) (given in the specification);

(b) a polynucleotide comprising a sequence that has 70-95% identity to a polynucleotide sequence encoding (IIa) over its entire length;

(c) an isolated polynucleotide comprising a sequence that has 70-95% identity to a defined 423 nucleotide sequence (Ia) given in the specification;

(d) a polynucleotide which encodes (IIa)

(e) a polynucleotide comprising (Ia);

(f) a polynucleotide obtained by screening a library under stringent conditions with a probe comprising (Ia);

(g) an isolated polynucleotide sequence encoding a mature fabZ

protein of *S. pneumoniae*; and/or

(h) a sequence complementary to (a)-(g);

(2) a **polypeptide** selected from:

(a) a **peptide** comprising an amino acid sequence having 70-95% identity to (IIa) over its entire length;

(b) a **peptide** comprising (IIa);

(c) a **peptide** that is (IIa); and/or

(d) a **polypeptide** encoded by a recombinant polynucleotide comprising (Ia);

(3) an antibody (III) antigenic for (Ia);

(4) a method (IV) for the treatment of an individual:

(a) in need of enhanced activity or expression of (II), comprising:

(i) administering an agonist of (II); and/or

(ii) providing the individual with (II) to produce the

polypeptide (and its activity) in vivo; or

(b) in need of inhibited activity of (II), comprising:

(i) administering an antagonist of (II); and/or

(ii) administering a nucleic acid molecule that inhibits the expression of (I); and/or

(iii) administering a **polypeptide** that competes with the

polypeptide for its ligand, substrate or receptor;

(5) a method (V) for diagnosing or prognosing a disease or a susceptibility to a disease in an individual related to expression or activity of (II), comprising:

(a) determining the presence or absence of a mutation in the sequence (IIa) in the **genome** of the individual; and/or

(b) analyzing and quantifying the presence of the **polypeptide** (II) in a sample from the individual;

(6) a method (VI) for screening to identify compounds that activate or inhibit the **function** of (II), comprising:

(a) measuring the binding of a candidate compound (CC) to (II) or to cells or membranes bearing (II) (of a fusion protein of (II)) using a label directly or indirectly associated with the CC;

(b) measuring the binding of a CC to (II) or to cells or membranes bearing (II) (of a fusion protein of (II)) in the presence of a labeled competitor;

(c) testing whether a CC results in a signal generated by activation or inhibition of (II), using detection systems appropriate to the cells or membranes bearing (II);

(d) mixing a CC with a solution containing (II) and measuring the activity of the polypeptide in the mixture, and comparing that activity to a standard;

(e) detecting the effect of a CC on the production of mRNA encoding (II) and (II) in cells using, for example, an enzyme linked immunosorbent assay; and/or

(f) a method comprising:

(i) contacting (II) with the CC and assessing their interactions ;

and

(ii) determining whether the compound interacts with and activates or inhibits the activity of (II) by detecting the presence or absence of a signal generated from the interaction of the compound and polypeptide);

(7) an (ant)agonist (VII) of the expression or activity of (I);

(8) an expression system (VIII) comprising the polynucleotide (I) and capable of expressing (II) when present in a host cell;

(9) a host cell (IX) comprising (VIII) or a membrane expressing (II);

(10) a process (XI) for producing a polypeptide comprising culturing (IX);

(11) a process (XI) for producing (IX) or a membrane of (IX) expressing (II), comprising transforming/transfecting a cell with (VIII), so that the cell expresses (II);

(12) a computer readable medium (XII), upon which is stored:

(a) (Ia) or sequence(s) comprising (Ia) (and/or other polynucleotide sequences);

(b) (IIa) or sequence(s) comprising (IIa) (and/or other polypeptide sequences);

(c) a data set representing (Ia);

(d) a data set representing polynucleotides encoding (IIa);

(13) a computer based method (XIII) for performing homology identification, comprising providing a sequence comprising (Ia) in a computer readable medium and comparing that sequence to other polypeptides and polynucleotide to identify sequence homology;

(14) a computerized method (XIV) for polynucleotide assembly, comprising providing a nucleic acid comprising (Ia) in a computer readable medium and screening for at least 1 overlapping region between that polynucleotide sequence and a second polynucleotide sequence; and

(15) a polynucleotide (XV) of the formula:

$$5' \text{ X-(E1)m-(E2)-(E3)n-Y } 3'$$

X = H, a metal or a modified nucleotide residue or together with Y defines a covalent bond;

Y = H, a metal or a modified nucleotide residue or together with X defines a covalent bond;

E1 and E3 = any nucleic acid residue or modified nucleic acid residue;

E2 = the nucleotide sequence (Ia); and

m and n = 0-1000.

ACTIVITY - Bactericidal.

MECHANISM OF ACTION - Vaccine.

No data given.

USE - (I) and (II) may be used in the prevention, treatment and diagnosis of diseases associated with fabZ expression and Streptococcal infection.

(I) or (II) may be administered to treat diseases by rectifying mutations or deletions in a genome that affect the activity of fabZ by expressing inactive proteins or to supplement the production of fabZ polypeptides. Additionally, (I) may be used to produce fabZ, according to standard recombinant DNA methodology, by inserting the nucleic acids into a host cell and culturing the cell to express the protein (either in vitro or in vivo). Antisense nucleic acid molecules may be administered to down regulate fabZ expression by binding with the cells own fabZ genes and preventing their expression.

(I) and complementary sequences may be used as probes in diagnostic assays to detect the presence of fabZ in samples.

The polypeptides may be used as antigens in the production of antibodies against fabZ and in assays to identify modulators of fabZ expression and activity. The anti-fabZ antibodies and fabZ antagonists may also be used to down regulate fabZ expression and activity. They may be used to treat S. pneumoniae infections.

The anti-fabZ antibodies may also be used as diagnostic agents for detecting the presence of fabZ polypeptides in samples.

Dwg.0/0

FS CPI EPI

FA AB; DCN

MC CPI: B04-B04C2; B04-B04M; B04-C01G; B04-E03F; B04-E04; B04-E05; B04-E06; B04-E08; B04-F0100E; B04-G07; B04-N03A0E; B11-A; B11-C07A4; B11-C08E; B11-C09; B12-K04A4; B12-K04E; B12-K04F; B14-A01E2; B14-S03; B14-S11B; D05-A01A4; D05-A01E; D05-A12B; D05-C12; D05-H04; D05-H07; D05-H08; D05-H09; D05-H11; D05-H12A; D05-H12D; D05-H12E; D05-H14; D05-H17A5; D05-H17A6; D05-H18

EPI: S03-E148; T01-J05B

TECH UPTX: J0001010

TECHNOLOGY FOCUS - BIOLOGY - Isolation: (I) and (II) were isolated from S.

pneumoniae.

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation: (I) and (II) encode may be prepared by standard methods.

L123 ANSWER 14 OF 72 WHIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-543000 [49] WHIX

DNN 2000-461327 DDC C2000-161324

TI Polynucleotides comprising polymorphic variants of a reference sequence for tumor necrosis factor receptor 1 (TNFR1), useful for studying the biological function of TNFR1 and identifying drugs targeting the **protein** for treating cancer.

DC B04 D16 T01

IN CHEW, A; NANDABALAN, K; SCHULZ, V P; STEPHENS, J C

FA (CHEW-1) CHEW A; (NENA-1) NAINAIDANCE PHARM INC; (NAND-1) NANDABALAN K; (SCHU-1) SCHULZ V P; (STEP-1) STEPHENS J C

CYC 99

PI WO 2000050436 A1 20000831 (200049)* EN 74p C07H01-02

PW: AT BE CH CY DE DK EA ES FI FR GB GR GM GR IE IT JE LS LU MC MW NL

QA PT SD SE SL SG SZ US SW

W: AE AL AM AT AU AZ BA BB BG BE BY CA CH CN CR CU CE DE DK DM EE ES

FI FR GE GR HH HU IL IN IS JP KE KG KP KR KZ LC LK LR LS

LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL

TM TN TR TT TZ UA UB US UE VN YU ZA SW

AU 2000036029 A 20000014 (200001) C07H01-02

ADT WO 2000050436 A1 WO 2000-034666 20000213; AU 2000036029 A AU 2000-36029 20000213

FDT AU 2000036029 A Based on WO 2000050436

PRAI US 1999-121314 19990213

IC 1EM C07H01-01

ICS A61N043-04; C12P01-08; C12P01-04; G06F017-00

AB WO 2000050436 A UPAP: 20001006

NOVELTY - An isolated polynucleotide (N1), or its complement, comprising a polymorphic variant of a reference sequence for tumor necrosis factor receptor 1 (TNFR1) gene, comprising at least 1 polymorphism selected from a thymine at PS (polymorphic site) 1, PS5, PS6, PS9 and PS10, adenine at PS2, PS4, PS7 and PS11 guanine at PS3, and cytosine at PS8 and PS12, is new.

DETAILED DESCRIPTION - An isolated polynucleotide (N1) comprising a polymorphic variant of a reference sequence for tumor necrosis factor receptor 1 (TNFR1) gene, comprising a thymine at PS1, PS5, PS6, PS10, adenine at PS2, PS4, PS7 and PS11 guanine at PS3, and cytosine at PS8 and PS12, is new. The reference sequence comprises defined 1139, 1358, or 2254 base pair (bp) sequences (given in the specification).

INDEPENDENT CLAIMS are also included for the following:

(1) a recombinant organism transformed or transfected with N1, where the organism expresses a TNFR1 **protein**;

(2) an isolated polynucleotide (N2) comprising a polymorphic variant of a reference sequence for the TNFR1 cDNA, where the reference sequence comprises a defined 368 bp sequence (given in the specification), comprising a polymorphism selected from guanine at nucleotide 36, thymine at nucleotide 224 or 269, adenine at nucleotide 362, and cytosine at nucleotide 403;

(3) a recombinant organism transformed or transfected with N2 expressing TNFR1;

(4) an isolated **polypeptide** (P1) comprising a polymorphic variant of a reference sequence for the TNFR1 **protein**, where the reference sequence comprises a defined 465 amino acid sequence (given in the specification), comprising a leucine at amino acid 75, methionine at amino acid 99, glutamine at amino acid 121 and histidine at amino acid 135;

(5) an isolated antibody to P1;

(6) a composition comprising at least 1 genotyping oligonucleotide for detecting a polymorphism in the TNFR1 gene at a polymorphic site selected from PS1-PS12;

(7) a method (M1) for genotyping the TNFR1 gene of an individual

comprising determining for the two copies of the TNFR1 gene present in the individual, the identity of the nucleotide pair at at least 1 PS selected from PS1-PS12;

(8) a method (M2) for haplotyping the TNFR1 gene of an individual as in M1 except that the identity of the nucleotide at the PS is for one copy of the TNFR1 gene;

(9) a method (M3) for predicting a haplotype pair for the TNFR1 gene of an individual comprising:

(a) identifying a TNFR1 genotype for the individual at at least 2 polymorphic sites selected from PS1-PS12;

(b) enumerating all possible haplotype pairs which are consistent with the genotype;

(c) accessing data containing the TNFR1 haplotype pairs determined in a reference population; and

(d) assigning a haplotype pair to the individual that is consistent with the data;

(10) a method (M4) for identifying an association between a trait and at least 1 genotype or haplotype of the TNFR1 gene comprising comparing the frequency of the genotype or haplotype in a reference population, where the genotype or haplotype comprises a nucleotide pair or nucleotide located at PS1-PS12, where a higher frequency of a genotype or haplotype in the trait population than in the reference population indicates that the trait is associated with the genotype or haplotype;

(11) a computer system for storing and analyzing polymorphism data for the TNFR1 gene comprising:

(a) a central processing unit (CPU);

(b) a communication interface;

(c) a display device; and

(d) a database containing the polymorphism data; and

(12) a method (M5) for screening for drugs targeting TNFR1 isoforms comprising contacting the TNFR1 isoform with a candidate agent and assaying for binding activity, where the reference sequence and polymorphic variants are as described in (4).

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - Determination of the polymorphisms in the TNFR1 gene is useful for studying the biological **function** of TNFR1 as well as for identifying drugs targeting the **protein** for treatment of disorders related to its abnormal expression or **function**.

Dwg.0/5

FS CPI EPI

FA AB; DCN

MC CPI: B04-B03C; B04-C01G; B04-E03D; B04-E03D; B04-E04; B04-E05; B04-F0100E;

B04-G04; B04-K01K0E; B11-C08E; **B12-K04A; B12-K04E**

; **B12-K04F; D05-H09; D05-H11; D05-H12A;**

D05-H13E1; D05-H13D1; D05-H13DE; D05-H14; D05-H17B4

EPI: T01-J

TECH UPTX: 20001006

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Polynucleotide:N1 comprises a TNFR1 isogene. N1 is DNA and further comprises regulatory elements.

Preferred Organism: The recombinant organism is a transgenic animal.

Preferred Composition: The genotyping oligonucleotide is an allele-specific oligonucleotide that specifically hybridizes to an allele of the TNFR1 gene at a region containing the polymorphic site.

Preferred Method: In M1 and M2 the determining step comprises:

(a) isolating a nucleic acid mixture comprising both copies of the TNFR1 gene;

(b) amplifying a target region containing at least 1 of the polymorphic sites;

(c) hybridizing a genotyping oligonucleotide to one allele of the amplified target region;

(d) performing a nucleic acid template-dependent primer extension reaction on the hybridized genotyping oligonucleotide in the presence of at least 2 different terminators of the reaction, where the terminators are complementary to the alternative nucleotides present at the polymorphic site; and

(e) detecting the presence and identity of the terminator in the extended genotyping oligonucleotide.

In M4 the trait is a clinical response to a drug targeting TNFR1.

L123 ANSWER 15 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 2000-441075 [45] WPIX
 CR 2000-43449 [25]; 2000-432362 [41]; 2000-514667 [41]
 DNN N2000-364428 DUC C2000-147611
 T1 In silico recombinant nucleic acid preparation by genetic algorithm guided gene synthesis involves providing a number of parental character strings, providing oligonucleotides and elongating them.
 DC B01 D1- T01
 IN DEL CAROAYRE, S; GUSTAFSSON, C; MINIHILL, J; PATTEN, P A; SELIFONOV, S A; JEMMER, W P C; TOBIN, M
 PA (MAXY-10) MAXYGEN INC
 CYC 01
 PI WO 2000042560 A2 20000726 (200004) EN 127p G06F019-00 ---
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA OT SD SE SL SZ T2 UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK DM EE ES
 FI GB GD GE GH GI GR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MA MD MG MK MN MW MX NA NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA US UG UZ VN YU ZA ZW
 A2 2000032101 A 20000801 (200004) 306F019-00 ---
 EP 1062614 A1 20001227 (200101) EN 306F019-00 ---
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 ADT WO 2000042560 A2 WO 2000-US1202 20000118; AU 2000032101 A AU 2000-32101
 20000118; EP 1062614 A1 EP 2000-303921 20000118; WO 2000-US1202 20000118
 FET AU 2000032101 A Based on WO 200042560; EP 1062614 A1 Based on WO 200042560
 PRAI US 2000-416837 20000118; US 1999-116447 19990119; US 1999-118513
 19990205; US 1999-118514 19990207; US 1999-111049 19990624; US
 1999-408392 19990928; US 1999-408393 19990928; US 1999-416370
 19991012; US 1999-416371 19991012; US 2000-416373 20000118
 IC ICM G06F019-00
 AB WO 200042560 A UPAB: 20010110
 NOVELTY - Preparing recombinant nucleic acid (I) from oligonucleotides which correspond to a set of character string subsequences (SCSS) comprising at least two parental character strings (PCS) corresponding to a number of nucleic acids, is new.
 DETAILED DESCRIPTION - Preparing recombinant nucleic acid (I) by aligning for maximum identity a number of parental character strings (PCS) corresponding to a number of nucleic acids, defining a set of character string subsequences (SCSS) comprising at least two of the PCS, providing a set of oligonucleotides corresponding to the SCSS and then annealing and elongating one or more oligonucleotides with polymerase or ligating at least two with ligase (I).
 INDEPENDENT CLAIMS are also included for the following:
 (1) preparing character strings (CS) by providing PCS encoding a polynucleotide or **polypeptide**, providing a set of oligonucleotide character strings of preselected length that encode a number of single-stranded oligonucleotide sequence comprising sequence fragments of PCS and its complement and creating a set of derivatives of parental sequence comprising sequence variant strings, a set of multiple mutations with one mutation per variant string;
 (2) a library prepared by the above said method;
 (3) facilitating recombination between two or more divergent nucleic acids by aligning PCS corresponding to divergent nucleic acids, identifying regions of sequence identity and regions of sequence diversity, defining a diplomat CS which is intermediate in PCS, synthesizing at least a portion of the diplomat sequence to produce a diplomat nucleic acid and recombining a mixture of parental nucleic acid and diplomat nucleic acid;
 (4) a mixture of selected nucleic acids produced by the above said method;
 (5) generating and recombining nucleic acids by inputting a number of amino acid sequence character strings (ASCS) into a digital system,

reverse translating ASCS in the digital system to a number of nucleic acid character strings which are species codon biased in a selected expression host and with optimized sequence similarity between a number of nucleic acid character strings and synthesizing one or more oligonucleotides from one or more reverse translated nucleic acid sequences;

(6) optimizing a activity of a nucleic acid by parameterizing a number of nucleic acids or **proteins** to provide a set of multidimensional datapoints, extrapolating one or more postulated multidimensional datapoint from the set of multidimensional datapoints and converting the postulated multidimensional datapoint to a new CS corresponding to a postulated nucleic acid or **protein**;

(7) providing a library of recombinant nucleic acids which is enriched for a sequence of interest and selecting the library by producing an initial library of at least about 100 recombinant nucleic acids, comprising at least about 100 different non-identical units, hybridizing the library to one or more population of nucleic acids that correspond to one or more subsequences in the different library units;

(8) the enriched library produced by the above said method;

(9) generating a library of biological polymers by generating a diverse population of CS in a computer, which in turn are generated by alteration of pre-existing CS, synthesizing the diverse population of CS in which diverse population comprises the library of biological polymers; and

(10) an integrated system comprising a computer having a first data set comprising a first CS, a second data set comprising a second CS, software for aligning the first and second CSs, software for performing a genetic operation on the first or second CS, an output file comprising a third data set comprising a third CS, the third CS comprising CS subsequences from the first and second CSs, and an oligonucleotide sequence output file comprising a plurality of overlapping oligonucleotide sequences corresponding to third CS.

DNE - The method is useful for rapid **evolution** of nucleic acids in vitro and in vivo and provides for generation of encoded molecules with new and/or improved properties. **Proteins** and nucleic acids of industrial, agricultural and therapeutic importance can be created or improved through DNA shuffling procedures.

ADVANTAGE - Physical access to genes or organisms is not required as sequence information is used for design and selection of oligo. Extensive sequence information is provided and sequences from inaccessible, non-cultivable organisms can also be used. Sequences from pathogens without actual handling of pathogens and all type sequences including damaged and incomplete genes are amenable to this method. All genetic operators and crossovers can be fully and independently controlled in a reproducible fashion removing human error and variability from physical experiments with DNA manipulations. Sequences with frame-shift mutations are eliminated or fixed. Wild type parents do not contaminate derivative libraries with multiple redundant parental molecules.

Dwg. 9/15

FS CPI EPI

FA AB; DCN

MC CPI: B04-B01; B04-B02; B04-B05; B11-B; B11-C09; D05-C07; D05-H10;
D05-H12A; D05-H12B1

EPI: T01-J

TECH CPTX: 4000997

TECHNOLOGY FOCUS - COMPUTING AND CONTROL - Preferred System: Character strings are aligned in a digital computer or in a web-based system. Optimizing the activity of nucleic acid further involves synthesizing the postulated nucleic acid or **protein**, analyzing principle components of the set of multidimensional data points, shuffling the postulated nucleic acid with an additional nucleic acid and parameterizing the set of nucleic acids or **proteins** by correlating each residue to a matrix of numeric indicators. The matrix is graphically represented as a tetrahedron having an assigned origin at its center with each corner representing a numeral with each residue being positioned at different corner thereby producing the matrix of numeric indicators. Each multidimensional datapoint is correlated by partial least square

projections to latent structure analysis with an output vector to identify a relationship between a matrix of dependent Y variables and a matrix of predictor X variables. Each multidimensional datapoint comprises one or more different parameters that are plotted against each other in a dimensional hyperspace comprising at least one dimension for each parameter. Population of nucleic acid is fixed to a solid substrate that comprises a column matrix material and a nucleic acid chip. Initial library is produced by recombining one or more homologous nucleic acids or by providing PCS and providing a set of oligonucleotides for elongating them with polymerase.

The integrated system further comprises an oligonucleotide synthesis machine for synthesizing overlapping nucleotides, a number of oligonucleotides encoded by overlapping oligonucleotides and which produce the third nucleic acid encoded by third CS when incubated in one or more cycles of chain extension and a program with an instruction set for applying one or more genetic operator to the first or second CS. The operator is a mutation, a multiplication, a fragmentation of the string or strings, a crossover between one or more strings, a ligation of strings, an elitism calculation, an alignment, a calculation of sequence homology or sequence similarity, a recursive use of one or more genetic operator for **evolution** of CSs, randomness, a deletion mutation, an insertion mutation, and death.

TECHNOLOGY FOCUS - BIOCHIP - Preferred Method: CS comprises one region of similarity when aligned for maximum identity. At least one PCS is an **evolutionary** or artificial intermediate and corresponds to a designed nucleic acid which represents an energy minimized design for an encoded **polypeptide**.

The method comprises applying one or more genetic operator to one or more PCS or one or more CSs. The genetic operator is:

- (1) a mutation, multiplication or fragmentation of the one or more PCS or one or more CS subsequences;
- (2) a crossover between any of the one or more PCS or one or more CS subsequences or an additional CS;
- (3) a ligation of the one or more PCS or one or more CS subsequence;
- (4) an elitism calculation;
- (5) a calculation of sequence homology or sequence similarity of aligned strings;
- (6) a recursive use of one or more genetic operator for **evolution** of CSs;
- (7) application of a randomness operator to the one or more PCS or the one or more CS subsequences;
- (8) a deletion, an insertion or subtraction mutation of one or more PCS or one or more CS subsequences with an inactive sequence;
- (9) selection of the one or more PCSs or one or more CSs or one or more of CS subsequences with an active sequence;
- (10) or death of the one or more PCSs, or one or more of CS subsequences.

The method further involves selecting a diplomat sequence comprising an intermediate level of sequence similarity between two or more CS.

The recombinant nucleic acid with a desired property is selected.

Recombinant nucleic acid with one or more homologous nucleic acids or oligonucleotide units for desired trait or property is selected by in vivo or in vitro selection assay, or by parallel solid phase assay. Recombinant nucleic acid is deconvoluted by sequencing or digesting, sequenced, cloned or synthesized by error-prone assembly polymerase chain reaction (PCR). Preparation of CS further involves reiterative shuffling or selection of library of recombinant nucleic acids.

Generating and recombining nucleic acids further involves fragmentation of one or more elongated nucleic acids, hybridizing the secondary fragments with each other or with a set of primary fragmented nucleic acid that encode amino acid polymer.

Pre-existing CS is altered by recombination. Biological polymers are selected from nucleic acids, **polypeptides** and **peptide** nucleic acids. Additional library or additional set of CS is filtered by subtracting additional library or additional set of CS with units of biological polymer library which display activity below or above the desired threshold.

Preferred Oligonucleotides: The set of oligonucleotides comprise a number of overlapping nucleotides and SCSS is defined by selecting a length for CS and subdividing at least two of the PCS into segments of selected length. The set of oligonucleotides is provided by synthesizing the oligonucleotides to comprise one or more modified PCS subsequence. The set of single-stranded oligonucleotides that correspond to SCSS are pooled, hybridized and extended as double-stranded nucleic acids which comprise sequences from at least two of the PCS. The double-stranded nucleic acids are denatured to produce a heterogeneous mixture of single-stranded nucleic acids which are then re-hybridized and extended with polymerase.

The set of oligonucleotide is synthesized to comprise one or more modified PCS subsequences comprising:

- (1) a replacement, deletion, insertion, inclusion of degenerate sequence at one or more randomly or non-randomly selected positions;
- (2) inclusion of CS from a second PCS subsequence at one or more positions;
- (3) a PCS subsequence biased based upon its frequency in a selected library of nucleic acids; or
- (4) PCS subsequences comprising one or more artificially included sequence motif such as an N-linked glycosylation sequence, an O-linked glycosylation sequence, a protease sensitive sequence, a collagenase sensitive sequence, a Rho-dependent transcriptional termination sequence, an RNA secondary structure sequence that affects the efficiency of transcription, RNA secondary structure sequence that affects the efficiency of translation, a transcriptional enhancer sequence, a transcriptional promoter sequence or a transcriptional silencing sequence. The oligonucleotide set contains one or more altered or degenerated positions compared to PCS and comprises a chimeric nucleic acid sequence and at least one oligonucleotide unit whose subsequences are separated by a crossover point which is selected by identifying a number of PCS, aligning the substrings to display pairwise identity between the substrings and selecting the point within the aligned sequence as the crossover point. The crossover point is selected randomly or non-randomly by selecting approximately in the middle of one or more identified pairwise identity regions. The method further involves adding one or more oligonucleotide units of the set of oligonucleotides at a concentration higher than additional oligonucleotide units and incubating them with recombinant nucleic acid and polymerase. Recombinant nucleic acid is denatured, contacted with additional nucleic acids produced by cleaving parental nucleic acid from PCS by chemical cleavage, using DNase or restriction endonuclease.

The oligonucleotide set comprises one or more oligonucleotide units of 20-60 nucleotides in length.

Preferred Protein: PCS encodes erythropoietin (EPO), insulin, a **peptide** hormone, a cytokine, epidermal growth factor, fibroblast growth factor, hepatocyte growth factor, insulin-like growth factor, interferon, interleukins, keratinocyte growth factor, leukemia inhibitory factor, oncostatin M, PD-ECSF (undefined), platelet derived growth factor (PDGF), pleiotropin, SCF (undefined), c-kit ligand, VEGF (undefined), G-CSF (undefined), oncogene, tumor suppressor, steroid hormone receptor, plant hormone, disease resistance gene, herbicide resistance gene, bacterial gene, monooxygenases, protease, nuclease or lipase.

L123 ANSWER 16 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 2000-481361 [42] WPIX

CR 2000-203449 [25]; 2000-491075 [41]; 2000-514667 [41]

DNN H2000-358256 DNC C2000-145150

TI Recombining homologous nucleic acids to produce family shuffle nucleic acids comprises hybridizing and elongating a set of family gene shuffling oligonucleotides and providing a population of recombined nucleic acids.

DC B04 B16 T01

IN BASS, S H; CRAMERI, A; GUSTAFSSON, C; MINSHULL, J; NESS, J E; PATTEN, P A; STEHMER, W P C; WELCH, M

PA (MAXY-N) MAXYGEN INC

CYC 91

FI WO 2000042561 A2 20000720 (200042561) EN 74p G06F019-00 <--
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL ST TH TG TW
 W: AE AL AM AT AU BA BB BG BR BY CA CH CN CR CU CE DE DK DM EE ES
 FI GR GD GE GH GM HP HU IO IL IN IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MA MD MG MF MN MW MX NO NS PL PT PO PU SD SE SG SI SK SL
 TJ TM TF TT TZ UA UG US UZ VN YU ZA ZW
 AG 2000032102 A 20000301 (2000054) G06F019-00 <--
 EP 1072010 A2 20010101 (2001000) EN G06F019-00 <--
 R: AT BE CH CY DE DK EN FI FR GB GR IE IT LI LU NC NL PT SE
 ADT WO 2000042561 A2 WO 2000-031203 20000118; AU 2000032102 A AU 2000-32102
 20000118; EP 1072010 A2 EP 2001-03020 2000 11-; WO 2000-031203 20000118
 FDT AU 2000032102 A Based on WO 200042561; EP 1072010 A2 Based on WO 200042561
 PRAI US 1999-416837 19991012; US 1999-116447 19990119; US 1999-115513
 19990201; US 1999-11-554 19990205; US 1999-141119 19990624; US
 1999-408392 19990923; US 1999-408393 19990923; US 1999-416375
 19991012
 IC ICM G06F019-00
 AB WO 200042561 A UPAB: 20010207
 NOVELTY - Recombining (R) homologous nucleic acids (I) comprises
 hybridizing and elongating a set of family gene shuffling oligonucleotides
 (II) and providing a population of recombined nucleic acids.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
 following:
 (i) introducing nucleic acid family diversity during nucleic acid
 recombination comprises:
 (i) providing a composition comprising at least a set of fragmented
 nucleic acids and a population of (II);
 (ii) recombining (II) with at least one of the fragmented nucleic
 acids;
 (iii) and regenerating a recombinant nucleic acid comprising a
 nucleic acid subsequence corresponding to (II);
 (iv) recombining homologous or **non-homologous**
 nucleic acid sequences having low sequence similarity comprises
 recombining one or more set of fragmented nucleic acids with a set of
 crossover nucleic acids which individually comprise a number of sequence
 diversity domains (SDD) corresponding to a number of SDD from homologous
 or **non-homologous** nucleic acids with low sequence
 similarity and producing a recombinant nucleic acid;
 (3) providing an oligonucleotide set for recombining homologous
 nucleic acids comprises:
 (i) aligning a number of (I) to identify one or more regions of
 sequence heterogeneity; and
 (ii) synthesizing a number of different oligonucleotide units
 corresponding to at least one of the regions of heterogeneity to provide a
 set of oligonucleotides comprising a region of sequence heterogeneity
 corresponding to (I);
 (4) family shuffling PCR amplicons comprising:
 (i) providing a number of non-homogeneous homologous template nucleic
 acids;
 (ii) providing a number of PCR primers which hybridize to
 non-homogeneous homologous template nucleic acids
 (iii) producing a number of PCR amplicons by PCR amplification; and
 (iv) recombining amplicons to provide recombinant nucleic acid;
 (5) recombining a number of parental nucleic acids comprising
 ligating or elongating a set of number of oligonucleotides comprising a
 number of nucleic acid sequences from parental nucleic acids to produce
 recombinant nucleic acids encoding a full length **protein**;
 (6) producing a recombinant nucleic acid comprising;
 (i) transducing a population of cells with a set of overlapping (II);
 and
 (ii) permitting recombination to occur between the set of (II) and
 one or more nucleic acids contained within the population of cells to
 provide a population of recombined nucleic acids within the resulting
 population of recombinant cells;
 (7) a population of recombinant nucleic acids and recombinant cells

produced in (6);

(8) an amplified nucleic acid (III) produced (6);

(9) a cell, a vector, or a virus produced by the above said method;

(10) a composition comprising a library of oligonucleotides comprising a number of oligonucleotide units corresponding to a number of subsequence regions of selected set of homologous target sequence units;

(11) recombining two or more sequences comprising:

(i) aligning two or more nucleic acids to identify regions of identity and regions of diversity;

(ii) providing a non-equimolar set of oligonucleotides corresponding to two or more nucleic acid sequences at least a region of diversity; and

(iii) extending the oligonucleotides with a polymerase to produce a number of recombinant nucleic acids;

(12) making a library of chimeraplasts by providing a number of homologous chimeraplasts each comprising a marker or other region of sequence similarity and at least a region of sequence diversity and producing a library of chimeraplast; and

(13) a library produced in (12).

USE - The method is useful to produce a family of shuffled nucleic acids, to produce recombinant molecules with greater molecular diversities and for generating classical mutagens.

ADVANTAGE - Homologous nucleic acids with low sequence similarity or non-homologous nucleic acids are easily recombined. The fragmented oligonucleotide derived from homologous or non-homologous nucleic acids can hybridize to one or more regions of crossover oligos, facilitating recombination.

DESCRIPTION OF DRAWING(S) - The figure shows oligonucleotide-directed in vivo shuffling using chimeraplasts.

Dwg. 0/3

FS CFI EPI

FA AB; ION

MC CFI: B04-E03; B04-E08; B04-F01; B04-F11; B11-C03E3; B11-C03E3; B12-K04F; D05-H12A; D05-H12E; D05-H12F; D05-H14

EPI: T01-J

TECH EPTX: 20000905

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Oligonucleotide: A set of (II) contains overlapping nucleotides and encodes an **evolutionary** intermediate nucleic acid. (II) further comprises a number of oligonucleotide units having consensus region subsequences derived from a number of first round screened nucleic acids or derived from homologous target nucleic acids. (II) further comprises module shuffling oligonucleotide units, each comprising a first subsequence from a first sequence module and a second subsequence from a second sequence module. (II) also comprises a number of codon-varied oligonucleotides and a number of oligonucleotide units comprising at least 3-10 units in approximately equimolar amounts or in non-equimolar amounts. Recombinant nucleic acid is selected from one or more desired trait or property and encodes a full length **protein**. The set of overlapping (II) are chimeraplasts. The library of oligonucleotide comprises at least 10-50 or more oligonucleotide units in non-equimolar amounts and each have a sequence identical to set of homologous target sequences comprising at least one variant subsequence. A number of subsequent regions comprises non-overlapping sequence regions on the selected set of homologous target sequences. The composition comprising a library of oligonucleotides further comprises polymerase, thermostable DNA polymerase, nucleic acid synthesis reagent, buffer, salt, magnesium, and one or more nucleic acids comprising a number of homologous target sequence units. Preferred Method: (R) involves elongating using polymerase or ligase. The method further comprises denaturing the population of recombinant nucleic acids, reannealing the denatured recombined nucleic acids, extending or ligating the resulting reannealed nucleic acids and optionally selecting one or more recombined nucleic acids for desired property. (R) further involves recombining the reannealed recombinant nucleic acids. Numerous populations of recombined nucleic acids can be screened and determined for a desired property to provide first round screened nucleic acids by hybridizing a second set of (II), derived from first round screened

nucleic acids and elongating the second set of (II) to provide a population of further recombinant nucleic acid sequence. The second set of (II) comprises numerous oligonucleotides comprising subsequences corresponding to at least one region of diversity. The composition comprising at least one fragmented nucleic acid and a population of (II) is provided by aligning homologous nucleic acid sequences to select conserved regions of sequence identity and regions of sequence diversity, synthesizing a number of (II) corresponding to sequences comprising regions of sequence diversity, providing a full length nucleic acid identical to or homologous with homologous nucleic acids, fragmenting the full length nucleic acid by cleavage with DNase or by partial chain elongation, and mixing the resulting set of nucleic acid fragments with a number of (II) to provide a composition comprising fragmented nucleic acids and a population of (II). The method further comprises selecting at least a second full length nucleic acid and cleaving it to provide a second set of nucleic acid fragments which is also mixed with population of (II). (II) are added to the composition by aligning homologous nucleic acid sequences, selecting at least one conserved region of sequence identity and a number of regions of sequence diversity comprising a number of domains and synthesizing (II) corresponding to domains of sequence diversity. (II) causes domain switching with the fragmented nucleic acid in the regenerated recombinant nucleic acid as compared to homologous nucleic acid sequences and encodes one or more domains of sequence diversity. Fragmented nucleic acid is obtained by cleaving a cloned nucleic acid or selecting a nucleic acid sequence and by synthesizing oligo nucleotide fragments corresponding to selected nucleic acid sequence. A number of oligonucleotide sequence are synthesized serially or in parallel. Homologous nucleic acid sequences are aligned in a system comprising computer with software for sequence alignment or by manual alignment. Oligonucleotide unit are selected by aligning a number of homologous target sequences, determining regions of identity and diversity, synthesizing oligonucleotides to encode at least a portion of region of identity, a region of diversity or both the regions and selecting them. Sequence diversity domains corresponds to adjacent sequence regions of homologous nucleic acids when aligned. Producing chimera-plast library further includes transducing a population of cells with the library and detecting the recombination of marker or other regions of similarity with one or more nucleic acids to identify the recombinant homologous chimera-plast and thus to identify active homologous chimera-plast. Active homologous chimera-plasts are recombined to produce a library which are then transduced with a second population of cells and identifying additional active homologous chimera-plasts.

L123 ANSWER 17 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 2000-482840 [42] WPIX

CR 1999-372624 [32]

DNC 02000-145234

TI Novel methods for selecting target sites for, and production of, zinc finger **proteins**, useful for controlling expression of target genes, e.g. for inhibiting oncogenes or treating sickle cell anemia.

DC B04 D16

IN CASE, C C; COX, I G U; EISENBERG, S F; JAMIESON, A; FEBAR, E U; COX, G N

PA (SANG-N) SANGAMO BIOSCIENCES INC

CYC 40

PI WO 2000042219 A1 20000720 (200042)* EN 82p C1LQ001-68

FW: AT BE CH CY DE DK EA ES FI FR GB GR HE IE IT KE LC LU MC MW NL
OA PT SD SE SL SJ TG UG ZW

W: AE AL AM AT AU AZ BA BE BG BR BY CA CH CN CF CU CE DE DK EM EE ES
FI GE GD GE GH GM HP HU ID IL IN IS JF KE KG KP KR LC LE LF LS
LT LU LV MA MD MG ME MI MW NX NY NZ PL PT RC RU SD SE SG SI SK SL
TJ TM TP TT TZ UA UG US VZ VN YC ZA ZW

GB 2348425 A 20001004 (200051) G06F017-50 C--

AU 2000027220 A 20000301 (200054) C1LQ001-68

ADT WO 2000042219 A1 WO 2000-03339 20000106; GB 2348425 A GB 2000-651
20000112; AU 2000037220 A AU 2000-07220 20000106

FDT AT 2000027220 A Based on WO 200042219

IRAI US 1999-229007 13390112
 IC ICM C120011-68; G06F017-50
 AB WO 200042119 A UPAB: 20000905

NOVELTY - Selecting a target site (TS) within a nucleic acid (I) to be targeted by a zinc finger **protein** (ZFP) by detecting a specific 10-base motif (A), is new.

DETAILED DESCRIPTION - Novel method for selecting a target site (TS) within a nucleic acid (I) to be targeted by a zinc finger **protein** (ZFP) by detecting a specific 10-base motif of formula (A).

5'-NNx any bNac-3' (A)

each of (x, a), (y, b) and (z, c) = (N, N) or (G, K) but at least 1 must be (G, K);

N = any nucleotide;

K = G or T.

INDEPENDENT CLAIMS are also included for the following:

- (a) selecting a TS by:
 - (i) identifying potential TSs comprising three contiguous triplets;
 - (ii) determining subscores for each combination of triplets and triplet positions by applying a correspondence regime;
 - (iii) combining subscores for all three triplets to give a score for the potential TS;
 - (iv) repeating the procedure for at least one other potential TS; and
 - (v) outputting at least 1 potential TS together with its score;
- (b) producing ZFP comprising constructing a database of many ZFPs where the nucleic acid sequences for each ZFP comprise at least 3 triplets bound specifically by the individual fingers of the ZFP, and in the same order (3' to 5') as the fingers are arranged (N to C) in the **protein**, identifying fingers that specifically bind to each triplet, and outputting the (sub)designations of the relevant ZFPs;
- (c) a computer program for selecting a TS, comprising code for providing a polynucleotide sequence, selecting a potential TS within the sequence, calculating a score for the potential TS from a combination of subscores for 3 triplets as in (a), repeating the selection and calculation steps at least once, and providing an output of the TS with its score;

(d) a system for selecting a TS, comprising a memory, a system bus, a processor operatively disposed to provide or receive a polynucleotide sequence, select a potential TS and calculate a score for the TS as in (c);

(e) a computer program for designing a ZFP, comprising code for a database of 3 fingered ZFPs with subdesignations for each finger and a corresponding nucleic acid for each ZFP, providing a TS, identifying ZFPs in the database that specifically bind to the TS and outputting the designations and subdesignations of the ZFPs;

(f) a system for selecting a TS, comprising a memory, a system bus, a processor operatively disposed to provide or a database of ZFP designations and output ZFP designations and subdesignations as in (e).

ACTIVITY - Antibacterial; antiviral; cytostatic; neuroprotectant; antianemic.

MECHANISM OF ACTION - Modulation of gene expression by the binding of a ZFP.

USE - Selection of TS is used to design ZFP that bind to preselected targets. ZFP bind to DNA and can modulate (inhibit or activate) the expression of a wide range of genes. Typical of many potential applications, of ZFP or the nucleic acids that encode them, are: inhibition of bacterial or viral genes, oncogenes or the apcE gene (implicated in Alzheimer's disease); inducing expression of fetal hemoglobin (for treating sickle cell anemia); and in plants to increase resistance to diseases or herbicides, or to increase oleic acid synthesis at the expense of linoleic or linolenic acids. ZFP can also be used diagnostically, e.g. to detect variant, disease-related alleles; to quantify copy numbers of a gene; to detect pathogenic microbes, and in analysis of phenotype and **function** of gene expression.

ADVANTAGE - ZFP can be controlled by small molecules, allowing the adjustment of the degree of repression or activation produced by ZFPs and, in transgenic animals, makes switching on a ZFP at a late stage in

embryonic development possible, so that effects can be studied in the adult. Nucleic acids encoding a ZFP can be introduced at any site (homologous recombination is not required) and because ZFPs are trans-dominant, only 1 chromosomal copy need be present (**functional** knockouts can be produced without backcrossing).

Fig. 1/3

FS CPI

FA AB; DCN

MC CPI: B04-N04; B11-C08; B11-C09; B12-K04A;

B12-K04D; B12-K04E; B14-A01; B14-A02; B14-F03;

B14-H01B; B14-H01A4; B14-N16; D05-C13; D05-H04; D05-H05; D05-H06;

D05-H09; D05-H17A5; D05-H17B6

TECH UPTX: 20000005

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Target Sites: In (A) at least 2, preferably all 3 of (x, a), (y, b) and (z, c) are (G, K) and TS may include two (A), preferably separated by at most 1 bases. Preferably, one segment is 5'-N8G-3' and the other is 5'-KXXatlybNac-3', with no intervening bases. TS may occur in a coding region or within, or outside, a regulatory region.

Preferred Process: Many different potential TSs are selected from a target gene. The ZFP of (A) has 3 fingers, 1 specific for each of kNk, aNy and NNK. Preferably each finger is selected and designed independently from a database of ZFP that contains designations of ZFP, subdesignations of individual fingers and nucleic acid sequences bound by the fingers. Alternatively, a finger is selected by screening variants of a zinc finger binding **protein** for specific binding to TS, thus identifying a variant that binds to TS. In the method of (a), at least 1 potential TS, with the highest score, is the output and the subscores are combined as their products. The correspondence regime comprises 64 triplets and 192 subscores. Subscores are determined by assigning different scores for a subset of triplets and corresponding positions for which there is an existing ZFP with a finger specific for the triplet from the same position as in the correspondence regime, a subset for which an existing finger specifically binds to the triplet from a different position, and a subset for which there is no known finger that specifically binds. The specification includes a table showing the correspondence regime. The subscore of at least 1 triplet may be combined with a context parameter (CP) to give a scaled subscore, preferably when the target site comprises the sequence 5'-NNGK-3'. A CP may also be combined with the score for a potential target to give a scaled score, particularly where the potential TS contains motif (A), and different CP are used depending on how many (x, a), (y, b) and (z, c) are (G, K) are included. A similar process to (b) may be used to produce a two-triplet target site and 2-finger ZFP. Once ZFP and nucleic acid sequences encoding them have been designed, the **proteins** can be produced by standard recombinant DNA methods.

L123 ANSWER 18 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 2000-442645 [38] WPIX

DINN N2000-330228 DMC C2000-134729

TI 3-D structure of sterile alpha motif domain used as model for determining 3-D structures of additional native or mutated SAM domain with unknown structure and structures of co-crystals of SAM domain with modulators.

DC B04 T01

IN SICHERI, F; STAPLETON, D

PA (MOUN) MOUNT SINAI HOSPITAL

CYC 90

PI WO 2000037500 A1 20000629 (200038)* EN 73p C07F014-705 <--

FW: AT BE CH CY DE DK EA ES FI FR GB GR HM HE IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TC US UW

W: AE AL AM AT AU AZ BA BE BG BR BY CA CH CN CO CU CZ DE DK DM EE ES
FI GB GD GE GR GM HE HU ID IL IN IS JP KE KG KP KE KI LC LR LE LS
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RD RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000017642 A 20000712 (200048)

C07F014-705 <--

ADT WO 2000037500 A1 WO 1999-CA1209 19991217; AU 2000017642 A AU 2000-17642 19991217

PDT AU 2000017642 A Based on WO 200037500

PRAI US 1999-112929 19991213

IC ICM C07K014-705

ICS A61K038-17; A61P025-00; C07K014-47; G06F017-50

AB WO 200037500 A UPAB: 200009311

NOVELTY - A purified three dimensional structure of a **polypeptide** (I) corresponding to one or more sterile alpha motif (SAM) domains.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a purified crystalline form (CF) of (I);

(2) forming a CF of (I);

(3) a potential modulator (II) of a function of a SAM domain of an Eph (Erythropoietin producing human hepatocellular carcinomas cell line) receptor identified using CF; and

(4) a **peptide** (III) which mediates SAM domain function comprises VVSV, SAVSV, FFAV, FSAVSV, FSAVSVGD, VVSVNWL, FNTV, FNTVDE, FNTVDEWL, TSPNTVDEWL, TSPNTV, YTSFNTV, RSEV, RSEVLG, RSEVLGVD, VPFSEV or VPFSEVLGW or has a formula I or II:

(I) X-X1-X2-X3-X4-X5-X6;

(II) X7-X8-X9-X10-X11-X12-X13-X14-X15-X16.

X = defined in DEFINITIONS: Full Definitions field

ACTIVITY - Cytostatic; immunosuppressive; vulnerary; neuroprotective; neurotropic; antiparkinsonian; cerebroprotective, antiarthritic, antiatherosclerotic.

MECHANISM OF ACTION - Eph (Erythropoietin producing human hepatocellular carcinomas cell line) receptor SAM domain modulators (claimed).

USE - The structural coordinates of a SAM domain or CF of (I) can be used as a model for determining the three dimensional structures of **polypeptides** with SAM domains of unknown structure. They are also used for identifying (M1) a potential modulator of a SAM domain of a Eph (Erythropoietin producing human hepatocellular carcinomas cell line) receptor **function** which involves seeking a computer representation of a structure of a compound with the computer representation of a structure of one or more SAM domains of an Eph receptor. (II) identified by the above method or a CF, can be used for treating a disease associated with inappropriate activity of SAM domain of an Eph receptor in cellular organism, such that a SAM domain **function** is activated or inhibitor to treat a cell proliferative disease such as cancer, angiogenesis, atherosclerosis, arthritis and diseases associated with the nervous system (claimed). The knowledge of the three dimensional structure of a SAM domain, in particular the EphA4 SAM domain enables us to identify homologues. The structure coordinates of a SAM domain or CF of (I) can be used for identifying additional native or mutated SAM domains with unknown structure, as well as the structures of co-crystals of SAM domains with compounds such as modulators. The structure coordinates and models of a SAM domain three dimensional can also be used to determine solution-based structures of native or mutant SAM domains. The structural coordinates of a SAM domain structure may be applied to nuclear magnetic resonance (NMR) data to determine the three dimensional structures of **polypeptides**. The rational design and identification of modulators of SAM domains can be accomplished by utilizing the atomic structural coordinates that define SAM domain's three dimensional structure. The new **peptides** (III) may be used to identify lead compounds for drug development. A comparison of the structure of **peptides** similar in sequence but differing in the biological activities they elicit in target molecules can provide information about the structure-activity relationship (SAR) of the target. Information obtained from the examination of SAR can be used to design either modified **peptides** or other small molecules or lead compounds which can be tested for predicted properties as related to the target molecule. The new **peptides** may be used to prepare antibodies. Antibodies and labeled antibodies specific for the new **peptides** may be used to screen for the **proteins** containing SAM domains. They may be used in the treatment and diagnosis of disorders associated with aberrant T cell signaling and to modulate

telomere function. In particular, they may be useful in methods for therapy of cellular senescence and immortalization controlled by telomere length and telomerase activity and selective immunosuppressants (e.g. in organ transplantation). They may also be useful in the treatment of cancer. The new three dimensional SAM domain structure, new **peptides** and modulators may be used to modulate the biological activity of an Eph receptor or Eph ligand in a cell and in particular modulating a pathway in a cell regulated by the ligand or the receptor, particularly those pathways involved in neuronal development, axonal migration, pathfinding and regeneration. The new three dimensional SAM domain structure **peptides** and modulators identified using the methods will be useful in pharmaceuticals to modulate axonogenesis, nerve cell interactions and regeneration, to treat conditions such as neurodegenerative diseases and conditions involving trauma and injury to the nervous system, for example Alzheimer's disease, Parkinson's disease, Huntington's disease, demyelinating diseases such as multiple sclerosis, amyotrophic lateral sclerosis, bacterial and viral infection of the nervous system, deficiency diseases such as Wernicke's disease and nutritional polyneuropathy, progressive supranuclear palsy, Shy Drager's syndrome, multistem degeneration and olive pontine cerebellar atrophy, peripheral nerve damage, trauma and ischemia resulting from stroke. The pharmaceutical composition may be used to stimulate or inhibit neuronal development, regeneration and axonal migration associated with neurodegenerative conditions and involving trauma and injury to the nervous system.

Dwg. 0/3

FS CFI EPI

FA AB; ECH

MC CFI: B04-C01; B14-A01; B14-A02; B14-709; B14-F07; B14-H01; B14-J01A3;
B14-J01A4; B14-N06; B14-S01

EPI: T01-E15

TECH UFTX: 20003811

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation: The CF of (I) is formed by mixing a volume of a SAM domain with a reservoir solution; and incubating the mixture obtained in previous step over the reservoir solution in a closed container under conditions suitable for crystallization (claimed).

Preferred Crystalline Form: CF has dimensions of about $a=b=77.14\pm0.3$ angstroms, $c=24.3\pm0.04$ angstrom and has a **protein** coordinate data as given in the patent specification.

Preferred Method: (M1) involves docking a computer representation of a compound from a computer database with computer representation of a selected site on a three dimensional structure of a SAM domain of an Eph (Erythropoietin producing human hepatocellular carcinomas cell line) receptor or CF, determining a conformation of the complex with a favorable geometric fit and favorable complementary interactions and then identifying compounds that best fit the selected site as potential modulators of SAM domain **function**. Alternately, the method

involves modifying computer representation of a compound complexed with a selected site on a three dimensional structure of a SAM domain of an Eph receptor or CF by deleting or adding a chemical groups, determining a conformation of the complex with a favorable geometric fit and favorable complementary interactions and then identifying a compound that best fits the selected site as potential modulators of SAM domain **function**.

The method can also be performed by selecting a computer representation of a compound from a computer database with computer representation of a selected site on a three dimensional structure of a SAM domain of an Eph receptor or CF, and then searching for molecules in a database that are similar to the compound using a computer searching program, or replacing portions of the compound with similar chemical structures from a database using a compound building computer program.

Preparation: (III) is prepared by standard solid phase **peptide** synthesis.

Preferred 3D Structure: The 3D structure of SAM domain is of the SAM domain of an Eph receptor preferably EphA, complexed with one or more compounds and comprising one or more heavy metal atoms.

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation: (III) is also prepared by standard recombinant techniques.

L123 ANSWER 19 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 2000-387560 [33] WPIX
 ENN N2000-200184 DNO C2000-117586
 TI New DnaB **polypeptide** from *Streptococcus pneumoniae*, useful, e.g. in vaccines, for diagnosis of infections, and for identifying antibacterial agents.
 DC B04 D16 T01
 IN CHAIKER, A F; HOLMES, D J; INCEBAHAM, H A; JANORSKI, E D; LENNOX, A L; MAY, E W; MACHULLA, M; PAY, G; WANG, M; WARREN, R L
 PA (SM12) AMITKLINE REECHAM COFF
 CYC 12
 PI WO 200028820 A1 20000520 (200033)* EN 59p A01N037-18
 RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 W: JP
 ADT WO 200028820 A1 WO 1994-US-A-93 19991111
 P5AI US 1998-191879 19981113
 IC ICM A01N037-18
 ICS A01N061-00; C07H021-02; C07H021-04; C07K001-00;
 C07K016-00; C12N011-00; C12P011-06; G06F017-00
 AB WO 200028820 A UPAB: 20000712
 NOVELTY - Isolated DnaB **polypeptide** (I) that is at least 70% identical with a 450 residue amino acid sequence, fully defined in the specification, over the entire length of it, comprises, or is, the 450 residue sequence, or is encoded by a recombinant polynucleotide comprising a 1953 base pair sequence, fully defined in the specification.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
 (1) polynucleotide (II) that
 (a) encodes the sequence, at least 70% identical to the 450 residue sequence;
 (b) is at least 70% identical with a sequence encoding the 450 residue sequence;
 (c) is at least 70% identical with the 1953 base pair sequence over the entire 301-1651 nucleotide (nt) segment of it;
 (d) encodes the 450 residue sequence;
 (e) is the 301-1651 nt segment of the 1953 base pair sequence;
 (f) is isolated by screening a library, under stringent conditions, with the 1953 base pair sequence, or a fragment of it;
 (g) encodes a mature **polypeptide** expressed by the DnaB gene of *Streptococcus pneumoniae*; or
 (h) is a complement of (a)-(g);
 (2) antibody (Ab) immunospecific for (I);
 (3) diagnosis or prognosis of disease, or susceptibility, related to expression or activity of (I), comprising determining the presence or absence of a mutation in the nucleotide sequence encoding the **polypeptide** in the genome of the individual, and analyzing for the presence or amount of the **polypeptide** expression in a sample derived from the individual;
 (4) screening methods for identifying compounds (A) that activate or inhibit function of (I), comprising:
 (a) measuring the binding of a candidate compound to the **polypeptide**, or to cells or membranes bearing the **polypeptide** or a fusion protein of it, using a label directly or indirectly associated with the candidate compound;
 (b) measuring the binding of a candidate compound to the **polypeptide** or to the cells or membranes bearing the **polypeptide** or a fusion protein of it, in the presence of a labeled competitor;
 (c) testing if the candidate compound results in a signal generated by activation or inhibition of the **polypeptide**;
 (d) mixing a candidate compound with a solution containing (I), measuring the activity of the **polypeptide**, and comparing it to a

standard;

(c) detecting the effect of a candidate compound on the production of mRNA encoding the **polypeptide**, and the **polypeptide** in cells, using e.g. enzyme linked immunosorbant assay (ELISA); or

(f) contacting a composition comprising the **polypeptide** with the compound to be screened to assess the interaction, the interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the **polypeptide** and compound, and determining if interaction occurs;

(g) agonists and antagonists of the expression or activity of (I);

(h) expression system comprising (II), present in a host cell;

(i) host cell, or its membrane, that contains the system of (c) and expresses (I);

or production of (I) by culturing cells of (i);

or production of cells of (i), or its membranes, by transformation or transfection;

(10) computer-readable medium containing at least the 450 residue sequence and/or the 1353 base pair sequence;

(11) computer-based method of homology identification, based on the 1353 base pair sequence;

(12) computer-based method of polynucleotide assembly based on identification of an overlap between the 1353 base pair sequence, and a second nucleic acid sequence; and

(13) polynucleotides of formula (IIa) X-(E10m-R2-(E30m-Y (IIa) .

X and Y = hydrogen, metal, modified nucleotide or together form a covalent bond;

each R1 and R2 = optionally modified nucleotide;

m and n = 0-1000;

R2 = optionally modified 1353 base pair sequence.

ACTIVITY - Antibacterial.

MECHANISM OF ACTION - Inhibition of SnaB, probably a replicative helicase, which is essential for growth and/or survival of *S. pneumoniae*.

USE - The 450 residue polypeptide, the product of the SnaB gene of *Streptococcus pneumoniae*, is used to screen for specific agonists and antagonists, potential therapeutic agents, to raise specific antibodies (Ab), in vaccines, and in rational drug design. Ab are useful as diagnostic immunoassay reagents and as therapeutic antagonists. Nucleic acids (II) that encode (I), or fragments, are used for recombinant production of (I), and as probes and primers to isolate homologous full-length or genomic clones, for diagnosis, prognosis, staging and typing infections, including detection of genomic mutations, and for chromosome identification or mapping. (II) can also be used in genetic immunization, and as antisense inhibitors. The therapeutic agents have bacteriostatic/bactericidal activity and are used to treat or prevent infections, especially those caused by *S. pneumoniae*, but also *Helicobacter pylori* infections and associated disorders, also for treatment of in-dwelling devices and wounds to prevent bacterial adhesion.

Dwg.0/0

FS CPI EPI

FA AB; DEN

MC CPI: B04-C01G; B04-E01F; B04-E05; B04-E06; B04-E05; B04-F10B4; B04-G01;

B04-N03A0E; B11-C07A; B11-C07A4; B11-C08E5; B12-K04A;

B12-K04E; B12-K04F; B14-A01; B14-A01B2; B14-S11B;

D05-C12; D05-H09; D05-H11; D05-H12A; D05-H14; D05-H17A6

EPI: T01-J

TECH UPTX: 20000712

TECHNOLOGY FOCUS - BIOLOGY - Preferred treatment: When increased expression/activity of (I) is required, an agonist of (I) or a (I)-encoding nucleic acid is administered, and when inhibition is required, an antagonist of (I), nucleic acid that inhibits (I) expression or a **polypeptide** that competes with (I) for ligand, substrate or receptor is administered.

Preferred diagnosis: This involves detecting a mutation in the **genomic** sequence encoding (I) or analysis for presence or amount of (I).

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation: (I) is isolated from *Streptococcus pneumoniae* 010993 (NCIMB 40800) by standard methods of cloning and screening (no more details). Once isolated, (I) can be expressed in any conventional vector/host system, optionally as a fusion protein.

1123 ANSWER 19 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 2500-38/559 (33) WPIX
 DNN NL000-290183 DND 01000-117585
 TI New pseudouridine synthase from *Streptococcus pneumoniae*, useful, e.g. in vaccines, for diagnosis of infections, and for identifying antibacterial agents.
 DC B-4 D16 T01
 IN POWELL, D J
 PA (SMITH) SMITHKLINE BEECHAM CORP
 CYC 1-
 PI WO 0000188-14 A1 20000000 (20000000) EN 55p A01N037-18
 KW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 W: JP
 ADT WO 0000188-19 A1 WO 1999-03264-33 19991109
 PRAI US 1999-190824 19981111
 IC ICM A01N037-18
 ICS A01N037-00; C07H011-02; C07H011-04; C07K001-00;
 C07K016-00; C12N019-00; C12P021-06; G06F017-00
 AB WO 0000188-19 A UPAB: 30000712
 NOVELTY - Isolated **polypeptide** (I) from *Streptococcus pneumoniae* is a pseudouridine synthase.
 DETAILED DESCRIPTION - Isolated **polypeptide** (I) is:
 (a) at least 70, 80, 90 or 95% identical over the entire length, to defined amino acid (aa) sequence (II) of 292 aa, given in the specification;
 (b) an isolated **polypeptide** comprising (II);
 (c) (II); or
 (d) is encoded by a recombinant polynucleotide comprising a 1061 bp sequence (III) given in the specification.
 INDEPENDENT CLAIMS are also included for the following:
 (1) an isolated polynucleotide (IV) which:
 (a) is an isolated polynucleotide encoding a **polypeptide** at least 70, 80, 90 or 95% identical over the entire length to (II);
 (b) comprises at least 70, 80, 90 or 95% identity over the entire length to a polynucleotide encoding (II);
 (c) comprises a nucleotide sequence with at least 70, 80, 90 or 95% identity over the entire length of nucleotides 97-973 of (III);
 (d) comprises a nucleotide sequence encoding (II);
 (e) is nucleotides 97-973 of (III);
 (f) is obtained by screening a library, under stringent conditions, with (III) or a fragment of (III);
 (g) encodes a mature **polypeptide** expressed by the YfiI (pseudouridine synthase) gene of *Streptococcus pneumoniae*; or
 (h) is a complement of (a)-(g);
 (2) antibody (Ab) immunospecific for (I);
 (3) methods of treating conditions requiring increased or reduced activity or expression of (I);
 (4) diagnosis or prognosis of disease (or susceptibility) related to expression or activity of (I);
 (5) screening methods for identifying compounds (A) that activate or inhibit **function** of (I);
 (6) agonists and antagonists of the expression or activity of (I);
 (7) expression system comprising (IV), present in a host cell;
 (8) host cell, or its membrane, that contains the system of (7) and expresses (I);
 (9) production of (I) by culturing cells of (8);
 (10) production of cells of (8), or its membranes, by transformation or transfection with (IV);
 (11) a host cell produced by the method of (10);
 (12) computer-readable medium containing at least sequences (II)

and/or (III);

(13) computer-based method of homology identification, based on sequence (III);

(14) computer-based method of polynucleotide assembly based on identification of an overlap between (III) and a second nucleic acid sequence; and

(15) polynucleotides of formula (IIa).

X-(R1)m-F2-(R3)n-Y (IIa)

X and Y = hydrogen, metal, modified nucleotide or together form a covalent bond;

each R1 and R3 = optionally modified nucleotide;

m and n = 0-1000;

R2 = region 57-73 of (I).

ACTIVITY - Antibacterial.

No biological data is given.

MECHANISM OF ACTION - Inhibition of pseudouridine synthase which is essential for growth and/or survival of *S. pneumoniae*.

USE - Sequence (II), the product of the Yfii (pseudouridine synthase) gene of *Streptococcus pneumoniae*, is used to screen for specific agonists and antagonists (potential therapeutic agents), to raise specific antibodies (Ab), in vaccines and in rational drug design. Ab are useful as diagnostic immunoassay reagents and as therapeutic antagonists. Nucleic acids (III) that encode (I), or fragments, are used for recombinant production of (I), as probes and primers to isolate homologous full-length or genomic clones, for diagnosis, prognosis, staging and typing infections (including detection of genomic mutations), and for chromosome identification or mapping, in genetic immunization; and as antisense inhibitors. The therapeutic agents have bacteriostatic/bactericidal activity and are used to treat or prevent infections, especially those caused by *S. pneumoniae*, but also *Helicobacter pylori* infections and associated disorders, also for treatment of in-dwelling devices and wounds to prevent bacterial adhesion.

Dwg.6/6

FS CFI EPI

FA AB; DCN

MC CFI: B04-E03E; B04-E06; B04-F0100E; B04-G03; B04-L05; B11-C03;

B12-K04A4; B12-K04F; B14-A01A; B14-A01E2;

D05-H09; D05-H11; D05-H12A; D05-H12E; D05-H14; D05-H17A3

EPI: T01-J

TECH METX: 20000712

TECHNOLOGY FOCUS - BIOLOGY - Preferred Treatment: When increased expression/activity of (I) is required, an agonist of (I) or a (I)-encoding nucleic acid is administered, and when inhibition is required, an antagonist of (I), nucleic acid that inhibits (I) expression or a **polypeptide** that competes with (I) for ligand, substrate or receptor is administered.

Preferred Diagnosis: This involves detecting a mutation in the **genomic** sequence encoding (I) or analysis for presence or amount of (I).

Preferred Screening Method: Method comprises:

(i) measuring binding of a test compound (TC) to (I), or cells or membranes carrying (I), or its fusion **protein**, from a label

(ii) directly associated with TC;

(iii) as (i) but in presence of labeled competitor;

(iv) determining if TC produces a signal generated by activation or inhibition of (I);

(v) incubating TC with (I), then measuring activity of (I);

(vi) determining the effect of TC on production of (I) or mRNA that encodes (I);

(vii) incubating (I) and TC and determining any interaction, from a second component that produces a detectable signal in response to this interaction.

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation: (III) is isolated from *Streptococcus pneumoniae* 0100993 (NCIMB 40800) by standard methods of cloning and screening (no more details). Once isolated, (III) can be

expressed in any conventional vector/host system, optionally as a fusion protein.

L123 ANSWER 21 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 2000-234656 [29] WPIX
 DNN H0000-254974 INFO C0600-103103
 TI Engineering **proteins** comprising searching a 3D computer database for framework **proteins** which can then be modified, useful for the design and engineering of cytokine mimetics.
 DC B04 D16 T01
 IN ANDREWS, P R; DOOLEY, M J; SMYTHE, M L
 PA (NY,NY) UNIV QUEENSLAND
 CYC 00
 FI W 2000023474 A1 20000427 (200004) EN 78p C07K014-61 ---
 PW: AT BE CH CY DE DK EA EG FI FF GE GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SS TS US ZW
 W: AE AL AM AT AU BA BE BG BY CA CE CN CF CU CZ DE DK EM EE ES
 FI GE GD GE GH GM HE HU ID IL IN IS JE KE KG KP KR KZ LC LK LR LS
 LT LU LV MA MD MG MK MN MW MX NO NZ PL PT PQ PU SD SE SG SI SK SL
 TG TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 2000011411 A 20000508 (200005) C07K014-61 ---
 ADT WO 2000023474 A1 WO 1999-AP014 19991021; AU 2000011411 A AU 2000-11411
 19941011
 EDT AU 2000011411 A Based on WO 200023474
 PRAI AU 1999-0606 19991011
 IC ICM C07K014-61
 ICS C07K014-535; C07K014-54; G06F017-30
 AB WO 200023474 A UPAB: 20000017
 NOVELTY - A method for **protein** engineering comprising searching a 3D computer database for framework **proteins** with desired structural features, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (1) a method of **protein** engineering comprising:
 - (a) creating a computer database with a number of entries, each entry corresponding to a description of a location and orientation in 3D space of side chains of amino acid residues of a framework **protein**;
 - (b) creating a query corresponding to a description of a location and orientation in 3D space of the respective side chains of at least 2 amino acid residues of a sample **protein**; and
 - (c) searching the database with the query to identify hits, where at least 1 of the hits corresponds to a respective framework **protein** which has structural similarity to the sample **protein**;
- (2) a modified framework **protein** produced by the method of (1) which is a cytokine mimetic;
- (3) an engineered **protein** comprising at most 70 amino acid residues and 2-11 disulfide bonds of a framework **protein**, together with at least 2 amino acid residues of another **protein** which are non-contiguous in primary sequence;
- (4) an engineered **protein** having an amino acid sequence selected from SCY01, SCY02, SCY03, ERF01, ERF02, ERF03 and VIB01;
- (5) a computer program for searching a **protein** database which comprises a number of entries, each entry corresponding to a distance matrix representation of at least 2 C alpha -C beta vectors, comprising:
 - (a) comparing a query with each database entry; and
 - (b) identifying hits by clique detection, where a hit is defined according to a minimum number of C alpha -C beta vector matches between the query and each entry; and
 - (c) a computer program which filters the hits identified at step (b) of (5).

USE - The method is useful for identifying **proteins** suitable for **protein** engineering, particularly for the design and engineering of cytokine mimetics.

ADVANTAGE - The method is advantageous since a modified framework **protein** may display one or more desired characteristics, such as a

function similar to, or inhibitory of the sample **protein**.

Dwg.0/14

FS MPI EPI

FA AB; DCN

MC CPI: B04-E08; B04-H03D; B04-H03G; B04-H04A; B04-J05; B04-N02; B11-C08;

B12-K04E; D05-H09

EPI: T01-J05B

TECH UPTX: 20000617

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The framework **protein** identified as a hit has a greater stability than the sample **protein**. The method further comprises modifying an amino acid sequence of the framework **protein** which corresponds to a hit, by substituting at least 1 amino acid residue with at least 1 amino acid residue of the sample **protein** to create a modified framework **protein**. At least two of the amino acid residues of the sample **protein** which substitute amino acid residues of the framework **protein** are non-continuous in primary sequence. The modified framework **protein** has increased structural similarity to the sample **protein**. The modified framework **protein** is capable of exhibiting a **function** which is either similar to, or inhibitory of, a **function** of the sample **protein**. The location and orientation of each amino acid side-chain of the framework **protein** and sample **protein** is simplified as a C-alpha-C-beta vector. The C-alpha-C-beta vector is in the form of a distance matrix representation. At step (c) the hits are ranked according to structural similarity with the sample **protein**. Searching at step (c) includes identification of the hits by clique detection and filtering the hits identified at step (a). The framework **protein** is a small cysteine-rich **protein** capable of internal disulfide bond formation. The small cysteine-rich **protein** comprises at most 70 amino acids, having 3-11 disulfide bonds. The sample **protein** is a cytokine.

Preferred Protein: The engineered **protein** exhibits a **function** either similar to, or inhibitory of a cytokine. The cytokine is selected from growth hormone (GH), interleukin (IL)-4, IL-6 and granulocyte-colony stimulating factor (G-CSF).

Preferred Computer Program: The computer program of (5) is a VECTRIX program, preferably a POSTVEC program.

L123 ANSWER 22 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-303449 [26] WPIX

CR 2000-482862 [41]; 2000-491075 [41]; 2000-514667 [41]

DIIN H2000-256734 DMC C2000-091051

TI Novel methods for recombining codon-altered libraries of nucleic acids used to produce new **proteins** and new vectors with reduced rates of reversion to wild type.

DC B04 C06 D16 J04 T01

IN LIN, L; FATTEN, P A; STEMMER, W P C

FA (MAXY-IN) MAXYGEN INC

CYC 37

PI WO 2000018306 A1 20000406 (200026)* EN 92p C12N015-10

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LC LU MC NW NL
OA PT SD SE SL SO TC TG TW

W: AE AL AM AT AU AZ BA BB BG BE BY CA CH CN CO CZ DE DK EE ES FI GB
GD GE GH GM GR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG US UZ VN YU ZA ZW

AU 2000011090 A 20000417 (200035) C12N015-10

ADT WO 2000018306 A2 WO 1999-022155 19990922; AU 2000111990 A AU 2000-11990 19990922

FMT AU 2000011990 A Based on WO 2000119900

PRAI US 1999-141049 19990624; US 1998-132362 19980919; US 1999-117729 19990129; US 1999-116813 19990205

IC ITM C12N015-10

ITS A61K039-21; B01J019-00; C07B061-00; C12N005-10; C12N007-04;
C12N015-11; G06F019-00

ICA C12N015-12; C12N015-43; C12N015-95

AB WO 200018406 A UPAB: 20000421

NOVELTY - A method of making codon altered nucleic acids (NAs), comprising providing a NA sequence (NA1, which encodes a **polypeptide** (P1), providing codon altered NA sequences, each encoding P1 or a modified form of it, and recombining the codon altered NA sequences to produce a target codon altered NA which encodes a second **protein**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a library of codon altered conservatively, or non-conservatively, modified NAs produced by the novel method;
- (2) the target codon altered NA produced by the novel method;
- (3) the cell, vector or virus comprising a target codon altered NA;
- (4) an attenuated virus, produced by recombining a target codon altered NA with a portion of the viral **genome**, which produces an immune response upon infection of the virus in a mammal;
- (5) a viral vector produced by recombining a target codon altered NA with a portion of the viral **genome**, where optionally the vector requires trans complementation for replication and has a reduced rate of reversion to a replicative form, compared to a wild type vector;
- (6) a method of making a library of codon altered NAs, comprising
 - (a) selecting a NA1 which encodes P1; and
 - (b) making codon altered NA sequences, comprising the library, each encoding P1 or a modified form of it;
- (7) a codon altered library made by the method of (6), which comprises at least 2, 5, 10, or 100 codon altered NAs;
- (8) a composition comprising codon altered NAs each of which encode P1 or a modified form of it;
- (9) a library of codon-altered NAs, comprising codon altered NAs derived from homologous NAs;
- (10) a kit comprising the library of (9), and a container and instructions for recombining two or more members of the library; and
- (11) an integrated system, comprising a computer or computer readable medium comprising a database having at least 2 artificial homologous codon altered NA sequence strings, and a user interface allowing an user to selectively view sequence strings in the database.

ACTIVITY - None given.

MECHANISM OF ACTION - Vaccine.

USE - The methods of the invention are used for recombining codon-altered libraries of nucleic acids to produce new **proteins**, which have improvements in a desirable characteristic. Target nucleic acids include those coding for therapeutic **proteins** such as EPO, insulin, **peptide** hormones, growth factors, cytokines, interferons, interleukins, leukemia inhibitory factor, and oncostatin M, as well as transcription and expression activators and **proteins** from infectious organisms for use as vaccines. The methods can also be used to produce attenuated viruses which have reduced rates of reversion to wild type.

DESCRIPTION OF DRAWING(S) - The figure is a schematic diagram of the human erythropoietin (EPO) wobble sequence space.

Dwg. 4/19

FS CFI EPI

FA AB; GI; DEN

MC CFI: B04-E02; B04-E03; B04-E05; B04-E08; B04-F0100E; B04-F1100E;

B04-N04; B11-C06; B11-C08E; B12-K04; B14-S11;

C04-E02; C04-E03; C04-E05; C04-E08; C04-F0100E; C04-F1100E;

C04-N04; C11-C06; C11-C08E; C12-K04; C14-S11;

D05-H07; D05-H09; D05-H12B2; D05-H11E; D05-H12F;

D05-H14; J04-B01

EPI: T01-J05B4P; T01-S03

TECH UPTX: 20000531

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: At least one of the codon altered NA sequences does not hybridize to NA1 under stringent conditions. The method further comprises shuffling a NA comprising a subsequence of NA1, or a substantially identical variant, with one or more of the codon altered NAs or with the target codon altered NA. The method

further comprises screening the second **protein** (P2) for a structural or **functional** property, and comparing this property to that of P1. P2 preferably has a structural or **functional** property equivalent to or superior to P1, or P1 and P2 are homologous. The codon altered NAs comprise a library of codon altered NAs, or a library of codon altered conservatively modified NAs. The codon altered NA is derived from forms of NA1, or comprises at least 3 codon altered NAs. The codon altered NA sequences comprise one or more of: codon usage divergence for each of the codon altered NAs of 50%, 75%, or 100% or more as compared to NA1, maximal codon usage divergence for each of the codon altered NAs as compared to NA1, non-overlapping non-conservative substitutions in each of the codon altered NAs as compared to NA1, lack of high stringency hybridization between one or more codon altered NAs and NA1, and modification of the codons to provide one or more different hydrophobic core residues for an encoded **polypeptide** as compared to the first **polypeptide**. The percent identity between P2 and P1 is lower than the percent identity between two of the codon altered NAs. Each of the codon altered NA sequences comprises at least two differences when compared to NA1. The method further comprises introducing the target codon altered NA into a cell, vector or virus.

Preferred Virus: The virus of (5) comprises viral elements from a lentivirus, a herpes virus, and an adenovirus-associated virus.

Preferred System: The system of (11) further comprises an automated oligonucleotide synthesizer operably linked to the computer or computer readable medium, which synthesizer is programmed to synthesize one or more oligonucleotides comprising one or more subsequences of one or more of the artificial homologous codon altered NAs.

Preferred library: The library of (9) comprises at least 2, 5, 10 or preferably 100 codon altered NAs.

TECHNOLOGY FOCUS - BIOLOGY - Preferred Polynucleotide: NA1 encodes erythropoietin alpha (EPO), granulocyte-colony stimulating factor (G-CSF), a viral envelope **protein**, a cytokine, and a phosphatase.

L123 ANSWER 23 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 2000-056855 (22) WPIX

DHN H2000-190969 DNC C2000-078429

TI Novel glycoprotease **polypeptides** and polynucleotides isolated from *Staphylococcus aureus*, used to screen for antibacterial compounds and to diagnose diseases.

DC B04 D16 S03 T01

IN KOSMATKA, A L; PALMER, L M; TRAINI, C M; WARREN, R L

PA (SMK) SMITHKLINE BEECHAM CORP

CYC 19

PI WO 2000013694 A1 20000316 (200022)* EN 59p A61K035-74

RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: JP

ADT WO 2000013694 A1 WO 1999-US19073 19990823

PPAI US 1998-149624 19980908

IC ICM A61K035-74

ICS A61K038-04; C07K016-00; C12N001-00; C12N015-00; C12N015-31;

C12P021-00; C12P001-68; G01N033-66; G06F017-30;

G06F159-00

AB WO 200013694 A UPAB: 20000508

NOVELTY - An isolated glycoprotease (gsp) **polypeptide** (I) selected from a **polypeptide** having at least 70%, 80%, 90% or 95% identity to a 341 residue amino acid sequence, over its entire length, a **polypeptide** comprising the 341 residue sequence, and a **polypeptide** encoded by a recombinant polynucleotide comprising the 1026 base pair (bp) sequence, is new. All sequences fully defined in the specification.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated polynucleotide (II) selected from a polynucleotide having 70%, 80%, 90% or 95% identity to a polynucleotide encoding (I); a polynucleotide having at least 70%, 80%, 90% or 95% identity to a 1026 bp

sequence, fully defined in the specification, over its entire length, a polynucleotide which has the 1026 bp sequence, a polynucleotide obtained by screening a library under stringent hybridization conditions with a probe having the 1026 bp sequence, or a fragment of it, a polynucleotide encoding a mature **polypeptide** expressed by the gcp gene of *Staphylococcus aureus*, and a polynucleotide sequence complementary to the them;

- (3) an antibody antigenic to or immunospecific for (1);
- (4) a method of treating of an individual in need of enhanced activity or expression of (1), comprising:
 - (a) administering to the individual an agonist to (1); or
 - (b) providing to the individual (II) in a form to effect production of the activity of (1) in vivo;
- (4) a method for treating an individual having need to inhibit activity or expression of (1), comprising:
 - (a) administering an antagonist to (1);
 - (b) administering a nucleic acid molecule that inhibits the expression (II); or
 - (c) administering a **polypeptide** that competes with (1) for its ligand, substrate or receptor;
- (5) a method for screening to identify compounds that activate or that inhibit the **function** of (1), comprising one of the following:
 - (a) measuring the binding of a candidate compound to (1) or to the cells or membranes bearing (1) or a fusion **protein** of it, using a label directly or indirectly associated with the candidate compound;
 - (b) measuring the binding of a candidate compound to (1) or to the cells or membranes bearing (1) or a fusion **protein** of it, in the presence of a labelled competitor;
 - (c) testing if the candidate compound results in a signal generated by activation or inhibition of the **polypeptide** using detection systems appropriate to the cells or cell membranes bearing (1);
 - (d) mixing a candidate compound with a solution containing (1), measuring activity of the **polypeptide** in the mixture, and comparing the activity to a standard;
 - (e) detecting the effect of a candidate compound on the production of mRNA encoding (1) and (I) in cells, using e.g. enzyme linked immunosorbant assay (ELISA); or
 - (f) contacting a composition comprising (1) with the compound to be screened under conditions permitting interaction between the compound and the **polypeptide** to assess the interaction of a compound, the interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the **polypeptide** with the compound, and determining if the compound interacts with and activates or inhibits an activity of (1) by detecting the presence or absence of a signal generated from the interaction of the compound with (1);
- (6) an agonist or an antagonist of the activity or expression of (1);
- (7) an expression system comprising a polynucleotide capable of producing (1) when the system is in a compatible host cell;
- (8) a host cell comprising the expression system of (8), or a membrane of the cell expressing (1);
- (9) a process for producing (1), comprising culturing a host cell of (9);
- (10) a process for producing a host cell comprising the expression system of (8) or a membrane of the cell expressing (1), comprising transforming or transfecting a cell with an expression system comprising a polynucleotide capable of producing (1) when present in a host cell;
- (11) a host cell produced by the process of (11) or a membrane of the cell expressing (1);
- (12) a computer readable medium onto which is stored a member selected from:
 - (a) a polynucleotide comprising the 1026 bp;
 - (b) a **polypeptide** comprising the 341 amino acid sequence;
 - (c) a set of polynucleotide sequences, at least one which comprises the 1026 bp sequence;

(d) a set of **polypeptide** sequences, at least one of which comprises the 341 amino acid sequence;

(e) a data set representing a polynucleotide sequence comprising the 1026 bp sequence; and

(f) a data set representing a polynucleotide sequence encoding a polypeptide sequence comprising the 341 amino acid sequence;

(13) a computer based method for performing homology identification, comprising providing a polynucleotide sequence comprising the 1026 bp sequence in a computer readable medium, and comparing the polynucleotide sequence to at least one polynucleotide or polypeptide sequence to identify homology; and

(14) a computer based method for polynucleotide assembly, comprising providing a polynucleotide sequence comprising the 1026 bp sequence, in a computer readable medium, and screening for at least one overlapping region between the polynucleotide sequence and a second polynucleotide sequence.

ACTIVITY - Antibacterial; cytostatic; antitumor; antiarthritic; vulnerary; immunosuppressive.

MECHANISM OF ACTION - The protein is a glycoprotease.

USE - The polynucleotides and polypeptides are used as research reagents for the discovery of treatments and diagnostics for diseases, particularly human diseases. The polynucleotides may be used as a source of hybridisation probes, for screening genetic mutations, and genotype, and for organism chromosome identification. The polypeptides can be used to produce antibodies, in vaccine formulations, to identify agonists and antagonists, and to screen for antibacterial drugs. These are used to prevent, inhibit or treat diseases, particularly of *Helicobacter pylori* infections, such as gastrointestinal carcinoma, gastric ulcers, and gastritis. Diseases diagnosed, treated and prevented by the products include osteomyelitis, septic arthritis, septic thrombophlebitis, acute bacterial endocarditis, Staphylococcal food poisoning, scalded skin syndrome, and toxic shock syndrome. The polypeptides can also be used to treat wounds and body implants to prevent bacterial adhesion and infection.

ADVANTAGE - The frequency of Staphylococcal infections has risen dramatically, and isolated *S. aureus* strains are increasingly resistant to standard antibiotics. The glycoprotease (gcp) products can be used screen for new antibacterial compounds that may target these resistant bacteria.

Dwg.0/0

FS CPI EPI

FA AB; DCN

MC CPI: B04-C01G; B04-E02E; B04-E08; B04-F0100E; B04-G03; B04-I05C0E;

B11-C07A4; B11-C08E5; **B12-K04A; B12-K04F;**

B14-A01; B14-A01A; B14-C03; B14-E08; B14-E10B; B14-G02; B14-N17A;

B14-N17E; B14-S06; D05-C03C; D05-H01; D05-H07; D05-H08;

D05-H09; D05-H11; D05-H12; D05-H12E; D05-H14; D05-H17A3;

E05-H16

EPI: S03-E14H4; S03-E14H1; T01-J05B

L123 ANSWER 24 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-204637 [18] WPIX

DNN H2000-152209 ENC C2000-063041

TI Database system for storing biomolecular sequence information in manner which permits sequences to be catalogued and searched according to one or more **protein function** hierarchies.

DC B04 B16 T01

IN AKERBLOM, I E; ALTUS, C M; AU-YOUNG, J; HILLMAN, J L; KLINGLER, T M; MASLYN, T J; RUSSO, F; SEILHAMER, J J

FA (INCY-N) INCYTE PHARM INC

CYC 1

PI US 6013659 A 20000208 (200013;+ 39p G06F007-08 <--

ADT US 6013659 A Provisional US 1996-28284 19961010, Provisional US 1996-32563 19961212, US 1997-812290 19970306

PRAI US 1997-812290 19970306; US 1996-28284 19961010; US 1996-32563 19961212

IC ICM G06F007-08

AB US 6027659 A UPAB: 20000413
 NOVELTY - At least some of the sequences in the database are grouped into a first hierarchy of **protein function categories** specifying biological **functions of proteins** corresponding to the sequences. The first hierarchy includes first and second sets of categories specifying **functions** at a cellular level and at a level above the cellular level respectively. A user interface allows a user to selectively view the information.

DETAILED DESCRIPTION - The sequences may include nucleic acid sequences and amino acid sequences. Records include descriptive information from an external database to which the biomolecular sequences are correlated. The external database may be GenBank. The second set of categories specifies biological **functions** at an organism or tissue level. At least some of the biomolecular sequences are grouped into a second hierarchy of **protein function categories**. These specify either the molecular or enzymatic **functions of proteins** corresponding to the sequences. The interface allows the user to selectively view information regarding a subset of the sequences which is grouped in selected categories from the first and second hierarchies, or sequence records associated with a category selected from the first hierarchy, or categories from the first hierarchy that are associated with a selected sequence record. Searches may be made using both the presence of keywords and the absence of anti-keywords.

INDEPENDENT CLAIM is included for a method and computer readable medium for using a computer to present information of biomolecular sequence records.

USE - The system stores and retrieves biological information. It may be used to catalogue animal sequences, e.g. human, primate, rodent, amphibian, insect, etc., plant sequences, and microbial sequences. The system may be used to establish a DNA **profile** for a given tissue and to evaluate changes in gene expression caused by disease progression, pharmacological treatment, aging, etc.

ADVANTAGE - The system allows sequence information to be catalogued and searched rapidly according to one or more **protein function hierarchies**.

DESCRIPTION OF DRAWING(S) - The drawing shows a block diagram of client-server Intranet for providing database services.
 Dwg.2A/6

FS CFI EPI
 FA AP; GI; DCN
 MC CFI: B04-B03C; B04-C01; E04-E01; **B04-N04**; B11-C08; B11-C08E4;
 B11-C09; **B12-K04A3**; **B12-K04E**; D05-H02;
D05-H09; D05-H12; D05-H18A; D05-C
 EPI: T01-E01A; T01-J05B1B; T01-C05B4M; **T01-S03**

L123 ANSWER 25 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-182726 [16] WPIX

CR 1999-312973 [26]

DNN NC000-134704 ENC C2000-057323

TI Determining **function of protein or polypeptide** domains, useful for drug discovery for **proteins** involved in neoplastic, metabolic, neurodegenerative, cardiovascular, psychiatric, inflammatory and infectious disorders.

DC B04 E16 **T01**

IN ANDERSON, S; HUANG, Y; MONTIELONE, G

PA (RUTE) UNIV RUTGERS STATE NEW JERSEY

CYC 86

PI WO 200005414 A1 20000103 (100010)* EN 71p C12001-68

FW: AT BE CH CY DE DK EA ES FI FF GB GH GM GP IE IT KE LS LU MC MW NL
 OA PT SD SE SL SO SW

W: AE AL AM AT AU AZ BA BB BG BR CA CH CN CU CL DE DK EE ES FI GB
 GD GE GH GM HR HU ID IL IN IS JP KE KG KM LC LF LR LS LT LU
 LV MD MG MH MI MW MX NO NZ PL PT RG RU SD SE SG SI SF SL TJ TM TR
 TT UA US UG UK VN YU ZA ZW

AU 9951155 A 20000114 (20000103)* EN 71p C12001-68

ADT WO 200005414 A1 WO 1999-US16417 19990721; AU 9951155 A AU 1999-51155

19990721

FDT AU 9851155 A Based on WO 200005414

PRAI US 1993-181601 19931219; US 1993-93641 19980721

IC ICM C120001-68

ICS C07K013-00; C12P019-34; G06F017-00

AB WO 200005414 A UPAB: 20000617

NOVELTY - A method for determining a biochemical **function** of a **proteins** or **polypeptide** domain comprises identifying a stable **polypeptide** domain and comparing 3-dimensional (3D) structure determined by nuclear magnetic resonance (NMR) to a known structure, is new.

DETAILED DESCRIPTION - A novel high-throughput method for determining a biochemical **function** of a **protein** or

polypeptide domain of unknown **function** comprises:

(a) identifying a putative **polypeptide** domain that properly folds into a stable **polypeptide** domain, the stable **polypeptide** having a defined 3D structure;

(b) determining 3D structure of the stable **polypeptide** domain from an automated analysis of NMR spectrometer spectra of the **polypeptide** domain, where the automated analysis is conducted by a NOESYAssign process;

(c) comparing the determined 3D structure of the stable **polypeptide** domain to known 3D structures in a **protein** data bank, where the comparison identifies known structures within the **protein** data bank that are homologous to the determined 3D structure; and

(d) correlating a biochemical **function** corresponding to the identified homologous structure to a biochemical **function** for the stable **polypeptide** domain.

INDEPENDENT CLAIMS are also included for the following:

(1) an integrated system for rapid determination of a biochemical **function** of a **protein** or **protein** domain of unknown **function** comprising:

(a) a first computer algorithm capable of parsing the target polynucleotide (tPN) into at least one putative domain encoding region;

(b) a designated lab for expressing the putative domain;

(c) a NMR spectrometer for determining individual spin resonances of amino acids of the putative domain;

(d) a data collection device capable of collecting NMR spectral data, where the data collection device is operatively coupled to the NMR spectrometer;

(e) at least one computer;

(f) a second computer algorithm capable of assigning individual spin resonances to individual amino acids of a **polypeptide**;

(g) a third computer algorithm capable of determining tertiary structure of a **polypeptide**, where the **polypeptide** has had resonances assigned to individual amino acids of the **polypeptide**;

(h) a database, where stored within the database is information about the structure and **function** of known **proteins** and determined **proteins**; and

(i) a fourth computer algorithm capable of determining 3D structure homology between the determined 3D structure of a **polypeptide** of unknown **function** to 3D structure of a **protein** of known **function**, where the **protein** of known structure is stored within the **protein** database, where the fourth computer algorithm determines the structure by an automated NOESYAssign process; and

(2) a high-throughput method for determining a biochemical **function** of a **polypeptide** of unknown **function** encoded by a tPN comprising:

(a) identifying at least one putative **polypeptide** domain encoding region of the tPN (parsing);

(b) expressing the putative **polypeptide** domain;

(c) determining if the expressed putative **polypeptide** domain forms a stable **polypeptide** domain with a defined 3D structure (trapping);

(d) determining the 3D structure of the stable **polypeptide** domain by an automated NMRAssign process;

(e) comparing the determined 3D structure of the stable **polypeptide** domain to known 3D structures in a **Protein** Data Bank to determine whether any such known structures are homologous to the determined structure; and

(f) correlating a biochemical **function** corresponding to the homologous structure to a biochemical **function** for the stable **polypeptide** domain.

USE - The methods can be used for elucidating the **function** of **proteins** and **protein** domains, particularly for drug discovery purposes. They can be used for domains from **proteins** genetically implicated in neoplastic, metabolic, neurodegenerative, cardiovascular, psychiatric and inflammatory disorders, such as Alzheimer's beta **peptide** precursor **protein** (APP), or domains from **proteins** associated with infectious agents, e.g. bacteria, fungi and viruses.

Dwg. G/23

FS CPI EPI

FA AB; DCN

MC CPI: B04-H02; B11-C04A; B12-K04A; D05-H09; D05-H12;
D05-H14; D05-H17

EPI: T01-J

TECH UPTX: 20000330

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred method: The novel method further comprises the prestep of parsing a target polynucleotide into at least one putative **polypeptide** domain. The parsing is performed by a first computer algorithm selected from a computer algorithm capable of determining exon phase boundaries of a polynucleotide and a computer algorithm capable of determining interdomain boundaries encoded in a polynucleotide. The method further comprises a computer algorithm which compares the putative **polypeptide** domain sequence with known domain sequences stored in a database. The NMR spectra are analyzed by a second computer algorithm which automatically assigns resonance assignments to the **polypeptide** sequence. The identification step comprises measuring a time course of amide hydrogen-deuterium exchange. Prior to the second step the **polypeptide** is optimally solubilized, comprising preparing an array of microdialysis buttons, each containing at least 1micro-l of an approximately 1mM solution of the **polypeptide** domain, dialyzing the members of the array against a different dialysis buffer, analyzing the dialyzed buttons to determine if the **polypeptide** domain has remained soluble, and selecting the domain having optimum solubility characteristics for NMR spectroscopy. The comparison of the 3D structures is performed by a third computer algorithm, preferably DALI, CATH or VAST, capable of determining 3D structure homology between the determined 3D structure and a member of the **protein** data bank (PDB).

L123 ANSWER 26 OF 75 WPIX COPYRIGHT 2001 DEEWENT INFORMATION LTD

AN 2000-136797 [12] WPIX

DNN N2000-100313 DMC C2000-041#90

TI An efficient, accurate and rapid computer database for estimating **protein functions** e.g. enzymatic activity, for **polypeptides** obtained from gene sequence translation.

DC B04 D16 T01

IN INAMURA, M; ITAI, A; ITAI, R; TOMIOKA, N

PA (MEDI-II) INST MEDICINAL MOLECULAR DESIGN INC

CYC 8)

FI WO 9962994 A1 19991202 (200012)* JA 26p G00F017-33 ---

FW: AT BE CH CY IE DE EA ES FI FF GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SO UG ZW

W: AL AM AN AU AD BA BB BC BE BF CA CH CN CU CD DE DF EE ES FI GR GE
GH GI GW HU ID IL IS KE KG KR KZ LC LF LG LH LT LU LV MD MG MK MN
MW MX NO NZ OL PT PQ PR PS SE SG SI SK SL TJ TM TR TT UA UG US UZ
VN YU ZW

AU 9874513 A 19991213 (200023)

G00F017-30 ---

ADT WO 9961004 A1 WO 1998-JP2302 19980526; AU 9874513 A AU 1998-74513
 19980526; WO 1998-JP2302 19980526
 FBT AU 9874513 A Based on WO 9961004
 PRAI WO 1998-JP2302 19980526
 IC I:M G06F017-30
 AB WO 9961004 A UPAB: 20000208

NOVELTY - A database containing information on the amino acid (aa) sequences of **proteins** of which 1 or more biological **functions** are known is new.

DETAILED DESCRIPTION - The database also contains additional information on the score of importance of each aa residue in the whole aa sequence in determining the known biological **functions**.

An INDEPENDENT CLAIM is also included for a method of preparing an **alignment** between aa sequences contained in the database and those of the unknown **polypeptide**. This is represented as the homology amongst various sites, each being identified as having a high score of importance in determining potential biological **functions**.

USE - The method is to enable an efficient estimation of the biological **functions**, particularly enzymatic and signaling activities, of (unknown **polypeptides** from their nucleotide sequences. Suitable **proteins** can then be isolated and purified by various means. This could be of considerable use in a biological and medical context.

ADVANTAGE - The computerized procedure is efficient, fast and accurate.

Dwg.0/1

FS CFI EPI

FA AB; DCN

MC CFI: B04-L05B; B04-L05A; B04-L05C; B04-N04; E11-C08;

B12-K04E; D05-H09

EMI: 2-1-1998

TECH UPTX: 20000308

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Database: The information contained in the database is particularly constructed from aa sequences of **proteins** with known biological **functions**, particularly information relating to the stereostructures of the applicable **proteins**. The database is incorporated into media with memory for use.

Preferred Method: A search procedure can be operated with the database to find homology between a **protein** in the database and unknown **protein**. A high correlation can be obtained by using sequence groups which contain 2 or more continuous aa residues of high importance score in exhibiting the biological **functions**. A final determination of homology and possible identity is obtained by the **alignment** of a single **protein** in the database and the target **protein**.

L123 ANSWER 27 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-097350 [08] WPIX

DNN H2000-075212 DDC C2000-028260

TI Optimization of agents to regenerate biosensor surfaces.

DC B04 D10 C04 S03 T01

IN ANDERSSON, K; HAEMAELEINEN, M; MALMQVIST, M; ROOS, R

FA (BIAC-N) BIACORE AB

CYC 21

PI WO 9963333 A1 19991109 (200008)* EN 131p G01N027-327

FW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: AU JP US

AU 9946658 A 19991129 (2000021) G01N027-327

ADT WO 9963333 A1 WO 1999-SR421 19990531; AU 9946658 A AU 1999-46658 19990531

FBT AU 9946658 A Based on WO 9963333

PRAI CF 1998-87402 19980519

IC I:M G01N027-327

ICS C10Q001-00; G01N033-543; G06F019-00

ICI G06F159:00

AB WO 9963333 A UPAB: 20000215

NOVELTY - A method for selecting an optimized regeneration solution for the regeneration of a biosensor surface having a surface-bound ligand and an analyte associated with the ligand, is new.

DETAILED DESCRIPTION - The method comprises:

(1) sequentially contacting the biosensor with first regeneration cocktails, where even one is in aqueous solution comprising at least one acidic, basic, ionic, organic, detergent or chelating stock solution, and where at least one of the cocktails comprises a mixture of at least two of the stock solutions;

(2) measuring the regeneration effect for each of the cocktails to determine which have the highest measured regeneration effect;

(3) selecting at least two different stock solutions present in the cocktails having the highest measured regeneration effect;

(4) combining the stock solutions in various ratios to generate another set of regeneration cocktails;

(5) sequentially contacting the biosensor surface with each of the new cocktails; and

(6) determining the regeneration effect of each cocktail, and identifying one as the optimized regeneration solution.

INDEPENDENT CLAIMS are also included for the following:

(1) a method for characterizing a ligand or analyte associated with a biosensor surface, comprising:

(a) contacting the biosensor surface, having a bound ligand, sequentially with characterization solutions;

(b) introducing the analyte into each solution, to interact with the bound ligand;

(c) measuring at least one of, association or dissociation rates, surface bound analyte concentration, and regeneration effect of the analyte and ligand interaction for each solution;

(d) characterizing the ligand or analyte from the results; and optionally

(e) comparing the characterization of the ligand and/or analyte associated with the biosensor surface with a set of predetermined characteristics of other test molecules, and predicting their activity; and

(2) a generated data signal, or computer memory containing a data structure, useful for communication of chemical perturbation information associated with an analyte-ligand interaction, comprising at least one kinetic parameter, each expressed as a mathematical model describing the relation between the parameter and analyte-ligand interaction in characterization solutions, so that the data can be used to communicate chemical perturbation information associated with the analyte-ligand interaction.

USE - Ligand-analyte binding pair interactions are used in assay work. They include antibody-antigen, hormone-hormone receptor, sense-antisense polynucleotides, avidin or streptavidin-biotin, enzyme-substrate or inhibitor, lectin-matching saccharide, lipid or polynucleotide-binding or matching **protein**, receptor-transmitter, drug target, **protein-protein**, DNA-DNA, and DNA-RNA. The process is used to break ligand-analyte interactions to regenerate a surface contaminated with analyte, for reuse in the next assay. Many surfaces suitable for carrying a required ligand are costly to produce, and must be reused if possible. As a notable example, the biosensor surface is a gold layer, which is capable of supporting surface plasmon resonance (SPR), or other optical detection and assay technique. The ligand is bound to this layer, preferably indirectly through a dextran matrix. The recovery can't be too harsh, or the ligand will be lost. The recovered analyte may be separated and collected for subsequent other assays if required. From a recovery **profile** from different solvents as determined with known samples, the analyte can also be characterized, even to detect minute differences, for quality control or other purposes. The interaction **profile** of ligand-analyte may be used to predict activity of the analyte, to be useful for screening. The regeneration and characterization procedures can be automated, using a computer. The computer is provided with a readable medium as a flowsheet, which instructs instrumentation to prepare the

various solutions (unless, initially, a kit is available), and following the contacting and assessment procedures as for manual control.

Dwg.0/33

FS CPI EPI

FA AB

MC CPI: B11-C07A; B11-C08E; B11-C08E3; B11-C08E5; B11-C09; B12-K04F; D05-A02; D05-H09; D05-H10; D05-H11; D05-H12D; J04-B01

EPI: S03-E04A5S; S03-E04B5; S03-E14H4; S03-E14H9; T01-J03; T01-J06A1;

T01-S01C; T01-S03

TECH UPTX: 20000215

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred components: The acidic solution is a mixture of acids having pK_a 7, and has a pH of 1-7. Specified acids include common inorganic, carboxylic and sulfonic acids, amino acids, phenols and purine acids, the most preferred acid is a mixture of oxalic, phosphoric, formic, and malonic acids. The basic solution is a mixture of bases having pK_a 12, examples include basic salts, ammonium, lead and zinc hydroxides, hydroxylamine and hydrazine, the most preferred is a mixture of ethanolamine, sodium phosphate, piperamine and glycine. The solvent is preferably a mixture of dimethyl sulfoxide, formamide, ethanol, acetonitrile and 1-butanol. The detergents anionic, cationic, zwitterionic and non-ionic, most preferably CHAPS, Switertgent 3-12 (RTM), Tween 80 (RTM), Tween 20 (RTM), and Triton X-100 (RTM). Chelating solutions include EDTA, EGTA, NTA, DCTA, GLEDTA, ETHEPTA, HDA and crown ethers, most preferably EDTA. A guiding concentration for each component is a minimum of 20mM. In the mixed solutions e.g. for KGE, nonpolar stock solutions may also be included. The characterization solutions are the same types (acidic, basic, ionic, organic, detergent and chelating, as the regeneration solutions and cocktails.

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred components: Ionic solutions are predominantly inorganic, the organic being acetic and haloacetic, and tetramethyloxonium, most preferably potassium thiocyanate, magnesium chloride, urea and guanidinium chloride.

L123 ANSWER 28 OF 73 WPIN COPYRIGHT 2001 DEWENT INFORMATION LTD

AN 2000-097278 [06] WPIN

DIN NZ000-075173 DMC C2000-013203

TI Novel **polypeptide** used to diagnose and treat bacterial infection.

DC B04 D16 S03 T01

IN BLACK, M T; JAWORSKI, D D; KOSMATKA, A L; SHILLING, L K; WANG, M; WILDING, E I

FA (SMIK) SMITHKLINE BEECHAM CORP

CYC 19

FI WO 9962527 A1 19991209 (200006)* EN 37p A61K035-74

FW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: JI

ADT WO 9962527 A1 WO 1999-US12301 19990603

PEAI US 1998-92218 19980605

IC ICM A61K035-74

ICS A61K038-04; C07K016-00; C12N001-00; C12N015-00; C12N015-31;

C12P001-02; C12Q001-01; G01N033-68; G06F017-30;

G06F159-00

AB WO 9962527 A UPAB: 20000215

NOVELTY - An isolated **polypeptide** (A) selected from: a **polypeptide** comprising at least 70, 80, 90 or 95% identity to the 719 residue amino acid sequence fully defined in the specification, a **polypeptide** which comprises, or is, the 719 residue sequence, and a **polypeptide** encoded by a recombinant polynucleotide comprising the 2100 bp DNA sequence fully defined in the specification, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated polynucleotide selected from: a polynucleotide comprising a polynucleotide sequence encoding (A); a polynucleotide comprising a sequence that has at least 70, 80, 90 or 95% identity to a

polynucleotide sequence encoding the 719 residue sequence, a polynucleotide sequence comprising at least 70, 80, 90 or 95% identity to the 2160 bp DNA sequence, a polynucleotide comprising a sequence encoding the 719 residue sequence, a polynucleotide which is the 2160 bp DNA sequence, an isolated polynucleotide obtained by screening a library under stringent hybridization conditions with a probe having the 2160 bp DNA sequence or a fragment of it, a polynucleotide encoding a mature **polypeptide** expressed by the *nmfE* gene contained in *Streptococcus pneumoniae*, and a polynucleotide sequence complementary to any of the isolated polynucleotides above;

- (1) an antibody antigenic or immunospecific for (A);
- (2) a method for the treatment of an individual:
 - (a) in need of enhanced activity or expression of (A) comprising administering to the individual an agonist to the **peptide**; or providing to the individual an isolated polynucleotide comprising the polynucleotide sequence encoding the **polypeptide** in a form so as to effect production of the **polypeptide** activity *in vivo*; or
 - (b) having need to inhibit the activity or expression of (A), comprising, administering to the individual an antagonist to the **peptide**, a nucleic acid molecule that inhibits the expression of a polynucleotide sequence encoding the **polypeptide**, or a **polypeptide** that competes with (A) for its ligand, substrate or receptor;
- (3) a process for diagnosing or prognosing a disease or susceptibility to a disease in an individual related to expression or activity of (A) comprising determining the presence or absence of a mutation in the nucleotide sequence encoding (A) in the **genome** of the individual, or analyzing for the presence or amount of (A) expression in a sample derived from the individual;
- (4) a method for screening to identify compounds that activate or inhibit the **function** of (A) comprising:
 - (a) measuring the binding of a candidate compound to (A) or to cell membranes bearing it or a fusion **protein** thereof by means of a label directly or indirectly associated with the candidate compound, or in the presence of a labeled competitor;
 - (b) testing whether the candidate compound results in a signal generated by activation or inhibition of (A), using detection systems appropriate to the cells or cell membranes bearing (A);
 - (c) mixing a candidate compound with a solution containing (A), to form a mixture, measuring activity of (A) and comparing the activity of the mixture to a standard;
 - (d) detecting the effect of a candidate compound on the production of mRNA encoding (A) and (A) in cells, using for instance an ELISA assay; or
 - (e) contacting a composition comprising (A) with the compound to be screened under conditions to permit interaction between the compound and (A) to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in response to the interaction of (A) with the compound, and determining whether the compound interacts with and activates or inhibits an activity of (A) by detecting the presence or absence of a signal generated from the interaction of the compound with (A);
- (5) an agonist or antagonist of the activity or expression of (A);
- (6) an expression system comprising a polynucleotide capable of producing (A) when the expression system is present in a compatible host cell;
- (7) a host cell comprising the expression system of (6) or a membrane of it expressing (A);
- (8) a process for producing (A) comprising the step of culturing the host cell of (6) under conditions sufficient for the production of (A);
- (9) a process for producing a host cell comprising the expression system of (6) or a membrane of it expressing (A) comprising the step of transforming or transfecting a cell with an expression system comprising a polynucleotide capable of producing (A) when the expression system is present in a compatible host cell, under appropriate conditions, produces (A);
- (10) a host cell produced by the process of (9) or a membrane

thereof expressing (A);

(12) a computer readable medium having stored thereon: a polynucleotide comprising the 2160 bp DNA sequence, a **polypeptide** comprising the 719 residue sequence, a set of polynucleotide sequence where at least one of the sequences comprises the 2160 bp DNA sequence, a set of **polypeptide** sequences where at least one of the sequences comprises the 719 residue sequence, a data set representing a polynucleotide sequence comprising the 2160 bp DNA sequence, and encoding a **polypeptide** sequence comprising the 719 residue sequence;

(13) a computer based method for performing homology identification, comprising providing a polynucleotide sequence comprising the 2160 bp DNA sequence in a computer readable medium and comparing the polynucleotide sequence to at least one polynucleotide or **polypeptide** sequence to identify homology; and

(14) a computer based method for polynucleotide assembly, the method comprising providing a first polynucleotide sequence comprising the 2160 bp DNA sequence in a computer readable medium, and screening for at least one overlapping region between the first polynucleotide sequence and a second polynucleotide sequence.

ACTIVITY - Antibiotic; antiinflammatory; auditory; antilulcer.

MECHANISM OF ACTION - Vaccine.

USE - The rnde sequences may be used in a diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs. The sequences are preferably used to diagnose bacterial infections, particularly those caused by *Streptococcus pneumoniae*. The sequences may also be used to prevent *Helicobacter pylori* infection, and stomach cancer, ulcers and gastritis caused by *H. pylori* infection. They may also be used to treat diseases caused or related to infection by bacteria, including otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema, and endocarditis.

ADVANTAGE - None given.

Dwg. 0/0

FS CPI EPI

FA AE; DCU

MC CPI: B04-C01G; B04-E02F; B04-E05; B04-E06; B04-E08; B04-F010E;

B04-W03A0E; B11-A01; B11-C03E5; **B12-K04A4; B12-K04F**

; B14-A01B2; B14-F01; B14-J01; B14-K01; B14-M03; B14-N04; D05-H08;

D05-H09; D05-H11; D05-H12A; D05-H12D1; D05-H12D2; D05-H12E;

D05-H13; D05-H14; D05-H17A0

EPI: S03-E14H4; S03-E14H5; T01-J16C4

L123 ANSWER 29 OF 73 WPIX COPYRIGHT 2001 REFRENT INFORMATION LTD

AN 2000-038624 [03] WPIX

DNN H2000-029163 DMC C2000-009847

TI Three dimensional computer modeling to identify HLA binding compounds useful for modulating immune responses.

DC B02 B05 D16 **T01**

IN KOHLEF, N; LIU, M; RICHERT, J F; WANG, S; WU, X; YIN, D

PA (SEOU) UNIV GEORGETOWN

CYC 35

PI WO 9955681 A1 19991104 (200003)* EN 64p C07D239-72

EW: AT BE CH CY DE DK EA ES FI FR GB GR GM HE IE IT KE LG LU MC MW NL
OA PT SD SE SL SG UG TW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU DE DK EE ES FI GB
GD GE GH GM HE HU ID IL IN IS JP KE KG KP KR KS LC LF LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG UC VN YU ZA ZW

AU 9936691 A 19991116 (200013) C07D239-72

ABT WO 9955682 A1 WO 1999-059218 19990429; A1 9936691 A AU 1999-36691 19990429

FDT AU 9936691 A Based on WO 9955682

PEAI US 1998-83426 19990419

IC ICM C07D239-72

ICS C07D215-16; C07D217-00; C07D217-10; C07D217-22; **G06F019-00**

AB WO 9955682 A UPAB: 20000113

NOVELTY - Methods (A) for identifying and using HLA (Histocompatibility Lymphocyte-A System) binding compounds as HLA-agonists and antagonists,

comprising the computational processing of a database containing 3-dimensional structures of receptor sites and chemical compounds, are new.

DETAILED DESCRIPTION - Method (A) of processing a compound data base containing 3-dimensional structures of chemical compounds to provide a lead compound capable of blocking a receptor site in a host molecule comprising:

- (1) modeling the 3-dimensional structure of the receptor site;
- (2) positioning a compound from the data base in the receptor site and assigning a geometrical-fit score, indicating the fit between the compound and the receptor site;
- (3) ranking the compounds in the data base according to their score, and forming a group of compounds with a rank of a predetermined value, or higher;
- (4) minimizing an energy function describing interactions between a compound and a receptor site by adjusting coordinates of the compound to obtain a minimum energy compound-host molecule complex structure;
- (5) ranking the compounds according to their minimum energy values and forming a subgroup of compounds with a minimum-energy rank of a predetermined value or higher; and
- (6) visualizing (on a computer) a minimum energy compound-host molecule complex and forming a second subgroup of compounds with a visual-fit satisfying a predetermined criterion.

An INDEPENDENT CLAIM is also included for a method of inhibiting the interaction of an HLA molecule to an antigen comprising the administration of at least one compound of formula (I).

R1, R2 = optionally substituted phenyl, benzyl or other 5- or 6-membered aromatic ring system, optionally containing one or more heteroatoms selected from O, S and N

R3, R4 = H, optionally substituted phenyl, benzyl or other aromatic ring system, 1-10 C alkyl, 1-10 C alkoxy, halogen, SO2M, amide, or COOR
M = H or alkyl

R1 = H or alkyl

R5, R6, R7, R8 = H, halogen (F, Cl, Br, I), alkyl, 1-10C alkoxy, amide, NO2, amine, 1-10C cycloalkyl, nitroso, OH, ether, ester, sulfonic acid, alkenyl or allyl

X, Y = H or C

ACTIVITY - Immunosuppressive.

MECHANISM OF ACTION - HLA-agonists and antagonists.

USE - Compounds identified by (A), or of formula (I) can be used to treat autoimmune diseases, graft versus host disease, transplant rejection and multiple sclerosis.

ADVANTAGE - (A) allows adjusting of a compound's structure to optimize the fit between the host molecule and homologous compound. The method also allows for the modeling of host **proteins** whose 3-D structure is unknown.

DESCRIPTION OF DRAWING(S) - The diagram shows a 3-D model of the HLA-DR301 molecule produced by homology modeling.

[wg.1/10]

FS CFI EPI

FA AE; G1; DYN

MC CFI: E04-R04C2; B04-C01; B04-E01; B04-G04; B04-G05; B04-N01; E06-D04; R06-D07; B10-AC0C; B11-C03; E14-G02; B14-G02C; B14-G02E; E14-L01; B14-L06; B14-S01; D05-H09; D05-H11
EPI: T01-J05B4B; T01-J05B4E; T01-J06A; T01-J10C4

TECH CPTX: 20000118

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Treatment: Compounds of formula (I) are further administered with another active agent selected from CD40-ligand antagonist, soluble CD40, anti-cytokine antibody or anti-cytokine receptor antibody. HLA-inhibition results in reduced cytokine, preferably IL-2, production.
Preferred Compound: (I) is 2-(4-(acetamino(phenyl)amino)-N-(6-(((4-(acetamino(phenyl)amino)sulfonyl)-4-oxo(3-hydroquinazolin-3-yl))acetamide or one of 15 disclosed analogues, especially 2-((2,4-dichlorophenyl)amino)-N-(7-(((2,4-dichlorophenyl)amino)sulfonyl)-1-

oxo(hydronaphthyl)acetamide.

TECHNOLOGY FOCUS - BI-TECHNOLOGY - Preferred Energy Function:

The energy **function** of (4) comprises a Van der Waals interaction term and an electrostatic interaction term. Minimizing the energy **function** comprises probing the compound's conformational flexibility. The minimum energy is a global minimum of the **function**. Modeling the 3-dimensional structure of the receptor sites comprises providing a set of three coordinates for each atom of the host molecule (preferably HLA-DR-1301) defining a position of the center of the atom in a 3-dimensional referential.

Preferred Processing Method: The host molecule is a **protein** with known primary and secondary structures, and unknown tertiary structure. The position of the center of each atom of the host molecule is provided by:

- (a) **aligning** the host molecule sequence with a homologous **protein** (preferably IF1 with a tertiary structure defined by an X-ray structure of 5S1 complexed with an influenza **peptide**) sequence obtained from a database of **proteins** with known tertiary structures;
- (b) assigning a sequence-homology score to each homologous **protein**, indicating the percentage of amino acids occupying identical positions in the host and homologous sequences, and forming a template host tertiary structure by overlaying the atoms of a host molecule backbone on the backbone of a homologous **protein** with a sequence-homology score of a predetermined value or higher, and overlaying the atoms of a host side chain with an equivalent side chain in the homologous **protein** on the corresponding atoms in the homologous **protein**; and
- (c) refining the tertiary structure template by adjusting the positions of atoms in a host side chain lacking an equivalent side chain in the homologous **protein** to provide a structure with a low energy value defined by interactions between the atoms in the host molecule. Refining the template tertiary structure preferably comprises positioning a template compound with known host-binding properties in the receptor site, and adding a term describing interactions between the template compound and a host molecule side chain to the internal energy **function**. The method further comprises testing identified compounds for their ability to specifically bind to HLA-DR1301 and selecting those with the greatest binding affinity. Analogues of the selected compounds are obtained, and are tested by an in vitro assay that measures binding to HLA-DR1301, and those with the greatest affinity are selected for in vivo usage.

Preferred Receptor Site: The receptor site comprises a negatively charged pocket and a hydrophobic pocket, and the template compound comprises the side chains of residues 154 and 162 of Myelin Basic **Protein**. The side chain of residue 154 is disposed in the hydrophobic pocket and the side chain of residue 162 is in the negatively charged pocket.

L123 ANSWER 30 OF 73 WPIX COPYRIGHT 1991 DEFWENT INFORMATION LTD

AN 1999-038354 (03) WPIX

DNN H2099-028949 DDC C0000-009744

TI Novel Staphylococcal and polynucleotides and **polypeptides** useful for screening for antibacterial compounds.

DC B54 D16 D21 D22 S03 T01

IN BLACK, M T

PA (SMITH) SMITHKLINE BEECHAM CORP

CYC 20

FI WO 9447147 A1 1999-0913 (199903) EN 55p A61K035-74

PW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: JP

EP 1064007 A1 20010103 (200101) EN A61K035-74

R: BE CH DE DK FF GB IT II NL

ADT WO 9447147 A1 WO 1999-038354 19990315; EP 1064007 A1 EP 1999-912551
19990315; WO 1999-038354 19990315

FLT EP 1064007 A1 Based on WO 9447147

FRAI US 1998-40213 19980317

IC ICM A61K035-74
 ICS A61K038-04; C07K016-00; C12N001-00; C12N015-00; C12N015-31;
 C12P021-02; C12Q001-68; G01N033-63; G06F017-30;
 G06F159-00

AB WO 9947147 A UPAB: 20000118
 NOVELTY - nrdG polynucleotide (II) isolated from *Staphylococcus aureus* and the **polypeptide** (I) it encodes, is new.

DETAILED DESCRIPTION - The isolated nrdG polynucleotide (II) selected from:

(a) an isolated polynucleotide that has at least 95% identity to, and over the entire length of, a nucleotide sequence encoding the 173 amino acid sequence (S1) given in the specification;

(b) an isolated polynucleotide comprising a nucleotide sequence which has at least 95% identity to the 534 basepair sequence (S2) given in the specification;

(c) an isolated polynucleotide that has or is the S2 sequence;

(d) an isolated polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a probe having the S1 sequence, or its fragment;

(e) an isolated polynucleotide encoding a mature **polypeptide** expressed by the nrdG gene of *S. aureus*; and

(f) a polynucleotide sequence complementary to the polynucleotides of (a) to (e).

INDEPENDENT CLAIMS are also included for the following:

(1) An isolated **polypeptide** selected from:

(a) an isolated **polypeptide** comprising an amino acid sequence having at least 95% identity to S1;

(b) an isolated **polypeptide** comprising S1;

(c) an isolated **polypeptide** which is S1;

(d) An antibody antigenic to or immunospecific for the **polypeptide** of (1);

(3) A method for the treatment of an individual in need:

(a) of enhanced activity or expression of (1);

(b) to inhibit activity or expression of the **polypeptide** of

(1);

(4) A process for diagnosing or prognosis a disease or a susceptibility to a disease in an individual related to expression or activity of (1), comprising:

(a) determining the presence or absence of a mutation in (II) in the **genome** of the individual; and/or

(b) analyzing for the presence or amount of expression of (II) in a sample derived from the individual;

(c) A method for screening to identify compounds that activate or that inhibit the **function** of the **polypeptide** of (1);

(6) An agonist or an antagonist of the activity or expression of the **polypeptide** of (1);

(7) An expression system comprising a polynucleotide capable of producing the **polypeptide** of (1) when the expression system is present in a compatible host cell;

(8) A host cell comprising the expression system of (7) or its membrane expressing the **polypeptide** of (1);

(9) A process for producing the **polypeptide** of (1) comprising culturing the host cell of (8) under conditions sufficient for the production of the **polypeptide**;

(10) A process for producing a host cell comprising the expression system of (7), comprising transforming or transfecting a cell with an expression system such that the host cell, under appropriate culture conditions, produces the **polypeptide** of (1);

(11) A host cell produced by the process of (10) or its membrane expressing **polypeptide** of (1);

(12) A computer readable medium having stored on it a member selected from the group consisting of:

(a) a polynucleotide comprising the S2 sequence;

(b) a polypeptide comprising the S1 sequence;

(c) a set of polynucleotide sequences wherein at least one of the sequences is S2;

- (d) a set of polypeptide sequences wherein at least one of the sequences comprises the S1 sequence;
- (e) a data set representing a polynucleotide sequence comprising the S2 sequence;
- (f) a data set representing a polynucleotide sequence encoding a polypeptide sequence comprising the S1 sequence;
- (g) a polynucleotide comprising the S2 sequence;
- (h) a polypeptide comprising the S1 sequence;
- (i) a set of polynucleotide sequences where at least one of the sequences comprises the S2 sequence;
- (j) a set of polypeptide sequences where at least one of the sequences comprises the S1 sequence;
- (k) a data set representing a polynucleotide sequence comprising the S2 sequence;
- (l) a data set representing a polynucleotide sequence encoding a polypeptide sequence comprising the S1 sequence; and
- (13) A computer based method for performing homology identification, comprising providing a polynucleotide sequence comprising the S2 sequence given in the specification in a computer readable medium, and comparing the polynucleotide sequence to at least one polynucleotide or polypeptide sequence to identify homology.

ACTIVITY - Antibacterial; Cytostatic; Vulnerary.

MECHANISM OF ACTION - Vaccine.

USE - The polynucleotides and polypeptides may be employed as research reagents and material for the discovery of treatments and diagnostics for diseases, particularly human diseases. They can be used for diagnosis of the disease and staging of disease, and as reagents in differential screening methods. The polynucleotides may be used as a source for hybridization probes, and for screening of genetic mutations, serotype, and identification, and for organism chromosome identification. The polypeptides can be used to produce antibodies. The polypeptides can also be used in vaccine formulations, and to identify agonists and antagonists. These are used to prevent, inhibit or treat diseases, particularly of *Helicobacter pylori* infections, such as gastrointestinal carcinoma. Diseases diagnosed, treated and prevented by the products include infections of the upper and lower respiratory tract, cardiac, gastrointestinal, CNS, eye, kidney and urinary tract, skin, bone and joint. The polypeptides can also be used to treat wounds and body implants to prevent infection.

ADVANTAGE - The frequency of Staphylococcal infections has risen dramatically, and it is no longer common to isolated *S. aureus* strain that are resistant to standard antibiotics. The rrdG products of the invention can be used screen for new antibacterial compounds that may target these resistant bacteria.

Dwg.0/0

FS CFI EPI

EA AB; DCN

MC CFI: B04-C01G; E04-E03F; E04-E05; E04-E08; E04-F10A3E; B04-F1100E;
 B04-G01; E04-N03A; **B12-K04A**; E14-A01; E14-E01; E14-J01;
 E14-L01; E14-L06; E14-N01; E14-N03; E14-N07; E14-N10; E14-N17B;
 E14-S11B; D05-A01A4; D05-A01B; D05-H07; D05-H08; **D05-H09**;
 D05-H11; D05-H12A; D05-H12D1; D05-H12E; D05-H14; D05-H17A6; D08-B09;
 D09-C01D
 EPI: S03-E14H; T01-J05B

L123 ANSWER 31 OF 75 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1999-579903 [49] WPIX

DNN N1999-428125 DMC C1999-168667

TI Identifying pathways of drug action.

DC B04 F16 S02 T01

IN FRIED, S H; STOUGHTON, R

PA (ROSE-N) ROSETTA PHARMATICS INC

CYC 36

PI US 5465352 A 19921011 (199249)* 47; C10001-00

WO 9453708 A1 19941116 (200001) EN C10001-00

FW: AT BE CH CY DE DK EA ES FI FF GB GH GM GR IE IT KE LS LU MC MW NL

OA PT SD SE SL SC SG SW

W: AE AL AM AT AU AS BA BB BG BR BY CA CH CN CU CI DE DK EE ES FI GB
GD GE GH GM HN HU ID IL IN IS JP KE KG KP KR KI LC LE LF LG LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TC TM TR
TT UA US UE UN VU ZA SW

AU 9928906 A 19991129 (200013) C12Q001-00

ADT US 5965353 A US 1998-74983 1999-0506; WO 99-58708 A1 WO 1999-US10056
19990507; AU 9938906 A AU 1999-24996 1999-0507

FDT AU 9938906 A Based on WO 9958708

FRA1 US 1998-74983 19980508

IC ICM C12Q001-00

ICS A61P044-00; C12N001-00; C12Q001-00; C01N003-30; G06F017-00;

G06F017-14

AB US 5965353 A UPAB: 19991124

NOVELTY - Methods for determining the primary and secondary biological pathways through which drugs act on cells and identifying the **proteins** and genes which are affected via each pathway, are new. Methods are also included for identifying the pathways affected by environmental change, disease and those through which the side-effects of drugs are mediated.

DETAILED DESCRIPTION - A method (I) for identifying the biological pathways involved in the action of a drug on a cell, comprises:

(i) determining the cellular response produced in the cell by different levels of exposure to the drug (by measuring its effects on a number of cellular constituents);

(ii) representing a model of drug response as a combination of biological pathway responses (produced by measuring the cellular constituents of a biological pathway in response to different levels of perturbation) in the cell, one of which is subject to an independent scaling transformation; and

(iii) determining best scaling transformations of the biological pathway responses which minimize the value of an objective **function** of the difference between the candidate drug response and the model drug response (the combination of the responses subject to the best scaling transformation identifies the biological pathways involved in the action of the drug on the cell type).

Other INDEPENDENT CLAIMS are included for similar methods for:

(1) determining a more pathway-specific drug candidate from an initial drug candidate;

(2) identifying specific biological pathways which are involved in the action of a drug and which mediate side-effects of the drug;

(3) identifying a number of specific biological pathways that are involved in mediating therapeutic efficacy for a disease or disorder;

(4) measuring the similarity of the effects of two drugs on a cell type;

(5) identifying biological pathways involved in the effects of an environmental change upon a cell type; and

(6) identifying biological pathways involved in the effects of an environmental change upon a cell type.

USE - The methods may be used to characterize the effects of drugs on cells, in particular for finding biological pathways in cells affected by drug action and by environmental change and disease. This information is useful in the discovery of new drugs and alternative therapies and in understanding efficacy, side effects, toxicities and activation of metabolic responses.

Dwg. 6/9

FS CPI EPI

FA AB; DCU

MC CPI: B04-F01; B11-A; B11-C03E1; B11-C03E2; B12-K04A;

B12-K04E; D05-A04; D05-H03; D05-H09

EPI: S03-E14H4; T01-J04B1

TECH UPTX: 19991124

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: In (I), step (iii) comprises determining an actual minimized value of the objective **function**. This is determined from the candidate drug response and the model drug response. Therefore, (I) further comprises a step of

assessing the statistical significance of the best scaling transformations in a number of pathways. This comprises:

- (i) obtaining an expected probability distribution of the minimized values of objective **function**; and
- (ii) assessing the statistical significance of the actual minimized value of objective **function** in view of the expected probability distribution of minimum values of objective **function**.

The expected probability distribution of the minimum values of objective **function** comprises:

- (i) randomizing the drug responses at different levels of drug exposure and randomizing the model drug response by randomizing a number of biological pathway responses at different levels of perturbation;
- (ii) determining a theoretical minimum value of the objective **function** by finding best scaling transformations of a number of the randomized pathway responses which minimize the objective **function** or the difference between the randomized responses and the randomized model responses; and
- (iii) repeating steps (i) and (ii) to determine a number of theoretical minimum values (which form an expected probability distribution of minimized values).

The method (I) may further comprise verifying that the biological pathways are actually involved in the action of the drug by selecting a model response (either the first or second model response) which behaves most similarly to a combined drug perturbation response. The drug perturbation response is provided by measuring a number of cellular constituents in a cell exposed simultaneously to varying levels of drug exposure and varying levels of perturbations within the biological pathways. The first and second model responses comprise a combination of several pathway responses subject to best scaling transformations evaluated at a number of sums (each sum is the sum of a number of levels of drug exposure subject to the scaling transformations and varying levels of perturbations to the pathways). The biological pathways are verified as pathways involved in the action of the drug if the first model response is used.

(I) may also comprise assigning a cellular constituent present in the drug response to one or more of the biological pathways (the biological pathway response of the constituent subject to its best scaling transformation has the greatest correlation with the drug response of the cellular constituent). The scaling transformations comprise transforming levels of drug exposure to corresponding levels of perturbation to the biological pathways. Transforming is done by linear mapping. The objective **function** is minimized by selecting best sets of parameters for the scaling transformations. The objective **function** comprises a sum of the squares of differences in drug responses at varying levels of exposure to the drug and the model response at differing levels of exposure (further subject to scaling transformations). The objective **function** comprises the negative of the correlation of the drug response and the model drug response.

The biological pathway responses are produced by a method comprising interpolating the measured values (by approximating a sum of spline **functions** or a Hill **function**). The pathways tested are chosen from a compendium of those likely to be involved in drug responses. The cellular constituent measured is preferably RNA, measured by contacting a gene transcript with RNA of the cell or with cDNA derived from it. The transcript array comprises a surface with attached nucleic acids or mimics which are capable of hybridizing to the RNA (or cDNA). The RNA levels in drug-treated and untreated cells is compared.

Protein levels may also be measured using antibody arrays (comprising a surface with attached antibodies which bind to the **proteins**; or by 2 dimensional electrophoresis.

The activities of the cellular constituents may also be measured. The biological pathways originate at a number of specific cellular constituents under the control of an expression system. Perturbations are caused by altering the expression and activity constituents (e.g. by transfection with a heterologous gene or by the action of ribozymes and antisense sequences). The expression of the constituents may also be altered by the expression of the **protein** as a fusion

protein comprising the **protein** and a degen (which degrades the **protein**), or by the use of antibodies to the **protein** or other antagonists, drugs and dominant negative mutant **proteins**.

Preferred Cells: The cells are substantially isogenic to *Saccharomyces cerevisiae*.

L123 ANSWER 32 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1999-979766 [48] WPIX

NNN N1999-429477 INC C1999-166577

TI Predicting the folded structure of **proteins**.

IC B04 B16 B04 B03 T01

IN BENNER, S A

FA (BENNER-1) BENNER, S A

CYC 1

E1 US 5958784 A 19990916 (199949)* 113p G01N033-00

ADT US 5958784 A US 1992-937224 19920325

PRAI US 1992-857324 19930325

IC ICM G01N033-00

ICS G06F015-00

AB US 5958784 A UPAB: 19991122

NOVELTY - Predicting the folded structure of **proteins**, by aligning sequences of homologous **proteins** and using patterns of **evolutionarily** conserved and varied sequences to assign positions, is new.

DETAILED DESCRIPTION - This method is used for predicting the folded structure of **proteins**, comprising aligning the sequences of homologous **proteins**, using patterns of conservation and sequence variation with clearly defined **evolutionary** relationships. Positions in the alignment are assigned to the surface or inside of the folded structure, active sites, and parsing segments. Secondary structural units are assigned by identifying periodicity in the assignments, and assembled into globular form using distance constraints imposed by disulfide bridges, active site assignments and co-variation analysis.

An INDEPENDENT CLAIM is also included for a method predicting the secondary structure of **proteins** using the above method up to the point of assigning secondary structural units.

USE - The predicted secondary structures are useful for identifying antigenic sites on a **protein** molecule, as guides for site directed mutagenesis studies, and for understanding the interaction of a **protein** with other molecules.

ADVANTAGE - The method is more efficient than prior art methods of predicting folded structure of **proteins**.

Dwg. C/28

FS CPI EPI

FA AB; DCU

MC CPI: B04-N04; B11-Q06E; B12-K04E; B05-H03; B04-B01

EPI: B03-E14; T01-7

TECH UPTX: 19991122

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Essential features: Essential features of the method are:

- (i) examining aligned sequences of several homologous **proteins** rather than a single sequence of a single **protein**;
- (ii) extracting information concerning the three dimensional structure of the **protein** family from patterns of conservation and variation within a set of homologous sequences, rather than by a simple averaging of a property of the sequences taken individually;
- (iii) combining algorithms that assign positions in the alignment to the surface or interior of the folded structure, and to the active site, as a first step for predicting secondary structural elements;
- (iv) identifying separate secondary structural elements in the alignment, using parsing algorithms that identify gaps in the alignment and specific parsing sequence motifs;
- (v) the algorithms are applied to subgroups of **proteins** with clearly identified **evolutionary** relationships, in particular a clearly specified sequence identity and **evolutionary** distance;

(vi) the algorithms are designed to reflect how natural selection and neutral drift influence the divergent **evolution** of **protein** sequences; and
 (vii) assembling the secondary structural elements to form super secondary and tertiary structural models by orienting these elements using disulfide bridges, active site assignments and co-variation analysis.

L123 ANSWER 33 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1999-461430 [33] WPIX

DNN N1999-346199 ENC C1999-11617A

TI Method for designing artificial **protein** - useful for producing **proteins** with required **functions**.

DC B04 D16 T01

PA (FIKA) FIFASAKU KENYUSHO

CYC 1

PI JF 11193197 A 14040731 (199933)* 10p G07K014-00 ---

ADT JF 11193197 A JF 1008-183552 19931006

PRAI JF 1997-272431 19971006

IC ICM C07K014-00

ICS C07P061-00; C07K014-805; C12N015-09; G06F017-30

AB JF 11193197 A UPAB: 19931004

A method for producing an ideal amino acid sequence comprises the following steps: (1) preparation of one initial amino acid sequence corresponding to the structure of a **protein**, (2) selecting the amino acid residues optimal to each site; (3) repeating the steps of selecting the amino acid residues optimum to each sites of the total amino acid residues constituting the N-order amino acid sequence (N is an integer not less than 1) to give an N+1-order amino acid sequence consisting of the selected amino acid residues until the N-order amino acid sequence comes to be same as the N+1-order amino acid sequence, and (4) selecting the resultant N-order amino acid sequence as the optimum amino acid sequence of said **protein**.

Also claimed is a **protein** having an amino acid sequence obtained by the above method.

ADVANTAGE - The method can design a **protein** with desired **functions** and properties.

Dwg.0/5

FS CFI EPI

FA AB

MC CFI: B04-C01; B11-C02; D05-H09

EPI: T01-J05B; T01-J16C4

L123 ANSWER 34 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1999-458333 [38] WPIX

DNN N1999-342838 ENC C1999-134564

TI Use of independent assay controls to perform and monitor assays, particularly immunoassays.

DC B04 D16 J04 S03 T01

IN ANDEFFERG, J M; BUECHLER, K F; MCPHERSON, F R

PA (BIOS-N) BIOSITE DIAGNOSTICS INC

CYC 85

PI WO 9935602 A1 19990715 (199936)* EN 148p G06F019-00 ---

EW: AT BE CH CY LE DK EA EG FI FF GB GH GM GF IE IT FE LS LU MC MW NL
 OA PT SD SE SG SW ZW

W: AL AM AT AU AZ BA BF BG BH BY CA CH CN CU CE DE DE EE ES FI GB GD
 GE GH GM HE HO ID IL IN IS JF KE EG FF KE EG LG IK LE LS LT LU LV
 MD MS MK MN MW MX NO NZ OL PT QO RU SD SE SG SI SF SL TJ TM TR TT
 UA US US UC VU YU ZW

AS 9921866 A 19990715 (199936)*

G06F019-00 ---

EP 1046122 A1 19991015 (2000055) EN

G06F019-00 ---

E: AT BE CH CY LE DK EG FI FF GB GF IE IT LI LU MC NL PT SE

ADT WO 9935602 A1 WO 1999-US261 19990104; AU 9921866 A AU 1999-21066 19990104;

EP 1046122 A1 EP 1999-901345 19990104, WO 1999-US261 19990104

FDT AU 9921866 A Based on WO 9935602; EP 1046122 A1 Based on WO 9935602

PRAI US 1998-3065 19980105

IC ICM G06F019-00

ICS G01N033-53

AB WO 9905602 A UPAB: 19990922

NOVELTY - Use of independent assay controls (IACs) for monitoring and performing assays.

DETAILED DESCRIPTION - Method for determining the rate of flow of solution through an assay device (comprising a reaction chamber (RC) and at least one diagnostic line (DL)) comprises

(i) providing a labeled member of a specific binding pair (MBP) in RC and a second MBP, bound to a solid phase, in DL, where neither MBP binds to assay reagents in the device; and

(ii) determining the rate of flow from the level of signal, from the label, detected in DL.

INDEPENDENT CLAIMS are also included for the following:

(a) similar methods for determining, in an assay device, the environmental conditions, progress and time to completion of the assay, and deviant assay results, also for smoothing results and for verifying location of a detection zone;

(b) apparatus and kits for these processes;

(c) methods for determining a corrected assay result from a measured result and one or more

(d) IAC results; and

(e) computer programs for performing calculations involved in (c).

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - IAC are used to monitor and perform immunoassays, particularly to correct results; detect deviant results and to determine rate of flow, environmental conditions, progress and time to completion of the assay, also for smoothing an assay signal and to verify location of detection zones.

ADVANTAGE - The use of IAC ensures that assay results are correct, even when the assay conditions vary. IAC are independent of the presence/concentration of assay reagents, but depend on the sample matrix and progress of the immunoassay reaction, so can verify that this reaction has occurred without error.

Dwg.0/18

FS CFI EPI

FA AB; DCN

MC CPI: B04-C01C; B04-G01; B11-C07A; B12-K04; B12-K04E;

D05-H09; J04-B01

EPI: S03-E14H4; T01-J

UPTX: 19990922

TECH

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred materials: MBP, and the assay reagents, are binding **proteins**, antibodies (or their fragments), **peptides** or organic molecules, and labels are dyes, colloidal solutions, enzymes or molecules that generate an electrical and/or magnetic signal. Preferred processes: To determine environmental conditions, both MBP (one labeled, the other with an affinity tag) are combined with the test sample and DL includes an affinity tag partner (atp). Environmental conditions are then related to the signal detected in DL. Particularly MBP are attached to the lid and/or base of RC and atp is immobilized in DL. To measure progress/time to completion, a label, preferably linked to MBP, is present in RC and a signal from the label is detected in a selected region of DL. Analysis is based on the absolute value of this signal or its rate of change. To detect a deviant assay result, a similar system is used, and an assay result (AS) and an IAC signal are detected, in at least two separate zones of DL, and their shapes compared. To determine a corrected result (Tc), from a measured result (Tm) and j measurements of an IAC, the difference between each IAC and a mean value of IAC is determined and the difference, for each value, **multiplied** by a constant (β) and the products added together. The total is subtracted from Tm, or a quotient between Tm and this total is determined. Each β is determined by a **matrix function** or by linear regression from a plot of differences between assay results and mean value of these results vs. differences between IAC and mean value for IAC. Alternatively, (a) a **function**, f , is determined for each IAC and a quotient calculated between Tm and

1+f, or (k) a difference between each IAC and a mean value of IAC is determined, **multiplied** by a constant, the sum of 1+ every j product calculated, and a quotient between Tm and this sum determined. The j IAC values are particularly signals measured in the new processes.

L123 ANSWER 25 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 1999-458146 [38] WPIX
 DNN N1999-342695 INC C1999-134481
 TI Predicting presence of abnormal levels of **protein** in blood clotting cascade.
 DC B64 S03 T01
 IN BFAUN, F; FISCHER, T G; GIVENS, T B
 PA (ALKU) AF20 NOBEL NV
 CYC 24
 PI WO 9934208 A1 19990708 (199938)* EN 94p G01N033-49
 PW: A1 BE CH CY DE DK ES FI FF GB GR IE IT LU MC NL PT SE
 W: AU CA JP KR US
 AU 9919503 A 19990719 (199951) G01N033-49
 EP 1042669 A1 20001011 (200052) EN G01N033-49
 E: AT BE CH CY DE DK ES FI FF GB GR IE IT LI LU MC NL PT SE
 AET WO 9934208 A1 WO 1998-US27865 19981230; AU 9919503 A AU 1999-19503
 19981230; EP 1042669 A1 EP 1998-864341 19981230; WO 1998-US27865 19981230
 FET AU 9919503 A Based on WO 9934208; EP 1042669 A1 Based on WO 9934208
 PRAI US 1997-1647 19971231
 IC ICM G01N033-49
 ICS G01N033-86; G06F019-00
 AB WO 9934208 A UPAB: 19990922
 NOVELTY - Predicting the presence of an abnormal level of at least 1 **protein** in the clotting cascade from at least one time-dependent measurement **profile** involves using a model that represents the relationship between the abnormal level of the **protein** in the clotting cascade and a set of predictor variables.
 DETAILED DESCRIPTION - Predicting the presence of an abnormal level of at least 1 **protein** in the clotting cascade from at least one time-dependent measurement **profile** comprises:
 (1) performing at least one time-dependent measurement on an unknown sample and measuring a respective property over time to derive a time-dependent measurement **profile**;
 (2) defining a set of predictor variables which define the data of the time-dependent measurement **profile**;
 (3) deriving a model that represents the relationship between the abnormal level of the **protein** in the clotting cascade and the set of predictor variables and
 (4) using the model of step (c) to predict the existence of the abnormal level of the **protein** in the clotting cascade and to predict which **protein** or **proteins** in the clotting cascade are at an abnormal level.
 The prediction of the **protein** or **proteins** at an abnormal level is a better prediction than an abnormal clot time alone.
 An INDEPENDENT CLAIM is also included for presenting a relationship between data from an assay relating to thrombosis-hemostasis on an unknown sample and data from assays relating to thrombosis-hemostasis from known sample populations which comprises:
 (A) providing data from at least one time dependent measurement **profile** for each of known blood samples;
 (B) performing at least one time-dependent measurement on an unknown blood sample and measuring a respective property over time to derive at least one time-dependent measurement **profile** for the unknown blood sample;
 (C) transforming data from step (2) to predictor variables which capture the information content of both the unknown blood sample time-dependent measurement **profile** and the known blood sample time-dependent measurement **profiles** and
 (D) presenting the data from the unknown blood sample time-dependent measurement **profile** relative to the data from the known blood sample time-dependent measurement **profiles**.

USE - Used for estimating the concentration of at least one **protein** in the clotting cascade.

Dwg.0/30

FS CPI EPI

FA AR; DCN

MC CFI: B04-B04D2; B04-N04; B11-C07; B12-K04

EPI: S03-E14H; S03-E14H1; T01-J

TECH OPTX: 19900312

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred method: In the prediction of the **protein** at an abnormal level, the specificity is at least 0.85 and the sensitivity is greater than 0.6. The samples with a measured concentration of less than 80% of normal for a specific factor are defined as being at an abnormal level.

The time-dependent measurement **profile** is at least one optical **profile** is produced by an automated analyzer for thrombosis and hemostasis testing. A number of optical measurements at one or more wavelengths are taken over time to derive at least one optical **profile**. The optical measurements correspond to changes in light scattering and/or light absorption in the unknown sample. The optical measurements are taken over time to derive at least one optical **profile**, and the optical measurements are each normalized to a first optical measurement. At least one optical **profile** is produced automatically by an analyzer. The unknown sample is automatically removed by an automated probe from a sample container to a test well. One or more reagents are automatically added to the test well to initiate the property changes within the sample. The development of the property over time is automatically optically monitored.

A predicted congenital or acquired imbalance or therapeutic condition is automatically stored in a memory of the automated analyzer and/or displayed on the automated analyzer. Assays for confirming the existence of the congenital or acquired imbalance or therapeutic condition are automatically effected. A set of data from known samples is produced which is used for deriving the model. The data from known samples is obtained by performing assays on the known samples.

Time dependent measurement **profiles** include at least two **profiles** from assays initiated with PT reagents, APTT reagents, fibrinogen reagents and TT reagents.

In (1), steps (3) and (4) comprise transforming a set of input parameters from the time-dependent measurement **profiles** for the known blood samples and the unknown blood sample, to corresponding individual output neurons whose location on an output map corresponds to the respective input data. Step (4) also comprises:

- (1) selecting weight vectors;
- (2) selecting a sample from a training set;
- (3) identifying best matching winning neuron at a particular time;
- (4) updating weight vectors and
- (5) repeating steps (1)-(4) until the map reaches equilibrium.

In step (3), data from the time-dependent measurement **profiles** is transformed into predictor variables that characterize timing, rate and magnitude of changes during the time-dependent measurement **profile** and the predictor variables are used as input for neural networks. The definition of the predictor variables is a position in a self-organizing feature map, trained with data from the time-dependent measurement **profiles** for the known blood samples.

Preferred materials: The **proteins** comprise factors II, V, VII, VIII, IX, X, XI and/or XII. The known blood samples and the unknown blood sample are samples of whole blood, plasma, or other part of whole blood. The known blood samples are samples of which are information is known relating to one or more intrinsic or extrinsic clotting factors and/or therapeutic agents. The known blood samples are samples of which are known the presence or absence of one or more abnormalities relating to at least one of fibrinogen level, oral anticoagulant, heparin, and one or more factor levels.

In step (4) one or more of normal sample, presence of heparin, and one or more factor deficiencies are presented on a PT map, or at least one of normal specimen, presence of heparin, abnormal fibrinogen, oral

anticoagulant, and one or more factor deficiencies are presented on an APTT map. The predictor variables are in terms of a standard deviation from a mean of at least one known blood sample population, and the unknown blood sample is characterized by variation from the mean of the known blood samples for each predictor variable.

L123 ANSWER 36 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 1999-418399 [35] WPIX
 DNN N1999-312316 DDC C1999-11.896
 TI Calculating relative stabilities of two molecules from conformational free energies.
 DC A71 B04 B04 D15 D16 B17 T01
 IN POLOSSEWY, I
 PA (NY00) UNIV COLUMBIA NEW YORK
 CYC 23
 PI WO 9917211 A1 19990409 (1999-5)* EN 83p G06F017-16 <--
 RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 W: AU CA JP MK US
 AU 9897796 A 19990403 (1999-5)
 US 6178384 B1 20010123 (2001-7) G06F019-00 <--
 ADT WO 9917211 A1 WO 1999-0320368 19990929; AU 9897796 A AU 1998-97796
 19980910; US 6178384 B1 US 1997-949115 19970929
 EDT AU 9897796 A Based on WO 9917211
 PRAI US 1997-949115 19970929
 IC INT G06F017-16; G06F019-00
 AB WO 9917211 A UPAB: 19990908

NOVELTY - The relative stabilities of two molecules, having defined connectivities and existing in defined environments, are determined by computer analysis of data representing low-energy minimum conformations to generate a total configuration integral (TCI) and thus the conformational free energy (CFE) for both molecules, then comparing the CFEs.

DETAILED DESCRIPTION - The initial data set is derived from molecular connectivity, a potential energy **function** and a conformational search method. A configuration integral, in all degrees of freedom, is calculated based on the contribution of each molecular conformation by performing importance-sampling, multidimensional Monte Carlo (MC) integration over a multidimensional volume (dependent on harmonic vibrational frequencies of the conformation and temperature) encoding a current conformation of the molecule in conformational space. This process is repeated for every conformation in the data set and the contributions summed to generate TCI.

The importance sampling involves preferentially sampling regions of the volume having dominant contributions to the CFE of the conformation and uses a physical background of normal modes of vibration, with sampling performed using an atomic coordinate transform based on eigenvectors of the Hessian matrix (H) associated with the particular conformation.

INDEPENDENT CLAIMS are also included for the following:

- (1) similar method for analyzing molecular complexes to determine relative binding affinities of molecules for a given host molecule; and
- (2) apparatus for the analysis.

USE - The method is used to select drug candidates.

ADVANTAGE - The method should identify agents with greater specificity for, and activity at, target sites. It does not require expensive free energy simulations or computational 'alchemy'.

Dwg. 0/4

FS CFI BPI
 FA AB; DCN
 MC CFI: A00-A; B04-B01; B04-N01; B11-C08; B12-K04; D05-H09
 EPI: T01-B04; T01-T04C
 TECH UPTX: 19990902

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred method: The low-energy minimum conformations are 15-35 kJ/mole above the lowest energy conformation and the potential energy **function** is based on molecular mechanics or on ab initio, semi-empirical or density-functional quantum mechanics. The atomic co-ordinates used are external (Cartesian) or internal (bond lengths, bond or torsional angles)

and H_i is exact or an approximation. The predetermined environment is presence of solvent, vacuum or a third molecule, and the molecules may be subjected to extrinsic environmental forces. The molecules being analyzed can be cyclic or acyclic, particularly water, biopolymers, bio-oligomers, **proteins**, enzymes, **peptides**, nucleic acid, carbohydrates, glycoproteins, receptors, lipid bilayers, biocompatible polymers, metals, (in)organic compounds, pharmaceuticals, drugs and drug candidates.

To analyze molecular complexes, four data sets are generated: one for each of the two test molecules and one for each of their complexes. The CFE difference between:

- (1) first and second test compounds D_1 and
- (2) the two complexes (D_2) are calculated, and the total difference (D_t) defined as $D_2 - D_1$.

If D_t is negative, then the first test compound has the higher affinity, if it is positive then the second compound has higher affinity. The procedure may be repeated with third molecules and complexes. In a particular case, the method is used for different stereoisomers of the same compound and in that case only the difference D_1 needs to be calculated. In this process, internal atomic coordinates may also be relative spatial position of the components of the complex, defined by 3 translational and 3 rotational degrees of freedom.

TECHNOLOGY FOCUS - COMPUTING AND CONTROL - The apparatus comprises devices able to generate the data sets; determine CFE and calculate differences between CFEs. Any workstation or supercomputer should be suitable, running standard software such as the 'Cybyl' program or its equivalents. Mathematics: The method uses a new MC integration technique, designated wide integration (WINTA), that operates in all the degrees of freedom, with the harmonic approximation used to provide highly accurate numerical integration of the high-dimensional configuration integral. A sampling function, very similar to the partition function near the low energy minimal on the potential energy surface, is derived by applying the harmonic approximation to each low-energy well by a local, second-order Taylor expansion of the potential energy function. The sampling functions are normalized gaussians defined in terms of the bottom of the particular energy well and its associated local H_i .

L123 ANSWER 37 OF 73 WPX COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 1999-326687 [27] WPX
 ENN N1999-245028 ENC C1999-096026
 TI Derivatives of alpha-conotoxin and their analogs.
 EC B04 D16 S03 T01
 IN CARTIER, G E; KOEPPER, S C; MCINTOSH, J M; OLIVERA, B M; RIVIER, J E;
 SHEN, G S; SHON, K; YOSHIMAMI, T
 PA (COGNIN) COGNETIX INC; (SALK) SALK INST; (UTCA-N) UNIV CASE WESTERN
 RESERVE; (UTAH) UNIV UTAH RES FOUND
 CYC 82
 PI WO 9921878 A1 19990506 (199917)* EN 175p C07F007-08 ---
 FW: AT BE CH CY DE DK EA ES FI FF GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SJ UG ZW
 W: AL AM AN AU AC BA BE BG BF BY CA CH CN CU CE EE EK EE ES FI GE GE
 GH GM HH HU ID IL IS JP KE KG KP KR LC LF LG LS LT LU LV MD MG
 MK MN MW MX NA NE NL ET FO FU CO SE SJ SI SK SL TJ TM TR TT UA UG
 UZ VN YU ZW
 AU 9911143 A 19990517 (199939) C07F007-08 ---
 EP 1033588 A1 20000906 (200044) EN C07F007-08 ---
 E: AT BE CH CY DE DK ES FI FF GB GR IE IT LI LV MC NL PT SE
 ADT WO 9921878 A1 WO 1998-0321368 19981021; AU 9911143 A AU 1999-11143
 19991023; EP 1033588 A1 EP 1998-453855 19981023, WO 1998-0321368 19981023
 FDT AU 9911143 A Based on WO 9921878; EP 1033588 A1 Based on WO 9921878
 PRAI US 1997-65514 19971114; US 1997-62783 19971024
 IC ICM C07K007-08
 ICS G01N014-08; G01N033-68; G06F017-30; G06F019-00
 AB WO 9921878 A UPAB: 19990714

NOVELTY - Derivatives (I) of alpha -conotoxin MII (II) with practically the same activity as (II) are new.

DETAILED DESCRIPTION - (I) are of formula X-Cys-Cys-X-X1-X2-X-Cys-X3-X4-X5-X-X-X-Cys (I')

X, X1, X2, X3 and X4 = same or different natural, modified or non-natural amino acids;

X5 = His or Asn

INDEPENDENT CLAIMS are also included for the following:

- (1) a **peptide** analog, **peptide** mimic or mimetic
- (A) of (II) specific for one or more subtypes of neuronal nicotinic acetylcholine receptor (nAChR);
- (B) screening compounds for antagonistic activity at an nAChR subtype by comparing on and off rates for (II) and a test compound to the different subunits of nAChR;
- (C) derivative, **peptide** analog, **peptide** mimetic or mimetic (F) of (II) which selectively modulates biological activity of nAChRs;
- (4) method for determining the three-dimensional (3-D) structure of an alpha -conotoxin analog (IIa), or part of it;
- (5) method for selecting and designing compounds able to bind to nAChR by analyzing the 3-D structure of (II), or part of it; and
- (6) machine-readable data storage medium which can display a graphical 3-D representation of an MII **peptide** or of an alpha -conotoxin (or parts of them).

ACTIVITY - Antitumor; anti-smoking; cardiovascular.

MECHANISM OF ACTION - Specific interaction with neuronal nicotinic acetylcholine receptors.

USE - (I), and its mimetics, are useful as cardiovascular agents; for treating or diagnosing small-cell lung carcinoma; and as gastric motility, urinary incontinence and anti-smoking agents.

ADVANTAGE - (I) and their mimetics can be designed to be selective for particular subtypes of nAChR, particularly the alpha 3 beta 2 and alpha 3 beta 4 subtypes.

Dwg.0/14

FS CFI EPI

FA AB; DCN

MC CFI: B04-C01E; E04-N02; B04-N04A; E11-C08E; B12-K04E;
B14-F01; B14-H01; B14-M01B; B14-N09; D05-H09; D05-H12B2
EPI: S03-E07; S03-F14H; T01-J; T01-J05B

TECH OPTY: 19900714

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred compounds: (I) is C-amidated and has X1 = Asn; X2 = Pro or hydroxy-Pro; X3 and X5 = His; X4 = Glu. They have practically the same biological activity as (II). (A) are specific for one of the receptor subtypes alpha3beta2; alpha3beta4 or alpha2beta2.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred process: To determine the 3-D structure of (IIa), NMR data are obtained for (IIa) and analyzed, with reference to known structural co-ordinates for MII, by molecular replacement. Selected (IIa) may then be tested for binding to an nAChR; inhibition of binding of ligand to nAChR and/or inhibition of biological **function** mediated by a natural ligand of nAChR. To select a compound able to bind to nAChR, the 3-D structure of MII is analyzed to identify regions that interact with particular **functional** groups, then databases examined for compounds having structures that best fit these interacting regions To design a compound able to bind to nAChR, a 3-D representation based on co-ordinates defining the structure (of part) of (II) is displayed and interaction with parts of a known ligand are characterized to identify suitable groups for replacement. Groups that can replace one or more parts of the ligand, while retaining at least some binding affinity, are then identified from a knowledge base of possible substitution groups. Alternatively, positions that are preferred with respect to favorability of interactions with **functional** groups are identified in the 3-D structure, and parts of a known ligand close to these positions are characterized. From a knowledge base, fragments or molecules that permit connection of the preferred positions to portions of the ligand are identified and the structure of the ligand is modified by

covalent attachment of these fragments or molecules, in the proper orientation and location. Compounds designed this way are then tested for modulatory activity at nAChRs.

Preparation: (I) are produced by usual methods of **peptide** synthesis.

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation: (I) may be produced by usual recombinant DNA methods (not exemplified).

TECHNOLOGY FOCUS - COMPUTING AND CONTROL - The data storage medium displays a 3-D representation based on all or some of the atomic coordinates taken from a table, reproduced in the specification, of the 3132 atoms of CH₁, deposited at the Protein Data Bank as 1n2c, or on coordinates with a root-mean-square deviation, for conserved backbone **protein** atoms, of not over 1.5 Angstrom. The medium may carry two sets of data: one a Fourier transform of at least part of the coordinates specified above and the other the coordinates of a molecule or molecular complex.

L123 ANSWER 2 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1999-316593 [27] WPIX

DNN M1999-144971 DMC C1999-193174

TI Voltage-gated, pH-sensitive potassium channel useful in gene therapy.

EC B04 116 033 T01

IN SARKOFF, D; SCHREIBER, M; SILVIA, C

PA (OHIO) UNIV WASHINGTON

CYC 84

PI WO 9906754 A1 19990419 (1999071) EN 92; C12N015-11

EW: AT BE CH CY DE DK EA ES FI FR GE GR IE IT KE LS LU MC MW NL

OA PT SE SF SJ SW BW

W: AL AM AN AT AV BA BB BC BD BE BF BG BH BI BJ BK BL BM BN BO

BP BR BS BT BU BV BW BX BY BZ CA CB CC CD CE CF CH CI CJ CK CL

CM CN CO CP CQ CR CS CT CU CV CW CX CY CZ DA DB DC DD DE DF DG

DH DI DJ DK DL DM DN DO DP DQ DR DS DT DU DV DW DX DY DZ EA EB

EC ED EE EF EG EH EI EJ

AU 9911122 A 19990510 (199908) EN 92; C12N015-11

EP 1029042 A1 20000803 (200041) EN 92; C12N015-11

FI: AT BE CH CY DE DK ES FI FR GE GR IE IT LI LU MC NL PT SE

ADT WO 9920754 A1 WO 1998-052331 19981021; AU 9911122 A AU 1999-11122

19991011; EP 1029042 A1 EP 1998-951857 19981021; WO 1998-052331 19981021

FDT AU 9911122 A Based on WO 9920754; EP 1029042 A1 Based on WO 9920754

PRAI US 1448-76172 1999-0217; US 1997-63138 19971012

IC ICM C12N015-11

ICS C07H021-04; C07K014-00; C07K016-00; C12N015-61;

C12N015-65; C12Q001-00; C12Q001-68; G01N033-53; G01N033-567;

G06F019-00

AB WO 9920754 A UPAB: 19990714

NOVELTY - A voltage-gated, pH sensitive potassium channel Slo3, expressed in spermatoocytes, is new.

DETAILED DESCRIPTION - Slo3 has, as a monomer, calculated molecular weight 130-136 kD; has unit conductance (as a **functional** tetramer, when expressed in *Xenopus* oocytes, of 40-120 pS; has increased activity at intracellular pH above about 7.1 and binds specifically to polyclonal antibodies against sequences (P1), (P2), (P3) or (P4), all given in the specification, with 1113 and about 110, 1050 and 1020 amino acids, respectively.

INDEPENDENT CLAIMS are also included for the following:

- (1) isolated nucleic acid (I) encoding Slo3;
- (2) isolated nucleic acids (Ia) encoding at least 15 contiguous amino acids from Slo3, and their conservatively modified variants;
- (3) antibodies (Ab) that bind selectively to murine or human Slo3;
- (4) expression vector containing (I);
- (5) host cell transfected with this vector;
- (6) method for identifying agents (A) that increase or decrease ion-flux through a pH-sensitive potassium channel;
- (7) detecting Slo3 in mammalian tissue by reaction with a selective binding agent;

(3) computer method of screening for mutations in Slo3 genes; and
 (3) computer method for identifying a three-dimensional Slo3 structure.

ACTIVITY - Contraceptive; fertility-regulating.

MECHANISM OF ACTION - Slo3 is involved in sperm capacitation and/or the acrosome reaction, essential steps in fertilization.

USE - Slo3, and (I), encoding it, are used to identify specific inhibitors and activators (potentially useful for treating infertility and as contraceptives), also for studying sperm physiology in vitro. Slo3-specific antibodies are used for diagnostic detection of Slo3 expression. Slo3, as part of a chimera with another channel **protein**, can be used as a reporter for measuring changes in potassium concentration, current flow, ion flux, etc.

Fragment(s) of (I) are useful as probes for identifying homologs, variants and mutants associated with disease; to detect Slo3-related mRNA or **protein**; for chromosomal localization; in gene therapy; for identifying potential modulators; to measure up-regulation of Slo3 in drug screening assays and for production of recombinant Slo3 **protein**.

Dwg.0/4

FS CPI EPI

FA AB; ICH

MC CPI: E04-E01; E04-E02; E04-G01; E04-H01; E11-G07A; B12-K04;

D05-H09; D05-H11; D05-H12A; D05-H12E; D05-H14; D05-H17A2

EPI: S03-B14H4; T01-J

TECH

CPTX: 19990714

TECHNOLOGY FOCUS - BIOLOGY - Preferred nucleic acid: (I) encodes murine or human Slo3, specifically (P1), murine, or (P3) or (P4), both human. (I) is or hybridizes under moderately stringent conditions with sequences (N1), (N2), (N3) or (N4), of about 4.7, 0.7, 1.2 and 1.1 kb, respectively, given in the specification.

Primer pairs (N5-N12) suitable for amplification of these four sequences are also given in the specification. Alternatively, (I) encodes the monomer of a pH-sensitive potassium channel that has a core domain with more than 60% amino acid sequence identity with the 35-641 region of the Slo3 core domain and is recognized by antibodies raised against the core domain of (P1), (P3), (P5) or (P4).

CTCGAAGTCCCTAAATCTTACAGAT (N5)

TTCCGTTGAGCCAGGGGTCACCAAGATT (N6)

TCTGCTTTGTGAAGCTAAATCT (N7)

TTTCAAAGCTCTTTAGCGGTAA (N8)

TTATGCCTGGATCTGCACTCTACATG (N9)

ATAGTTTCCGTCTACTACCGAAA (N10)

GGCAGCGCTCATTCTTTCTCTCCTT (N11)

TGCCCAAAACCTCAACCCAAAATA (N12)

Preferred process: To identify (A), a test compound is applied to a eukaryotic cells (or its membrane) that has expressed a Slo3 monomer, and any effect of the compound determined, particularly by measuring the whole cell conductance to detect increase/decrease in ion flux. Particularly the monomer is a recombinant **protein**. To detect Slo3, the specific

binding agent is an antibody, oligonucleotide or nucleic acid probe. To screen for mutations in Slo3 genes, sequences (particularly where associated with disease) are compared, over at least 30 nucleotides (nt), with sequences (N1), (N2), (N3) or (N4).

Preparation: Antibodies against Slo3 are raised by usual immunization and cell fusion methods.

TECHNOLOGY FOCUS - COMPUTING AND CONTROL - To determine the three-dimensional structure of Slo3 **protein**, data covering at least 10 amino acids of the **protein**, or 30 nt of the nucleic acid, are analyzed to generate a primary **protein** structure. This may then be converted, using energy terms associated with the structure, to secondary or tertiary structures, and optionally anisotropy terms in the tertiary structure used to devise a quaternary structure. The resulting structures may be used to identify ligand-binding sites and, from these, the ligands themselves.

L123 ANSWER 19 OF 21 W-1X COPYRIGHT 2001 DERWENT INFORMATION LTD

DNN 01 999-409426 DDC 01 999-367366

DC P04 D16 T01 T00

PA OKARU-1; PRECISE I

CYC 81

PI WO 9911518 A1 19990311 (199919)* JA 42p C12Q001-63

EM: AE BE CH CY DE EN EA ES FI FR GR GA GM GE IE IT KE LS LU MC MW NL
 OA PT RU SE SG UG ZW

W: AA AM AT AU BA BB BE BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH GM HN HU IL IO JF KE KG KF KZ LC LK LR LS LT LU LV MD MG MK
NH NW NN NO NZ PL PT RC RU RD SE SG SI SK SL TO TM TR TT UA UG US
VE VN YR ZW

AU 3888667 A 19990322 (199931) C120001-63

ADT WO 9911113; AI WO 1998-011134 19980113; AU 9888867 A AU 1998-38867 19980628

FILE NO. 100-37177-7 A. Raza et al. WO 2011/1516

PRAI DE 1947-1948 1947-1948

IC 70M 61-0001-58:

103 C07H001-00; C07K001-00; C07K007-00;

C07K014-00; C12N015-11; G06F015-42

AB WO 9911813 A UPAB: 19190518

NOVELTY - Molecular design is carried out by shuffling exons within a library of similar DNA sequences, followed by ranking of the products of reshuffling by their fit to the desired **functionality**, and repeating the shuffling and ranking until a product of the desired **functionality** is obtained. A similar process may be carried out using **polypeptide** sequences.

DETAILED DESCRIPTION - New **functionality** is obtained or existing **functionality** is improved in **polypeptides** or **nucleic acids** by:

(1) synthesising a group of **polypeptides** or nucleic acids with differing sequences;

(2) measuring the fit of these sequences to the desired **functionality** by laboratory experiment;

(3) ranking the sequences in order of this degree of fit;

(4) preparing a 'shuffling library' of sequences by shuffling parts of these sequences between individuals ranking highly;

(c) synthesising the resulting shuffled sequences;

(b) repeating the above steps a sufficient number of times to obtain one or more sequences with close fit to the desired **functionality**

USE - The technique can be used for the improvement of function, and devising of new functions, of polypeptides and nucleic acids, for a broad range of uses such as drugs and foodstuffs.

ADVANTAGE - **Evolution** of high functional fit is rapid compared to the use of conventional genetic evolution algorithms.

Dwg. 3/4

FS CPI EPI

FA AB; DCN

MC CRI: B04-C01; B04-E01; B04-N0400E; B11-C01; B12-K04E;
D05-H

EPI: T01-X; T06-D02; T06-D10

TECH OPTX: 19990510

TECHNOLOGY FOCUS - BIOTECHNOLOGY - The shuffling of parts of the sequences may be supplemented by steps in which one or more bases or amino acids of the sequence are mutated (by addition, deletion or substitution).

L123 ANSWER 40 OF 72 WEIX COPYRIGHT 2001 LEBWENT INFORMATION LTD

AN 1999-159339 [14] WEIX

LNH N1999-111679 INT 0199-04-113

TI New Streptococcus pneumoniae Response Regulator (RR) **polypeptide** and polynucleotide - useful as diagnostic reagents and for prevention and treatment of Streptococcus infections which cause conjunctivitis, sinusitis and meningitis.

DC B04 D16 300

IN BICWAS, S; GE, Y; HOLMES, D J; INGRAHAM, K A; THEOUF, J; WALLIS, N G; ZALACAIN, M; HOLMES, D; INGRAHAM, K; WALLIS, N

PA (SMK) SMITHKLINE BEECHAM CORP

CYC 27

PI EF 990846 A2 19990310 (199914) EN 36p C12N015-31
F: AL AI BE CH CY DE DK ES FI FF GE GF IF IT LI LT LU LV MC MK NL PT
EO SE SI

CA 243656 A1 19990309 (199914) EN C12N015-31

JP 11193198 A 19990721 (199919) 36p C07K014-315 C--

ADT EF 990846 A2 EP 1999-307064 19990301; CA 243656 A1 CA 1999-2243656
19990908; JP 11193198 A JP 1998-190066 19980903

PRAI US 1997-60714 19970909

IC ICM C07K014-315; C12N015-31

ICJ A61K031-00; A61K031-70; A61K037-00; A61K038-10; A61K039-045;

A61K039-69; A61K039-395; A61K41-10; A61K48-00; C07K014-705

; C07K016-12; C12N015-04; C12F031-03; C12P001-68;

G01N033-15; G01N033-48; G01N033-50; G01N033-55; G01N033-566;

G01N033-569; G01N033-577; G06F019-00; G11B023-00

ICI C12H015-09; C12R001:46

AB EF 990846 A UIAB: 19990413

NOVELTY - An isolated **polypeptide** comprising an amino acid at least 70% identical to (I), a fully defined 428 Streptococcus pneumoniae Response Regulator (RR) **protein**, which is part of the two component signal transduction system (TCSTS).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) an isolated polynucleotide (II) comprising a nucleotide sequence at least 70% identical to a polynucleotide encoding (I); (2) an expression system comprising polynucleotide (II); (3) a host cell comprising the expression system or a membrane of; (4) an antibody immunospecific for (I); (5) an agonist or antagonist (III) to (I); (6) use of: (i) an agonist or antagonist (III); (ii) polynucleotide (II); or (iii) a nucleic acid molecule that modulates expression of (II); in therapy; (7) preparation of (I); (8) an isolated polynucleotide comprising a nucleotide sequence at least 70% identical to (V), a fully defined 3453 bp nucleic acid given in the specification; and (9) a **polypeptide** which comprises an amino acid sequence at least 70% identical to (IV), a fully defined 428 amino acid **protein** given in the specification.

USE - RR sequences are useful for diagnosing a disease or susceptibility to a disease related to RR **polypeptide** (I) levels by determining the presence/absence of a mutation in the gene, or analysing for the presence or amount of (I) expressed in a sample, due to an infection with an organism with the gene (claimed). They can diagnose the stage and type of infection. They are also useful for screening for compounds (III) which stimulate or inhibit **polypeptide** (I) **function** by determining the effect on activity of (I) (claimed). Agonists and antagonists are useful for treatment of conditions associated with RR imbalance, and are therefore potential antibacterial compounds. RR polynucleotides are useful for genetic immunisation and antisense sequences are useful for inhibition of expression of (II). RR **polypeptides** are administered to treat individuals in need of RR

polypeptides (directly or via a vector i.e. gene therapy), and as an antigen for inducing an immune response. They can prevent adhesion of bacteria to matrix **proteins**, and are useful for use on wounds and body implants to prevent bacterial infection. Anti-RF antibodies induced by the **polypeptide** are useful for preventing or treating infections, especially bacterial infections, and also for isolating clones expressing RF (I), or purifying the **polypeptide** by affinity chromatography. Diseases prevented, diagnosed and treated include those caused by bacterial infection, especially *Streptococcus pneumoniae* infections, which cause otitis media, conjunctivitis, pneumonia, bacteremia, sinusitis, pleural empyema, endocarditis and especially meningitis.

Dwg. 0/0

FS CPI EPI

FA AB

MC CPI: B04-E01F; B04-E06; B04-F0100E; B04-G07; B04-G0700E; B04-G21;

B04-G2100E; B04-G22; B04-G2200E; B04-N01A0E; **B12-K04A4;**

B12-K04E; B12-K04F; B14-A01; B14-A01B2; B14-F01;

B14-F02; B14-K01; B14-L01; B14-L06; B14-N02; B14-N03; B14-N04;

B14-N16; B14-N17B; B14-S03; B14-S11B; D05-C12; D05-H04; D05-H07;

D05-H09; D05-H11A1; D05-H11A2; D05-H11B; D05-H12A; D05-H12B2;

D05-H14; D05-H17A6

EPI: S03-E14H4

L123 ANSWER 41 OF 73 WPIK COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1999-120378 [10] WPIK

DNN N1999-087835 EPC C1999-035124

TI Inferring the biological **function** of a **protein** using a ligand database - from the **function** of known **proteins** to which a ligand binds which is also capable of binding to the **protein** under examination.

DC B04 T01

IN IMAMURA, M; ITAI, A

PA (ITAI-I) ITAI A

CYC 83

PI WO 9901409 A1 19990114 (199910)* JA 33p C07B001-00

FW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL

OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR CA CH CN CU CZ DE DK EE ES FI GB GE

GH GM GW HR HU ID IL IS JP KE KG KR KZ LC LK LE LS LT LU LV MD MG

MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG

US UZ VN YU ZW

AU 9879366 A 19990125 (199923)

C07B001-00

EP 1008572 A1 20000614 (200033) EN

C07B001-00

R: CH DE FR GB IT LI

ACT WO 9901409 A1 WO 1998-JP2986 19980702; AU 9879366 A A1 1998-79366 19980702; EP 1008572 A1 EP 1998-929306 19980702, WO 1998-JP2986 19980702

PFT AU 9879366 A Based on WO 9901409; EP 1008572 A1 Based on WO 9901409

PFAI JP 1997-177933 19970703

IC ICM C07B001-00

ICS C07K001-00; G06F015-40; G06F017-30;

G06F017-50

AB WO 9901409 A UPAB: 19990310

Inferring the biological **function** or activity of a **protein** whose three-dimensional configuration is known or can be inferred comprises: (i) constructing a database of three-dimensional structures of a large number of physiologically active compounds which are known to bind to target **proteins** with known biological **function** or activity; (ii) extracting candidate ligands to the **protein** (I) under examination from the database and their ability to form a complex with (I) is investigated with a suitable docking program; (iii) a candidate ligand is chosen from the database which has the best docking with (I), i.e. forms the most stable complex with (I); and (iv) it is then inferred that the **function** or activity of (I) is similar to that of the target **protein** or **proteins** recorded in the database as binding to the chosen ligand. A suitable

program for carrying out this investigation is ADAM&EVE (described in WO9613785, Ariko Itai) which determines the best docking conformation of the ligand with the target **protein** and then calculates the energy of interaction between them in this conformation.

USE - The method is rapid and accurately infers the biological **function** or activity of **proteins**, such as **proteins** of previously unknown **function** discovered during the human **genome** project, for use (for example) in metabolic investigations or drug design.

Dwg. 6/3

FS CFI EPI

FA AB

MC CFI: B01-A01; B01-A; B04-A04; B04-N04; B06-D01; B10-A17;
B10-G01; B11-C08E; B12-K04

EPI: P01-J05P; T01-J15

L123 ANSWER 42 OF 73 WPIM COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1999-108349 [10] WPIM

DNC C1999-032522

TI New SecA **polypeptides** and polynucleotides - useful as diagnostic reagents and for prevention and treatment of Streptococcus pneumoniae infections, especially meningitis.

EC B04 D16 303

IN JAWORSKI, D D; ODWYER, K M; SHILLING, L F; TRAINI, C M; WANG, M; WILDING, E J; ODWYER, K M

FA (SMK) SMITHKLINE BEECHAM COFF; (SMK) SMITHKLINE BEECHAM PLC

CYC 27

EI EP 894857 A 19990003 (199910) EN 34p C12N015-31

R: AL AT BE CH CY DE DK ES FI FR GB GE IE IT LI LT LU LV MC ME NL PT
RO SE SI

CA 2238672 A 19990001 (199900) C12N015-31

JP 11190091 A 19990721 (199907) 83p C12N015-09

ALT EP 894857 A2 EP 1998-30537; 19980713; CA 2238672 A CA 1998-2238672
19980724; JP 11190091 A JP 1998-250289 19980731

PEAI US 1998-099720 19980313; US 1997-54563 19970801

IC ICM C12N015-09; C12N015-31

ICS A61F031-70; A61K035-70; A61K038-00; A61K039-10; A61F039-09;

A61K039-395; A61K045-00; A61K048-00; C07K014-315;

C07K016-12; C12N001-15; C12N001-19; C12N001-31; C12N005-10;

C12P021-02; C12Q001-02; C12Q001-68; G01N033-50; G01N033-569;

G06F019-00; G11B023-00

ICA C12P021-06

ICI C12N015-09, C12P001:44

AB EP 894857 A UFAB: 19990310

A secA **polypeptide** at least 70% identical to sequence (I), a fully defined 837 amino acid **protein** given in the specification is new. Also claimed are: (1) an isolated polynucleotide (II) (DNA or RNA) complementary or at least 70% identity to a polynucleotide encoding (I); (2) a vector comprising polynucleotide (II); (3) a host cell comprising the vector; (4); an antibody against secA **polypeptide** (I); (5) an antagonist which inhibits activity or expression of secA **polypeptide** (I); (6) an isolated polynucleotide (IV) comprising at least 70% identity to a polynucleotide encoding **polypeptide** (III), a fully defined 693 amino acid **protein** given in the specification; and (7) a computer readable medium stored with data selected from: (i) secA polynucleotides (II)/(IV) or **polypeptides** (I)/(III); (ii) a set of polynucleotides or **polypeptides**, where at least one sequence is a secA polynucleotide or **polypeptide**; and (iii) a data set representing secA polynucleotides or **polypeptides**.

USE - SecA polynucleotides and **polypeptides** are useful for diagnosing susceptibility to diseases by detecting mutations or polymorphisms in the secA gene or analysing for the presence of amount of secA **polypeptide** expressed in a patient sample (claimed). SecA PCP probes are useful for diagnosing diseases, and can characterise the response of the infectious organism to drugs. SecA **polypeptides**

and polynucleotides are also useful for screening for antagonists, agonists and drugs against infectious micro-organisms by binding with *secA* **polypeptide** (1) and observing interaction and activation or inhibition of the **polypeptide function** (claimed). *SecA* **polypeptides** and antagonists are useful for treating conditions associated with abnormal *secA* **protein** levels (claimed), and *secA* agonists, antagonists and drugs are bacteriostatic and bacteriocidal compounds which can be used in treatment to enhance (agonist) or block (antagonist or antisense sequences) *secA* activity, therefore treating microbial diseases, especially *Streptococcus* pneumoniae diseases including otitis media, bacteremia, conjunctivitis, pneumonia, sinusitis, pleural empyema, endocarditis and especially meningitis. *Regulators of secA* **polypeptides** and polynucleotides are useful immunogens for producing anti-*secA* antibodies for prevention of bacterial infections, and *secA* polynucleotides can be used in genetic immunisation (gene therapy) using the vector to prevent infections (claimed). *SecA* **polypeptides**, polynucleotides and their antagonists can prevent adhesion of bacteria to matrix **proteins**, and are useful for use on wounds and body implants to prevent bacterial infection. *SecA* **polypeptides** and polynucleotides may also be used as reagents for differential screening methods e.g. using *secA* probes in RT-PCR to identify and quantify genes expressed in bacterial tissue. *SecA* **polypeptides** are useful for mapping genes to chromosomes, allowing gene inheritance to be studied through linkage analysis. The computer based method (7) is useful for performing homology identification by comparing a polynucleotide with *secA* sequences, and is also useful for polynucleotide assembly, by screening for overlapping sequences between a polynucleotide and *secA* polynucleotide at (7) (claimed).

F3 CFI EPI

FA AF

MC CFI: B04-E03F; B04-E08; B04-F010E; B04-G07; B04-G21; B04-G22; B04-N03A; B04-N03AE; B12-K04A4; B12-K04E; B14-A01; B14-A01E2; B14-F01; B14-F02; B14-E01; B14-L06; B14-N02; B14-N03; B14-N04; B14-S03; D05-C12; D05-H07; D05-H09; D05-H11; D05-H12A; D05-H12D1; D05-H12E; D05-H14; D05-H17A
EPI: S03-E14H4

L123 ANSWER 43 OF 73 WPIN COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1999-062659 [06] WPIN

DNN IN1999-046530 DUC C1999-018841

TI New isolated *gidA1* **polypeptide** from *Streptococcus pneumoniae* - useful in diagnosis, treatment and prevention of bacterial infections.

EC B04 D16 S03

IN BERNHAM, M; FEDON, J C; JAWORSKI, D D; FALLENDER, R; LENOX, A L; PALMER, L M; WANG, M

FA (SMK) SMITHKLINE BEECHAM CORP; (SMK) SMITHKLINE BEECHAM PLC

CYC 27

PI EP 889128 A2 19990107 (199906)* EN 34p C12N015-31

F: AL AT BE CH CY DE DK ES FI FR GE GF IE IT LI LT LU LV MC MK NL PT
FO SE SI

CA 2236425 A 19990101 (199924) C12N015-31

JP 11127263 A 19990525 (199931) 115p C12N015-09

JP 200010093 A 20000801 (200011) 48p C12N015-09

AET EP 889128 A2 EP 1998-205174 19980630; CA 2236425 A CA 1998-2236425 19980629; JP 11127263 A JP 1998-105545 19980701; JP 200010093 A Div ex JP 1998-223543 19980701, JP 2000-53620 19990701

PEAI US 1997-51379 19970701

IC ICM C12N015-09; C12N015-31

ICC A61K031-70; A61K031-708A; A61K034-10; A61K039-10; A61K039-395;

A61K045-00; A61K045-00; A61K045-00; A61K045-00; A61K045-00; C07K014-315

; C07K016-12; C12N001-15; C12N001-15; C12N001-15; C12N001-15;

C12N005-10; C12P021-01; C12P021-01; C12P021-01; C12P021-01; G01N033-50;

G01N033-50; G01N033-50; G01N033-50; G01N033-50; G06F017-30

; G06F019-00; G11B013-00

ICA C12P021-01

ICI C12N015-09, C12F001:46; C12F001:46; C12N015-09

AB EP 899120 A UPAB: 19390217
New isolated **polypeptide** (II) comprises/is (1) at least 70 identity to sequence (.), 637 amino acids (aa) or (4) 623 aa, over their entire length and/or is encoded by a recombinant polynucleotide comprising sequence (1) 3109 bp or (3) 1871 bp (all sequences fully defined in the specification). Also claimed are: (A) an isolated polynucleotide (I); (B) an antibody antigenic to or immunospecific for **polypeptide** (II); (C) a process for diagnosing or prognosing a (susceptibility to) disease in an individual related to expression or activity of (II); (D) a method for screening to identify compounds that activate or inhibit the **function** of (II); (E) an agonist/antagonist of the activity or expression of (II); (F) an expression system comprising (I) capable of producing (II) when present in compatible host cell; (G) a host cell comprising the above expression system/membrane expressing (II); (H) a process for producing (II) comprising culturing the host cell; (I) a process for producing the host cell comprising the expression system for (II); (J) a recombinant host cell capable of expressing (II); (K) a computer readable medium with stored sequences (1)-(4); and (L) a computer based method for performing homology identification.

USE - (I), its agonists or (II) are used to treat conditions requiring increased activity or expression of (I) (conditions not cited), while conditions (particularly bacterial infections) requiring inhibition of (I) are treated by administering an antagonist, inhibitory nucleic acid or competitive **polypeptide** e.g. *S. pneumoniae* infection, particularly meningitis and also *Helicobacter pylori* infections e.g. related cancers, ulcers and gastritis. These antibacterial agents may also be used to treat in-dwelling devices to prevent infection or generally as wound treatments to prevent adhesion of bacteria to matrix **proteins**. (I)-related conditions, or susceptibility to them, can be diagnosed, staged or prognosed by (i) detecting mutations in (I)-encoding nucleic acid or (ii) by determining presence or amount of (I). (I), or cell membranes of (E), are used to screen for (II) (in any standard binding assay) and cells of (E) are used to produce recombinant (I), used (i) to raise Ab (for use in identifying/isolating (I)-expressing clones, for affinity purification, as therapeutic agent and in competitive drug screens); (ii) to identify (III) or specific receptors; (iii) in rational drug design and (iv) as immunogen for vaccines. (II), or its fragments, are used as antisense/ribozyme therapeutics; as probes and primers to isolate homologous sequences; to detect (mutant) (II); for chromosomal mapping; to determine bacterial serotype; for genetic immunisation; to screen for (III) and in rational drug design.

Dwg.070

FS CFI EPI

FA AB

MC CFI: B04-C01G; B04-E00F; B04-E01; B04-F0100E; B04-F10E4; B04-G0700E;

B04-N04A; B11-C07A; B11-C08E1; **B12-K04A4**; B14-A01;

B14-A01B2; B14-E08; B14-E10E; B14-H01; B14-L01; B14-L06; B14-N17B;

B14-S11; D05-C1.; D05-H07; **D05-H09**; D05-H11; D05-H12A;

D05-H12B; D05-H12E; D05-H14; D05-H17A

EPI: S03-E14H4

L123 ANSWER 44 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1999-034633 [03] WPIX

DNN N1999-005941 DMC C1999-010381

TI Determination of 3D structure of **protein** - from amino acid sequence using hierarchical approach in which number of candidate structures decreases at each stage.

DC B04 D16 S03 **T01**

IN DEBE, D A; GODDARD, W A

FA (CALY) CALIFORNIA INST OF TECHNOLOGY

CYC 02

PI WD 9848270 A1 19991029 (199903)* EN 72p G01N033-00

AW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC NW NL

OA PT SD SE SC UG ZW

W: AL AM AT AU AC BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE

GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG

MM MN MW MX NO NZ FL FT RD RU SD SE SG SI SK SL TJ TM TR TT UA UG
VE VN YU ZW

AU 9871466 A 19981112 (199913) G01N033-00
EP 977985 A1 20000209 (200013) EN G01N033-00
P: CH DE FR GB LI

ADT WO 9848270 A1 WO 1998-038077 19980421; AU 9871466 A AU 1998-71466
19980421; EP 977985 A1 EP 1998-918562 19980421; WO 1998-038077 19980421
FDT AU 9871466 A Based on WO 9848270; EP 977985 A1 Based on WO 9848270
PRAI US 1998-44124 19980420; US 1997-44124 19970422
IC ICM G01N033-00
ICS G06F017-00

AB WO 9848270 A UPAB: 19990112
The three-dimensional backbone structure of an n **protein** is determined by selecting a finite set of torsion angles and generating an ensemble of conformations representing an exhaustive enumeration of self-avoiding backbone conformations for the selected set.
USE - The method is used for determining a **protein's** three-dimensional structure from its amino acid structure. This structure is often the key to elucidating the **function** and mechanism of the **protein** of interest, allowing researchers to discover new or more potent drugs.

ADVANTAGE - The method provides an accurate and easy to use method for initial structure prediction.
Dwg.1/9

FS CPI EPI
FA AB; GI
MC CPI: B04-N04; B11-C08; B12-K04E; D05-H09;
D05-H18A
EPI: S03-E14; T01-C

L123 ANSWER 46 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1999-013184 (02) WPIX

DNN N1999-014856 INC C1999-005774

TI Determination of **protein** biological function -
comprises use of amino acid sequences database containing the relevant information.

DC B04 T01
FA (IYAK-U) IYAKU BUNSHI SEKKI KENKYUSHO KK
CYC 1

FI JP 10287696 A 19981027 (199902) 11p C07K001-00 <--

ADT JP 10287696 A JP 1997-93577 19970411

PRAI JP 1997-93577 19970411

IC ICM C07K001-00
ICS G06F017-30

AB JP 10287696 A UPAB: 19990113
A database containing the information for amino acid sequence of **protein** with at least 1 biological **function** with added a score on importance of expression of the biological information for each amino acid residue, is new.

USE - The database is useful for determination of unknown biological **function** of a **protein** or **polypeptide** based on the homology of amino acid sequence, e.g. steric structure of **protein**, and includes retrieval and evaluation of high homologous relationship for the determination of mostly resembling **protein**.

ADVANTAGE - The database allows for correct and rapid retrieval and presumption of **protein** and **polypeptide** having biological **functions**.

Dwg.1/1

FS CPI EPI
FA AB; GI
MC CPI: B04-C01; B04-N02; B11-C08; B12-K04A
EPI: T01-J00B

L123 ANSWER 46 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1998-437455 (37) WPIX

DNN N1998-340768 INC C1998-133088

TI Prediction of **functional** site of **protein** in species -
used to improve **protein functionality** by mutation at
identified **functional** site.

DC B04 D16 S05 T01

IN D01, H; HIRAKI, H; KANAI, A

PA (D01H-1) D01 H; (KANA-N) KASAKI GIJUTSU SHINKO JIGYODAN; (KANA-I) KANAI A;
(HIRA-I) HIRAKI H; (NISC-N) JAPAN SCI & TECHNOLOGY CORP

CYC 21

PI WO 9833900 A1 19980906 (199837)* JA 95p C12N015-09
KW: AT EE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: SG US

JP 10210019 A 19980111 (199844) 1p C12N015-09
JP 10212446 A 19980401 (199844) 11p GC F017-00 <--
JP 11155079 A 19990015 (199933) 10p C12N015-09
JP 11210001 A 19990410 (199942) 14p GC F017-00 <--
EP 1013759 A1 19990015 (200035) EN C12N015-09
E: CH DE FR GB LI NL

ADT WO 9833900 A1 WO 1998-JP430 19980202; JP 10210079 A JP 1997-19248
19970131; JP 10212446 A JP 1997-19249 19970131; JP 11155573 A JP
1997-332100 19971202; JP 11213003 A JP 1998-18699 19980130; EP 1013759 A1
EP 1998-901095 19980202; WO 1998-JP430 19980202

FDT EP 1013759 A1 Based on WO 9833900

PRAI JP 1998-18699 19980130; JP 1997-19248 19970131; JP 1997-19249
19970131; JP 1997-332100 19971202

IC B04 G06F017-00; G06F017-30
H03 C07K014-00; C12N003-10; C12N003-12; C12N015-54; C12P021-02;
C12Q001-68; G06F019-00

ICA G07K014-195; C12N015-09; G06F19-00

ICI G06F19-00; C12N015-09; C12R001-19; C12N003-10; C12R001-13

AB WO 9833900 A UFAR: 19980916

Functional site of a selected **protein** in a species for
which **genomic** data or extensive cDNA analysis data is available,
is predicted by:

(a) calculating the occurrence frequency of each oligopeptide of a
specific length within the total **protein** sequences of the
species and determining the length (n) for which:

(i) there are fewer oligopeptides of length (n) occurring once than
twice and

(ii) there are more oligopeptides of length (n+1) occurring once than
twice;

(b) examining the sequence of the particular **protein** of
interest (total length L) and determining the occurrence frequency in the
total **protein** sequences of the species of:

(i') oligopeptides (Aj) of length (n+1) containing amino acid residue
j from the N-terminus of the **protein** (where (n+1) at least j at
most (L-n)), this residue j being at position i from the N-terminal of the
oligopeptide (where i at least 1 at most (n+1));

(ii') oligopeptides (Xi) of length (n+1) derived from these by
substitution of amino acid residue j in oligopeptide Aj by another,
arbitrary residue;

(c) calculating the ratio (Yji) of the occurrence frequency of Aj and
Xi;

(d) calculating a mean value (Yj) of Yji over i by the formula $Yj = [Yji]/(n+1)$;

(e) calculating the value of a **function** Zj of Yj; the
function being a continuously increasing or decreasing
function (a preferred **function** is $Zj = -\log(Yj)$), and

(f) repeating steps (b) to (e) for each value of j from j=(n+1) to
j=(L-n).

The value of Zj is an indicator of the degree of contribution of
amino acid residue j to the **functionality** of the **protein**.
Zj may be plotted as a distribution curve (number of residues with a
particular value of Zj, against value of Zj) and the peak value and
standard deviation calculated. This gives a measure of which amino acid
residues contribute most to the **functionality** of the
protein (i.e. have Zj more than one standard deviation above the

mean), and from this information the **functional** site or sites can be predicted.

Also claimed are:

- (1) an apparatus (e.g. computer systems) for automating this process;
- (2) three- heat-resistant DNA synthetase enzymes (sequences given in the specification) obtained by modification of *Pyrococcus furiosus* DNA synthetase at its **functional** sites using the information obtained by this process;
- (3) DNA coding for (2);
- (4) vectors containing (3);
- (5) transformant *Escherichia coli* containing (4) (*E.coli* HMS174(DE3)/pDP320 (FERM P-16312), *E.coli* HMS174(DE3)/pDP5017 (FERM BP-6184) and *E.coli* HMS174(DE3)/pDP504 (FERM BP-6190)), and
- (6) a preparation of the heat-stable enzymes by culture of the transformants.

USE - The process and the materials are used for the prediction of the **functional** sites of a **protein** from **genomic** or cDNA analysis data and use of this information to produce **proteins** of improved **functionality** by mutation at the **functional** sites so identified.

Dwg.16/24

ES CFI EPI

FA AB; GI

MC CFI: B04-E00E; B04-E03; B04-F10A3E; B11-C08E4; **B12-K04F**;
D05-A00F; **D05-H09**; D05-H12B2; D05-H12E; D05-H14A1;
D05-H17B3
EPI: S05-C; T01-J0VA

L123 ANSWER 47 OF 73 WPIX COPYRIGHT 2001 SERWENT INFORMATION LTD

AN 1998-389201 [34] WPIX

DNN 1998-383557 DMC C1403-117420

TI Determining spatial structure of **proteins** from analysis of accessibility of **protein** side chains - then forming and refining model structures from conformational energies, used e.g. in pharmaceutical development.

DC B04 D16 S03 T01

IN NOELTING, B

FA (NOEL-I) NOELTING B

CYC 1

F1 DE 19756284 A1 19980716 (199834)* 8p G01N033-68

ADT DE 19756284 A1 DE 1997-19756284 19971211

FFAI DE 1997-19756284 19971211

IC ICM G01N033-68

ICS G01N037-62; G01N033-50; **G06F017-50**

AB DE 19756284 A UPAB: 19980826

The spatial structure of a **protein** (I) of known primary structure is established by:

(a) determining the surface accessibility (SA) of **protein** side groups;

(b) determining conformations that are compatible with SA and physically possible, and

(c) forming and refining a structural model.

SA is examined by mutagenesis and step (c) involves analysis of conformational energies.

USE - The method is used in molecular biology, medicine, biotechnology, genetics and pharmacy, e.g. to study interactions between enzymes and their substrates or inhibitors, or between **proteins**. The defined structures can help to understand the effects of biomolecules and to develop pharmaceuticals that modulate the **function** and properties of biomolecules.

ADVANTAGE - The method can be used where usual methods (nuclear magnetic resonance or X-ray diffraction) are not suitable; it is based on the fact that, apart from free energy and partial volume, SA is an important co-ordinate in structure determination. Including SA reduces the number of physically acceptable conformations so much that computer modelling becomes practicable. Good quality structures are produced

quickly with few material requirements.

Dwg.370

ES CPI EPI

FA AB

MC CPI: B04-L01; B04-N04; B11-C08; B12-K04;

D05-H09

EPI: S03-E10; S03-E14H; T01-J15

L123 ANSWER 48 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1996-044834 [24] WPIX

DNN N1996-254159

TI Structural **alignment** method for comparative analysis of **protein** structures - using double dynamic programming algorithm.

DC T01

IN TOH, H

FA (RISM-N) BIOMOLECULAR ENG RES INST; (SEIB-N) SEIBUTSU BUNSHI KOGAKU KENKYUCHO KP

CYC 10

PI EF 84-000 A2 19960614 (199329)* EN 40p G06F017-30 <--
P: AL AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC ME NL PT RO
SE SI

JP 10125305 A 19960714 (199338) 21p G01N033-68

US 6115311 A 20000906 (200051) G06F019-00 <--

ADT EF 84-000 A2 EF 1997-210365 19971219; JP 10185923 A JP 1996-341727
19961120; US 6125331 A US 1997-992176 19971217

PRAI JP 1996-340727 19961220

REP NC-35.Pub

IC ICM G01N033-68; G06F017-30; G06F019-00

ICS G01N033-68; G06F017-30

AB EF 84-000 A EFAB: 19960722

The structural **alignment** method involves using a double dynamic programming algorithm. Distance cut-off approximation is performed, in which a sphere having a predetermined radius and centred on the side chain of a residue of a **protein** is defined, and residues with side chains centres that are present within the sphere are selected as constituent elements of a structural environment of the residue.

A cut-off approximation is performed for selectively comparing residue pairs obtained by the distance cut-off approximation and having similar local environments.

USE - Comparative analysis of **protein** structures to obtain information regarding structure, **function** and **evolution** of **proteins**.

ADVANTAGE - Enables structural **alignment** to be constructed in reduced period of time.

Dwg.3731

ES EPI

FA AB; GI

MC EPI: T01-J15H

L123 ANSWER 49 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1998-072130 [24] WPIX

DNN N1998-213034 INC C1998-034971

TI Evaluating structure of **proteins** by classification of codons in corresponding nucleic acids - used to identify important or mutation-prone regions, **functionally** similar **proteins** or coding regions.

DC B04 D10 T04

IN FRESCO, F R; HALITSKY, D

FA (CUMU-N) CUMULATIVE INQUIRY INC

CYC 75

PI WD 9610314 A1 19960517 (199324)* EN 56p C07K001-00 <--

RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
SD SE SG UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH
HU ID IL IS JP KE KG KP KR KZ LC LE LR LS LT LU LV MD MG MK MN MW
MX NO NZ PL PT RD RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN

YU ZW

ADT AU 9850961 A 19980522 (199840) C07K01-00 ---
 WO 9818814 A1 WO 1997-0319673 19971027; AU 9850961 A AU 1998-50961
 19971027

EDT AU 9850961 A Based on WO 9818814

IPRAI US 1998-07241 19970213; US 1998-29521 19961028

IC ICM C07K001-00

ICS G06F017-50

AB WO 9818814 A EPAB: 19980311

Structure of a **protein** (I) is evaluated by:

(i) assigning bases in the nucleic acid sequence (II) encoding (I) into triplets, and

(ii) assigning these triplets into classes of a binary choice alphabet of n degrees of freedom, these classes being generated by applying n binary choice parameters (which are **functions** of a message-level properties of (II)) to a triplet to yield second classes.

Also claimed are:

(i) a class-constant table of nearest neighbour (NN) relationships for amino acid (aa) residues that provides, for each class of class-constant NN, a frequency of occurrence for each NN pair in a collection of at least 10 **proteins**;

(ii) a machine-readable medium on which these tables are stored, and

(iii) a method for evaluating a **protein**:

(i) for resistance to **evolutionary** or mutational change by identifying regions encoded by runs of a single subclass, or

(ii) for presence of critical aa by identifying minority codons in runs of codons of a single class or subclass.

USE - The method is used:

(i) to identify **functionally** and structurally important regions of (I);

(ii) to detect coding regions;

(iii) to identify structural and **functional** similarities in **proteins**, and

(iv) to identify mutation-prone regions of viral (II).

Particularly it is used for design of new **proteins** with selected structural or **functional** properties, especially biological activity.

ADVANTAGE - The method can identify structural homologies between **proteins** even where sequence homology is low.

Dwg.0/0

ES CFI EPI

FA AB

MC CFI: B04-E01; B04-N04; B11-C07; B12-K04;

D05-H09; D05-H18A

EPI: T04-A00B

I123 ANSWER 50 OF 73 WPIN COPYRIGHT 1991 DERWENT INFORMATION LTD

AN 1998-297333 [18] WPIN

DNC C1998-069400

TI DNA encoding calcium-activated potassium channel - useful in assays to identify compounds which increase or decrease potassium ion flux.

DC B04 D16

IN ABELMAN, J P; BOND, C T; MAYLIE, J; SILVIA, C P

PA (ICAG-N) ICAGEN INC; (UYOE-N) UNIV OREGON HEALTH SCI; (ICAG-N) ICA-GEN INC

CYC 50

PI WO 9811134 A1 19980314 (199818) EN 151p C07K014-705 <--

FW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
 SD SE SG UG ZW

W: AL AM AT AU AZ BA BB BE BF BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH HU ID IL IS JP KE KG KP KR KZ LC LE LR LS LT LU LV MD MG MK MN
 MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ
 VN YU ZW

AU 9742500 A 19980401 (199818) C07K014-705 <--

EP 948542 A1 19991013 (199947) EN C07K014-705 <--

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

JP 2000014310 W 20001031 (200059) 156p C12N015-09

AU 726159 B 20001106 (2000062) C07K014-705 ---
 ADT WO 9811139 A1 WO 1997-051603 19970910; AU 9742660 A AU 1997-42660
 19970910; EP 94-542 A1 EP 1997-541009 19970910; WO 1997-051603 19970910;
 JP 2000514310 W WO 1997-051603 19970910; JP 1993-013228 19970910; AU
 726158 B AU 1997-42660 19970910
 FDT AU 9742660 A Based on WO 9811139; EP 94-542 A1 Based on WO 9811139; JP
 2000514310 W Based on WO 9811139; AU 726158 B Previous Publ. AU 9742660,
 Based on WO 9811139
 PRAI US 1997-45133 19990417; US 1996-26451 19960911; US 1997-40052
 19970907
 IC ICM C07K014-705; C12N013-39
 ICS C07K016-00; C07K016-28; C12N011-15; C12N011-19;
 C12N011-21; C12N011-11; C12N013-09; C12N013-12; C12N015-01;
 C12P011-02; C12P011-01; C12P011-03; G01N013-15; G01N013-31;
 G01N013-53; G06F017-30
 AB WO 9811139 A EPAR: 19981132
 A new nucleic acid (A) encodes a monomer of a calcium-activated potassium
 channel (A), where the monomer: (i) has a calculated molecular weight of
 between 40 and 60 kDa; (ii) has a unit conductance of between 3 and 60 pS
 when the monomer is in the **functional** polymeric form of a
 potassium chain and is expressed in a *Xenopus* oocyte; and (iii)
 specifically binds to antibodies generated against the following sequence,
 where the C-terminal E is optionally absent: AKFLELTFAEKHVHNFMMDTQLTK(R)
 All sequences are given in the specification. Also claimed are: (1) an
 isolated nucleic acid encoding at least 15 contiguous amino acids from
 (A), which has one of 3 sequences; and conservatively modified variants,
 with the proviso that the contiguous amino acids do not consist of a
 glutamine repeat amino acid sequence; (2) an isolated nucleic acid of at
 least 30 nucleotides which specifically hybridises, under stringent
 conditions, to a nucleic acid encoding an intermediate (A) having a 428
 amino acid sequence or (A) which has one of 3 sequences; (3) an isolated
 (A) having at least 15 contiguous amino acids from one of 3 sequences,
 their conservatively modified variants, where the variants specifically
 react, under immunologically reactive conditions with an antibody reactive
 to one of the 3 **proteins**; (4) an antibody specifically reactive
 to (A) which has one of 3 sequences; (5) an expression vector comprising a
 nucleic acid encoding (A) as described above; (6) a host cell transfected
 with the vector of (5);
 USE The antibody and probe can be used to detect the presence of (A)
 or (I) in a sample. Host cells expression (A) can be used in assays to
 identify compounds which increase or decrease the potassium ion flux
 through (A). The transfected host cell can also be used for the
 recombinant production of (A). The nucleic acid sequences encoding (A) can
 also be used for determine mutation in the SK and IK genes in a computer
 system. The **proteins** encoded by the SK and IK genes can be used
 in a computer system for determining their three dimensional structure,
 which is useful for determining ligands that bind to the **proteins**
 . (All claimed).
 Dwg. 0/0
 FS CPI
 FA AB
 MC CPI: B04-E01; B04-F01; B04-G01; D05-H09; D05-H11; D05-H12A;
 D05-H12B1; D05-H12E; D05-H14
 L123 ANSWER 51 OF 73 WPIN COPYRIGHT 2001 DERWENT INFORMATION LTD
 AN 1999-145797 [13] WPIN
 DNC C1999-047743
 TI Identifying optimal molecular structures by variable basis Monte Carlo
 method - particularly to determine biologically active conformation(s) of
 neurotrophin domains involved in receptor binding and subsequent
evolution of active ligands.
 DC B04 T01
 IN RIOPELLE, R J; ROSS, S M; SHAMOVSKY, I L; WEAVER, D F
 PA (TOOR) UNIV QUEENS KINGSTON
 CYC 7-
 PI WO 9806048 A1 19980212 (199813)* EN 170p G06F017-50 <--

PW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH HU IL IS JP KE KG KH KF LZ LF LG LT LU LV ML MG MK MN MW
MX NO NC PL PT PO PU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZW

AU 9736174 A 19990125 (199829)

G06F017-50 ---

US 6013114 A 20000122 (200017)

G06F019-00 ---

ADT WO 9806048 A2 WO 1997-08339 19970711; AU 9736174 A AU 1997-36174 19970731;
US 6013114 A US 1997-004446 19970711

FDT AT 9736174 A Based on WO 9806048

IPRAI GE 1996-16116 19960711

IC ICM G06F017-50; G06F019-00

ICS C07K014-00; G06F017-00

AB WO 9806048 A (FAS: 19980320)

Variable basis Monte Carlo (VBMC) simulated annealing method for identifying an optimal molecular structure comprises (a) providing a Markov chain with an initial basis set of N configuration variables defining a structure; (b) translating, by an amount randomly chosen within a predetermined range, these variables along a basis vector (BV) to produce a new structure; (c) calculating the potential energy (PE) of this structure; (d) deciding, on the basis of a temperature-dependent transition **function**, whether or not to accept this structure, and if it is accepted using it to replace the existing structure; (e) repeating (b)-(d), each time with a new BV for a specified number of repetitions at a preselected upper temperature; (f) decreasing the temperature according to a preselected cooling schedule; (g) repeating (b)-(d, and (f), each repetition having a new BV for a preselected number of repetitions; (h) storing current molecular structure; (i) repeating (g) and (h) until a predetermined number of structures has been stored; (j) rotating the set of conformational variables according to a distribution of stored structures such that the BV is directed along low energy valleys of a PE hypersurface, so accelerating conformational motions and structural transitions, while erasing structures from (h) and (i); (k) repeating (i) and (j) until, after an appropriate number of repetitions, a preselected low temperature is reached, resulting in an unrefined global minimum structure; (l) refining this structure to identify at least one local minimum on the PE hypersurface. Also new are (1) ligands (I) that bind the TrkA and B receptors containing at least 3 elements able to bind to 3 binding areas in the receptor; (2) ligands (II) that bind the common neurotrophin receptor p75NTR containing at least 2 elements that bind to 2 binding areas in this receptor; (3) designing (I) and (II) by computational **evolution**.

USE - The method is used to identify the biologically active conformations of **peptide** domains of ligands, particularly neurotrophins (NT), that bind to a receptor. Once such conformations have been identified, small molecules that either inhibit NT-binding or act as agonists of the native ligand can be developed.

ADVANTAGE - The VBMC is more effective than known Monte Carlo methods because (i) translation about the BV is limited and (ii) rotation of the basis set is avoided at high temperature and only introduced at low temperature.

PREFERRED PROCESS - BV is chosen randomly or deterministically within a predetermined range, and the number of repetitions in (g) is at least 1N. The refining step, (l), is non-linear minimisation, using a gradient descent, conjugate gradient, quasi-Newtonian (Newton-Raphson), Marquardt, variable metric or Powell minimisation. The molecular system particularly includes at least one **peptide** domain and the basis set includes torsional angles between alpha-carbon atoms of each amino acid and neighbouring C and N atoms, but keeping such angles that describe planar parts of the structure constant. Equations describing the temperature-dependent transition **function** are presented, and the upper and lower temperatures are 1000 and 120 K. To identify a binding domain, (nearly) optimised structures of domains in a large number of ligand analogues (at least one being able to bind the receptor) are identified, as local PE minima, using the new VBMC method, then these

structures compared to detect structural features common to active ligands. Specifically the method is applied to (a) nerve growth factor/TrkA; (b) brain-derived neurotrophic factor, NT3 or 4/TrkB; (c) NT3/TrkC and (d) the receptor p75NTR. PREFERRED LIGAND - (1) comprises elements with proper spatial occupancy, relative atomic positions, bond type and charge for defining a 3-dimensional configuration able to bind the 5 binding areas. TrkA includes a leucine-rich motif (LFM, amino acids 93-117, with 5 binding areas: (A) Phe105A (hydrophobic interaction); (B) Phe111A, Phe113A and Thr114A (hydrophobic interaction); (C) Asp109A and His111A (ionic); (D) Lys112A (ionic) and (E) Asn95A-Ile99A (multiple parallel beta-strand type hydrogen bonds). Particularly (1) has elements that bind (A, C and D (respectively Trp; Arg and Lys and Asp), optionally also one of B and E, optionally as their isosteres. A similar analysis of binding areas in TrkB and p75NTR is given. ALGORITHM - The specification includes a computer program, in Fortran-77, for implementing VEMO. The algorithm is interfaced with the CHARMM force field so that torsional distortion, van der Waals and electrostatic interactions and hydrogen bonding are accounted for explicitly.

EXAMPLE - A set of 6 proteins (3 active and 3 inactive in TrkA binding) was analysed by VEMO to identify low energy conformations of the termini. The algorithm shows that the N (1-11) and C (112'-118') termini of the dimeric (1-118) NGF form a complex that includes a rigid region (3-11 and 112'-118') and a flexible loop (1-8), with the main stabilising factor being ionic contact between Glu11 and Arg112'. Separation of the two regions is caused by repulsion between His4 and His8, Arg4 and Arg112'. This geometrical arrangement is recognised by the receptor. Inactive proteins lack the proper geometry of the rigid region.

Swg. 1/13

EP: CFI EP1
 PA: AB
 MC: CFI: B.4-K11
 EPI: T01-W15K

L123 ANSWER 52 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1998-065463 (97) WPIX

DEN N1998-051473 DMC C1998-061305

TI Rapid identification of easily synthesised candidate drug compounds - utilising computerised representation of biological macromolecule surface binding site and lists of available reagents to generate virtual libraries of candidates.

DC B04 D16 J04 T01

IN MURRAY, C; YOUNG, S C

PA (PROT-N) PROTEUS MOLECULAR DESIGN LTD

CYC 23

PI EP 818744 A2 19960114 (199707)* EN 24p G06F017-50 <--
 R: AU AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT FO SE
 SI

ALT EP 818744 A2 EP 1997-304412 19970624

PRAI GB 1996-16862 19960907; GB 1996-14322 19960708

IC ICM G06F017-50

ICS C07K001-00; C07K005-08; C12N009-74

AB EP 818744 A UPAB: 19960216

Identifying drug candidate (DC) comprises: (1) obtaining a computerised representation of the 3-dimensional structure of a binding site (BS) on the surface of a biological macromolecule; (2) generating a computerised model (CM) of the functional structure of BS which may be used to identify favourable and unfavourable interactions between BS and a DC molecule; (3) identifying a molecular fragment (MF) capable of placement within BS and capable of carrying at least 1 substituent group (SG), where MF is either capable of being synthesised from reagent compounds (RC) accessible in substituted form to introduce SG on synthesis of MF or is present in an RC capable of substitution with SG by reaction with further RC's; (4) generating lists of accessible RC's, such that combination of compounds from each list may be reacted to produce a DC compound containing SG's, to generate a first virtual library (VL) of DC's

especially the theoretical list of compounds producible by reaction of the members of the lists, each member of each list containing a component common to the other members of that list and a component unique within that list; (5) limiting the number of members of each list using a first set of exclusion rules to generate a restricted second VL of DC's, where operation of the rules involves involving for each member of each list comparisons for (un)favourable interactions between CM and a structure comprising MF and an SG deriving from the unique component within the list of that member, MF and CM being held in fixed spatial relationship to each other for the comparison; (6) evaluating and ranking by computer the members of the second VL for favourable/unfavourable interactions with CM and thus generating a restricted third VL of DC's ranked as having favourable interactions; (7) optionally selecting at least 1 further MF from the third VL and repeating steps (4)-(6) to generate an alternative third VL; (8) screening the third VL using a second set of exclusion rules to generate a restricted fourth VL of compounds which are candidates for synthesis and experimental evaluation of drug efficacy; (9) synthesising some or all of the compounds of the fourth VL to produce a DC compound library; (10) experimentally evaluating the DC compounds for drug efficacy; (11) analysing the experimental efficacy data for structure-activity relationship information; (12) using the obtained information to select a revised set of lists of accessible EC's, expanded to include, and optionally restricted to exclude, selected EC's present in the lists generated in step (5); (13) repeating steps (6) and (7) to identify further candidate compounds for synthesis and experimental efficacy evaluation; (14) synthesising and evaluating the further compounds; (15) if required repeating steps (11)-(14) at least 1 time, and (16) identifying as lead candidate a compound synthesised and experimentally evaluated as above. Also claimed are: (A) novel active compounds identified by the above process, and (B) a method for manufacturing a drug comprising steps (11)- (16) as above followed by: (a) manufacturing the compound identified in step, and (b) optionally admixing the product with at least a carrier or excipient.

ADVANTAGE - A relatively small set of readily synthesisable DC's is rapidly generated, with a high success rate in terms of drug efficacy and hence a high predictive value for directing subsequent iterations. The synthesis is simplified and minimised and the success rate is maximised. The identified DC's are implicitly readily synthesised.

Fig.0/3

FS CPI EPI

FA AB

MC CPI: B04-M01; B12-K04; D05-H09; J04-B01

EPI: T01-J15X

L123 ANSWER 53 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1997-374922 [35] WPIX

DNC C1997-120959

TI Polynucleotide(s) and **proteins** derived from *Staphylococcus aureus* - stored on computer readable medium and used in the production of anti-*S.aureus* vaccines.

DC B04 D16

IN BAFASH, S C; CHOI, G; DILLON, P J; FANNON, M R; KUNSCR, C A; POSEN, C A; CHOI, G H

FA (HUMA-H) HUMAN GENOME SCI INC

CYC 25

FI EF 7-6519 A1 19-76716 (199709)* EN C12N015-00

F: AL AT BE CH DE DK ES FI FF GR HE IE IT LI LT LU IN MC NL PT RO SE SI

CA 2194411 A 19970706 (199707) C12N015-31

JP 09322781 A 19971216 (199803) C12N015-09

AMT EF 7-6519 A1 EP 1997-100117 19970107; CA 2194411 A CA 1997-2194411 19970106; JP 09322781 A JP 1997-20169 19970106

FEAI US 1-66-9861 19960105

REP No-SF-Pub

IC ICM C12N015-00; C12N015-09; C12N015-31

ICS A61K039-085; A61K039-395; C07H021-04; C07K014-31;

C07K016-12; C12N001-19; C12N001-21; C12N005-10; C12Q001-62;
G01N023-568; G06F017-30; G06F019-00

ICA C12P021-02; C12P011-08

ICI C12N015-00; C12P001-04

AB EP 796519 A UPAB: 19970828

The following are new: (a) computer readable medium, preferably selected from a floppy or hard disk, random access memory (RAM), read-only memory (ROM) or CD-ROM, having recorded on it a nucleotide sequence of the *Staphylococcus aureus* **genome** having one of the 5191 sequences given in the specification, a fragment of these, or a sequence which is at least 85% identical to these sequences, or degenerate variants; and (b) a computer-based system for identifying fragments of the *S.aureus* **genome** of commercial importance comprising: (i) a data storage means comprising the 5191 nucleotide sequences above, a fragment or a sequence which is at least 25% identical to these sequences; (ii) search means for comparing a target sequence to the nucleotide sequence of the data storage means to identify homologous sequences; and (iii) retrieval means for obtaining the homologous sequences.

USE - Homology searches using the new *S.aureus* DNA sequences allows putative **functions** to be assigned so that **protein**-encoding or regulatory regions of commercial, therapeutic or industrial importance can be obtained. Specifically, sequences which are likely to encode antigens have been identified and these **polypeptides** can be used in a vaccine composition against *S.aureus* infection (claimed). The **polypeptides** can also be used in a claimed kit for the immunodetection of *S.aureus* in a sample. *S.aureus* is implicated in numerous human diseases, including cellulitis, eye, etc infections, food poisoning, osteomyelitis, skin and surgical wound infections, scalded skin syndrome, toxic shock syndrome, etc. The transformed organisms can be used for recombinant production of the **polypeptides**. The new DNA sequences (and their fragments) are useful as primers or probes for isolating homologues or any of the 5191 *S.aureus* sequences (claimed).

Dwn.5/2

ES CFI

FA AB

MC CFI: B04-E033; B04-E03F; B04-E03; B04-G01; B04-N03; B04-P0100E; B04-P01E;
B14-C11B; D05-H04; D05-H07; D05-H12A; D05-H12D1; D05-H12D5; D05-H12E;
D05-H14; D05-H17A5

L123 ANSWER 54 OF 73 WHIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1997-244768 [23] WHIX

DNN N1997-001912 DMC C1997-079164

TI Preparing database of molecular fragments by counting all fragments in a molecule - and storing counts in computer memory, useful for analysing structure-activity relationships, especially of drugs and toxins.

DC B04 J04 S03 T01

IN BONE, R G A; VILLAR, R O

PA (TERR-0) TERRAPIN TECHNOLOGIES INC

CYC 26

FI WO 9714106 A1 19970417 (199722)* EN 48p G06F017-30 <--
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU CA JP

AU 9673987 A 19970430 (199734) G06F017-30 <--

ADT WO 9714106 A1 WO 1996-0516196 19961010; AU 9673987 A AU 1996-73987 19961010

FDT AU 9673987 A Based on WO 9714106

FRAI US 1996-500647 19961031; US 1996-542642 19961013

REP 1.Intl.Ref; EP 496902

IC ICM G06F017-30

ICS G01N023-00; G06F017-50

AB WO 9714106 A UPAB: 19970530

Database of molecular fragments is prepared by:

(a) identifying all sequentially attached fragments within a selected molecule,

(b) counting the occurrences of each unique fragment and

(c) storing information correlating fragment counts with fragment

identity in computer-readable form.

Also claimed are:

- (1) data processing system for creating such databases, and
- (2) computer-readable medium on which the databases are stored.

USE - Comparison of fragment counts between a molecule and a reference molecule of known activity can be used to predict which compound will have this particular activity. The method is especially applied to libraries of drugs (e.g. central nervous system drugs), toxins or randomly chosen compounds.

ADVANTAGE - The databases provide a complete and systematic classification of **function** activity based on specific topological characteristic of fragments of small molecules, and is suitable for construction of combinatorial libraries covering the whole of chemical space or focused on part of it for precise selection of active molecules.

Dwg.11a/13

FS CFI EPI

FA AB; GI

MC CFI: E-4-E31; B12-K04A; C04-E

EPI: S03-E14A1; S03-E14H; S03-E14X; T01-J03; T01-J05B2A; T01-J05B3;
T01-J1004

L123 ANSWER TO CP 73 WIIX COPYRIGHT 2001 DLRWENT INFORMATION LLC

AN 1996-100839 [30] WPIX

ENC C1926-100877

TI Predicting tendency to form amphiphilic alpha and beta structures - using a novel algorithm to calculate values for subsequent graphical analysis to predict **protein** structure.

DC B11 T01

IN CHENG, M; CIEGLEDY, F; FLOCHBERG, J; ICEROVICH, P; LI, J

PA (2000) UNIV COLUMBIA NEW YORK

CYC 33

PI WO 9618957 A1 19960620 (199630)* EN 109p G06F017-10 ---
FW: AT BE CH DE DK ES FR GE GR IE IT LU MC NL PT SE
W: AU CA JP

AU 9644684 A 19960703 (199641) G06F017-10 ---

US 5940307 A 19990817 (199930) G06F017-11 ---

ADT WO 9618957 A1 WO 1996-US16126 19951213; AU 9644684 A AU 1996-44684
19951213; US 5940307 A US 1994-355:44 19941214

FDT AU 9644684 A Based on WO 9618957

PRAI US 1994-355344 19941214

REP 6.Jul.Ref; US 4853871; US 4929666; US 5263030

IC ICM G06F017-10; G06F017-11

ICS G06F017-50; G06F019-00

AB WO 9618957 A USAB: 19960701

Predicting the tendency of a **protein** to form either: (a) an amphiphilic alpha-structure or (b) an amphiphilic beta-structure comprises: (i) calculating a series of values for (a) U-alpha-x using equation (1) or (b) U-beta-x using equation (2), for a series of portions of the **protein**, each portion having a span of x residues, where the series of portions spans the **protein** and x is an integer: Equation (1) is $U\text{-alpha-x} = Hx + \mu\alpha\text{-alpha-x} - [pt]$ and Equation (2) is $U\text{-beta-x} = Hx + \mu\alpha\text{-beta-x} - [pt]$. In equations (1) and (2), Hx is the average hydrophobicity for a span of x residues using the Kyte-Doolittle scale, $\mu\alpha\text{-alpha-x}$ is the hydrophobic moment (span x) for alpha-structures, the angle between one residue and the successive residue being 100deg., $\mu\alpha\text{-beta-x}$ is the hydrophobic moment (span x) for beta-structures, the angle between one residue and the successive residue being 160deg., and [pt] is the position dependent turn propensity, and (ii) depicting the values for U-alpha-x or U-beta-x graphically to form a series of peaks, where (a) peaks wide enough to correspond to a segment of the amino acid sequence long enough to span the membrane as an alpha-helix are predicted to be alpha-structures and (b) peaks that are too narrow to correspond to a segment of the amino acid sequence long enough to span the membrane as an alpha-helix but which are wide enough to correspond to a segment of the amino acid sequence with a length between 6 and 14 amino acid residues are

predicted to be beta-structures.

USE - The methods are used partic. for predicting the structure of membrane **proteins** such as glucose transporter **proteins** (GLUTs). They can be used to discern the **function** of **proteins**. They can also be used for the rational design or identification of **spds.** which interact with the **proteins** or to engineer **proteins** having particular structures.

Dwg.0/4

ES CFI EPI

FA AP

MC CFI: B04-N04; B12-K04

EPI: T01-J00A; T01-S

L123 ANSWER 06 OF 73 WPIX COPYRIGHT 1991 (PERKENT INFORMATION LTD)

AN 1995-086795 [01, WPIX

CR 1997-525719 [48]

DNN N1995-005454 DMC C1995-002386

TI Analysis and modification of **protein** structure - by identification of favoured and suppressed patterns of hydrophobic amino acid residues.

DC B04 D16 T01

IN HUMPHREYS, P E

FA (ANTI-N) ANTIGEN EXPRESS INC

CYC 19

FI WO 9426783 A1 19941124 (199511)* EN Esp C07K013-00 ---

FW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: CA JP

ADT WO 9426783 A1 WO 1994-US5558 19940518

FFAI US 1993-63908 19930519

REP 01Jnl.Fef

IC ICM C07K013-00

ICS G06F015-00

AB WO 9426783 A UPAB: 19971209

(A) Identification of favoured and suppressed patterns of hydrophobic residues from the group Leu, Ile, Val, Phe and Met indicated F and other residues indicated S, comprises: (a) providing amino acid (AA) sequences from naturally occurring **proteins**; (b) applying templates of 3 to 9 positions composed of all combinations of F and S in each position of the amino acid sequences of (a); (c) scoring the frequency with which each template is found; (d) determining the standard deviation (SD) by which a template occurs from the expected frequency for an empirical distribution of F and S positions based upon the frequencies of the AAs in the naturally occurring **proteins** of (a); and (e) ranking the patterns on a scale of preferred and suppressed on the base of those SDs between observed and expected frequencies. Also claimed are: (B) alteration of the structure of a predetermined AA copolymer, comprising: (a) providing the sequence of AA residues in an AA copolymer; (b) providing the identity of favoured and suppressed patterns of hydrophobic aa residues as determined by (a)-(e) as in (A); (c) identifying patterns of hydrophobicity in the provided AA copolymer on the basis of (b); (d) comparing the concordance of the observed AA residues to patterns which have been determined to be favoured or suppressed; and (e) altering the identity of the observed aa residues to effect a structural change; (C) identification of the extent and density of the pool of hydrophobic side chains in the core of a **protein** into which hydrophobic side chains of an alpha-helix are immersed, comprising: (a) providing X-ray crystallographic coordinates of naturally occurring **proteins**; (b) applying the strip-of-helix template (X---X---X---X---, joined in a circle) to each of the alpha-helices in the **proteins** of (a) to maximise the mean hydrophobicity of residues in X positions; (c) extending the template pattern defined by the application in step (b) to adjacent non-helical regions; (d) determining the template-specified positions from the gp. of (i) all X positions in the helix, (ii) the N-terminal X position, (iii) the C-terminal X position, (iv) the X positions in the helix between the N-terminal X position and the C-terminal X position, (v) the X position with the smallest residue, (vi) the X position with the

least hydrophobic residue, (vii) the first X position beyond the helix at the N-terminus, (viii) the first X position beyond the helix at the C-terminus, (ix) all non-X positions in the helix and (x) the X position contg. one of two sequential residues in the primary sequence from the gp. Leu, Ile, Val, Phe and Met; (e) determining the identity of all AAs as a **function** of the distance of their C- α from the distal non-hydrogen atom of the side chain of AAs in the template-defined positions and (f) determining the mean density, cumulative hydrophobicity and shell hydrophobicity of each residue identified in step (e) around each template-defined position; (g) altering the structure of an alpha-helix and/or altering the structure of the appositional hydrophobic pool to that helix, in a predetermined AA copolymer, comprising: (a) providing a sequence of AAs from a predetermined AA copolymer; (b) step (b)-(f) as in (C); (c) comparing the concordance of the observed AA residues in the positions of the strip-of-helix template-defined positions and in the appositional pool of residues to patterns which have been determined to most favour or most suppress helix extension; and (d) altering the identity of the observed AA residues to effect a structural change; (E) predicting open reading frames (ORFs) in DNA sequences, comprising: (a) providing a DNA sequence to be analysed for the presence of ORFs; (b) determining the DNA codon pattern corresponding to SFFSS and SFSES, the respective DNA codes being -nonT--T--T--nonT--nonT- and -nonT--T--nonT--T--nonT-, where T is a deoxyribonucleotide with the base thymine and nonT is a deoxyribonucleotide with a base selected from adenine, cytosine, guanine and thymine; (c) scoring the occurrence of each pattern within the DNA sequence; (d) selecting polynucleotide segments which are bounded by DNA nucleotide patterns corresponding to this SFFSS as pattern and which hold the SFFSS pattern more than one SD from the empirical frequency of that pattern in a standard set of DNA sequences and which exclude the SFSES pattern more than one SD from the empirical frequency of that pattern in a standard set of DNA sequences; and (e) identifying segments contg. the individual or merged positive selections as the predicted ORFs; (F) predicting of alpha-helices, comprising: (a) providing an AA sequence to be analysed for the presence of a helix; (b) scoring the segments in which the SFFSS pattern is found; (c) extending the scored segment toward the N-terminus and/or the C-terminus to include additional residues which fall within favoured composite patterns which are identified with this invention to include the highly favoured pattern; (d) identifying individual or overlapping segments identified in this manner as the predicted alpha-helices.

The methods can be used for the analysis and modification of **protein** structure. They can be used to design **polypeptides** de novo or to modify natural prods. to provide the most efficiently folded and stable forms of AA copolymers. The technique can be applied to drug design.

Dwg.0/3

FS CPI EPI

FA AB; GI

MC CPI: B04-C01; B04-E01; **B04-N04**; B10-B02; **B12-K04**;

D05-H12B1; D05-H12D1

EPI: T01-J03

L123 ANSWER 57 OF 73 WPIX COPYRIGHT 2001 REFWENT INFORMATION LTD

AN 1994-120230 [15] WPIX

DNC C1994-055596

TI Method of resurfacing of rodent antibodies to produce humanised antibody forms - for producing non human antibodies with improved therapeutic efficiency by presenting human surface on V-region.

DC B04 D16

IN GUILD, B C; PEDERSEN, J T; REES, A R; ROGUSKA, M A; SEAFLE, S M J

PA (PEDE-I) PEDERSEN J T; (IMMU-N) IMMUNOGEN INC

CYC 16

PI EP 552105 A1 19940413 (199413)* EN 220p C12N15-13

F: BE CH DE DK ES FR GB IE IT LI LU NL SE

CA 2105644 A 19940310 (199421) C07H015-26 ---

JP 07067633 A 19950314 (199519) 134p C12P021-08

US 5639641 A 19970617 (199730) 158p C12N015-00
 ADT EP 592106 A1 EP 1993-307051 1:430907; CA 2105644 A CA 1993-2105644
 1:430907; JP 07067068 A JP 1994-324722 19:030909; US 5639641 A US
 1991-042145 19920909

PRAI US 1991-042245 19920909

REP 01Jr1.1.ref; EP 519590; WO 910990.7

IC ICM C07K015-28; C12N015-00; C12N015-13; C12P031-00

ICS A61K039-399; C07K015-00; C07K016-00;

C07K016-46; C12N015-61; G01N023-22; G01N033-68;

G06F015-42

ICA G01N033-531

AB EP 592106 A UPAB: 19:41531

Humanising a rodent antibody (Ab) or fragment by resurfacing comprises:
 (a) determin. of the conformational structure of the variable region of the
 rodent Ab or fragment by constructing a 3D model of the rodent Ab variable
 region; (b) generating sequence **alignments** from relative
 accessibility distributions from X-ray crystallographic structures of the
 rodent Ab variable region heavy and light chains to give a set of heavy
 and light chain framework positions; (c) defining a set of heavy and light
 chain surface exposed amino acid residues using the set of framework
 positions generated in (b); (d) identifying from human antibody amino acid
 sequences a set of heavy and light chain surface exposed amino acid
 residues that is most closely identical to the set of residues defined in
 (c); (e) substituting the set of heavy and light chain surface exposed
 amino acid residues defined in (c) with the set of residues identified in
 (d); (f) constructing a 3D model of the rodent antibody variable region
 resulting from the substitution of (e); (g) identifying any amino acid
 residues from the set identified in (f), that are within 5 Angstrom of any
 atom of any residue of the complementarity determin. regions (CDRs) of the
 rodent Ab to be humanised; and (h) changing any residue identified in (g)
 from the human to the original rodent amino acid residue. Step (a) need
 not be conducted first, but must be conducted prior to step (g).

USE - The humanised antibodies permit the produ. of
functional altered Abs, which retain the binding parameters of the
 original non-human antibody, with improved therapeutic efficiency in
 patients due to the presentation of a human surface on the variable
 region.

Dwg. 0/10

FS CFI

FA AB

MC CFI: B04-G01; B11-C08; B12-K04; D05-H11

ABEQ US 5639641 A UPAB: 19970723

A method for producing a humanized rodent antibody or fragment thereof by
 resurfacing, said method consisting essentially of:

(a) generating position **alignments** from relative
 accessibility distributions from x-ray crystallographic structures of a
 pool of rodent and human antibody heavy and light chain variable regions
 to give a set of heavy and light chain variable region framework surface
 exposed positions wherein the **alignment** positions for all rodent
 and human variable regions are at least about 98% identical;

(b) defining for a rodent antibody or fragment thereof a set of heavy
 and light chain variable region framework surface exposed amino acid
 residues using said set of heavy and light chain variable region framework
 surface exposed positions generated in said step (a);

(c) identifying from human antibody amino acid sequences a set of
 heavy and light chain variable region framework surface exposed amino acid
 residues that is most closely identical to said set of rodent surface
 exposed amino acid residues defined in said step (b);

(d) substituting, in the variable region framework amino acid
 sequence of said rodent antibody or fragment thereof, said set of heavy
 and light chain variable region framework surface exposed amino acid
 residues defined in said step (b) with said set of heavy and light chain
 variable region framework surface exposed amino acid residues identified
 in said step (c);

(e) constructing three-dimensional models of said variable region of
 said rodent antibody or fragment thereof and of said variable region of

said rodent antibody or fragment thereof resulting from the substituting specified in said step (d);

(f) comparing said three-dimensional models constructed in said step (e), and identifying any amino acid residues from said sets identified in said steps (b) or (c), that are within 5 Angstroms of any atom of any residue of the complementarity determining regions of said rodent antibody or fragment thereof;

(g) changing any residues identified in said step (f) from the human to the original rodent amino acid residue to thereby define a humanizing set of surface exposed amino acid residues;

(h) replacing the set of rodent antibody variable region framework surface exposed amino acid residues defined in said step (b) with the humanizing set of variable region framework surface exposed amino acid residues defined in said step (g); and

(i) producing said humanized rodent antibody or fragment thereof having binding specificity.

Dwg. 0710

L123 ANSWER 53 OF 72 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1994-093190 [10] WPIX

CP 1993-018139 [02]

DNN N1994-064957 ENC C12N015-13

TI Preparation of improved humanised antibodies - by comparison of consensus and import complementarity determining regions and framework region sequences, e.g. to humanise murine.

DC B01 D10 T01

IN CARTER, P J; PARSTA, L G

PA (CETH) GENENTECH INC

CYC 20

FI WO 9404679 A1 19940303 (199411) 12p C12N015-13

FW: AT BE CH DE DK EJ FR GB GR IE IT LU MC NL PT SE

W: AU CA JP

AU 9350831 A 19940315 (199408) C12N015-13

US 5821337 A 19981013 (199804) C07K016-00 <--

US 6084297 A 20000425 (200007) A61K039-395

AIT WO 9404679 A1 WO 1993-US7633 19930820; AU 9350831 A AU 1993-10831

19930820; US 5821337 A CIP of US 1991-715272 19910614, CIP of WO

1992-US5126 19920615, US 1992-934373 19920821; US 6084297 A CIP of US

1991-715272 19910614, CIP of WO 1992-US5126 19920615, Cont of US

1992-934373 19920821, US 1995-437642 19950509

FIIT AU 9350831 A Based on WO 9404679; US 6084297 A Cont of US 5821337

PFAI US 1992-934373 19920821; US 1991-715272 19910614; WO 1992-US5126

19920615; US 1995-437642 19950509

REP 3.Int.Ref; WO 9007661; WO 9312652

IC ICM A61K039-395; C07K016-00; C12N015-13

ICS C07K013-00; C07K016-30; C12N005-10; C12PG21-08;

G06F015-00

AB WO 9404679 A UPAB: 20000600

A method for making a humanised antibody (Ab) composed of an amino acid sequence of a non-human, import Ab, and a human Ab, comprises the steps of: (a) obtaining the AA sequence of at least a portion of an import variable domain and a consensus human variable domain; (b) identifying the complementary determining region (CDR) AA sequences in both variable sequences; (c) substituting an import CDR sequence for the corresponding human CDR sequence; (d) aligning the AA sequences of a framework region (FR) of the import Ab and the FR of the consensus Ab; (e) identifying import Ab FR residues in the aligned FR sequences that are **non-homologous** to the corresponding consensus Ab residues; (f) determining whether the **non-homologous** import AA residue is reasonably expected to have one of the following effects; (1) non-covalently bind antigen directly; (2) interacts with a CDR; or (3) participates in the VL-VH interface; and (g) for any **non-homologous** import Ab AA residue which is reasonably expected to have at least one of these effects, substituting that residue for the corresponding AA residue in the consensus Ab FR sequence.

A humanised version of murine monoclonal antibody MuMAb4D5 (ATCC CRL

10463) is provided which retains the binding specificity of the parent but is non-immunogenic in humans. The parent Ab is also directed to the extracellular domain of p185(HER2) and has potential for treatment and imaging of e.g. human breast and ovarian cancers. (The single-step humanisation is shown in the fig.)

USE/ADVANTAGE - The method provides an efficient means of humanising antibodies, so as to retain or to improve the affinity of the non-human donor antibody for a given antigen. The antibodies are less antigenic in humans than non-human antibodies.

Dwg. 1 7

FS CFI EPI

FA AB; GI

MC CFI: B04-C016; B04-G01; B04-N04B; B12-K04A1; B05-R09; D05-H11A2;

D05-H17A1; D05-H18

EPI: T01-J06A

L123 ANSWER 5 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1994-067329 [39] WPIX

DNN N1994-051467 DNC C1994-030047

TI Database classification method based on sequence comparisons - by dividing DNA or **protein** sequences into structural words taking into account structural and **functional** relationships.

DC B04 T01

IN WITTIG, B

FA SOFT-ND-SOFT GENE RHINOWELUNGS & VERTRIEFGES

CYC 8

PI EP 58755 A1 19941216 (199410) DE Hep G06F015-401 <--

E: AT CH DE FR GE IT LI SE

ADT EP 58755 A1 EP 1992-250216 19921102

FRAL EP 1992-160200 19920802

REP .X1.Ber

IC ICM G06F015-401

AB EP 58755 A UFAB: 19950822

Method comprises cleaving the sequences into structural words which include analysable information about structural and **functional** relationships.

The structural words pref. are (a) nucleotide sequences (NucIndex), pref. taking into account the degenerative nature of the genetic code, the DNA recognition sequences for binding **proteins** and allowing mismatches (N) or (b) aminoacid sequences (AA, IdenIndex and ChemIndex), pref. taking into account their chemical and steric properties for grouping them.

NucIndex is based on the considerations that (i) 10-12 nucleotides form one helical repeat, (ii) the degenerative code occurs mostly in the third, sometimes in the first, position of DNA triplets, (iii) that the binding sites for regulatory **proteins** usually are segments of 5-6 nucleotides, i.e. half a helical repeat (i). Therefore mismatches are allowed on the other half of helical repeats, (iv) the significance of the number of matches (SigA) depends on the sequence length (SigS); and ChemIndex is based on the considerations that (a) **proteins** are either helices (helical repeat of 3-6 AA) or beta-sheet and turn (at least 4 AA), (b) some AA lead to the same structure and similar characteristics. Additionally, frequently occurring structural words are of a lesser significance than words which occur less frequently.

USE/ADVANTAGE - The method is used for database classification of DNA and **protein** sequences. Compared to prior art methods, the new method is faster and allows better detection of sequence similarities.

Dwg. 6/0

Dwg. 6/0

FS CFI EPI

FA AB

MC CFI: B04-E01; B11-C08; B12-K04

L123 ANSWER 60 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1993-308303 [39] WPIX

DNN N1993-237572 DNC C1993-136720

TI Gene information testing device to evaluate similarity between aminoacid sequence and reference aminoacid - comprises unit to detect number of longest common letter between the sequences and calculation unit to find ratio of longest common letter detected.

BO4 D16 B04 S03 T01

PA (EUIT) EUITLTD LTD

CYC 1

PI JP 05019032 A 19930-31 (199339)* 17p C12M001-00

ADT JP 05.19932 A JP 1992-11012 19930206

PRAI JP 1992-1101. 19930206

IC PM C12M001-00

ICS G06F015-40; G06F015-42

AB JP 11010032 A UPAB: 10051103

Gene information testing device comprises a detection unit (10) to detect the number of the longest common letters between the amino acid sequence to be tested and the reference amino acid sequence each expressed by letters, and a calculation unit (11) to calculate the ratio of the number of the longest common letters detected by the detection unit (10) to the number of letters of the amino acid sequence to be tested or the reference amino acid sequence.

USE/ADVANTAGE - Used to evaluate the similarity between an amino acid sequence to be tested and a reference amino acid sequence. It is necessary for the development of medicines, etc. From the data information such as structure, function, etc. of protein can be found. In

an example, where the amino acid sequence to be tested is expressed by letters "ABCBQAB" and the reference amino acid sequence is "EDCABA". The detection unit detects the number of the longest common letters which is "4"; and the calculation unit calculates the ratio: $4/7$ ($= 4 - 7$) to the number of letters of the amino acid sequence to be tested and $4/7$ ($= 4 - 7$) to the number of letters of the reference amino acid sequence. Thus, the similarity can be evaluated according to a simple processing mechanism.

Dwg.1a,b/1

ES CFI EPI

FA AB; GI

MC CFI: B04-B04A1; B11-C03; B12-K04A; D05-H09;

D05-H12; J04-B01

EPI: S03-E14H9; S05-C09; T01-J0CA

L123 ANSWER 61 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1993-267046 [34] WPIX

INN N1993-204584 INC C1993-113919

TI Analysis of chromosome shape to determine main axis of symmetry - by forming curved main axis from mid points of 2 peak positions of density in image.

IC B04 P01 S03 T01

PA (KAGG) IAT PES INST METALS; (NIKR) NIKON CORP

CYC 1

PI JP 05180633 A 19930723 (199374)* 11p G01N033-50

ADT JP 05180632 A JP 1991-190982 19910705

PRAI JP 1991-190982 19910705

IC ICM G01N033-50

ICS A01E010-00; G06F015-62; G06F015-70

AB JP 05180632 A UPAB: 12031119

In the analysis a curved main axis is obtained by connecting the middle points of 2 peak points of density value of picture elements along each of lines perpendicular to a linear main axis of an image of chromosome.

USE/ADVANTAGE - Used to determine the main axis of a chromosome when identifying chromosome. When identifying chromosome, an axis of symmetry (main axis) that separate symmetrically a chromosome into 2 blocks is determined, and, then, various analyses (e.g., detection of centromere) are made. Therefore, it is very important to determine properly the main axis in the identification of chromosomes.

In an example, a linear main axis is obtained on an image of chromosome by the conventional technique; a density profile is taken along a line (x) perpendicular to the linear main axis; in the graph

indicating the density **profile**, 2 peak values (p1,p2) of density are selected; the middle point (g₁) of the 2 point (p1,p2) on the x-axis is obtained; the middle point (g) is plotted at the corresponding point on the image of chromosome; in the same procedure as mentioned above, the lines (x) perpendicular to the main axis (a1) are taken at different positions, the middle points (g) are obtained, and they are plotted at the corresponding positions on the image of chromosome; and, by connecting the middle points (g) obtained, a curved main axis (a2) can be obtained. Thus, a curved main axis can be properly obtained even for a chromosome having 2 arms on both sides of the centromere (2).

FS CFI EPI GMFI

FA AB

MC CFI: B04-B04A1; B11-K04; B12-K1A1

EPI: S04-B14B0; T01-C10B2

L123 ANSWER 01 OF 01 WJIN COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1993-199301 [14] WJIN

DNC C1993-087384

TI Selecting oligo-nucleotide probe for identifying allele of polymorphic gene - by choosing the min. number of probes necessary for unequivocal discrimination from mutant forms of consensus sequence.

DC B04 D16

IN BOUGUELERET, L; COHEN, D; COHEN, N; DAUSSET, J

FA (BERU) BERTIN & CIE

CYC 11

PI WO 9311262 A1 19930610 (199314)* EN 4sp C12Q001-68

FW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: AU CA JP KR US

EP 149348 A1 19930630 (199316) FR 26p C12Q001-68

B: AT BE CH DE DK ES FR GB GR IE IT LU NL SE

FR 169468 A1 19930611 (199316) 19p C12Q001-68

AP 9333550 A 19930628 (199316) C12Q001-68

JP 07501449 W 19930616 (199316) C12Q001-68

ADT WO 9311262 A1 WO 1992-FR1141 19921203; EP 149348 A1 EP 1992-408267 19921203; FR 2684688 A1 FR 1991-14996 19911204; AU 9333550 A AU 1993-33550 19921203; JP 07501449 W WO 1992-FR1141 19921203, JP 1993-509904 19921203

FDT AU 9333550 A Based on WO 9311262; JP 07501449 W Based on WO 9311262

PFAI FR 1991-14996 19911204

REP 3.Jnl.5a-f; EP 103900; EP 237362; EP 412898; WO 8904875; WO 8911547; WO 9208117; WO 9210582; WO 9211382; 3.Jnl.Ref

IC ICM C12Q001-68

ICS C07H021-09; C12N019-11; G06F015-20

AE WO 9311262 A UFAB: 19931116

Process for selecting, from a set of allelic sequences of a polymorphic gene (PG), at least one mutation screen able to specify at least one oligonucleotide probe for distinguishing between all alleles, comprises: (1) selecting all or part of a known consensus sequence (CS) of PG; (2) producing a matrix of mutations with sequences corresponding to known alleles; (3) identifying indiscernible sequences by pairwise comparison (i.e. alleles having the same mutation **profile** in CS) and excluding one member of each pair; (4) identifying and numbering obligatory mutations and 'marker' mutations (i.e. those which are necessary and sufficient to distinguish 2 otherwise identical alleles; set C of obligatory mutations), and (5) producing at least one minimal mutation screen comprising at least these obligatory mutations.

To identify alleles, the screen selected in step (5) which is most suitable for produ. of probes to differentiate between the alleles is chosen, and these probes used for hybridisation typing of the alleles.

USE/ADVANTAGE - This method provides rapid and reliable identification of alleles without requiring a large no. of probes. It can identify homozygotic doublets and differentiate them from heterozygotic doublets.

Dwg.0/0

FS CFI

FA AB

MC CFI: B04-B04A1; B12-K04; D05-H11; D05-H12

AREQ EF 549338 A UPAR: 19931116

Selecting, from a set of allelic sequences of a polymorphic gene (PG), at least one mutation screen able to specify at least one oligonucleotide probe for distinguishing between all alleles, comprises (1) selecting all or part of a known consensus sequence (CS) of PG; (2) producing a matrix of mutations with sequences corresp. to known alleles; (3) identifying indiscernible sequences by pairwise comparison (i.e. alleles having the same mutation **profile** in CS) and excluding one member of each pair; (4) identifying and numbering obligatory mutations and 'marker' mutations (i.e. those which are necessary and sufficient to distinguish 2 otherwise identical alleles; set 0 of obligatory mutations), and (5) producing at least one minimal mutation screen comprising at least these obligatory mutations. To identify alleles, the screen selected in step (5) which is most suitable for prom. of probes to differentiate between the alleles is chosen and these probes used for hybridisation typing of the alleles.

USE/ADVANTAGE - This method provides rapid and reliable identification of alleles without requiring a large number of probes. It can identify homozygotic doublets and differentiate them from heterozygotic doublets.

Dwg.0/10

AREQ FE 1694688 A UPAR: 19931122

Process comprises: (1) selecting all or part of a known consensus sequence (CS) of PG; (2) producing a matrix of mutations with sequences corresp. to known alleles; (3) identifying indiscernible sequences by pairwise comparison (i.e. alleles having the same mutation **profile** in CS) and excluding one member of each pair; (4) identifying and numbering obligatory mutations and 'marker' mutations (i.e. those which are necessary and sufficient to distinguish 2 otherwise identical alleles; set 0 of obligatory mutations), and (5) producing at least one minimal mutation screen comprising at least these obligatory mutations.

USE/ADVANTAGE - This method provides rapid and reliable identification of alleles without requiring a large no. of probes. It can identify homozygotic doublets and differentiate them from heterozygotic doublets.

Dwg.0/10

L123 ANSWER 63 OF 73 WPIX COPYRIGHT 2001 BERWENT INFORMATION LTD

AN 1993-027210 [03] WPIX

DNN N1993-020821

TI Fuzzy interference appts. e.g. for tunnel trenching by shield machine - **multiplies** oblivescence coefft. by membership **function** of conclusion portion of each operating linguistic control rule, with coefft. determined by fuzzy interference to vary weight of importance of given rule.

DC T01 T06

IN IOKIBE, T

PA (MEID) MEIDENSHA CORP; (MEID) MEIDENSHA KK

CYC 2

PI US 5175861 A 19921229 (199303)* Sp G05B013-02

KR 9705457 B1 19970416 (199939) G06F009-44 ---

ADT US 5175861 A US 1990-581770 19900913; KR 9705457 B1 KR 1990-14495 19900913

PFAI JP 1989-239514 19890314

IC ICM G05B013-02; G06F009-44

AB US 5175861 A UPAR: 19930924

The appts. includes an operating variable fuzzy inference portion (10) which receives input values, i.e., a deviated distances X1 and X2 in horizontal and vertical directions between a planned trenching line and an actual direction of advance of the shield machine. A **function** infers a target value of a stroke quantity of each shield machine jack through fuzzy inference. The portion comprises a linguistic fuzzy control rule storage portion (operating rule storage portion (1) a membership **function** storage portion (2), an oblivescence coefft. storage portion (3) and a fuzzy inference mechanism (4).

The operating rule storage contains a number e.g. n linguistic control rules, which receive X1 and X2 as input values and provide the

stroke quantities Y1, Y2,---, respectively, for inferred values (concluded values) supplied to said portion of the shield machine.

ADVANTAGE - Accounts for obsolescence of knowledge base in sewing protein.

1/4

FS EPI
FA AB; GI
MC EPI: T01-J10B; T06-A05A1

L123 ANSWER 04 OF 73 WPIX COPYRIGHT 2001 PERWENT INFORMATION LTD

AN 1993-018139 [00] WPIX

CA 1994-01190 [10]

DNN N1997-01810 DNC (1993-008-26

TI Humanisation of antibodies - by molecular modelling of the variable domains and alteration by gene conversion mutagenesis.

DC B04 D1; T01

IN CARLEF, P J; FESTA, L G

PA (GETH) GENENTECH INC

CYC 18

FI WO 9222653 A1 19921223 (199301)* EN 186p C12N015-1;

EW: AT BE CH DE DK EC EP FR GB GR IT LU MC NL SE

W: AU CA JP US

AF 9222653 A 19930111 (199317) C12N015-1;

EE 590058 A1 19940406 (199414) FN C12N015-1;

F: AT BE CH DE DK EC EP FR GB GR IT LI LU MC NL SE

JP 06598267 W 19940301 (199441) 41p C12P021-0;

AT 675916 E 19970217 (199717) C12N015-1;

EE 940468 A1 19940904 (199441) EN C12N015-1;

F: AT BE CH DE DK EC EP FR GB GR IT LI LU MC NL SE

ADT WO 9222653 A1 WO 1992-001136 19920615; AU 9222653 A AU 1992-22509 19920615; EP 1993-01103 A1 EP 1992-314820 19920615; WO 1993-071126 19920615; JP 06598267 W WO 1992-001136 19920615; JP 1993-511103 19920615; AU 675916 B AU 1992-22509 19920615; EP 940468 A1 Div ex EP 1992-314820 19920615; EP 1993-105332 19920615

FDT AT 9222509 A Based on WO 9222653; EE 590058 A1 Based on WO 9222653; JP 06598267 W Based on WO 9222653; AU 675916 B Previous Publ. AU 9222509, Based on WO 9222653; EP 940468 A1 Div ex EP 590058

PRAI US 1991-715272 19910614

REP 3.Jal.Pat; WO 9007861

IC ICM C12N015-13; C12P021-0;

ICS C07K013-00; C07K016-28; C07K016-46;

C12N065-10; C12N015-62; G06F015-00

AB WO 9222653 A ABAB: 13401011

A method for making a humanised antibody comprising an amino acid sequence of a non-human, import antibody and a human antibody is claimed comprising (a) obtaining the amino acid sequences of at least a portion of an import variable region and of a consensus human variable domain, (b) identifying Complementary Determining Region (CDR) amino acid sequences in the import and the human variable domain sequences, (c) substituting an import CDR amino acid sequence for the corresponding human CDR amino acid sequence, (d) aligning the amino acid sequences of a Framework Region (FR) of the import antibody and the corresponding FR of the consensus antibody, (e) identifying import antibody FR residues in the aligned FR sequences that are **non-homologous** to the corresponding consensus antibody residues, (f) determining if the **non-homologous** import amino acid residue is reasonably expected to have at least one of the following effects; (i) non-covalently binds antigen directly, (ii) interacts with a CDR or (iii) participates in the V_H-V_H interface and (g) for any **non-homologous** import antibody amino acid residue which is reasonably expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody FR sequence.

Also claimed are: (A) a method comprising (a) providing at least a portion of an import, non-human antibody variable domain amino acid sequence having a CDR and a FR, (b) obtaining the amino acid sequence of at least a portion of a consensus human antibody variable domain having a

CDR and a FF, (c) substituting the non-human CDR for the human CDR in the consensus human antibody variable domain and (d) substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites: 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 99L, 2H, 4H, 24H, 36H, 37H, 39H, 40H, 45H, 49H, 52H, 60H, 67H, 68H, 69H, 70H, 72H, 74H, 75H, 76H, 78H, 91H, 94H, 98H and 104H; (B) a humanised antibody variable domain having a non-human CDR incorporated into a human antibody variable domain, where the improvement comprises substituting an amino acid residue for the human residue at a site selected from those defined in (A); (C) a **polypeptide** comprising the amino acid sequence (I) or (II); (D) a method for engineering a humanised antibody comprising introducing amino acid residues from an import antibody variable domain into an amino acid sequence representing a consensus of mammalian antibody variable domain sequences; (E) a computer comprising the sequence data of the amino acid sequence (III) or (IV); (F) a computer representation of the amino acid sequences (III) and (IV); (G) a method comprising storing a computer representation of the amino acid sequences (III) and (IV).

USE/ADVANTAGE - The methods allow the rapid humanisation of antibodies and require less DNA synthesis than previous methods. The humanised antibodies have desired binding and other characteristics and activities but are less antigenic in humans than non-human antibodies.

Dwg. 2/6

ES CPI EPI

FA AB; GI

MC CPI: B04-B04C5; B04-P04C6; B04-C01G; D05-C11; D05-H11

EPI: T01-J00A

1223 ANSWER 65 OF 73 WPIX COPYRIGHT 2001 PERWENT INFORMATION LTD

AN 1992-3-5500 [47] WPIX

DNN N1991-393880 DNC C1992-11121

T1 Correction of algorithm for identification of biological sample - involves comparing parameters with standard values, correcting membership characteristic **function** and identifying type of organism.

DC B04 D16 J04

FA (OMRO) OMEON CORP

CYC 1

PI JP 04283876 A 19921008 (199247)* 5p G06F015-62 <--

ADT JP 04283876 A JP 1991-48118 19910313

FFAI JP 1991-48118 19910313

IC ICM G06F015-62

ICS G01N033-48; G01N033-49

ICA G06F009-44

AB JP 04283876 A UPAB: 19931116

Biological samples including several organisms of two or more types are dried and stained after application, the images of the organisms are input as image signals, characteristic parameters for each organism are computed from the image signals, and the types of the organisms are identified using the characteristic parameters. The characteristic parameters obtd. from the biological samples are compared with the characteristic parameters (standard values) used for the determin. of identification algorithm. According to the variation, the membership characteristic **function** of the identification algorithm is corrected, and the types of the organisms are identified using the corrected algorithm.

USE/ADVANTAGE - Used to correct the identification algorithm in classification of the types of organisms existing in a biological sample using the characteristic parameters based upon the morphological/ density (colour) characteristics of organisms (e.g., cell sorting, leukocyte sorting, etc.). The membership characteristic **function** of identification algorithm is corrected according to the variation between the characteristic parameters obtd. from biological sample and those used for determining identification algorithm, so, even if the characteristic parameters vary, classification can be made with comparatively good accuracy.

2/5

Dwg. 2/5

FB CFI
FA AB; BI
MC CFI; B04-B04A; B04-B04D1; B11-B17B1; B12-K04;
D05-H09; J04-E01

L123 ANSWER 66 OF 73 WPX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1992-366389 [44] WPX

CR 1989-130048 [17]; 1989-309404 [42]; 1991-161985 [22]; 1992-398889 [48];
1994-109199 [17]; 1994-371740 [17]; 1995-195497 [14]; 1995-115549 [18];
1995-115513 [20]; 1995-185111 [28]; 1995-163531 [22]; 1996-361955 [36];
1996-433027 [42]; 1996-446406 [44]; 1997-051892 [45]; 1997-089915 [09];
1997-513131 [40]; 1997-917141 [11]; 1999-513131 [40]; 2000-189871 [13]

DNN N1990-278206 DE 1992-162745

T1 Identification of analyte compsn. of sample - comprising assessing sample
w.r.t. survey parameter and classifying using **SC profiles**, for
recognising herbicides, therapeutic use etc..

DC B.4.007 D16 S03

IN AMELER, S M; KAUVAR, L M

FA (TEFF-0) TERRAFIN TECHNOLOGIES INC; (TELI-0) TELIK INC

CYC 21

FI WO 9217784 A1 19921015 (1992544)* EN 32p G01N033-503
FW: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
W: AD CA HU JP KP US

AU 6019878 A 19941102 (1994301) G01N033-503

EP 581881 A1 19940209 (1994094) EN G01N033-503

R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

US 5838659 A 19940816 (1994321) 10p G12Q001-00

JP 06509865 W 19941102 (1994094) 10p G01N033-503

EP 581881 A4 19940706 (1994321) G01N033-503

AU 602001 B 19950817 (1995411) G01N033-503

EP 581881 P1 19940806 (1994111) EN G01N033-503

R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DE 6028539 E 19940408 (1994201) G01N033-503

JP 3101323 B2 20001928 (200056) 12p G01N033-503

ADT WO 9217784 A1 WO 1992-US2716 19920402; AU 9219878 A AU 1992-19878
19920402; WO 1992-US2716 19920402; EP 581881 A1 EP 1992-912207 19920402,
WO 1992-US2716 19920402; US 5838659 A US 1991-678849 19910402; JP 06509865
W JP 1990-511681 19920402, WO 1992-US2716 19920402; EP 581881 A4 EP
1992-912207 ; AU 602001 B AU 1992-19878 19920402; EP 581881 B1 EP
1992-912207 19920402, WO 1992-US2716 19920402; DE 6028539 E DE
1992-628539 19920402, EP 1991-912207 19920402, WO 1992-US2716 19920402; JP
3101323 B2 JP 1990-511681 19920402, WO 1992-US2716 19920402

FET AU 9219878 A Based on WO 9217784; EP 581881 A1 Based on WO 9217784; JP
06509865 B Based on WO 9217784; AU 602001 B Previous Publ. AU 9219878,
Based on WO 9217784; EP 581881 B1 Based on WO 9217784; DE 6028539 E Based
on EP 581881, Based on WO 9217784; JP 3101323 B2 Previous Publ. JP
06509865, Based on WO 9217784

FFAI US 1991-078849 19910402

REP 1.Jnl.Ref; 2.Jnl.Ref; WO 8606991

IC IFM G12Q001-00; G01N033-53; G01N033-543; G01N033-543

ICS G01N033-557; G01N033-566; G01N033-58; G01N033-54; G06F015-40
; G06F017-30

AB WO 9217784 A UFAB: 20001106

Determn. of the analyte compsn. of a sample contg. at least one member
analyte of a cross-reactive set of analytes comprises: (a) assessing the
sample w.r.t. each of n information channels in a panel contg. n
information channels for characteristic parameters of the members of the
set to obtain a survey of characteristics (**SC profile**); and (b)
comparing the **SC profile** with a reference set of
profiles obt'd. from known compsn. of the members of the
cross-reactive set.

USE/ADVANTAGE - Analysis of samples for recognising classes of
analytes, e.g., herbicides, in clinical analysis of biological samples
(e.g., steroids, **protein** hormones or their metabolites),
artificial materials designed for therapeutic use (e.g., beta-blockers,
chemotherapeutic agents, prostaglandin, inhibitors, etc.). Illicit drugs

may be detected and distinguished for forensic purposes.

Dwg.1A/3

FS CFI EPI

FA AB; GI; DGN

MC CFI: B04-B02D; C04-B02D; E04-B02E; C04-B02E; B04-B04C5; C04-B04C5;
B07-B03; C07-B03; B12-B01; C12-B01; B12-K04A; C12-K04A; B12-P05;
C12-P05; D03-H03

EPI: S03-B14H4

ABEQ US 5133659 A UFAB: 19940922

Identification of analyte compsn. is enhanced by applying pattern recognition techniques. Samples are reacted with binding reagents to produce a databank for known compsn. of each analyte, which is stored in a computer. Unknown samples are then matched against the patterns.

ADVANTAGE - Identification is precise.

Dwg.1a/3

L123 ANSWER 67 OF 73 WPIM : COPYRIGHT 1991 PERWENT INFORMATION LTD

AN 1992-349151 [47] WPIM

CR 1992-415705 [50]; 1994-348451 [20]

DMN N1992-266381 DND C1992-155994

TI New lactam derivs. cross-reactive with antibody CDR - useful for producing prophylactic or therapeutic immune response.

DC B03 B04 B05

IN GREENE, M I; KAHN, M; SARAGOV, H P

FA (USPS-18) UNIV PENNSYLVANIA

CYC 18

PI WO 9216548 A1 19921001 19940217 EN 45p C07F005-02 <--

FW: AT BE CH DE DK ES FR GB GR IT IU MC NL SE

W: AU CA JP KR

AU 9217731 A 19921011 19940217 EN 45p C07F005-02 <--

JP 9217741 W 19921101 19940217 EN 11p C07F005-02

ALT WO 9216548 A1 WO 1992-US2383 19920324; AU 9217731 A AU 1992-17731
19920324, WO 1992-US2383 19920324; JP 06510741 W JP 1992-509980 19920324,
WO 1992-US2383 19920324

FDT AU 9217731 A Based on WO 9216548; JP 06510741 W Based on WO 9216548

PRAI US 1991-674866 19910325

REF S.Jnl.Ref; US 4939666; US 4946778

IC ICM C07K005-02

ICS A61K031-395; A61K039-395; C07D255-02; C07K005-12;

C07K015-28; G06F003-14

AB WO 9216548 A UFAB: 19940921

(I) is immunologically cross reactive with at least one complementarity determining region (CDR) of at least one antibody (Ab), the CDR having a plurality of hydroxyl gps. positioned in three-dimensional space, where (I) comprises the same number of hydroxyl gps. as the CDR and there exists at least one conformation of the synthetic cpd. where the 3-D positioning of its hydroxyl gps. is identical to the 3-D positioning of the hydroxyl gps. of the CDR. The synthetic cpd. (I) is of formula: where R1, R2 and R3 = chemical **functional** gps. each comprising at least one hydroxyl gp.

USE/ADVANTAGE - (I') may be included in compsns. for admin. to mammals to elicit a prophylactic or therapeutic immune response. Methods are provided for the prepn. of synthetic cpds. which are immunologically cross reactive with individual Ab CDRs. These cpds. may be used in studying the role of a CDR chemical **functionality** to Ab or CDR activity e.g. in studying the role of specific aminoacid residues in the interaction of the monoclonal Ab 87.92.6 light chain variable region with the reovirus type 3 receptor. Compsns. comprising relatively small synthetic cpds. may be developed to mediate the biological effects of Abs or other ligands. These cpds. should possess beneficial properties such as increased half-life, the ability to cross the blood-brain barrier, and lack of immunogenicity and thus should be useful for the development of new pharmaceutical, therapeutic, diagnostic and receptor binding agents.

5/5

Dwg.5/5

Dwg.5/5

FS CFI EPI
 FA AB; GI; ION
 MC CFI: B01-V03; B07-D05; B07-D13; B11-C08; **B12-K04**
 EPI: S03-E14H4

L123 ANSWER 62 OF 73 WPIN COPYRIGHT 2001 DEFWENT INFORMATION LTD
 AN 1992-133433 [16] WPIN
 DNE C1992-060732
 TI Appts. to analyse and process **genome** - comprises a
genome character sequence analyser with window **function**
 unit allowing character sequence extrn..
 DC B04 D16
 FA (FUIT) FUJITSU LTD
 CYC 1
 PI JP 04075582 A 19920310 (199210)* 3p
 JP 04075582 E2 19921118 (199351) 13p G06F017-30 <--
 AET JP 04075582 A JP 1990-188364 19900717; JP 0325948 E2 JP 1990-188364
 19900717
 FET JP 0325948 E2 Previous Publ. JP 04075582
 PRAI JP 1990-188364 19900717
 IC C12M001-00
 ICM **G06F017-30**
 ICS C12M001-00
 AP JP 04075582 A UPAB: 19931006
 Appts. comprises a **genome** character sequence analyser with a
 window **function** unit to scan a character sequence. This
 specifies the **genome** to thereby extract the character sequence.
 USE - For use in biological laboratories. (0/0)
 0/0
 FS CFI
 FA AB
 MC CFI: **B04-B04A1**; B11-C08; **B12-K04A**; D05-H09

L123 ANSWER 69 OF 73 WPIN COPYRIGHT 2001 DEFWENT INFORMATION LTD
 AN 1992-009201 [02] WPIN
 DNE N1992-007078 DNE C1992-003939
 TI Obtaining signals representing different species in analysis - using
 ratios of signals obt'd. in different manner and reacting differently to
 species, used to obtain DNA sequence information.
 DC B04 D16 J04 S03
 IN DAM, R J; DAVIS, J E; HOCHBERG, A M; PROBER, J M
 FA (DUPLO) DU PONT DE NEMOURS & CO E I
 CYC 10
 PI EP 463591 A 19920102 (199202)* 24p
 F: DE FR GB IT NL SE
 CA 2045720 A 19911230 (199213)
 US 5119316 A 19920602 (199215) 13p G01N030-00
 JP 05068598 A 19930323 (199316) 13p C12Q001-68
 EP 463591 B1 19970924 (199743) EN 21p G01N027-447
 F: DE DK FR GB IT NL SE
 DE 69127721 E 19971030 (199749) G01N027-447
 JP 2993191 B2 19991229 (200005) 13p C12Q001-68
 AET EP 463591 A EP 1991-110342 19910622; US 5119316 A US 1990-545746 19900629;
 JP 05068598 A JP 1991-184041 19910628; EP 463591 B1 EP 1991-110342
 19910622; DE 69127721 E DE 1991-637721 19910622; EP 1991-110342 19910622;
 JP 2993191 E JP 1991-184041 19910628
 FET DE 69127721 E Based on EP 463591; JP 2993191 B2 Previous Publ. JP 05068598
 PRAI US 1990-545746 19900629
 REP EP 157280; EP 136403; EP 242623; EP 294524; EP 294996
 IC ICM C12Q001-68; G01N027-447; G01N030-00
 ICS G01N021-64; G01N027-44; **G06F015-353**; **G06F017-17**
 ICA C12N015-00
 AE EP 463591 A UPAB: 19931006
 Two signals which react differently to different species, following
 species separation in time or space, are generated, each signal varying in
 amplitude in respective senses to form peaks as a **function** of

the nature of the species, each peak being representable by the sum of three or more peak templates. A template is derived for fitting to each of the signals to obtain the peak amplitude of the signals and a third signal is derived, from the ratio of a **function** of the peaks of the first and second signals, the amplitude of the third signal being indicative of the identity of each of the species.

USE/ADVANTAGE - Partic. in obtaining DNA sequence information.

Allows the underlying peak shape to be periodically redetermined and fitted to the data in a way that yields accurate ratios, even when the precise location of the peak is not known. The method contains self consistency checks so that potentially erroneous ratios, and hence base determinations may be recognised.

4A/4

FS CFI EPI

FA AB; G1

MC CFI: B04-B04A1; B11-C03; B12-K04; D05-H09;
L05-H12; J04-B01

EPI: S03-E03E

ABEQ US 5119316 A UPAP: 19031006

Determin. of DNA sequences comprises generating signal by a sequencer that varies in amplitude to form peaks as a **function** of the nature of the species and generating second signal varying in amplitude in a second sense different from the first. A fraction of the first signal is subtracted from the second signal, from the peak centre of the first peak to the peak centre of the second signal peak in each peak sequence, so amplitude of peaks in each difference is zero, giving a prototypical template for the peak. The template is fitted to the first and second signals to give a third signal indicative of the identity of each of the species.

ADVANTAGE - Improved accuracy of sequence information.

ABEQ EP 463501 E UPAP: 19071030

A method of identifying the sequence of bases in a particular DNA fragment by means of signals characteristic of reporter molecules associated with a particular base the method including (a) electrophoretically separating fragments in time and/or space, (b) for the particular fragment, producing an emission spectra which is passed through separate filters having different characteristics to generate a first and second signal, each signal varying in amplitude as a **function** of the reporters associated with the bases in the fragment, to form peaks which correspond to a particular reporter associated with a particular base, any peak of first and second signal being approximately representable by the sum of three or more peak templates, and (c) obtaining a third signal corresponding to the ratio of the first and second signals, the amplitude of the third signal being indicative of the identity of each of the bases,

characterised in that the third signal is obtained by the steps: finding a sequence of peaks XYZ in each of the first and second signals where X represents one base and Y represents another base, subtracting from the peak centre of the first X to the peak centre of the second X in each signal such that the amplitude of the X peaks in the difference is substantially zero, thereby obtaining a prototypical template for the peak of each signal, and fitting the respective prototypical template to the respective first and second signal spectrums to obtain the peak amplitude of the first and second signals for obtaining the third signal from the ratio of such peak amplitudes.

Dwg.0/4

L123 ANSWER 70 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1991-198303 [25] WPIX

DNN 1991-147985 INC C1991-083710

TI High resolution optical scanner for viewing object - uses flat support and linear optical sensor with drive mechanism to successively seal object.

DC B04 D16 S03 S05

IN EMERY, F J; HEMMINGER, F W; EMERZY, R J

FA (USBI-N) US BIOCHEMICAL CORP; (USBI-N) US BIOCHEM CORP

CYC 26

PI WO 9108465 A 19910613 (199126)*

PW: AT BE CH DE DF ES FF GB GR IT LU NL SE

W: AU BG BR CA FI HU JP KP KR NO RO SD SU

AU 9171671 A 19910626 (199133)

US 5297388 A 19940272 (199411) 69p G06F009-44 <--

ADT US 5297388 A Div ex US 1993-442553 19991128, Cont of US 1991-640471
19910119, US 1992-497616 19921613

PRAI US 1989-442553 19931118

PEP 1, Jnl. R-8; US 4717219; US 1811911; US 4962929

IC G01N011-7

ICM G06F009-44

ICS G01N011-75; G06F013-10; G06F015-42;

G06F015-70

AB WO 91/0105 A DEAB: 1993012

The apparatus for optically scanning an object comprises a flat support for holding the object. A linear optical sensor is held in a fixed position on one side of support. A light source is held in a fixed position on the other side of the support for projecting light through the object toward the optical sensor. A drive mechanism moves the object along one direction to successive scanning positions. The user may create custom application computer programs for performing desired image desired image scanning and analysis on an object.

The system stores software tools capable of performing an image scanning or analysis **function**, stores interpreter program corresponding to the natural language identifier for the **functions** and provides an interactive computer environment for user.

USE - Analysing autoradiographic image of prods of deoxyribonucleic acid sequencing reaction.

17/17

FS CFI EPI

FA AB

MC CFI: B04-B04A1; B11-C07B; B12-K04A; D05-H09
; D05-B11

EPI: S03-B04; S03-B14H; S05-009

ABEQ US 5297388 A DEAB: 19940428

A data processing system comprises a computer, an image scanner and a natural language interface responsive to user input. The system creates and executes a custom application programme with a sequence of user-specified software tools for scanning an analysing an image with four vertical sections, each with no or some horizontal bands with non-uniform perimeters.

Tools are stored for directing scanning and analysis and custom programme is created by storing a user-defined sequence of tools using the natural language identifiers, and the programme is executed to scan the image and store the data, using the data to locate the horizontal bands and to correlate each of these to a predetermined shape.

USE/ADVANTAGE - Partic. for analysing DNA autoradiogram, for general imaging, populations screening and diagnosis including AIDS testing, and micro-titre plate reading. Provides high resolution analysis of a wide range of formats in an interactive computer environment.

Dwg. 17A/17

L123 ANSWER 71 OF 75 WPBX COPYRIGHT 2011 DERWENT INFORMATION LTD

AN 1990-254111 [13] WPBX

CR 1993-336978 [42]; 1994-065543 [08]; 1994-176282 [21]; 1999-494069 [33]

DNN N1990-196931 LNC C1999-119079

TI Screening for foetus with Down syndrome - by measuring pregnant woman's blood levels of free beta sub-unit of human chorionic gonadotropin.

BC B04 B16 B05 S15

IN MACRI, J N

FA (MACR-1) MACRI J N

CYC 33

PI WO 9008385 A 19900726 (199033)* 51p

PW: AT BE CH DE DF ES FF GB GR IT LU NL OA SE

W: AU BG BR CA DK FI HU JP KP KR LR MC MG MW NO RO SD SU

AU 9050936 A 19900813 (199344)

EP 499956 A 19910130 (199105)

R: AT BE CH DE ES FR GB IT LI LU NL SE
 CN 147390 A 1944118 (139132)
 JP 04505128 W 19411107 (139131)
 US 5452907 A 19411107 (139345) 26p G06F015-00 ---
 US 544608 A 19440618 (139425) 25p G01N033-53
 EP 000477 A1 19900309 (139436) EN 42p G01N033-76
 R: AT BE CH DE ES FR GB IT LI LU NL SE
 EP 419456 B1 19900817 (139617) EN 42p G01N033-76
 R: AT BE CH DE ES FR GB IT LI LU NL SE
 DE 6006153 E 19900503 (139613) G01N033-76
 ES 2084689 T3 19900510 (139617) G01N033-76
 JP 004477 E 19411107 (139711) 22p G01N033-76
 ADT EP 409906 A EP 1990-0309:6 19400116; JP 04505128 W JP 1990-503251
 19900116; US 5358907 A CIP of US 1989-247451 19881221, CIP of US
 1989-311808 19890317, CIP of US 1989-349373 19890309, CIP of US
 1989-366603 19890601, Div ex US 1989-410775 19891012, US 1991-709019
 19910311; US 534608 A CIP of US 1989-247451 19890117, CIP of US
 1989-311808 19890317, CIP of US 1989-349373 19890309, CIP of US
 1989-366603 19890601, Cont of US 1989-410775 19891012, US 1993-51761
 19930107; EP 000477 A1 EP 1940-104733 19900116; EP 409906 B1 EP
 1990-03096 19900116, WO 1990-03291 19900116; DE 6006153 E DE 1990-626153
 19900116, EP 1990-00086 19900116, WO 1990-US291 19900116; ES 2084689 T3
 EP 1940-03086 19900116; JP 0444373 B2 JP 1990-503251 19900116, WO
 1990-03291 19900116
 PDT US 518007 A CIP of US 5026809; EP 409906 B1 Based on WO 9005325; DE
 6006153 E Based on EP 409906, Based on WO 9005325; ES 2084689 T3 Based on
 EP 409906; JP 0444373 B2 Previous Publ. Cf 139613, Based on WO 9005325
 PRAI US 1989-410775 19891012; EP 1940-247451 19890117; US 1989-311808
 19890317; US 1989-349373 19890309; US 1989-366603 19890601; US
 1989-410775 19891012; WO 1990-03096 19900116; US 1993-51761
 19930107
 REP 1.Int.Ref; 4.Int.Ref; EP 199773; JP 5416023; WO 9006096; 4.Int.Ref; DE
 611767
 IC G01N033-76
 ICM G01N033-53; G01N033-52; G01N033-76; G06F015-00
 ICS G01N033-08; G06F019-00
 ICI G06F15:00
 AB WO 9005325 A EPAB: 19900325
 (A) A method for determining if a pregnant woman is at significant risk
 of carrying a fetus with down syndrome (DS) is claimed comprising
 measuring a pregnant woman's maternal serum level of free beta subunit of
 human chorionic gonadotropin (hCG), incorporating the measurement of the
 level and the pregnant woman's gestational age into a probability density
function to compare with a set of normative data to determine the
 pregnant woman's risk of carrying a fetus with DS. (B) Also claimed is a
 method for determining if a pregnant woman is at significant risk of
 carrying a fetus with DS comprising assaying a pregnant woman's blood for
 free beta subunit of hCG, the results of the assay being indicative of
 increased risk of fetal DS. The method may further comprise assaying a
 pregnant woman's blood for alpha-fetoprotein (A). (C) Also claimed is an
 assay for measuring a person's blood level of the free beta subunit of hCG,
 (D) Also claimed is an appts. for receiving a measurement of a pregnant
 woman's maternal blood level of the free beta subunit of hCG and a computer
 for comparing the measurement of the level to a set of reference data to
 determine fetal chromosomal abnormalities.
 ADVANTAGE - The method correctly predicts a higher percentage of
 fetal DS cases with a lesser false positive rate than other known methods.
 Detection efficiency for Trisomy 21 as high as 83% has been achieved. The
 method can also be used for detecting chromosomal trisomies such as
 trisomy 13 and trisomy 18.
 Dwg. 0/14
 FS CPI EPI
 FA AB; DCN
 MC CPI: B04-B02D4; B04-B04D5; B04-B04L; B11-C; B11-C06; B12-K04A3;
 D05-H09
 EPI: S03-E14H; S05-L

ABEQ US 5253907 A UPAB: 19931020

Appts. for determining if a pregnant woman is at significant risk of carrying a fetus with Down's syndrome measures the maternal serum level of free beta human chorionic gonadotrophin and has a computer to calculate a set of normative data and incorporate the measurement and the gestational age into a probability density function, thus comparing the actual measurements with the normative data set.

The computer prog. generates the function by a linear discriminant analysis procedure. Measurements of intact human chorionic gonadotrophin, alpha-fetoprotein and unconjugated oestriol may also be input into the computer for comparison with normative data.

ADVANTAGE - Currently predicts a higher percentage of foetal Down's syndrome cases with a lower false positive rate than conventional methods. Lwg.07/14

ABEQ US 5311608 A UPAB: 19940710

Screening pregnant women for a Down's syndrome fetus comprises measuring free beta-HCG and comparing this and the woman's gestational age to reference values in pregnant women with normal/Down's syndrome fetuses. Higher level of beta-HCG indicates a higher probability of Down's syndrome.

ADVANTAGE - Greater percentage of foetal Down's syndrome with a lesser false positive rate. Lwg.11/12

ABEQ EP 489956 E UPAB: 19960408

An in vitro screening method for determining if a pregnant woman is carrying a fetus with Down syndrome comprising: assaying a pregnant woman's blood for free beta human chorionic gonadotropin (hCG), the results of the assay being indicative of increased risk of fetal Down syndrome. Lwg.12/14

L123 ANSWER 72 OF 73 WPIX COPYRIGHT 2001 DEFWENT INFORMATION LTD

AN 1990-100808 [14] WPIX

DNN N1990-077925 DDC C1990-044237

TI Measurement of lipoprotein constituents of blood - by building up reference NMR spectra of individual constituents to match measured NMR spectrum of blood.

DC B04 S03 S05

IN OTVOS, J B

PA (OTOB-I) OTOBOS J A; (OTVO-I) OTVOS J D

CYC 12

PI EP 361214 A 19900404 (199014)* EN 45p

F: BE CH DE ES FF GB IT LI NL

JP 02116743 A 19900501 (199023)

US 4933844 A 19900612 (199031)

CA 1327993 C 19940322 (199417)

EP 361214 B1 19940713 (199437) EN 43p G01N024-08

F: BE CH DE ES FF GB IT LI NL

DE 68916729 E 19940818 (199431) G01F033-46

ES 2056173 T3 19941001 (199440) G01F033-46

JP 3059181 B2 20000704 (200016) 39p G01N024-00

ADT EP 361214 A EP 1989-116979 19890913; JP 02116743 A JP 1984-246216

19890920; US 4933844 A US 1988-148750 19880920; CA 1327993 C CA

1989-012678 19890922; EP 361214 B1 EP 1989-116979 19890913; DE 68916729 E

DE 1989-016729 19890913; EP 1984-116979 19890913; ES 2056173 T3 EP

1989-116979 19890913; JP 3059181 B2 JP 1989-246216 19890920

FIT DE 68916729 E Based on EP 361214; ES 2056173 T3 Based on EP 361214; JP

3059181 B2 Previous Publ. JP 02116743

PRAI US 1988-248750 19880920

REP 5.Intl.Pat. EP 234324; 4.Intl.Pat.

IC G01N024-08; G01N033-92; G01F033-46; G06F015-42

ICM G01N024-00; G01N024-09; G01F033-46

ICS A01P006-055; G01N033-92; G06F015-42

AB EP 361214 A UPAB: 19930929

NMR spectrum of each lipoprotein constituent of blood is stored as a reference spectrum for that constituent and the measured NMR spectrum of a

plasma or serum sample of blood to be analysed is compared with a calculated lineshape produced by adding together the reference spectrum for each constituent, in amts. determined by respective constituent coeffs. which are adjusted until the calculated lineshape matches the measured NMR spectrum of the sample. The concn. of at least one lipoprotein constituent of the blood sample can be calculated as a **function** of the constituent coeffit. **USE/ADVANTAGE** - In the measurement of cholesterol in blood samples. Constituents of blood VLDL, LDL, HDL, and **protein** have NMR spectral properties invariant from person to person, so any differences in NMR spectrum of blood samples are due to the differences in levels of the constituents.

The process is simple and reliable and provides accurate measurements of lipoprotein content of blood.

4/4

FS CPI EPI
FA AB; GI; LFN
MC CPI: E01-E02; B04-B04D0; E04-E04L4; B11-B08A; **B12-K04A**
EPI: S03-E07; S03-E14H1; S05-C01; S05-D02X
ABEQ US 4933444 A UPAB: 19930928

The lipoprotein constituents of blood are measured by (i) storing the NMR spectrum of each lipoprotein constituent as a reference spectrum for that constituent; (ii) acquiring an NMR signal produced by plasma or serum sample of the blood to be analysed in an NMR spectrometer; (iii) producing an NMR spectrum of the sample by transforming the signal; (iv) producing a calculated lineshape by adding together the reference spectrum for each constituent in amts. determined by respective constituent coeffs.; (v) adjusting the coeffs. to fit the calculated lineshape to the NMR spectrum of the sample; and (vi) calculating the concn. of at least one lipoprotein constituent as a **function** of the value of its constituent coeffit.

ADVANTAGE - A method for the accurate and reliable measurement of the lipoprotein constituents of blood is provided.

ABEQ EP 361114 B UPAB: 19940414

A method for measuring the lipoprotein constituents of blood, the steps comprising: storing the NMR spectrum of each lipoprotein constituent as a reference spectrum for that constituent; acquiring the NMR spectrum of a plasma or serum sample of blood to be analysed; producing a calculated line shape by adding together the reference spectrum for each constituent in amounts determined by respective constituent coefficients; adjusting the constituent coefficients to fit the calculated line shape to the NMR spectrum of the sample; and calculating the concentration of at least one lipoprotein constituent as a **function** of the value of its constituent coefficient.

Dwg.0/4

L123 ANSWER 73 OF 73 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1986-286983 [44] WPIX
DNN H1986-213729 DUC 01986-123760
TI Determining base sequence of nucleic acid - by subjecting digital signals from auto-radiograph to signal processing.
DC B04 B16 R08 S03
IN HARA, M
FA (FUJIF) FUJI PHOTO FILM CO LTD
CYC 5
PI EP 149327 A 19861029 (1986044)* EN 36p
F: DE FR NL
JP 61243361 A 19861029 (1986050)
JP 61243362 A 19861029 (1986050)
US 4720786 A 19860119 (1986050)
EP 149327 B 19860104 (1986210)
F: DE FR NL
DE 3684030 G 19860409 (1986116)
JP 64061341 B 19861006 (1986114) 10p G01N033-00
JP 64061342 B 19861006 (1986114) 10p G01N033-00
ADT EP 149327 A EP 1986-105493 19860421; JP 61243361 A JP 1985-85275 19850419;
JP 61243362 A JP 1985-85276 19850419; US 4720786 A US 1986-854381

19860421; JP 04062341 B JP 1985-85275 19850419; JP 04062342 B JP 1985-85276 19850419

FDT JP 04062341 B Based on JP 61243361; JP 04062342 B Based on JP 61243362

PRAI JP 1985-85275 19850419; JP 1985-85276 19850419

REP 1.Jul.1981; A3...8939; EP 132621; JP 5-076754; No-SP.Pub

IC ICM G01N033-00

ICS G01N001-08; G01N027-447; G01N033-00; G01T001-28; G06F015-20

AB EP 199307 A UPAB: 19930921

A signal processing method for determining base sequence of nucleic acids comprises subjecting digital signals to signal processing. The digital signals corresp. to an autoradiograph of resolved rows which are formed by resolving a mixt. of base-specific DNA fragments or base-specific RNA fragments labelled with a radioactive element in one-dimensional direction on a support medium.

Method comprises (a) detecting at least 2 bands in the lower part of each resolved row and numbering the bands consecutively from the lower end, (b) obtaining correlation between the band's number and a resolved distance for each resolved row and (c) determining difference in the resolved distance between the resolved rows from the resulting correlation and making correction for resolved position on each row by taking the difference as locational deviation of the rows from each other.

USE/ADVANTAGE - The base sequence of the nucleic acids can be simply determined with high accuracy by processing the digital signals through a signal processing circuit having a **function** capable of making the correction for offset distortion even when the resolved pattern causes the offset distortion.

0/6

FS CPI EPI

FA AB

MC CPI: B04-B04A1; B11-C07B5; B12-K04E; B05-H12; F00-B; K00-E

EPI: S03-E14H

ABEQ DE 3684030 G UPAB: 19930921

A signal processing method for determining base sequence of nucleic acids comprises subjecting digital signals to signal processing. The digital signals corresp. to an autoradiograph of resolved rows which are formed by resolving a mixt. of base-specific DNA fragments or base-specific RNA fragments labelled with a radioactive element in one-dimensional direction on a support medium.

Method comprises (a) detecting at least 2 bands in the lower part of each resolved row and numbering the bands consecutively from the lower end, (b) obtaining correlation between the band's number and a resolved distance for each resolved row and (c) determining difference in the resolved distance between the resolved rows from the resulting correlation and making correction for resolved position on each row by taking the difference as locational deviation of the rows from each other.

USE/ADVANTAGE - The base sequence of the nucleic acids can be simply determined with high accuracy by processing the digital signals through a signal processing circuit having a **function** capable of making the correction for offset distortion even when the resolved pattern causes the offset distortion. (1)

ABEQ EP 199327 B UPAB: 19930912

A signal processing method for determining the base sequence of nucleic acids by subjecting digital signals (Dx3y) to signal processing, said digital signals (Dx3y) corresponding to an autoradiograph of plural resolved rows which are formed by resolving a mixture of base-specific DNA fragments or base-specific RNA fragments in one dimensional direction on a support medium, to form bands (n), said fragments being labelled with a radioactive element, said method comprising the steps of: (1) detecting at least two bands (n) in the lower part of each resolved row, and numbering all the bands (n) consecutively from the lower end, (2) obtaining a correlation between the number of which band (n) and the corresponding migration distance (y') for each resolved row, (3) determining the difference in the migration distance (y') between the resolved rows from the resulting correlations, and making corrections for the migration positions on each row by taking said differences as the locational

deviation of the rows from each other.

ABEQ US 47207-6 A UPAS: 19970922

Signal processing method for nucleic acid base sequence determin. is applied to digital signals corresp. to an autoradiograph of resolved rows formed by resolving a mixt. of base specific DNA or RNA fragments labelled with radioactive element in one dimensional direction on a support medium.

At least two bands in the lower part of each resolved row are detected and numbered from the lower end. Correlation between band number and resolved distance is obtained from each resolved row. Difference in resolved distance between the resolved rows from the resulting correlation is determined and correction is made for the resolved position of each row by taking the difference as location deviation of the rows from each other.

ADVANTAGE - Method is automatic and highly accurate.

=> d all abeq tech tot

1127 ANSWER 1 OF 2 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 1901-071531 (08) WPIX

DNN H0031-084116 ENO 0001-120110

TI Methods, computer programs and databases for analyzing and make use of gene haplotype information.

DC B34 Dlt SIF T01

IN TENTION, R R; JUSON, R S; RUANG, G; STEPHENS, J C; WINDEMUTH, A F; XU, C

PA GENA-10 GENAISANCE PHARM INC

CYC 94

PI WO 2001001118 A2 20010104 (200104) EN 277p G-07 01-00 ---

PW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KR LS LU MC MW MZ

NI OA PT QD QE SL SJ T2 TJ UK

W: AE AG AL AM AT AU BA BE BG BR BY CA CH CN CO CE DE DK DM

DS EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC

LK LR LS LT LU LV MA MD MG MK MN MW MX MO NZ PL PT RO RU SD SE

SG SI SK SL TJ TM TR TT TC UA UG US UZ VN YU ZA ZW

ADT WO 2001001118 A2 WO 2000-0217540 20000626

PRAI US 1999-141521 19990625

IC ICM G06F000-00

AB WO 200101218 A UPAS: 20010107

NOVELTY - Methods, computer programs and databases for analyzing and make use of gene haplotype (HT) information, e.g. to determine the frequency of HTs in a population, to find correlations between HTs or genotype and a clinical outcome and to predict HTs from an genotype for a gene, are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a method (M) for generating a HT database for a population, comprising data elements representative of the HTs for at least 1 locus from the individuals (indivs) in the data base;

(2) a (M) of predicting the presence of a HT pair in an indiv;

(3) a (M) for identifying a correlation between a HT pair and a clinical response to a treatment, or other phenotype Pt.;

(4) a (M) for identifying a correlation between a HT pair and a susceptibility to a condition or a disease of interest (OI), or other Pt. (OI);

(5) a (M) of predicting an indivs response to a medical or pharmaceutical treatment;

(6) a computer implemented (C-I) (M) for generating a gene structure screen for display on a display device (DD);

(7) a C-I (M) for generating a HT pair frequency screen for display on a DD;

(8) a C-I (M) for generating a linkage screen for display on a DD;

(9) a C-I (M) for generating a **phylogenetic** tree screen for display on a DD;

(10) a C-I (M) for generating a genotype (St.) analysis screen for display on a DD;

(11) a (M) of displaying clinical response values of a subject

population as a function of HT pairs of the indivs in the population;

(12) a C-I (M) for carrying out a genetic algorithm for finding an optimal set of weights to fit a function of polymorphic site data to a clinical response measurement;

(13) a C-I (M) for displaying correlations between clinical outcome values for a selected population;

(14) a (M) for conducting a clinical trial of a treatment protocol for a medical condition. (OI);

(15) a (M) of inferring Gts. of indiv subjects for a selected gene having polymorphic sites;

(16) a (M) of determining polymorphic sites or sub-HTs that correlate with a clinical response or outcome (OI);

(17) a (M) of determining polymorphic sites or sub-HTs that correlate with a clinical response or outcome (OI);

(18) a computer capable (C-U; medium (Md.) having computer readable (C-R) program code (PC) stored upon it, for causing a computer (Comp.) to adjust observed HT pair frequencies within a population group (the HT pair frequencies are stored in a C-R database of HT information for a gene or gene feature (OI));

(19) a C-U Md. having C-R PC stored upon it, for causing HT pair assignments to be made to an indiv member of a population whose Gt. information for a gene feature (OI) is stored in a C-R form;

(20) a C-U Md. having C-R PC stored upon it, for causing a Comp. to identify a correlation between a clinical response to a treatment or other Pt. and a HT or HT pair present at a candidate locus associated with the clinical response or other Pt.;

(21) a C-U Md. having C-R PC stored upon it, for causing a Comp. to identify a correlation between an indiv's susceptibility to a condition or disease (OI) or other Pt., and a HT or HT pair present at a candidate locus associated with the susceptibility to the condition or disease (OI) or other Pt. (OI);

(22) a C-U Md. having C-R PC stored upon it, for causing a Comp. to predict an indivs response to a medical or pharmaceutical treatment based on one or more selected HTs or HT pairs of the indiv;

(23) a C-U Md. having C-R PC stored upon it, for causing a Comp. to display a gene's structure and gene features on a display device DD;

(24) a C-F Md. having C-R PC stored upon it, for causing a Comp. to display on a DD, HT frequency data within a population of indivs, for a selected gene or gene feature;

(25) a C-F Md. having C-R PC stored upon it, for causing a Comp. to display on a DD, polymorphic site linkage data for a gene or gene (OI);

(26) a C-R Md. having C-R PC stored upon it, for causing a Comp. to display on a DD a **phylogenetic** tree;

(27) a C-F Md. having C-R PC stored upon it, for causing a Comp. to display a Gt. analysis screen in a DD;

(28) a C-U Md. having C-R PC stored upon it, for causing a Comp. to display clinical response values, or other Pt. data, of a subject population as a function of HT pairs of the indivs in the population;

(29) a C-U Md. having C-R PC stored upon it, for causing a Comp. to display on a DD, clinical response values, or other Pt. data, of a subject population as a function of HT pairs of the indivs in the population for a gene or gene feature (OI);

(30) a C-U Md. having C-R PC stored upon it, for causing a Comp. to carry out a genetic algorithm for finding an optimal set of weights to fit a function of polymorphic site data for a gene or gene feature (OI) to a clinical response measurement;

(31) a C-U Md. having C-R PC stored upon it, for causing a Comp. to display on a DD, correlation between clinical outcome values obtained from selected clinical outcome measures for a selected population;

(32) a C-U Md. having C-R PC stored upon it, for causing a Comp. to provide information of use in conducting clinical trials of a treatment protocol for a medical condition. (OI);

(33) a C-U Md. having C-R PC stored upon it, for causing a Comp. to infer Gts. of indiv subjects for a selected gene having polymorphic sites;

(34) C-U media having C-R PC stored upon it, for causing a Comp. to determine polymorphic sites or sub-HTs that correlate with a clinical

response or outcome (OI), or other Pt. (OI);

(35) Comps. programmed to carry out the above (Ms) or comprising the above Comp.-useable or -readable media, comprising a memory with at least 1 region for storing Comp. executable PCs and a processor for executing the PC stored in the memory;

(36) a data structure for storing an organizing biological information, stored on a C-R Md. and accessible by a processor, which comprises a single parent table which is adapted for storing, organizing and retrieving a number of genetic features by the relative positional relationships between the genetic features;

(37) a (M) for storing and organizing biological information; and

(38) a data structure for storing an organizing biological information, stored on a C-R Md. and accessible by a processor, which comprises at least 2 different fields, one of which included a number of genetic features, and the other of which included relative positional relationships between the genetic features.

Note: Further details of the above are given in the specification but had to be omitted from this abstract due to insufficient space.

USE - The methods, computer programs and databases for analyzing and make use of gene haplotype HT information, e.g. to determine the frequency of HTs in a population, to find correlations between HTs or genotypes and a clinical outcome or the effects of a therapeutic intervention and/or to predict HTs from an individual's genotype for a gene.

[Wg.07/4]

FS CPI EPI

FA AB

MC CPI: B04-E01; B11-C08E; B11-C09; B12-K04A3; D05-H01; D05-H09; D05-H12;

B05-H18; D05-J

EPI: S03-E14H; T01-G06A1; T01-S03

L127 ANSWER 2 OF 2 WPIN COPYRIGHT 2001 DRAWENT INFORMATION LTD

AN 0000-000002 [03] WPIN

DIIN H2000-019943 INC C2000-006875

TI Transition/transversion ratio estimation method - for purine, pyridine in DNA involves creating a taxonomic tree from input base sequence data.

DC B04 D16 T01

FA (SEIB-N) SEIBUTSU BUNSHI KOGAKU KENKYUSHO KK

CYC 1

PI JP 11259530 A 19990924 (200003)* JA 28p G06F017-30 <--

ADT JP 11259530 A JP 1998-307740 19980925

PRAI JP 1998-35313 19980112

IC ICM G06F017-30

ICS C12NC15-00

AB JP 11259530 A UPAB: 20000118

NOVELTY - The base substitution number assessed from type of transition-transversion is to create a taxonomic tree. The branch lengths of taxonomic tree are supposed. The presumed type of transition/transversion ratio is applied and assessed value of transition/transversion ratio is output. The base substitution number is assessed using a predefined equation that relates to compared sequence number.

DETAILED DESCRIPTION - The base sequence data with more than three sequences are input to data processor.

An INDEPENDENT CLAIM is also included for creating a **phylogenetic** tree from the actual base sequence data. Repeated calculations are done using the maximum evolution distance and the results are converged by a specified method, to obtain a right tree form.

USE - For estimation of transition/transversion ratio of components such as purine, pyridine in deoxyribonucleic acid (DNA) using their base sequence data e.g. of mitochondria of human and chimpanzee (claimed).

ADVANTAGE - The transition/transversion ratio in controlled domains such as human of mitochondrial DNA is assessed correctly and the taxonomic tree is also built correctly.

[Wg.07/6]

FS CPI EPI

FA AB

EC CPI: B04-E01; B06-D09; B07-D12; B11-C08E; B12-F04E; D05-H09
EPI: T01-J05B

=> fil medline

FILE 'MEDLINE' ENTERED AT 14:57:21 ON 12 FEB 2001

FILE LAST UPDATED: 27 OCT 2000 (20001027/UP). FILE COVERS 1960 TO DATE.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2000 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1968 through 1965.
Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the
Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE
SUBSTANCE IDENTIFICATION.

MEDLINE UPDATES ARE ON HOLD UNTIL AFTER THE ANNUAL RELOAD HAS BEEN
COMPLETED. NOTICE WILL BE GIVEN ONCE THE RELOAD IS COMPLETED AND
RELOAD DETAILS WILL BE FOUND IN HELP RELOAD.

=> d all tbt

1157 ANSWER 1 OF 23 MEDLINE

AN 1999030436 MEDLINE

DN 99083436

TI B30.2-like domain proteins: update and new insights into a rapidly
expanding family of proteins.

AU Henry J; Mather I H; McDermott M F; Pontarotti P

CS Centre National de la Recherche Scientifique URA 1485, Faculte de
Medicine, Limoges, France.

SO MOLECULAR BIOLOGY AND EVOLUTION, (1998 Dec) 15 (12) 1696-705.

Journal code: MOR. ISSN: 0737-4038.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199903

EW 19990304

AB The B30.2 domain is a conserved region of around 170 amino acids
associated with several different protein domains, including the
immunoglobulin folds of butyrophilin and the RING finger domain of ret
finger protein. We recently reported several novel members of this family
as well as previously undescribed protein families possessing the B30.2
domain. Many proteins have subsequently been found to possess this domain,
including pyrin/marenostrin and the midline 1 (MID1) protein. Mutations in
the B30.2 domain of pyrin/marenostrin are implicated in familial
Mediterranean fever, and partial loss of the B30.2 domain of MID1 is
responsible for Opitz G/BBB syndrome, characterized by developmental
midline defects. In this study, we scrutinized the available sequence data
bases for the identification of novel B30.2 domain proteins using highly
sensitive database-searching tools. In addition, we discuss the
chromosomal localization of genes in the B30.2 family, since the encoded
proteins are likely to be involved in other forms of periodic fever,
autoimmune, and genetic diseases.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't

Amino Acid Sequence

Autoimmune Diseases: GE, genetics

Cattle

Chromosome Mapping

Databases***Evolution, Molecular**

*Hereditary Diseases: GE, genetics

Molecular Sequence Data

*Multigene Family

*Phylogeny

Proteins: CH, chemistry**Proteins: GE, genetics**

Sequence Alignment

Sequence Homology, Amino Acid

Zinc Fingers

CN 0 (Proteins)

L157 ANSWER 2 OF 3? MEDLINE

AN 199909409 MEDLINE

DN 990909409

TI Three novel proteins of the syntaxin/SNAP-25 family.

AU Steegmaier M; Yang B; Yoo J S; Huang B; Shen M; Yu S; Luo Y; Scheller R H

CS Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305-5045, USA.

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 Dec 18) 273 (51) 34171-9.

Journal code: HIV. ISSN: 0021-9258.

CY United States

JT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

OS GENBANK-AF115331; GENBANK-AF115435; GENBANK-AF115436

EM 199903

AB Intracellular membrane traffic is thought to be regulated in part by soluble N-ethylmaleimide-sensitive factor-attachment protein receptors (SNAREs) through the formation of complexes between these proteins present on vesicle and target membranes. All known SNARE-mediated fusion events involve members of the syntaxin and vesicle-associated membrane protein families. The diversity of mammalian membrane compartments predicts the existence of a large number of different syntaxin and vesicle-associated membrane protein genes. To further investigate the spectrum of SNAREs and their roles in membrane trafficking we characterized three novel members of the syntaxin and SNAP-25 (synaptosome-associated protein of 25 kDa) subfamilies. The proteins are broadly expressed, suggesting a general role in vesicle trafficking, and localize to distinct membrane compartments. Syntaxin 8 co-localizes with markers of the endoplasmic reticulum. Syntaxin 17, a divergent member of the syntaxin family, partially overlaps with endoplasmic reticulum markers, and SNAP-29 is broadly localized on multiple membranes. SNAP-29 does not contain a predicted membrane anchor characteristic of other SNAREs. In vitro studies established that SNAP-29 is capable of binding to a broad range of syntaxins.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't

Amino Acid Sequence

Blotting, Northern

Cell Line

COS Cells

Databases, Factual

Endoplasmic Reticulum: ME, metabolism

Ethylmaleimide: PD, pharmacology

Evolution, Molecular***Membrane Proteins: CH, chemistry*****Membrane Proteins: GE, genetics**

Membrane Proteins: IP, isolation & purification

Molecular Sequence Data

Multigene Family

Nerve Tissue Proteins: CH, chemistry**Nerve Tissue Proteins: GE, genetics**

Nerve Tissue Proteins: ME, metabolism

Phylogeny

Rats

Recombinant Proteins: BI, biosynthesis
 Recombinant Proteins: CH, chemistry
 Sequence Alignment
 Sequence Homology, Amino Acid
 Transfection

RN 122-53-0 (Ethylmaleimide); 157546-56-0 (syntaxin)
 CN 0 (synaptosomal-associated protein 25); 0 (Membrane Proteins); 0 (Nerve
 Tissue Proteins); 0 (Recombinant Proteins)

L157 ANSWER 3 OF 23 MEDLINE

AN 1999057994 MEDLINE

DN 99057994

TI Sequence comparisons using multiple sequences detect three times as many
 remote homologues as pairwise methods.

AU Park J; Karpplus K; Barrett C; Hughey R; Haussler D; Hubbard T; Chothia C

CS MRC Laboratory of Molecular Biology, Hills Road, Cambridge, CB2 2QH, UK.

SO JOURNAL OF MOLECULAR BIOLOGY, (1998 Dec 11) 284 (4) 1201-10.

Journal code: J6V. ISSN: 0022-2836.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199903

EW 19990105

AB The sequences of related proteins can diverge beyond the point where their
 relationship can be recognised by pairwise sequence comparisons. In
 attempts to overcome this limitation, methods have been developed that use
 as a query, not a single sequence, but sets of related sequences or a
 representation of the characteristics shared by related sequences. Here we
 describe an assessment of three of these methods: the SAM-T98
 implementation of a hidden Markov model procedure; PSI-BLAST; and the
 intermediate sequence search (ISS) procedure. We determined the extent to
 which these procedures can detect evolutionary relationships between the
 members of the sequence database PDBD40-J. This database, derived from the
 structural classification of proteins (SCOP), contains the sequences of
 proteins of known structure whose sequence identities with each other are
 40% or less. The evolutionary relationships that exist between those that
 have low sequence identities were found by the examination of their
 structural details and, in many cases, their functional features. For nine
 false positive predictions out of a possible 432,680, i.e. at a false
 positive rate of about 1/50,000, SAM-T98 found 35% of the true homologous
 relationships in PDBD40-J, whilst PSI-BLAST found 30% and ISS found 25%.
 Overall, this is about twice the number of PDBD40-J relations that can be
 detected by the pairwise comparison procedures FASTA (17%) and GAP-BLAST
 (15%). For distantly related sequences in PDBD40-J, those pairs whose
 sequence identity is less than 30%, SAM-T98 and PSI-BLAST detect three
 times the number of relationships found by the pairwise methods. Copyright
 1998 Academic Press.

CT Check Tags: Comparative Study; Support, U.S. Gov't, Non-P.H.S.; Support,
 U.S. Gov't, P.H.S.

Databases, Factual

Evaluation Studies

Evolution, Molecular

Markov Chains

Proteins: CH, chemistry

Proteins: GE, genetics

*Sequence Alignment: MT, methods

Sequence Alignment: SN, statistics & numerical data

Sequence Homology, Amino Acid

CN 0 (Proteins)

L157 ANSWER 4 OF 23 MEDLINE

AN 1998417653 MEDLINE

DN 98417653

TI Supersites within superfolds. Binding site similarity in the absence of
 homology.

AB Russell R B; Casicini P D; Steinberg M J E
 CC Biomolecular Modelling Laboratory, Lincoln's Inn Fields, 10 Box 123,
 London WC2A 3PX, UK.
 SO JOURNAL OF MOLECULAR BIOLOGY, (1998 Oct 2) 282 (4) 903-19.
 Journal code: J6V. ISSN: 0022-2836.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199909
 EW 19990903
 AB A method is presented to assess the significance of binding site
 similarities within superimposed protein three-dimensional (3D) structures
 and applied to all similar structures in the Protein Data Bank. For
 similarities between 3D structures lacking significant sequence
 similarity, the important distinction was made between remote homology (an
 ancient common ancestor) and analogy (likely convergence to a folding
 motif) according to the structural classification of proteins (SCOP)
 database. Supersites were defined as structural locations on groups of
 analogous proteins (i.e. superfolds) showing a statistically significant
 tendency to bind substrates despite little evidence of a common ancestor
 for the proteins considered. We identify three potentially new superfolds
 containing supersites: ferredoxin-like folds, four-helical bundles and
 double-stranded beta helices. In addition, the method quantifies binding
 site similarities within homologous proteins and previously identified
 supersites such as that found in the beta/alpha (TIM) barrels. For the
 nine superfolds, the accuracy of predictions of binding site locations is
 assessed. Implications for protein evolution, and the prediction of
 protein function either through fold recognition or tertiary structure
 comparison, are discussed. Copyright 1998 Academic Press.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't

*Binding Sites

*Databases, Factual

Evolution, Molecular

Ferredoxins: ME, metabolism

Ligands

Models, Molecular

Protein Conformation

*Protein Folding

Protein Structure, Secondary

*Proteins: CH, chemistry

Proteins: ME, metabolism

Sequence Alignment

Sequence Homology, Amino Acid

Statistical Distributions

Structure-Activity Relationship

CN 0 (Ferredoxins); 0 (Ligands); 0 (Proteins)

1157 ANSWER 5 OF 23 MEDLINE

AN 1998391734 MEDLINE

DN 98391734

TI p500ASL, a 3'-5' oligoadenylate synthetase like protein: a novel human
 gene related to the 3'-5' oligoadenylate synthetase family.

AB Hartmann E; Olsen H S; Widder S; Jorgensen R; Justesen J

CC Department of Molecular and Structural Biology, University of Aarhus, C.
 F. Mollers alle Building 130, DK-8000 Aarhus C, Denmark and Human Genome
 Sciences Inc., 9410 Key West Avenue, Rockville, MD 20850, USA.

SO NUCLEIC ACIDS RESEARCH, (1998 Sep 15) 26 (18) 4121-8.

Journal code: OEL. ISSN: 0305-1948.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

OS GENBANK-AJ225089; GENBANK-AJ225090

EM 199901

EW 19990104

AB The 2'-5' oligoadenylate synthetases form a well conserved family of interferon induced proteins, presumably present throughout the mammalian class. Using the Expressed Sequence Tag databases, we have identified a novel member of this family. This protein, which we named p59 2'-5' oligoadenylate synthetase-like protein (p59OASL), shares a highly conserved N-terminal domain with the known forms of 2'-5' oligoadenylate synthetases, but differs completely in its C-terminal part. The C-terminus of p59OASL is formed of two domains of ubiquitin-like sequences. Here we present the characterisation of a full-length cDNA clone, the genomic sequence and the expression pattern of this gene. We have addressed the evolution of the 2'-5' oligoadenylate synthetase gene family, in the light of both this new member and new 2'-5' oligoadenylate synthetase sequence data from other species, which have recently appeared in the databases.

CT Check Tags: Animal; Female; Human; Male; Support, Non-U.S. Gov't
 Amino Acid Sequence
 Chickens
 Cloning, Molecular
 Consensus Sequence
 Conserved Sequence
Databases, Factual
Evolution, Molecular
 Exons
 Mice
 Molecular Sequence Data
 Multigene Family
 Organ Specificity
 Phylogeny
 Pigs
Recombinant Proteins: BI, biosynthesis
Sequence Alignment
Sequence Homology, Amino Acid
 Swine
Ubiquitin: CH, chemistry
 2',5'-Oligoadenylate Synthetase: BI, biosynthesis
 2',5'-Oligoadenylate Synthetase: CH, chemistry
 2',5'-Oligoadenylate Synthetase: GE, genetics

CN EC 2.7.7.- (p59 2',5'-oligoadenylate synthetase-like protein); EC 2.7.7.- (2',5'-Oligoadenylate Synthetase); 0 (Recombinant Proteins); 0 (Ubiquitin)

L157 ANSWER 6 OF 23 MEDLINE

AN 1498362532 MEDLINE

DN 98362532

TI Function driven protein evolution. A possible proto-protein for the RNA-binding proteins.

AU Fetrov J S; Godzik A

CS University at Albany, SUNY, Albany, USA.

SO PACIFIC SYMPOSIUM ON BIOCOMPUTING, (1998) 435-46.
 Journal code: CWQ.

CY Singapore

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199901

EW 19990104

AB We introduce a hypothesis that present day proteins evolved from "proto-proteins," small 15-25 residue peptides with some elements of secondary structure and primitive function. Increasingly stable and functional proteins arose by adding structural elements to produce the small domains or protein modules that we would recognize today. From this point of view, the surprising similarities between small structural fragments of large proteins, that are usually taken as examples of convergent, function-driven evolution, are interpreted in exactly the opposite way--as traces of common evolutionary origin. As an example, a hypothetical evolutionary tree for two families of RNA binding proteins, the OB fold, a family of all beta proteins, and RBD fold, an alpha/beta protein family is presented. We argue that both protein families could

have evolved from the same RNA-binding proto-protein, which had a form of beta-loop-beta RNA binding motif.

CT Check Tags: Human; Support, U.S. Gov't, Non-P.H.S.

Amino Acid Sequence

Bacteria

Binding Sites

Computer Graphics

Computer Simulation

DNA-Binding Proteins: CH, chemistry

DNA-Binding Proteins: GE, genetics

DNA-Binding Proteins: ME, metabolism

*Evolution, Molecular

Models, Genetic

Models, Molecular

Molecular Sequence Data

Protein Folding

*Protein Structure, Secondary

*RNA-Binding Proteins: CH, chemistry

*RNA-Binding Proteins: GE, genetics

*RNA-Binding Proteins: ME, metabolism

Sequence Alignment

Sequence Homology, Amino Acid

CN 0 (DNA-Binding Proteins); 0 (RNA-Binding Proteins)

L157 ANSWER 7 OF 23 MEDLINE

AN 1998362531 MEDLINE

DN 98362531

TI Protein disorder and the evolution of molecular recognition: theory, predictions and observations.

AU Dunker A K; Garner E; Guillet S; Romero P; Albrecht K; Hart J; Obradovic Z; Kissinger C; Villafranca J E

CS Department of Biochemistry & Biophysics, Washington State University, Pullman 99164-4660, USA.. dunker@mail.wsu.edu

SO PACIFIC SYMPOSIUM ON BIOCOMPUTING, (1998) 473-84.

Journal code: CWQ.

CY Singapore

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199901

AB Observations going back more than 20 years show that regions in proteins with disordered backbones can play roles in their binding to other molecules; typically, the disordered regions become ordered upon complex formation. Thought-experiments with Schulz Diagrams, which are defined herein, suggest that disorder-to-order transitions are required for natural selection to operate separately on affinity and specificity. Separation of affinity and specificity may be essential for fine-tuning the molecular interaction networks that comprise the living state. For low affinity, high specificity interactions, our analysis suggests that natural selection would parse the amino acids conferring flexibility in the unbound state from those conferring specificity in the bound state. For high affinity, low specificity or for high affinity, multiple specificity interactions, our analysis suggests that the disorder-to-order transitions enable alternative packing interactions between side chains to accommodate the different binding targets. Disorder-to-order transitions upon binding also have significant kinetic implications as well, by having complex effects on both on- and off-rates. Current data are insufficient to decide on these proposals, but sequence and structure analysis on two examples support further investigations of the role of disorder-to-order transitions upon binding.

CT Algorithms

Amino Acid Sequence

Binding Sites

Calmodulin: CH, chemistry

*Evolution, Molecular

Macromolecular Systems

*Protein Conformation
 Protein Structure, Secondary
 *Proteins: CH, chemistry
 Proteins: GE, genetics
 Selection (Genetics)
 Sequence Alignment
 Sequence Homology, Amino Acid
 *Software

CN 0 (Calmodulin); 0 (Macromolecular Systems); 0 (Proteins)

L157 ANSWER 3 OF 23 MEDLINE

AN 1998348042 MEDLINE

DN 98348042

TI Detecting distant relatives of mammalian LPS-binding and lipid transport proteins.

AU Beamer L J; Fischer D; Eisenberg D

CS Biochemistry Department, University of Missouri-Columbia, 65211, USA.

SO PROTEIN SCIENCE, (1998 Jul) 7 (7) 1643-5.

Journal code: BNW. ISSN: 0961-8368.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199812

EW 19981104

AB In mammals, a family of four lipid binding proteins has been previously defined that includes two lipopolysaccharide binding proteins and two lipid transfer proteins. The first member of this family to have its three-dimensional structure determined is bactericidal/permeability-increasing protein (BPI). Using both the sequence and structure of BPI, along with recently developed sequence-sequence and sequence-structure similarity search methods, we have identified 13 distant members of the family in a diverse set of eukaryotes, including rat, chicken, *Caenorhabditis elegans*, and *Biomphalaria galbrata*. Although the sequence similarity between these 13 new members and any of the 4 original members of the BPI family is well below the "twilight zone," their high sequence-structure compatibility with BPI indicates they are likely to share its fold. These findings broaden the BPI family to include a member found in retina and brain, and suggest that a primitive member may have contained only one of the two similar domains of BPI.

CT Check Tags: Animal; Human; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Biomphalaria

Blood Bactericidal Activity

*Blood Proteins: CH, chemistry

*Blood Proteins: GE, genetics

Blood Proteins: ME, metabolism

Caenorhabditis elegans

*Carrier Proteins: CH, chemistry

Carrier Proteins: GE, genetics

Carrier Proteins: ME, metabolism

Chickens

Databases, Factual

Disulfides

Evolution, Molecular

Lipopolysaccharides: ME, metabolism

Molecular Sequence Data

Nerve Tissue Proteins: CH, chemistry

Nerve Tissue Proteins: GE, genetics

Protein Folding

Protein Structure, Tertiary

*Proteins: CH, chemistry

Rats

Sequence Alignment

Sequence Homology, Amino Acid

Sequence Homology, Nucleic Acid

CN 0 (bactericidal permeability increasing protein); 0 (cholesterol ester transfer proteins); 0 (lipopolysaccharide-binding protein); 0 (Blood Proteins); 0 (Carrier Proteins); 0 (Disulfides); 0 (Lipopolysaccharides); 0 (Nerve Tissue Proteins); 0 (Proteins); 0 (TENP protein)

L157 ANSWER 9 OF 23 MEDLINE

AN 1998348035 MEDLINE

DN 98348035

TI The discoidin domain family revisited: new members from prokaryotes and a homology-based fold prediction.

AU Baumgartner J; Hofmann K; Chiquet-Ehrismann R; Bucher P

CS Lund University, Department of Cell & Molecular Biology, Sweden...

Stefan.Baumgartner@medkem.lu.se

SO PROTEIN SCIENCE, (1998 Jul) 7 (7) 1826-31.

Journal code: BNW. ISSN: 0961-8308.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

PS Priority Journals

EM 199812

EW 19981304

AB Members of the discoidin (DS) domain family, which includes the C1 and C2 repeats of blood coagulation factors V and VIII, occur in a great variety of eukaryotic proteins, most of which have been implicated in cell-adhesion or developmental processes. So far, no three-dimensional structure of a known example of this extracellular module has been determined, limiting the usefulness of identifying a new sequence as member of this family. Here, we present results of a recent search of the protein sequence database for new DS domains using generalized profiles, a sensitive multiple alignment-based search technique. Several previously unrecognized DS domains could be identified by this method, including the first examples from prokaryotic species. More importantly, we present statistical, structural, and functional evidence that the D1 domain of galactose oxidase whose three-dimensional structure has been determined at 1.7 Å resolution, is a distant member of this family. Taken together, these findings significantly expand the concept of the DS domain, by extending its taxonomic range and by implying a fold prediction for all its members. The proposed alignment with the galactose oxidase sequence makes it possible to construct homology-based three-dimensional models for the most interesting examples, as illustrated by an accompanying paper on the C1 and C2 domains of factor V.

CT Check Tags: Support, Non-U.S. Gov't

Amino Acid Sequence

*Bacterial Proteins: CH, chemistry

Bacterial Proteins: CL, classification

Databases, Factual

Evolution, Molecular

*Fungal Proteins: CH, chemistry

Fungal Proteins: CL, classification

*Galactose Oxidase: CH, chemistry

Galactose Oxidase: CL, classification

Molecular Sequence Data

Protein Folding

Protein Structure, Tertiary

Sequence Alignment

Sequence Homology, Amino Acid

CN EC 1.1.3.9 (Galactose Oxidase); 0 (discoidins); 0 (Bacterial Proteins); 0 (Fungal Proteins)

L157 ANSWER 10 OF 23 MEDLINE

AN 1998309401 MEDLINE

DN 98309401

TI Phylogenetic relationships of fungi, plantae, and animalia inferred from homologous comparison of ribosomal proteins.

AU Vauthey A L; Bittar G

CS Departement de Biochimie Medicale, Universite de Gen'eeve, Switzerland.

SO JOURNAL OF MOLECULAR EVOLUTION, (1998 Jul) 47 (1) 81-92.
Journal code: J75. ISSN: 0022-2844.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199810

EW 1998100?

AB The complete set of available ribosomal proteins was utilized, at both the peptidic and the nucleotidic level, to establish that plants and metazoans form two sister clades relative to fungi. Different phylogenetic inference methods are applied to the sequence data, using archaeans as the outgroup. The evolutionary length of the internal branch within the eukaryotic crown triad is demonstrated to be, at most, one-tenth of the evolutionary length of the branch leading to the ancestor of these three kingdoms.

CI Cited Tags: Animal; Comparative Study
*Animals: CL, classification
*Computer Simulation
*Evolution, Molecular
*Fungi: CL, classification
Models, Genetic
Phylogeny
*Plants: CL, classification
*Ribosomal Proteins: GE, genetics
Sequence Alignment
Sequence Homology, Amino Acid
Sequence Homology, Nucleic Acid

CN 0 (Ribosomal Proteins)

L157 ANTWFF 11 OF 23 MEDLINE

AN 1998100839 MEDLINE

DN 19981008

TI The expanding beta 4-galactosyltransferase gene family: messages from the databanks.

AN Lu N W; Shaper J H; Pevsner J; Shaper N L

CS Department of Pharmacology and Molecular Sciences, Kennedy Krieger Institute, Baltimore, MD, USA.

NC CA45799 (NCI)

SO GLYCOBIOLOGY, (1998 May) 8 (5) 517-26.
Journal code: BEL. ISSN: 0959-6653.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

OS GENBANK-AF038660; GENBANK-AF038661; GENBANK-AF038662; GENBANK-AF038663; GENBANK-AF038664

EM 199810

AB From a systematic search of the UniGene and dbEST databanks, using human beta 4-galactosyltransferase (beta 4GalT-I), which is recognized to function in lactose biosynthesis, as the query sequence, we have identified five additional gene family members denoted as beta 4GalT-II, -III, -IV, -V, and -VI. Complementary DNA clones containing the complete coding regions for each of the five human homologs were obtained or generated by a PCR-based strategy (RACE) and sequenced. Relative to beta 4GalT-I, the percent sequence identity at the amino acid level between the individual family members, ranges from 33% (beta 4GalT-VI) to 55% (beta 4GalT-II). The highest sequence identity between any of the homologs is between beta 4GalT-V and beta 4GalT-VI (63%). beta 4GalT-II is the ortholog of the chicken beta 4GalT-II gene, which has been demonstrated to encode an alpha-lactalbumin responsive beta 4-galactosyltransferase (Shaper et al., J. Biol. Chem., 272, 31389-31399, 1997). As established by Northern analysis, beta 4GalT-II and -IV show the most restricted pattern of tissue expression. High steady state levels of beta 4GalT-II mRNA are seen only in fetal brain and adult heart, muscle, and pancreas; relatively high levels of beta 4GalT-VI mRNA are seen only in adult brain. When the corresponding mouse EST clone for each of the beta 4GalT family members

was used as the hybridization probe for Northern analysis of murine mammary tissue, transcription of only the beta 4GalT-1 gene could be detected in the lactating mammary gland. These observations support the conclusion that among the six known beta 4GalT family members in the mammalian genome, that have been generated through multiple gene duplication events of an ancestral gene(s), only the beta 4GalT-1 ancestral lineage was recruited for lactose biosynthesis during the evolution of mammals.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Adult

Amino Acid Sequence

***Databases, Factual**

Evolution, Molecular

Fetus

Galactosyltransferases: BI, biosynthesis

Galactosyltransferases: CH, chemistry

Mice

Molecular Sequence Data

*Multigene Family

Phylogeny

Polymerase Chain Reaction

Recombinant Proteins: BI, biosynthesis

Recombinant Proteins: CH, chemistry

RNA, Messenger: ME, metabolism

Sequence Alignment

Sequence Homology, Amino Acid

Transcription, Genetic

CN EC 2.4.1.1- (Galactosyltransferases ; 1 (Recombinant Proteins); 0 (RNA, Messenger)

1157 ANSWER 11 OF 23 MEDLINE

AN 1098104936 MEDLINE

DN 98104936

TI Chimeric structure of the NAD(P)+- and NADP+-dependent malic enzymes of *Rhizobium* (*Sinorhizobium*) *meliloti*.

AU Mitsch M G; Viegold R T; Cowie A; Osteras M; Finan T M

CS Department of Biology, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada.

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 Apr 10) 273 (15) 9380-6.

Journal code: HIV. ISSN: 0021-9258.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199807

AB Malic enzymes catalyze the oxidative decarboxylation of malate to pyruvate in conjunction with the reduction of a nicotinamide cofactor. We determined the DNA sequence and transcriptional start sites of the genes encoding the diphosphopyridine nucleotide-dependent malic enzyme (DME, EC 1.1.1.39) and the triphosphopyridine nucleotide-dependent malic enzyme (TME, EC 1.1.1.40) of *Rhizobium* (*Sinorhizobium*) *meliloti*. The predicted DME and TME proteins contain 773 and 764 amino acids, respectively, and are approximately 320 amino acids larger than previously characterized prokaryotic malic enzymes. The increased size of DME and TME resides in the C-terminal extensions which are similar in sequence to phosphotransacetylase enzymes (EC 2.3.1.8). Modified DME and TME proteins which lack this C-terminal region retain malic enzyme activity but are unable to oligomerize into the native state. Data base searches have revealed that similar chimeric malic enzymes were uniquely present in Gram-negative bacteria. Thus DME and TME appear to be members of a new class of malic enzyme characterized by the presence of a phosphotransacetylase-like domain at the C terminus of the protein.

CT Check Tags: Comparative Study; Support, Non-U.S. Gov't

Amino Acid Sequence

Bacteria: EN, enzymology

Bacteria: GE, genetics
 Chimeric Proteins: BI, biosynthesis
 Chimeric Proteins: CH, chemistry
 Chimeric Proteins: ME, metabolism
 *Evolution, Molecular
 *Malate Dehydrogenase: CH, chemistry
 *Malate Dehydrogenase: GE, genetics
 Malate Dehydrogenase: ME, metabolism
 Molecular Sequence Data
 Phylogeny
 Sequence Alignment
 Sequence Homology, Amino Acid
 *Sinorhizobium meliloti: EN, enzymology
 Sinorhizobium meliloti: GE, genetics
 Software

CN EC 1.1.1.37 (Malate Dehydrogenase); EC 1.1.1.39 (malate dehydrogenase (decarboxylating)); EC 1.1.1.40 (malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+)); 0 (Chimeric Proteins)

L157 ANSWER 13 OF 23 MEDLINE

AN 1998181064 MEDLINE

CN 98181064

TI Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences.

AU Rose T M; Schultz E B; Henikoff J G; Pietrokovski S; McCallum C M; Henikoff S

CS Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA.

SO NUCLEIC ACIDS RESEARCH, (1998 Apr 1) 26 (7) 1622-35.

Journal code: GBL. ISSN: 0305-1048.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199807

EW 19980705

AB We describe a new primer design strategy for PCR amplification of unknown targets that are related to multiply-aligned protein sequences. Each primer consists of a short 3' degenerate core region and a longer 5' consensus clamp region. Only 3-4 highly conserved amino acid residues are necessary for design of the core, which is stabilized by the clamp during annealing to template molecules. During later rounds of amplification, the non-degenerate clamp permits stable annealing to product molecules. We demonstrate the practical utility of this hybrid primer method by detection of diverse reverse transcriptase-like genes in a human genome, and by detection of CENNA methyltransferase homologs in various plant DNAs. In each case, amplified products were sufficiently pure to be cloned without gel fractionation. This CONsensus-DEgenerate Hybrid Oligonucleotide Primer (CODEHOP) strategy has been implemented as a computer program that is accessible over the World Wide Web (<http://blocks.fhcrc.org/codehop.html>) and is directly linked from the BlockMaker multiple sequence alignment site for hybrid primer prediction beginning with a set of related protein sequences.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

Amino Acid Sequence

Arthritis, Rheumatoid: GE, genetics

Base Sequence

Codon

Computer Communication Networks

Consensus Sequence

Conserved Sequence

*DNA Modification Methylases: CH, chemistry

DNA Modification Methylases: GE, genetics

*DNA Primers

*Evolution, Molecular

Molecular Sequence Data
Nucleic Acid Hybridization
*Phylogeny
Polymerase Chain Reaction: MT, methods
***RNA-Directed DNA Polymerase: CH, chemistry**
RNA-Directed DNA Polymerase: GE, genetics
Sarcoma, Kaposi: GE, genetics
Sequence Alignment
Sequence Homology, Amino Acid
Sequence Homology, Nucleic Acid
Software

CN EC 2.1.1.1.- (DNA Modification Methylases); EC 2.7.7.49 (RNA-Directed DNA Polymerase); 0 (Codon); 1 (RNA Primers)

L157 ANSWER 14 OF 13 MEDLINE

AN 1998169454 MEDLINE

DN 98169454

TI Seeking an ancient enzyme in *Methanococcus jannaschii* using ORF, a program based on predicted secondary structure comparisons.

AU Aurora R; Pose G D

CS Department of Biophysics and Biophysical Chemistry, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.

SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 Mar 17) 95 (6) 2318-23.
Journal code: PNAS. ISSN: 0027-8424.

CY United States

DT Journal; Article-; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199806

FW 19980601

AB We have developed a simple procedure to identify protein homologs in genomic databases. The program, called ORF, is based on comparisons of predicted secondary structure. Protein structure is far better conserved than amino acid sequence, and structure-based methods have been effective in exploiting this fact to find homologs, even among proteins with scant sequence identity. ORF is a secondary structure-based method that operates solely on predictions from sequence and requires no experimentally determined information about the structure. The approach is illustrated by an example: Thymidylate synthase, a highly conserved enzyme essential to thymidine biosynthesis in both prokaryotes and eukaryotes, is thought to be used by Archaea, but a corresponding gene has yet to be identified. Here, a candidate thymidylate synthase is identified as a previously unassigned open reading frame from the genome of *Methanococcus jannaschii*, viz., MJ0757. Using primary structure information alone, the optimally aligned sequence identity between MJ0757 and *Escherichia coli* thymidylate synthase is 7%, well below the threshold of sensitivity for detection by sequence-based methods.

CT Check Tags: Comparative Study; Support, U.S. Gov't, P.H.S.

Amino Acid Sequence

Archaeal Proteins: CH, chemistry

Bacteria: EN, enzymology

Evolution, Molecular

**Methanococcus*: EN, enzymology

Models, Molecular

Molecular Sequence Data

*Protein Structure, Secondary

Protein Structure, Tertiary

Saccharomyces cerevisiae: EN, enzymology

***Sequence Alignment: MT, methods**

Sequence Homology, Amino Acid

***Software**

*Thymidylate Synthase: CH, chemistry

CN EC 2.1.1.45 (Thymidylate Synthase); 0 (Archaeal Proteins)

L157 ANSWER 15 OF 23 MEDLINE

AN 1998051772 MEDLINE
 DN 98051972
 TI An approach to detection of protein structural motifs using an encoding scheme of backbone conformations.
 AU Matsuda H; Taniguchi F; Hashimoto A
 CO Department of Informatics and Mathematical Science, Graduate School of Engineering Science, Osaka University, Japan.. matsuda@ics.es.osaka-u.ac.jp
 SO PACIFIC SYMPOSIUM ON BIOCOMPUTING, (1997) 280-91.
 Journal code: CWO.
 CY Singapore
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 PR Priority Journals
 EM 199803
 EW 19980301
 AB This paper presents an approach to detection of protein structural motifs. In our approach, first all protein backbone conformations are converted into character strings using an encoding scheme. Then we use the Smith-Waterman local alignment algorithm to detect common structural motifs. By comparing results with the PROSITE regular expression patterns, our method can detect several motifs which the PROSITE patterns fail to detect.
 CT Check Tags: Support, Non-U.S. Gov't
 Amino Acid Sequence
 Calcium-Binding Proteins: CH, chemistry
 Computer Simulation
 Crystallins: CH, chemistry
 Databases
 Databases, Factual
 Evolution, Molecular
 Information Storage and Retrieval
 Models, Molecular
 Molecular Sequence Data
 *Protein Conformation
 Protein Structure, Secondary
 *Proteins: CH, chemistry
 *Proteins: GE, genetics
 Sequence Alignment
 Sequence Homology, Amino Acid
 Software
 CH 0 (Calcium-Binding Proteins); 0 (Crystallins); 0 (Proteins)
 L157 ANSWER 16 OF 23 MEDLINE
 AN 1998061595 MEDLINE
 DN 98061595
 TI Evolutionary conservation and predicted structure of the Drosophila extra sex comb repressor protein.
 AU Ng J; Li F; Morgan E; Simon J
 CO Department of Biochemistry, University of Minnesota, St. Paul 55108, USA.
 NC 6M49650 (NIGMS)
 SO MOLECULAR AND CELLULAR BIOLOGY, (1997 Nov) 17 (11) 6663-72.
 Journal code: NGY. ISSN: 0270-7306.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 PR Priority Journals
 CC GENBANK-AF003603; GENBANK-AF003604; GENBANK-AF003605
 EM 199801
 AB The Drosophila extra sex comb (esc) protein, a member of the Polycomb group (PcG), is a transcriptional repressor of homeotic genes. Genetic studies have shown that esc protein is required in early embryos at about the time that other PcG proteins become engaged in homeotic gene repression. The esc protein consists primarily of multiple copies of the WD repeat, a motif that has been implicated in protein-protein interaction. To further investigate the domain organization of esc

protein, we have isolated and characterized esc homologs from divergent insect species. We report that esc protein is highly conserved in housefly (71% identical to Drosophila esc), butterfly (55% identical), and grasshopper (50% identical). We show that the butterfly homolog provides esc function in Drosophila, indicating that the sequence similarities reflect functional conservation. Homology modeling using the crystal structure of another WD repeat protein, the G-protein beta-subunit, predicts that esc protein adopts a beta-propeller structure. The sequence comparisons and modeling suggest that there are seven WD repeats in esc protein which together form a seven-bladed beta-propeller. We locate the conserved regions in esc protein with respect to this predicted structure. Site-directed mutagenesis of specific loops, predicted to extend from the propeller surface, identified conserved parts of esc protein required for function in vivo. We suggest that these regions might mediate physical interaction with esc partner proteins.

CT Check Tags: Animal; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Amino Acid Sequence

Butterflies: GE, genetics

Cloning, Molecular

Computer Simulation

Conserved Sequence

Drosophila: EM, embryology

*Drosophila: GE, genetics

DNA, Complementary: GE, genetics

***Evolution, Molecular**

Grasshoppers: GE, genetics

Houseflies: GE, genetics

Insect Proteins: CH, chemistry

***Insect Proteins: GE, genetics**

Insect Proteins: ME, metabolism

Models, Molecular

Molecular Sequence Data

Mutagenesis, Site-Directed

Protein Binding

Protein Conformation

*Protein Structure, Tertiary

Repressor Proteins: CH, chemistry

***Repressor Proteins: GE, genetics**

Repressor Proteins: ME, metabolism

Sequence Analysis, DNA

Sequence Homology, Amino Acid

Structure-Activity Relationship

FN 134549-01-2 (Polycomb protein, insect)

CN 0 (DNA, Complementary); 0 (Insect Proteins); 0 (Repressor Proteins)

L157 ANSWER 17 OF 23 MEDLINE

AN 97435515 MEDLINE

DN 97435515

TI Homeoboxes in sea anemones (Cnidaria:Anthozoa): a PCR-based survey of Nematostella vectensis and Metridium senile.

AU Finnerty J R; Martindale M Q

CS Department of Organismal Biology and Anatomy, University of Chicago, Illinois 60637, USA.

NC HD07136 (NICHQ)

SO BIOLOGICAL BULLETIN, (1997 Aug) 193 (1) 61-76.

Journal code: A26. ISSN: 0006-3135.

CY United States

BT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

OS GENBANK-U42726; GENBANK-U42727; GENBANK-U42728; GENBANK-U42729; GENBANK-U42730; GENBANK-U42731; GENBANK-U42732; GENBANK-U42733; GENBANK-U42734; GENBANK-U42735; GENBANK-U42736; GENBANK-U42737; GENBANK-M62872; GENBANK-S15548; GENBANK-M62871; GENBANK-D44629; GENBANK-D37042; GENBANK-L09690; GENBANK-E37042; GENBANK-A35511;

GENBANK-C44636; GENBANK-I44623; GENBANK-F44636; GENBANK-H48200;
GENBANK-S33663; GENBANK-S75223; GENBANK-S36773; GENBANK-A60092;
GENBANK-XC6133; GENBANK-S22516; ;

EM 199712

EW 19971201

AB Homeobox genes belong to a phylogenetically widespread family of regulatory genes that play important roles in pattern formation and cell-fate specification in several model systems (e.g., *Drosophila*, mouse, and *C. elegans*). Although the evolution of many classes of homeobox genes predates the diversification of the Bilateria, comparatively little is known about homeobox genes in outgroups to the Bilateria, such as the Cnidaria. We used the polymerase chain reaction to recover 12 partial homeoboxes from 2 species of sea anemones, *Metridium senile* and *Nematostella vectensis* (phylum Cnidaria; class Anthozoa). These homeoboxes appear to represent 3 distinct, mutually paralogous homeobox genes, 5 of which belong to previously identified cnidarian homeobox classes, and 4 of which appear to represent previously unidentified classes. The evolutionary relationships between the homeodomains of sea anemones and of bilaterian animals were assessed through database searches and phylogenetic analyses. As many as 5 of the anemone homeoboxes may belong to the Hox class, which suggests that the Hox gene complement of cnidarians is larger than previously expected. Homologs of the even-skipped gene of *Drosophila* were also identified in both *Metridium* and *Nematostella*.

CT Check Tags: Animal; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Amino Acid Sequence

Base Sequence

Caenorhabditis: GE, genetics

Cloning, Molecular

Drosophila: GE, genetics

*Evolution

Evolution, Molecular

*Genes, Homeobox

Homeodomain Proteins: BI, biosynthesis

*Homeodomain Proteins: CH, chemistry

Homeodomain Proteins: GE, genetics

Information Systems

Mice

Molecular Sequence Data

Phylogeny

Polymerase Chain Reaction: MT, methods

Recombinant Proteins: BI, biosynthesis

Recombinant Proteins: CH, chemistry

Sea Anemones: CL, classification

*Sea Anemones: GE, genetics

Sequence Alignment

Sequence Homology, Amino Acid

Sequence Homology, Nucleic Acid

CN 0 (Homeodomain Proteins); 0 (Recombinant Proteins)

L157 ANSWER 18 OF 23 MEDLINE

AN 37411608 MEDLINE

DN 37411608

TI The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry.

AU Liu L; Zhao C; Heng H H; Ganz T

CS Department of Medicine and Will Rogers Institute for Pulmonary Research, University of California at Los Angeles School of Medicine, 90095, USA.

NC HL-97014 (NHLBI)

HL-35640 (NHLBI)

HL-46309 (NHLBI)

SO GENOMICS, (1997 Aug 1) 43 (3) 316-20.

Journal code: GEN. ISSN: 0888-7543.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 OS GENBANK-U50930; GENBANK-U50931; GENBANK-X92744
 EM 19901
 AB We cloned a novel human beta-defensin gene and determined its full-length cDNA sequence. The entire gene spanned more than 7 kb and included a large 662-bp intron. The 363-bp cDNA encoded a prepropeptide that corresponded precisely to the recently identified human beta-defensin HBD-1, an antimicrobial peptide implicated in the resistance of epithelial surfaces to microbial colonization. By two-color fluorescence in situ hybridization on both metaphase chromosome and released chromatin fiber, HBD-1 gene (HBE1 in HUGO/GDB nomenclature) mapped to chromosomal region 8p23.1-p23.2 in close proximity (within 100-150 kb) to the gene for the human neutrophil alpha-defensin HNP-1 (DEFB1). Thus, despite a complete lack of DNA sequence similarity and despite differences in their disulfide-pairing pattern, the alpha- and beta-families appear to have evolved from a common primate/mammalian defensin gene.

CT Check Tags: Human; Support, U.S. Gov't, P.H.S.

Algorithms

Amino Acid Sequence

*Anti-Infective Agents: ME, metabolism

Base Sequence

*Blood Proteins: GE, genetics

Chromosome Mapping

Chromosomes, Human, Pair 8: GE, genetics

Databases, Factual

Disulfides: CH, chemistry

DNA, Complementary: AM, analysis

DNA, Complementary: CH, chemistry

DNA, Complementary: GE, genetics

Evolution, Molecular

*Genes, Structural: GE, genetics

In Situ Hybridization, Fluorescence

Molecular Sequence Data

*Multigene Family

Peptides: CH, chemistry

Peptides: GE, genetics

Protein Structure, Secondary

Sequence Alignment: MT, methods

Sequence Homology, Amino Acid

CN 0 (defensins); 0 (Anti-Infective Agents); 0 (Blood Proteins); 0 (Disulfides); 0 (DNA, Complementary); 0 (Peptides)

1157 ANSWER 19 OF 23 MEDLINE

AN 97233150 MEDLINE

DN 97233150

TI Optimum superimposition of protein structures: ambiguities and implications.

AU Feng Z K; Sippl M J

CS Center for Applied Molecular Engineering, University of Salzburg, Australia.

SO FOLDING AND DESIGN, (1996) 1 (2) 125-32.

Journal code: CUD. ISSN: 1359-0278.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199707

EW 19970701

AB BACKGROUND: Techniques for comparison and optimum superimposition of protein structures are indispensable tools, providing the basis for statistical analysis, modeling, prediction and classification of protein folds. Observed similarity of structures is frequently interpreted as an indication of evolutionary relatedness. A variety of advanced techniques are available, but so far the important issue of uniqueness of structural

superimposition has been largely neglected. We set out to investigate this issue by implementing an efficient algorithm for structure superimposition enabling routine searches for alternative alignments. RESULTS: The algorithm is based on optimum superimposition of structures and dynamic programming. The implementation is tested and validated using published results. In particular, an automatic classification of all protein folds in a recent release of the protein data bank is performed. The results obtained are closely related to published data. Surprisingly, for many protein pairs alternative alignments are obtained. These alignments are indistinguishable in terms of number of equivalent residues and root mean square error of superimposition, but the respective sets of equivalent residue pairs are completely distinct. Alternative alignments are observed for all protein architectures, including mixed alpha/beta folds.

CONCLUSIONS: Superimposition of protein folds is frequently ambiguous. This has several implications on the interpretation of structural similarity with respect to evolutionary relatedness and it restricts the range of applicability of superimposed structures in statistical analysis. In particular, studies based on the implicit assumption that optimum superimposition of structures is unique are bound to be misleading.

CT Check Tags: Support, Non-U.S. Gov't

***Algorithms**

Amino Acid Sequence
Evaluation Studies
Evolution, Molecular
Models, Molecular
Molecular Sequence Data
Molecular Structure
Protein Folding
Protein Structure, Secondary

***Proteins: CH, chemistry**

Proteins: GE, genetics
Sequence Alignment
Sequence Homology, Amino Acid

CN 0 (Proteins)

L157 ANSWER 10 OF 23 MEDLINE

AN 97224626 MEDLINE

DN 97224626

TI Evolutionary motif and its biological and structural significance.

AU Tateno Y; Ikee K; Imanishi T; Watanabe H; Endo T; Yamaguchi Y; Suzuki Y; Takahashi K; Tsunoyama K; Kawai M; Kawanishi Y; Naitou K; Gojohori T

CS Center for Information Biology, National Institute of Genetics, Mishima, Japan.. ytateno@genes.nig.ac.jp

SO JOURNAL OF MOLECULAR EVOLUTION, (1997) 44 Suppl 1 S38-43.

Journal code: J76. ISSN: 0022-2944.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199706

EW 19970601

AB We developed a method for multiple alignment of protein sequences. The main feature of this method is that it takes the evolutionary relationships of the proteins in question into account repeatedly for execution, until the relationships and alignment results are in agreement. We then applied this method to the data of the international DNA sequence databases, which are the most comprehensive and updated DNA databases in the world, in order to estimate the "evolutionary motif" by extensive use of a supercomputer. Though a few problems needed to be solved, we could estimate the length of the motifs in the range of 20 to 200 amino acids, with about 60 the most frequent length. We then discussed their biological and structural significance. We believe that we are now in a position to analyze DNA and protein not only in vivo and in vitro but also in silico.

CT Check Tags: Animal; Human

Amino Acid Sequence
Amino Acids: GE, genetics

Databases, Factual

DNA: GE, genetics

***Evolution, Molecular**

***Proteins: GE, genetics**

Sequence Alignment

***Sequence Homology, Amino Acid**

RN 9607-43-2 (DNA)

CN 0 (Amino Acids); 0 (Proteins)

L157 ANSWER 11 OF 23 MEDLINE

AN 96163541 MEDLINE

DN 96163541

TI Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families.

AU Coulier F; Pontarotti P; Rounin R; Hartung H; Goldfarb M; Birnbaum D

CS Laboratoire d'Oncole Moleculaire, U.119 INSERM, 27 Bd. Le Bourne, 13009 Marseille, France.

SO JOURNAL OF MOLECULAR EVOLUTION, (1997 Jan) 44 (1) 43-56.

Journal code: J76. ISSN: 0022-2844.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

PS Priority Journals

OS GENBANK-AC013552

EM 1-9776

AB FGFs (fibroblast growth factors) play major roles in a number of developmental processes. Recent studies of several human disorders, and concurrent analysis of gene knock-out and properties of the corresponding recombinant proteins have shown that FGFs and their receptors are prominently involved in the development of the skeletal system in mammals. We have compared the sequences of the nine known mammalian FGFs, FGFs from other vertebrates, and three additional sequences that we extracted from existing databases: two human FGF sequences that we tentatively designated FGF10 and FGF11, and an FGF sequence from *Caenorhabditis elegans*. Similarly, we have compared the sequences of the four FGF receptor paralogs found in chordates with four non-chordate FGF receptors, including one recently identified in *C. elegans*. The comparison of FGF and FGF receptor sequences in vertebrates and nonvertebrates shows that the FGF and FGF receptor families have evolved through phases of gene duplications, one of which may have coincided with the emergence of vertebrates, in relation with their new system of body scaffold.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't

Amino Acid Sequence

Caenorhabditis elegans: GE, genetics

Databases, Factual

***Evolution, Molecular**

***Fibroblast Growth Factor: GE, genetics**

Genes, Structural

Molecular Sequence Data

Multigene Family

Phylogeny

***Receptors, Fibroblast Growth Factor: GE, genetics**

Sequence Alignment

Sequence Homology, Amino Acid

*Vertebrates: GE, genetics

RN 9631-54-3 (Fibroblast Growth Factor)

CN 0 (Receptors, Fibroblast Growth Factor)

L157 ANSWER 12 OF 23 MEDLINE

AN 96404124 MEDLINE

DN 96404124

TI Teleost HoxD and HoxA genes: comparison with tetrapods and functional evolution of the HoxD complex.

AU van der Hoeven F; Sordino P; Fraudeau N; Izpisua-Belmonte J C; Duboule D

CS Department of Zoology and Animal Biology, University of Geneva, Switzerland.

SO MECHANISMS OF DEVELOPMENT, (1996 Jan) 54 (1) 9-21.
 Journal code: AXF. ISSN: 0925-4773.
 CY Ireland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 OS GENBANK-X87750; GENBANK-X87751; GENBANK-X87752; GENBANK-X87753
 EM 199702
 AB In tetrapods, Hox genes are essential for the proper organization and development of axial structures. Experiments involving Hox gene inactivations have revealed their particularly important functions in the establishment of morphological transitions within metameric series such as the vertebral column. Teleost fish show a much simpler range of axial (trunk or appendicular) morphologies, which prompted us to investigate the nature of the Hox system in these lower vertebrates. Here, we show that fish have a family of Hox genes, very similar in both number and general organization, to that of tetrapods. Expression studies, carried out with HoxE and HoxA genes, showed that all vertebrates use the same general scheme, involving the colinear activation of gene expression in both space and time. Comparisons between tetrapods and fish allowed us to propose a model which accounts for the primary function of this gene family. In this model, a few ancestral Hox genes were involved in the determination of polarity in the digestive tract and were further recruited in more elaborate axial structures.
 CT Check Tags: Animal; Comparative Study; Support, Non-U.S. Gov't
 Amino Acid Sequence
 Chick Embryo
 Digestive System: EM, embryology
 Digestive System: ME, metabolism
 DNA, Complementary: GE, genetics
 *Evolution, Molecular
 Fetal Development: GE, genetics
 Gene Expression Regulation, Developmental
 *Genes, Homeobox
 Homeodomain Proteins: BI, biosynthesis
 *Homeodomain Proteins: GE, genetics
 In Situ Hybridization
 Mice
 Models, Biological
 Molecular Sequence Data
 Morphogenesis: GE, genetics
 RNA Probes
 Sequence Alignment
 Sequence Homology, Amino Acid
 Species Specificity
 Trans-Activators: BI, biosynthesis
 *Trans-Activators: GE, genetics
 Transcription Factors: BI, biosynthesis
 *Transcription Factors: GE, genetics
 Urogenital System: EM, embryology
 Urogenital System: ME, metabolism
 Vertebrates: CL, classification
 Vertebrates: EM, embryology
 *Vertebrates: GE, genetics
 Zebrafish: EM, embryology
 *Zebrafish: GE, genetics
 RN 157907-48-7 (HoxA protein)
 CN 0 (DNA, Complementary); 0 (Homeodomain Proteins); 0 (Hoxd-13 protein); 0 (HoxD-10 protein); 0 (HoxD-11 protein); 0 (HoxD-12 protein); 0 (RNA Probes); 0 (Trans-Activators); 0 (Transcription Factors)
 L157 ANSWER 23 OF 23 MEDLINE
 AN 96180620 MEDLINE
 DN 96180620
 TI An evolutionary trace method defines binding surfaces common to protein families.

AC Lichtarge O; Bourne H R; Cohen F E
 CS Department of Cellular and Molecular Pharmacology, University of
 California San Francisco, 94143-0450, USA.
 SO JOURNAL OF MOLECULAR BIOLOGY, (1996 Mar 29) 257 (2) 342-58.
 Journal code: J6V. ISSN: 0022-2836.
 CY ENGLAND; United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199603
 AB X-ray or NMR structures of proteins are often derived without their
 ligands, and even when the structure of a full complex is available, the
 area of contact that is functionally and energetically significant may be
 a specialized subset of the geometric interface deduced from the spatial
 proximity between ligands. Thus, even after a structure is solved, it
 remains a major theoretical and experimental goal to localize protein
 functional interfaces and understand the role of their constituent
 residues. The evolutionary trace method is a systematic, transparent and
 novel predictive technique that identifies active sites and functional
 interfaces in proteins with known structure. It is based on the extraction
 of functionally important residues from sequence conservation patterns in
 homologous proteins, and on their mapping onto the protein surface to
 generate clusters identifying functional interfaces. The SH2 and SH3
 modular signaling domains and the DNA binding domain of the nuclear
 hormone receptors provide tests for the accuracy and validity of our
 method. In each case, the evolutionary trace delineates the functional
 epitope and identifies residues critical to binding specificity. Based on
 mutational evolutionary analysis and on the structural homology of protein
 families, this simple and versatile approach should help focus
 site-directed mutagenesis studies of structure-function relationships in
 macromolecules, as well as studies of specificity in molecular
 recognition. More generally, it provides an evolutionary perspective for
 judging the functional or structural role of each residue in protein
 structure.
 CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't,
 P.H.S.
 src Homology Domains
 Amino Acid Sequence
 *Binding Sites
 Conserved Sequence
 Databases, Factual
 DNA-Binding Proteins: CH, chemistry
 *Evolution, Molecular
 Models, Molecular
 Molecular Sequence Data
 Mutation
 Protein Conformation
 *Proteins: CH, chemistry
 Receptors, Glucocorticoid: CH, chemistry
 Sequence Alignment: MT, methods
 Sequence Homology, Amino Acid
 Zinc Fingers
 CN 0 (DNA-Binding Proteins); 0 (Proteins); 0 (Receptors, Glucocorticoid)

=> d all tot

L162 ANSWER 1 OF 8 MEDLINE
 AN 1998452316 MEDLINE
 DN 98452316
 FI Sequence, structural, functional, and phylogenetic analyses of three
 glycosidase families.
 AU Mian I S
 CS Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley,

CA 94/20, USA.. SMian@lbl.gov
 NO BLOOD CELLS, MOLECULES, AND DISEASES, (1993 Jun) 24 (2) 83-100.
 Journal code: BSA. ISSN: 1073-9796.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199301
 EW 19930104
 AB Glycosidases, which cleave the glycosidic bond between a carbohydrate and another moiety, have been classified into over 63 families. Here, a variety of computational techniques have been employed to examine three families important in normal and abnormal pathology with the aim of developing a framework for future homology modeling, experimental and other studies. Family 1 includes bacterial and archaeal enzymes as well as lactase-phlorizin-hydrolase and α -mannosidase, glycosidases implicated in disaccharide intolerance II and aging respectively. A statistical model, a hidden Markov model (HMM), for the family 1 glycosidase domain was trained and used as the basis for comparative examination of the conserved and variable sequence and structural features as well as the phylogenetic relationships between family members. Although the structures of four family 1 glycosidases have been determined, this is the first comparative examination of all these enzymes. Aspects that are unique to specific members or subfamilies (substrate binding loops) as well those common to all members (a beta/alpha) β barrel fold) have been defined. Active site residues in some domains in α -mannosidase and lactase-phlorizin hydrolases differ from other members and in one instance may bind but not cleave substrate. The four invariant and most highly conserved residues are not residues implicated in catalysis and/or substrate binding. Of these, a histidine may be involved in transition state stabilization. Glucosylceramidase (family 30) and galactosylceramidase (family 59) are mutated in the lysosomal storage disorders Gaucher disease and Krabbe disease, respectively. HMM-based analysis, structure prediction studies and examination of disease mutations reveal a glycosidase domain common to these two families that also occurs in some bacterial glycosidases. Similarities in the reactions catalyzed by families 30 and 59 are reflected in the presence of a structurally and functionally related (beta/alpha) β barrel fold related to that in family 1.
 CT Check Tags: Animal; Comparative Study; Human; Support, U.S. Gov't, Non-P.H.S.
 Amino Acid Sequence
 Amino Acid Substitution
 Bacteria: EN, enzymology
 Bacterial Proteins: CH, chemistry
 Bacterial Proteins: CL, classification
 Bacterial Proteins: GE, genetics
 Binding Sites
 Evolution, Molecular
 Glycoside Hydrolases: CH, chemistry
 *Glycoside Hydrolases: CL, classification
 Glycoside Hydrolases: GE, genetics
 Invertebrates: CH, chemistry
 Invertebrates: CL, classification
 Invertebrates: GE, genetics
 Mammals: ME, metabolism
 Markov Chains
 Models, Molecular
 Molecular Sequence Data
 Multigene Family
 Phylogeny
 Plant Proteins: CH, chemistry
 Plant Proteins: CL, classification
 Plant Proteins: GE, genetics
 Plants: EN, enzymology
 *Protein Conformation
 Sequence Alignment

Sequence Homology, Amino Acid
Structure-Activity Relationship

CN EC 3.2.1. (Glycoside Hydrolases); 0 (Bacterial Proteins); 0 (Plant Proteins)

L162 ANSWER 2 OF 3 MEDLINE

AN 1998417653 MEDLINE

DN 98417653

TI Supersites within superfolds. Binding site similarity in the absence of homology.

AU Russell R B; Sasiemi P D; Sternberg M J E

CS Biomolecular Modelling Laboratory, Lincoln's Inn Fields, 20 Box 123, London WC2A 3EK, UK.

SO JOURNAL OF MOLECULAR BIOLOGY, (1998 Oct 2) 282 (4) 903-18.

Journal code: JMB. ISSN: 0022-2834.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199809

EW 19980903

AB A method is presented to assess the significance of binding site similarities within superimposed protein three-dimensional (3D) structures and applied to all similar structures in the Protein Data Bank. For similarities between 3D structures lacking significant sequence similarity, the important distinction was made between remote homology (an ancient common ancestor) and analogy (likely convergence to a folding motif) according to the structural classification of proteins (SCOP) database. Supersites were defined as structural locations on groups of analogous proteins (i.e. superfolds) showing a statistically significant tendency to bind substrates despite little evidence of a common ancestor for the proteins considered. We identify three potentially new superfolds containing supersites: ferredoxin-like folds, four-helical bundles and double-stranded beta helices. In addition, the method quantifies binding site similarities within homologous proteins and previously identified supersites such as that found in the beta/alpha (TIM) barrels. For the nine superfolds, the accuracy of predictions of binding site locations is assessed. Implications for protein evolution, and the prediction of protein function either through fold recognition or tertiary structure comparison, are discussed. Copyright 1998 Academic Press.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't

*Binding Sites

*Databases, Factual

Evolution, Molecular

Ferredoxins: ME, metabolism

Ligands

Models, Molecular

Protein Conformation

*Protein Folding

Protein Structure, Secondary

*Proteins: CH, chemistry

Proteins: ME, metabolism

Sequence Alignment

Sequence Homology, Amino Acid

Statistical Distributions

Structure-Activity Relationship

CN 0 (Ferredoxins); 0 (Ligands); 0 (Proteins)

L162 ANSWER 3 OF 3 MEDLINE

AN 1998362531 MEDLINE

DN 98362531

TI Protein disorder and the evolution of molecular recognition: theory, predictions and observations.

AU Dunker A K; Garner E; Guilliot S; Romero P; Albrecht K; Hart J; Obradovic Z; Kissinger C; Villafranca J E

CS Department of Biochemistry & Biophysics, Washington State University,

Pullman 99164-4660, USA.. dunker@mail.wsu.edu
SO PACIFIC SYMPOSIUM ON BIOCOMPUTING, (1998) 473-44.
Journal code: CWQ.
CY Singapore
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199901
AB Observations going back more than 20 years show that regions in proteins with disordered backbones can play roles in their binding to other molecules; typically, the disordered regions become ordered upon complex formation. Thought-experiments with Schulz Diagrams, which are defined herein, suggest that disorder-to-order transitions are required for natural selection to operate separately on affinity and specificity. Separation of affinity and specificity may be essential for fine-tuning the molecular interaction networks that comprise the living state. For low affinity, high specificity interactions, our analysis suggests that natural selection would parse the amino acids conferring flexibility in the unbound state from those conferring specificity in the bound state. For high affinity, low specificity or for high affinity, multiple specificity interactions, our analysis suggests that the disorder-to-order transitions enable alternative packing interactions between side chains to accommodate the different binding targets. Disorder-to-order transitions upon binding also have significant kinetic implications as well, by having complex effects on both on- and off-rates. Current data are insufficient to decide on these proposals, but sequence and structure analysis on two examples support further investigations of the role of disorder-to-order transitions upon binding.

C1 Algorithms
Amino Acid Sequence
Binding Sites
Calmodulin: CH, chemistry
*Evolution, Molecular
Macromolecular Systems
*Protein Conformation
Protein Structure, Secondary
*Proteins: CH, chemistry
Proteins: GE, genetics
Selection (Genetics)
Sequence Alignment
Sequence Homology, Amino Acid
*Software

CN 0 (Calmodulin); 0 (Macromolecular Systems); 0 (Proteins)

L162 ANSWER 4 OF 8 MEDLINE
AN 1998330762 MEDLINE
DN 98330762
TI Protein fold irregularities that hinder sequence analysis.
AU Russell R B; Ponting C P
CS SmithKline Beecham Pharmaceuticals, Bioinformatics, New Frontiers Science Park (North), Essex, UK.. russelrl@mh.uk.sbphrd.com
SO CURRENT OPINION IN STRUCTURAL BIOLOGY, (1998 Jun) 8 (3) 364-71. Ref: 70
Journal code: BVV. ISSN: 0959-446X.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199812
EW 19981201
AB The detection of homologous protein sequences frequently provides useful predictions of function and structure. Methods for homology searching have continued to improve, such that very distant evolutionary relationships can now be detected. Little attention has been paid, however, to the problems of detecting homology when domains are inserted or permuted. Here

we review recent occurrences of these phenomena and discuss methods that permit their detection.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't

Amino Acid Sequence

Evolution, Molecular

Models, Molecular

Molecular Sequence Data

*Protein Folding

*Protein Structure, Secondary

*Proteins: CH, chemistry

*Proteins: ME, metabolism

Sequence Alignment

Sequence Homology, Amino Acid

CN 0 *Proteins

L162 ANSWER 9 OF 3 MEDLINE

AN 1998263252 MEDLINE

DN 98263252

TI Protein folding and protein evolution: common folding nucleus in different subfamilies of c-type cytochromes?

AU Ptitsyn O B

CS Laboratory of Experimental and Computational Biology National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-5677, USA.

SO JOURNAL OF MOLECULAR BIOLOGY, (1998 May 8) 278 (3) 655-66.

Journal code: JMB. ISSN: 0022-2836.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 1998

EW 19981813

AB Amino acid sequences of seven subfamilies of cytochromes c (mitochondrial cytochromes c, cl; chloroplast cytochromes c6, cf; bacterial cytochromes c3, c550, c551; in total 164 sequences) have been compared. Despite extensive homology within eukaryotic subfamilies, homology between different subfamilies is very weak. Other than the three heme-binding residues (Cys13, Cys14, His16, in numeration of horse cytochrome c) there are only four positions which are conserved in all subfamilies: Gly/Ala6, Phe/Tyr10, Leu/Val/Phe94 and Tyr/Trp/Phe97. In all 17 cytochromes c with known 3D-structures, these residues form a network of conserved contacts (6-94, 6-97, 10-94, 10-97 and 94-97). Especially strong is the contact between aromatic groups in positions 10 and 97, which corresponds to 13 interatomic contacts. As residues 6, 10 and residues 94, 97 are in (i, i+4) and (i, i+3) positions in the N and C-terminal helices, respectively, the above mentioned system of conserved contacts consists mainly of contacts between one turn of N-terminal helix and one turn of C-terminal helix. The importance of the contacts between interfaces of these helices has been confirmed by the existence of these contacts in both equilibrium and kinetic molten globule-like folding intermediates, as well as by mutational evidence that these contacts are involved in tight packing between the N and C-helices. Since these four residues are not involved in heme binding and have no other apparent functional role, their conservation in highly diverged cytochromes c suggests that they are of a critical importance for protein folding. The author assumes that they are involved in a common folding nucleus of all subfamilies of c-type cytochromes. Copyright 1998 Academic Press Limited.

CT Check Tags: Animal

Amino Acid Sequence

Bacteria: ME, metabolism

Binding Sites

Chloroplasts: ME, metabolism

Conserved Sequence

*Cytochrome c: CH, chemistry

*Cytochrome c: GE, genetics

Cytochrome c: ME, metabolism

*Evolution, Molecular

Heme: ME, metabolism
Horses
Kinetics
Mitochondria: ME, metabolism
Models, Molecular
Molecular Sequence Data
*Protein Conformation
*Protein Folding
Saccharomyces cerevisiae: ME, metabolism
Sequence Alignment
Sequence Homology, Amino Acid

PN 14375-94-1 (Heme); 2007-43-1 (Cytochrome c)

L162 ANSWER 6 OF 3 MEDLINE

AN 1998051972 MEDLINE

DN 97081972

TI An approach to detection of protein structural motifs using an encoding scheme of backbone conformations.

AU Matsuda H; Taniguchi F; Hashimoto A

CS Department of Informatics and Mathematical Science, Graduate School of Engineering Science, Osaka University, Japan.. matsuda@ics.es.osaka-u.ac.jp

SO PACIFIC SYMPOSIUM ON BIOCOMPUTING, (1997) 280-91.

Journal code: CWO.

CY Singapore

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Fidelity Journals

EM 199805

FW 19980505

AB This paper presents an approach to detection of protein structural motifs. In our approach, first all protein backbone conformations are converted into character strings using an encoding scheme. Then we use the Smith-Waterman local alignment algorithm to detect common structural motifs. By comparing results with the PROSITE regular expression patterns, our method can detect several motifs which the PROSITE patterns fail to detect.

CT Check Tags: Support, Non-U.S. Gov't

Amino Acid Sequence

Calcium-Binding Proteins: CH, chemistry

Computer Simulation

Crystallins: CH, chemistry

Databases

Databases, Factual

Evolution, Molecular

Information Storage and Retrieval

Models, Molecular

Molecular Sequence Data

*Protein Conformation

Protein Structure, Secondary

*Proteins: CH, chemistry

*Proteins: GE, genetics

Sequence Alignment

Sequence Homology, Amino Acid

Software

CN 0 (Calcium-Binding Proteins); 0 (Crystallins); 0 (Proteins)

L162 ANSWER 7 OF 8 MEDLINE

AN 97233150 MEDLINE

DN 97233150

TI Optimum superimposition of protein structures: ambiguities and implications.

AU Feng Z K; Sippl M J

CS Center for Applied Molecular Engineering, University of Salzburg, Australia.

SO FOLDING AND DESIGN, (1996) 1 (2) 123-32.

Journal code: CUD. ISSN: 1359-0278.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199707
 EW 19970701
 AB BACKGROUND: Techniques for comparison and optimum superimposition of protein structures are indispensable tools, providing the basis for statistical analysis, modeling, prediction and classification of protein folds. Observed similarity of structures is frequently interpreted as an indication of evolutionary relatedness. A variety of advanced techniques are available, but so far the important issue of uniqueness of structural superimposition has been largely neglected. We set out to investigate this issue by implementing an efficient algorithm for structure superimposition enabling routine searches for alternative alignments. RESULTS: The algorithm is based on optimum superimposition of structures and dynamic programming. The implementation is tested and validated using published results. In particular, an automatic classification of all protein folds in a recent release of the protein data bank is performed. The results obtained are closely related to published data. Surprisingly, for many protein pairs alternative alignments are obtained. These alignments are indistinguishable in terms of number of equivalent residues and root mean square error of superimposition, but the respective sets of equivalent residue pairs are completely distinct. Alternative alignments are observed for all protein architectures, including mixed alpha/beta folds. CONCLUSIONS: Superimposition of protein folds is frequently ambiguous. This has several implications on the interpretation of structural similarity with respect to evolutionary relatedness and it restricts the range of applicability of superimposed structures in statistical analysis. In particular, studies based on the implicit assumption that optimum superimposition of structures is unique are bound to be misleading.
 CT Check Tags: Support, Non-U.S. Gov't
 *Algorithms
 Amino Acid Sequence
 Evaluation Studies
 Evolution, Molecular
 Models, Molecular
 Molecular Sequence Data
 Molecular Structure
 Protein Folding
 Protein Structure, Secondary
 *Proteins: CH, chemistry
 Proteins: GE, genetics
 Sequence Alignment
 Sequence Homology, Amino Acid
 CN C (Proteins)

L162 ANSWER 3 OF 3 MEDLINE
 AN 96180020 MEDLINE
 DN 96180020
 TI An evolutionary trace method defines binding surfaces common to protein families.
 AU Lichtarge O; Bourne H R; Cohen F E
 CS Department of Cellular and Molecular Pharmacology, University of California San Francisco, 94143-0450, USA.
 SO JOURNAL OF MOLECULAR BIOLOGY, (1996 Mar 29) 257 (2) 342-58.
 Journal code: J6V. ISSN: 0022-2836.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199608
 AB X-ray or NMR structures of proteins are often derived without their ligands, and even when the structure of a full complex is available, the area of contact that is functionally and energetically significant may be

a specialized subset of the geometric interface deduced from the spatial proximity between ligands. Thus, even after a structure is solved, it remains a major theoretical and experimental goal to localize protein functional interfaces and understand the role of their constituent residues. The evolutionary trace method is a systematic, transparent and novel predictive technique that identifies active sites and functional interfaces in proteins with known structure. It is based on the extraction of functionally important residues from sequence conservation patterns in homologous proteins, and on their mapping onto the protein surface to generate clusters identifying functional interfaces. The SH2 and SH3 modular signaling domains and the DNA binding domain of the nuclear hormone receptors provide tests for the accuracy and validity of our method. In each case, the evolutionary trace delineates the functional epitope and identifies residues critical to binding specificity. Based on mutational/evolutionary analysis and on the structural homology of protein families, this simple and versatile approach should help focus site-directed mutagenesis studies of structure-function relationships in macromolecules, as well as studies of specificity in molecular recognition. More generally, it provides an evolutionary perspective for judging the functional or structural role of each residue in protein structure.

CT Check Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.

src Homology Domains

Amino Acid Sequence

*Binding Sites

Conserved Sequence

Databases, Factual

*DNA-Binding Proteins: CH, chemistry

*Evolution, Molecular

Models, Molecular

Molecular Sequence Data

Mutation

Protein Conformation

*Proteins: CH, chemistry

Rece

Receptors, Glucocorticoid: CH, chemistry

Sequence Alignment: MT, methods

Sequence Homology, Amino Acid

Zinc Fingers

CN C (DNA-Binding Proteins); C (Proteins); C (Receptors, Glucocorticoid)

=> d his

(FILE 'HOME' ENTERED AT 12:33:16 ON 12 FEB 2001)
SET COST OFF

FILE 'MEDLINE' ENTERED AT 12:34:00 ON 12 FEB 2001

E MARCOTTE E/AU

L1 17 S E3,E4

E EISENBERG D/AU

L2 227 S E3-E9

E THOMPSON M/AU

L3 511 S E7,E14

E PELLEGRINI M/AU

L4 204 S E3-E10

E YEATES T/AU

L5 42 S E4

L6 975 S L1-L5

E SEQUENCE ALIGNMENT/CT

E E3+ALL/CT

L7 24992 S E4+NT/CT

L8 26 S L6 AND L7

L9 136 S L1./CT AND L6

L10 63 S D12,NOT AND L9
E SEQUENCE ANALYSIS+ALL/CT
L11 38171 S E4+NT/CT
L12 11 S L11 AND L6
L13 3 S L10 AND L12
E SEQUENCE HOMOMOLOGY+ALL/CT
L14 451340 S E14+NT/CT
L15 134 S L6 AND L14
L16 45 S L12 AND L13
L17 11 S L8 AND L16
L18 44 S L11,L12,L16,L17
E PHYLOGENY/CT
E E4+ALL/CT
L19 46181 S E4+NT/CT
L20 11 S L13 AND L6
L21 11 S L12 AND L13
L22 48 S L21,L12
E GENOME/CT
E E4+ALL/CT
L23 18380 S E6+NT/CT
L24 4 S L6 AND L23
L25 48 S L22,L24
L26 46 S L21 AND D12,NOT
L27 3 S L21 NOT L12
L28 1 S L27 NOT D12,NOT
L29 1 S L28 AND L12
L30 1 S L28 AND L-,L11,L14,L15,L19,L23
E ALGORITHM/CT
E E4+ALL/CT
L31 23540 S E11+NT/CT
E DATABASES/CT
L32 13061 S E3+NT/CT
E PROTEIN CONFORMATION+ALL/CT
L33 95911 S E9+NT/CT
E PROTEIN FOLDING/CT
E E4+ALL/CT
L34 8912 S E4+NT/CT
L35 164 S L6 AND L31-L34
L36 33 S L35 AND L25-L30
L37 11 S L36-L39 NOT L36
L38 7 S L37 NOT D12,NOT
L39 45 S L36,L38

FILE 'MEDLINE' ENTERED AT 12:47:05 ON 12 FEB 2001
SEL L34 AN 7 11-15 19 29 30 33-38 40 41

L40 15 S E1-E15
L41 30 S L39 NOT L40
L42 11 S L41 AND L9
L43 30 S L41,L42
L44 17 S L42 AND TALIGHT
L45 30 S L43,L44

FILE 'MEDLINE' ENTERED AT 12:57:13 ON 12 FEB 2001

FILE 'BIOSIS' ENTERED AT 12:57:57 ON 12 FEB 2001

E MASCOFFE B/AU
L46 32 S E3,E6,E7
E EISENBERG D/AU
L47 244 S E7-E8,E13-E16
E THOMPSON M/AU
L48 611 S E3,E21,E22
E THOMPSON MICH/AU
L49 44 S E4,E12
E PELLEGRINI M/AU
L50 203 S E3-E12,E25
E YEATES T/AU

L51 48 S E3-E6
 L52 1199 S L46-L51
 L53 1018263 S (*10054 OR *10054)/CC
 L54 281 S L53 AND L52
 L55 29 S 04560/CC AND L54
 L56 114 S 10560/CC AND L54
 L57 8 S 01060/CC AND L54
 L58 43 S L55,L57
 L59 19 S L56 AND L58
 L60 431 S L51 AND (00520/CC OR CONFERENCE/DT)
 L61 454 S L51 AND (CONFERENCE OR CONGRESS OR POSTER OR SYMPOS? OR MEETI
 L62 455 S L51,L61
 L63 81 S L61 NOT CONFERENCE/DT
 L64 16 S L63 NOT ARTICLE/DT
 L65 SEL DN 1 2 3 4
 L66 1 S E1-E3
 L67 1 S L64 NOT L65
 L68 434 S L66,L66
 L69 61 S L67 AND L68
 L70 6 S L68 AND L69
 L71 16 S L68 AND L69
 L72 19 S L69-L71
 L73 11 S L71 AND (LIVER OR REPLACEMENT OR MELLITIN OR MILK OR ENCEPHAL
 L74 31 S L71 NOT L73
 L75 16 S L71 NOT L69-L74
 L76 13 S L71 AND (EFFECT? OR EVOLUTION? OR PATTERN? OR ALGORITHM? OR PR
 L77 13 S L76 NOT L71
 L78 37 S L71,L77

FILE 'BIOTIS' ENTERED AT 13:19:50 ON 12 FEB 2001

FILE 'WPIX' ENTERED AT 13:26:37 ON 12 FEB 2001

L79 1 S E3
 E MARCOTTE E/AU
 L80 159 S E2,E13,E14
 E EISENBERG D/AU
 E THOMPSON M/AU
 L81 12 S E1-E6
 E YEATES T/AU
 L82 6 S E3,E4
 E EISENBERG D/AU
 L83 12 S E2-E6
 L84 186 S L79-L83
 L85 19 S L84 AND G06F/IC
 L86 7 S L84 AND T01-J1/MC
 L87 19 S L85,L86
 L88 3 S L87 AND (PROTEIN OR PEPTIDE OR POLYPEPTIDE)
 L89 14 S L84 AND C07K/IC
 L90 10 S L84 AND (B04-B04A? OR C04-B04A? OR B04-N04? OR C04-N04?)/MC
 L91 8 S L84 AND V01/M0,M1,M2,M3,M4,M5,M6
 L92 20 S L89-L91
 L93 1 S L87 AND L92
 L94 3 S L88,L93
 L95 13 S L91 NOT L94

FILE 'WPIX' ENTERED AT 13:31:46 ON 12 FEB 2001

L96 11402 S E7A
 E G06F016/IC
 L97 414153 S (T01 OR T01)/DC
 L98 309436 S G06F/IC
 L99 1234 S T01-B04A/MC
 E T01-S+ALL/MC
 L100 6953 S T01-S/MC
 L101 447966 S L96-L100

L102 464 S L101 AND (PROTEIN OR PEPTIDE OR POLYPEPTIDE OR CD7K/IC OR (BO
 L103 104 S L102 AND FUNCTION?
 L104 16 S L102 AND PROFIL.
 L105 4 S L102 AND (N HOMOLOG? OR NON HOMOLOG?)
 L106 55 S L102 AND MULTIPLE?
 L107 15 S L103 AND L104-L106
 L108 4 S L103 AND EVOL?
 L109 31 S L103 AND GENOM.
 L110 34 S L103 AND ALIGNM.
 L111 25 S L103 AND L108-L110
 L112 34 S L107, L111
 L113 50 S L103, L105, L108, L112
 L114 1 S L103 AND L105
 L115 31 S L103, L114
 L116 260 S L103 AND (E12-K04 OR C12-K04 OR D05-H09)/MC
 L117 240 S L103 AND (E12-K04 OR C12-K04)/MC
 L118 70 S L103, L117 AND L103
 L119 30 S L103, L115 NOT L01-L05
 L120 11 S L103 AND GOLF/10M
 L121 67 S L103 NOT L103
 L122 47 S L103 AND GOLF/10M
 L123 73 S L103, L122
 L124 30 S L103 NOT L103

FILE 'WPIX' ENTERED AT 14:30:17 ON 12 FEB 2001

L125 6 S L101 AND PHYLOG.
 L126 7 S L101 AND PHYLOG.
 L127 3 S L103 NOT L01-L05

FILE 'MEDLINE' ENTERED AT 14:41:50 ON 12 FEB 2001

L128 460415 S L7, L11, L14 OF READING FRAMES+NT/CT OR MOLECULAR SEQUENCE DATA
 L129 23379 S L128 AND L128
 L130 10242 S L128 AND L128
 L131 47028 S L128 AND L23, L24
 E PROTEIN STRUCTURE/CT
 E E4+ALL/CT
 L132 12561 S PHYLOG? AND L129-L131
 L133 12566 S PHYLOGENY+NT/CT AND L129-L131
 L134 12561 S L132, L133
 L135 6774 S L134 AND 2HOMOLOG?
 L136 2334 S L134 AND FUNCTION?
 L137 1637 S L135 AND L136
 L138 115 S L137 AND L137
 L139 1184 S L137 AND D12./CT
 L140 70 S L139 AND L139
 L141 1180 S L139 NOT L39-L45
 L142 15 S L141 AND PROTEIN FOLD?
 L143 822 S L139 AND PY=1398
 L144 7 S L143 AND L141
 L145 46 S L143 AND L143
 L146 52 S L144, L145
 L147 46113 S SEQUENCE HOMOLOG, AMINO ACID/CT
 L148 1617 S EVOLUTION, MOLECULAR, CT AND L147
 L149 941 S L148 AND PY=1448
 L150 153 S L11 AND L149
 L151 273 S L7 AND L149
 L152 36 S L150 AND L151
 L153 25 S L23 AND L150, L151
 L154 302 S L150, L151 AND D12./CT NOT L153
 L155 14 S L154 NOT AB/FA
 L156 302 S L154 NOT L151
 L157 15 S L156 AND L15/CT

FILE 'MEDLINE' ENTERED AT 14:57:21 ON 12 FEB 2001

L158 56 S L156 AND L37, L34
 L159 156 S L156 AND PHYLOG?

| | |
|------|------------------------------------|
| L160 | 20 S L159 AND L158 |
| L161 | 56 S L158,L160 |
| | SEL L161 AN 5 11 15 19 24 37 45 54 |
| L162 | 8 S E1-E8 |